



(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 3/00 (2006.01)

A61K 31/4375 (2006.01) A61P 3/04 (2006.01)

A61K 31/404 (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2018/029749

(22) International Filing Date:

27 April 2018 (27.04.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/492,618 01 May 2017 (01.05.2017) US

(71) Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE [US/US]; 10901 North Torrey Pines Road, La Jolla, California 92037 (US).

(72) Inventors: PINKERTON, Anthony B.; 10901 North Torrey Pines Road, La Jolla, California 92037 (US). ARDECKY, Robert J.; 10901 North Torrey Pines Road, La Jolla, California 92037 (US). ZOU, Jiwen; 10901 North Torrey Pines Road, La Jolla, California 92037 (US).

(74) Agent: BONNEFOUS, Celine M.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF

(57) Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

**INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE
PHOSPHATASE (LMPTP) AND USES THEREOF**

CROSS-REFERENCE

[001] This application claims benefit of U.S. Provisional Patent Application No. 62/492,618 filed on May 1, 2017, which is incorporated herein by reference in its entirety.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

[002] This invention was made with the support of the United States government under Research Project Grant R01 DK106233-01 by the National Institutes of Health.

FIELD OF THE INVENTION

[003] Described herein are inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP), methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LMPTP activity.


BACKGROUND OF THE INVENTION

[004] Obesity is frequently complicated by a combination of metabolic and cardiovascular anomalies, called the metabolic syndrome, which significantly increases morbidity and mortality of affected individuals. Insulin resistance is an important component of the metabolic syndrome. Protein tyrosine phosphatases (PTPs), including low molecular weight protein tyrosine phosphatase (LMPTP) regulate insulin signaling. LMPTP is highly expressed in liver, muscle, adipocytes, heart and other tissues. Genetic association studies in humans support a negative role for LMPTP in insulin resistance and the metabolic complications of obesity.

BRIEF SUMMARY OF THE INVENTION


[005] Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

[006] In one aspect, described herein is a compound that has the structure of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof:




Formula (I)

wherein,



or



A

is an aryl or a heteroaryl;

each R^a is independently H, halogen, -CN, -OH, -OR¹³, -SR¹³, -S(=O)R¹³, -S(=O)₂R¹³, -N(R¹²)S(=O)₂R¹³, -S(=O)₂NR¹²R¹³, -C(=O)R¹³, -OC(=O)R¹³, -CO₂R¹², -OCO₂R¹³, -NR¹²R¹², -NR¹²R¹³, -C(=O)NR¹²R¹², -C(=O)NR¹²R¹³, -OC(=O)NR¹²R¹², -OC(=O)NR¹²R¹³, -NR¹²C(=O)NR¹²R¹², -NR¹²C(=O)NR¹²R¹³, -NR¹²C(=O)R¹³, -NR¹²C(=O)OR¹³, substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstituted C₁-C₆fluoroalkyl, or substituted or unsubstituted C₁-C₆heteroalkyl;

m is 0, 1, or 2;

each R^b is independently H, substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstituted C₁-C₆fluoroalkyl, or substituted or unsubstituted C₁-C₆heteroalkyl;

n is 0, 1, or 2;

L^2 is $-L^7-Y^1-$;

L⁷ is absent, substituted or unsubstituted C₁-C₄alkylene, -CH=CH-, -C≡C-, substituted or unsubstituted C₃-C₆cycloalkylene, -Y²-L⁸-, or -L⁸-Y²-L⁸-;

Y¹ is -C(=O)NR^c-, -C(=O)-, -SO₂NR^c-, -C(=O)O-, -C(=NR^c)-, -C(=N-OR^c)-, -C(=NR^c)NR^c-,
or -C(=N-OR^c)-NR^c-;

each L⁸ is independently substituted or unsubstituted C₁-C₄alkylene or substituted or unsubstituted C₃-C₆cycloalkylene;

Y² is -O-, -S-, -S(=O)-, -SO₂-, -NR^c-, -C(=O)NR^c-, -C(=O)-, -NR^cC(=O)-, -SO₂NR^c-, -NR^cSO₂-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OC(=O)NR^c-, -NR^cC(=O)O-, or -NR^cC(=O)NR^c-;

each R^c is independently H or substituted or unsubstituted C₁-C₆alkyl;

R^3 is H or $-L^3-R^5$:

L³ is absent, substituted or unsubstituted C₁-C₆alkylene, or substituted or unsubstituted C₁-C₆heteroalkylene;

R⁵ is H, substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroarvl;

or R^3 and R^c are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;

Z^1 is $-NR^d$ -, $-O$ -, $-S$ -, $-SO_2$ -, $-SO_2NR^d$ -, $-C(=O)NR^d$ -, $-NR^dC(=O)$ -, $-OC(=O)$ -, $-C(=O)O$ -, $-OC(=O)O$ -, $-C(=O)$ -, $-OC(=O)NR^d$ -, $-NR^dC(=O)O$ -, or $-NR^dC(=O)NR^d$;

each R^d is independently H or substituted or unsubstituted C_1 - C_6 alkyl;

L^4 is absent or $-L^5-L^6$;

L^5 is substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;

L^6 is absent, substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, $-NR^6$ -, $-C(=O)NR^6$ -, $-NR^6C(=O)$ -, or $-NR^6C(=O)NR^6$;

R^4 is H, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

or R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;

X^1 is CR^7 or N;

X^2 is N or CR^8 ;

X^3 is N or CR^9 ;

X^4 is N or CR^{10} ;

X^5 is N or CR^{11} ;

where at least one of X^2 , X^3 , X^4 , and X^5 is N;

R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from H, halogen, $-CN$, $-OH$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{13}$, $-S(=O)_2R^{13}$, $-N(R^{12})S(=O)_2R^{13}$, $-S(=O)_2NR^{12}R^{13}$, $-S(=O)NR^{12}R^{13}$, $-C(=O)R^{13}$, $-OC(=O)R^{13}$, $-CO_2R^{12}$, $-OCO_2R^{13}$, $-NR^{12}R^{12}$, $-C(=O)NR^{12}R^{12}$, $-C(=O)NR^{12}R^{13}$, $-OC(=O)NR^{12}R^{12}$, $-OC(=O)NR^{12}R^{13}$, $-NR^{12}C(=O)NR^{12}R^{12}$, $-NR^{12}C(=O)NR^{12}R^{13}$, $-NR^{12}C(=O)R^{13}$, $-NR^{12}C(=O)OR^{13}$, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 fluoroalkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, a substituted or unsubstituted C_3 - C_6 cycloalkyl, a substituted or unsubstituted C_2 - C_6 heterocycloalkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl;

each R^{12} is independently selected from the group consisting of H, C_1 - C_6 alkyl, and C_1 - C_6 fluoroalkyl, and C_1 - C_6 heteroalkyl;

each R^{13} is independently selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, C_1 - C_6 heteroalkyl, a substituted or unsubstituted C_3 - C_6 cycloalkyl, a substituted or unsubstituted C_2 - C_6 heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted $-C_1$ - C_4 alkylene- C_3 - C_{10} cycloalkyl, a substituted or

unsubstituted -C₁-C₄alkylene-C₂-C₁₀heterocycloalkyl, a substituted or unsubstituted -C₁-C₄alkylene-aryl, and a substituted or unsubstituted -C₁-C₄alkylene-heteroaryl;
or when R¹² and R¹³ are attached to the same N atom then R¹² and R¹³ are taken together with the N atom to which they are attached to form a substituted or unsubstituted C₂-C₁₀heterocycle.

[0007] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.

[0008] In one aspect, provided herein is a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.

[0009] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.

[0010] In one aspect, described herein is a method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity in a mammal comprising administering to the mammal a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.

[0011] In some embodiments of the method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity, a mammal has insulin resistance, metabolic syndrome, type 2 diabetes, cardiovascular disease, or combinations thereof.

[0012] In some embodiments of a method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity, the mammal has an impaired glucose tolerance.

[0013] In some embodiments of a method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity, the mammal is pre-diabetic.

[0014] In some embodiments of a method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity, the mammal is obese.

[0015] In some embodiments of a method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity, the method further comprises administering an additional therapeutic agent to the mammal. In some embodiments of a method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity, the additional therapeutic agent is a peroxisome proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a glucagon-like peptide-1 (GLP-I) analog, insulin or an insulin analog, an insulin secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a human amylin analog, a biguanide, a glucophage, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, a sulfonylurea, or any combination thereof. In some embodiments of a method of inhibiting low molecular weight protein tyrosine phosphatase

(LMPTP) activity, the additional therapeutic agent is an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, diuretic, calcium channel blocker, inhibitor of renin-angiotensin system (RAS), blood-thinning medication, a statin, a fibrate, or any combination thereof.

[0016] In another aspect, described herein is a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal comprising administering to the mammal a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.

[0017] In some embodiments of a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal, the mammal has abdominal obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, low high-density cholesterol levels (HDL), or combinations thereof.

[0018] In some embodiments of a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal, the mammal has an impaired glucose tolerance.

[0019] In some embodiments of a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal, the mammal is obese.

[0020] In some embodiments of a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal, the compound modulates glucose and lipid metabolism.

[0021] In some embodiments of a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal, the method further comprises administering an additional therapeutic agent to the mammal. In some embodiments of a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal, the additional therapeutic agent is a peroxisome proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a glucagon-like peptide-1 (GLP-I) analog, insulin or an insulin analog, an insulin secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a human amylin analog, a biguanide, a glucophage, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, a sulfonylurea, or any combination thereof. In some embodiments of a method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal, the additional therapeutic agent is an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, diuretic, calcium channel blocker, inhibitor of renin-angiotensin system (RAS), blood-thinning medication, a statin, a fibrate, or any combination thereof.

DETAILED DESCRIPTION

[0022] Protein phosphorylation represents a key post-translational modification that is critical to the control of many cellular functions. The reversible phosphorylation of tyrosine residues of proteins is a significant regulatory event in eukaryotes compared to other protein phosphorylation processes and is crucially important for the regulation and progression of various cellular signaling cascades, especially those induced by receptor activation mechanisms. The appropriate functioning of these signaling pathways is controlled by the concerted and dynamic activities of protein tyrosine kinases (PTKs) and

phosphotyrosine protein phosphatases (PTPs) which play vital roles in numerous fundamental physiological cellular processes, such as growth, differentiation, survival, migration, metabolism, cell-cell communication and adhesion, immune response, and gene transcription.

[0023] PTPs are implicated in the pathogenesis of human diseases, including diabetes, obesity, cancer, inflammation, autoimmune, and cardiovascular diseases.

[0024] Low molecular weight PTPs (LMPTPs) have emerged as attractive targets for the pharmacological control of postreceptor events involved in the development of metabolic and neoplastic pathologies as well as for therapeutic intervention in infectious diseases.

[0025] LMPTP is a small (18 kD) cytosolic enzyme that is expressed ubiquitously but has particularly high expression in adipocytes. As a result of an alternative mRNA splicing mechanism, LMPTP is usually found as two isozymes, called LMPTP-A and -B (the rodent isoforms are called respectively LMPTP-IF1 and -IF2). In humans the total enzymatic activity of LMPTP is variable and is determined by a common genetic polymorphism.

[0026] LMPTPs have been identified and isolated from a wide variety of prokaryotic and eukaryotic organisms, such as bacteria, yeasts, and mammals. LMPTPs from different organisms generally display a high degree of homology, especially in their tertiary structure.

[0027] Human LMPTPs exert sophisticated control over cell growth and differentiation through the modulation of signaling pathways induced by several growth factors and kinases. The enzyme also negatively regulates the metabolic responses to insulin, and the sensitivity of specific tissues to the hormone is consequently enhanced as a result of the LMPTP suppression.

[0028] LMPTP is an inhibitor of insulin signaling. In cell lines LMPTP is able to inhibit both the metabolic and growth-inducing effects of insulin. Also in vitro the phosphatase dephosphorylates peptides derived from the phosphorylated IGF-1 receptor and insulin receptor (IR). Increased insulin signaling was observed in the adipose tissue of obese mice treated with anti-LMPTP antisense oligonucleotides (ASO). It was shown that LMPTP can also easily be co-precipitated with the IR. Multiple lines of evidence suggest that LMPTP plays an important role in the metabolic syndrome. The first line of evidence comes from human genetic studies. The ACP1 gene is located in one of the candidate genome regions for obesity on chromosome 2p25 and is currently included in the obesity gene map. Carriers of ACP1 alleles associated with low enzymatic activity tend to have lower non-fasting glucose levels and are protected from obesity-associated lipid anomalies. Strong in vivo evidence suggesting that inhibition of LMPTP decreases the insulin resistance associated with obesity, by treating mice with anti-LMPTP ASOs. Leptin-deficient or diet-induced obese mice treated with specific anti-LMPTP ASOs showed a marked improvement of lipid profiles, and of glucose and insulin tolerance, in the absence of significant side effects.

[0029] Obesity is frequently complicated by a constellation of metabolic and cardiovascular anomalies, called the metabolic syndrome, which significantly increases morbidity and mortality of affected individuals. Insulin resistance is an important component of the metabolic syndrome. Protein tyrosine

phosphatases (PTPs) that regulate insulin signaling are targets for insulin resistance syndromes. One of the PTPs, the low molecular weight protein tyrosine phosphatase (LMPTP), is encoded by the ACP1 gene. LMPTP is highly expressed in adipocytes. There is strong *in vitro* and *in vivo* evidence that LMPTP is a negative regulator of insulin signaling. Genetic association studies in humans support a negative role for LMPTP in insulin resistance and the metabolic complications of obesity. *In vivo*, partial knock-down of LMPTP expression by specific antisense oligonucleotides (ASOs) led to improved glycemic and lipid profiles and decreased insulin resistance in diet-induced obese C57BL/6 mice. Interestingly, anti-LMPTP ASOs did not induce any metabolic phenotype in lean mice. LMPTP is considered to play a critical negative role in adipocyte insulin signaling, while it is less important in liver and muscle, where it can be at least partially compensated for by PTP1B, a critical negative regulator of insulin signaling in liver and skeletal muscle, and/or other prominent PTPs. Inhibition of LMPTP can significantly reduce obesity associated insulin resistance and decrease the severity of the metabolic syndrome in obesity.

[0030] It has been estimated that every year in the U.S. more than 70 billion dollars are spent for the treatment of obesity-related conditions and almost 300,000 deaths/year can be attributed to the complications of obesity. Obese patients often show multiple metabolic and cardiovascular anomalies known as “the metabolic syndrome”, including glucose intolerance, hyperlipidemia (especially high triglycerides with low HDL), and hypertension.

[0031] Obesity-induced insulin resistance is believed to be a central pathogenic factor in the metabolic syndrome. Obese patients are routinely treated with oral hypoglycemic agents, however even combinations of multiple agents are often insufficient to ensure adequate glycemic control, requiring the addition of parenteral insulin to the regimen. Reduced signal transduction at several levels after engagement of the insulin receptor (IR) has been observed in multiple insulin resistance syndromes, including the metabolic syndrome.

[0032] The IR is a protein tyrosine kinase, and tyrosine phosphorylation plays an important role in insulin signal transduction. Modification of the activity of the IR and/or tyrosine phosphorylation of IR targets are viewed as a promising way to reduce insulin resistance.

[0033] Provided herein are methods for improving insulin sensitivity in a subject comprising administering to the subject a LMPTP inhibitor; and thereby improving insulin sensitivity in the subject. In certain embodiments, the subject has insulin resistance. In some embodiments, the individual with insulin resistance has fasting insulin levels of at least 20 $\mu\text{U/mL}$. In some embodiments, the individual with insulin resistance has fasting insulin levels that exceed 100 $\mu\text{U/mL}$. In some embodiments, the LMPTP inhibitor treats a metabolic disorder by improving insulin resistance. In some embodiments, the LMPTP inhibitor treats a metabolic disorder by improving insulin sensitivity. In certain embodiments, the methods comprise selecting a subject having insulin resistance.

[0034] Provided herein are methods for treating metabolic disorders with a LMPTP inhibitor. The LMPTP inhibitor can treat, delay or prevent the onset of a metabolic disorder, wherein such metabolic disorders include, but are not limited to, metabolic syndrome, elevated blood glucose levels, insulin

resistance, glucose intolerance, type 2 diabetes, type 1 diabetes, pre-diabetes, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and obesity.

[0035] Insulin resistance may be detected using a procedure known as the hyperinsulinemic euglycemic clamp, which measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia. In some embodiments, the methods disclosed herein comprise administering a LMPTP inhibitor to a subject with insulin resistance. In some embodiments, the LMPTP inhibitor improves insulin sensitivity. In some embodiments, the LMPTP inhibitor treats a metabolic disorder. In some embodiments, the LMPTP inhibitor treats a metabolic disorder by improving insulin sensitivity. In some embodiments, the LMPTP inhibitor delays or prevents the onset of the metabolic disorder by improving insulin sensitivity.


[0036] In some embodiments, described herein is a method of improving glucose tolerance in an individual comprising administering a LMPTP inhibitor to the subject with impaired glucose tolerance. In some embodiments, the individual has a metabolic disorder and the metabolic disorder is treated by improving glucose tolerance. In some embodiments, the LMPTP inhibitor delays or prevents the onset of a metabolic disorder in an individual by improving glucose tolerance.

[0037] In some embodiments, described herein is a method of treatment of a metabolic disorder in a subject that is overweight or obese. In some embodiments, a LMPTP inhibitor is used to treat obesity in a subject. In some embodiments, the LMPTP inhibitor decreases adipose tissue expansion in the subject that is overweight or obese. In some embodiments, the metabolic disorder is treated by decreasing adipose tissue expansion.

[0038] In some embodiments, administration of a LMPTP inhibitor to a subject delays or prevents the onset of a metabolic disorder by decreasing adipose tissue expansion. In some embodiments, the subject is at risk for developing a metabolic disorder.


Compounds


[0039] Described herein are small molecule LMPTP inhibitors. In one aspect, described herein is a compound of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof:



Formula (I)

wherein,





A

is an aryl or a heteroaryl;

each R^a is independently H, halogen, -CN, -OH, -OR¹³, -SR¹³, -S(=O)R¹³, -S(=O)₂R¹³, -N(R¹²)S(=O)₂R¹³, -S(=O)₂NR¹²R¹³, -C(=O)R¹³, -OC(=O)R¹³, -CO₂R¹², -OCO₂R¹³, -NR¹²R¹², -NR¹²R¹³, -C(=O)NR¹²R¹², -C(=O)NR¹²R¹³, -OC(=O)NR¹²R¹², -OC(=O)NR¹²R¹³, -NR¹²C(=O)NR¹²R¹², -NR¹²C(=O)NR¹²R¹³, -NR¹²C(=O)R¹³, -NR¹²C(=O)OR¹³, substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstituted C₁-C₆fluoroalkyl, or substituted or unsubstituted C₁-C₆heteroalkyl;

each R^b is independently H, substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstituted C₁-C₆fluoroalkyl, or substituted or unsubstituted C₁-C₆heteroalkyl;

m is 0, 1, or 2; n is 0, 1, or 2;

$$L^2 \text{ is } -L^7-Y^1-;$$

L⁷ is absent, substituted or unsubstituted C₁-C₄alkylene, -CH=CH-, -C≡C-, substituted or unsubstituted C₃-C₆cycloalkylene, -Y²-L⁸-, or -L⁸-Y²-L⁸-;

Y¹ is -C(=O)NR^c-, -C(=O)-, -SO₂NR^c-, -C(=O)O-, -C(=NR^c)-, -C(=N-OR^c)-, -C(=NR^c)NR^c-,
or -C(=N-OR^c)-NR^c-;

each L⁸ is independently substituted or unsubstituted C₁-C₄alkylene or substituted or unsubstituted C₃-C₆cycloalkylene;

Y² is -O-, -S-, -S(=O)-, -SO₂-, -NR^c-, -C(=O)NR^c-, -C(=O)-, -NR^cC(=O)-, -SO₂NR^c-, -NR^cSO₂-, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -OC(=O)NR^c-, -NR^cC(=O)O-, or -NR^cC(=O)NR^c-;

each R^c is independently H or substituted or unsubstituted C₁-C₆alkyl;

R^3 is H or $-L^3-R^5$:

L³ is absent, substituted or unsubstituted C₁-C₆alkylene, or substituted or unsubstituted C₁-C₆heteroalkylene;

R⁵ is H, substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

or R³ and R^c are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;

Z^1 is $-\text{NR}^d-$, $-\text{O}-$, $-\text{S}-$, $-\text{SO}_2-$, $-\text{SO}_2\text{NR}^d-$, $-\text{C}(=\text{O})\text{NR}^d-$, $-\text{NR}^d\text{C}(=\text{O})-$, $-\text{OC}(=\text{O})-$, $-\text{C}(=\text{O})\text{O}-$, $-\text{OC}(=\text{O})\text{O}-$, $-\text{C}(=\text{O})-$, $-\text{OC}(=\text{O})\text{NR}^d-$, $-\text{NR}^d\text{C}(=\text{O})\text{O}-$, or $-\text{NR}^d\text{C}(=\text{O})\text{NR}^d-$;

each R^d is independently H or substituted or unsubstituted C₁-C₆alkyl;

L^4 is absent or $-L^5-L^6$;

L^5 is substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;

L^6 is absent, substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, $-NR^6$ -, $-C(=O)NR^6$ -, $-NR^6C(=O)-$, or $-NR^6C(=O)NR^6$ -;

R^4 is H, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

or R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;

X^1 is CR^7 or N;

X^2 is N or CR^8 ;

X^3 is N or CR^9 ;

X^4 is N or CR^{10} ;

X^5 is N or CR^{11} ;

where at least one of X^2 , X^3 , X^4 , and X^5 is N;

R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from hydrogen, halogen, $-CN$, $-OH$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{13}$, $-S(=O)_2R^{13}$, $-N(R^{12})S(=O)_2R^{13}$, $-S(=O)_2NR^{12}R^{12}$, $-S(=O)_2NR^{12}R^{13}$, $-C(=O)R^{13}$, $-OC(=O)R^{13}$, $-CO_2R^{12}$, $-OCO_2R^{13}$, $-NR^{12}R^{12}$, $-NR^{12}R^{13}$, $-C(=O)NR^{12}R^{12}$, $-C(=O)NR^{12}R^{13}$, $-OC(=O)NR^{12}R^{12}$, $-OC(=O)NR^{12}R^{13}$, $-NR^{12}C(=O)NR^{12}R^{12}$, $-NR^{12}C(=O)NR^{12}R^{13}$, $-NR^{12}C(=O)R^{13}$, $-NR^{12}C(=O)OR^{13}$, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 fluoroalkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, a substituted or unsubstituted C_3 - C_6 cycloalkyl, a substituted or unsubstituted C_2 - C_6 heterocycloalkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl;

each R^{12} is independently selected from the group consisting of H, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, and C_1 - C_6 heteroalkyl;


each R^{13} is independently selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, C_1 - C_6 heteroalkyl, a substituted or unsubstituted C_3 - C_6 cycloalkyl, a substituted or unsubstituted C_2 - C_6 heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted $-C_1$ - C_4 alkylene- C_3 - C_{10} cycloalkyl, a substituted or unsubstituted $-C_1$ - C_4 alkylene- C_2 - C_{10} heterocycloalkyl, a substituted or unsubstituted $-C_1$ - C_4 alkylene-aryl, and a substituted or unsubstituted $-C_1$ - C_4 alkylene-heteroaryl;


or when R^{12} and R^{13} are attached to the same N atom then R^{12} and R^{13} are taken together with the N atom to which they are attached to form a substituted or unsubstituted C_2 - C_{10} heterocycle.

[0040] For any and all of the embodiments, substituents are selected from among a subset of the listed alternatives. For example, in some embodiments, m is 0, 1 or 2. In other embodiments, m is 0. In some other embodiments, m is 1. In some other embodiments, m is 2.


[0041] In some embodiments, n is 0, 1 or 2. In other embodiments, n is 0. In some other embodiments, n is 1. In some other embodiments, n is 2.

[0042] In some embodiments, L^2 is $-L^7-Y^1-$; L^7 is absent, substituted or unsubstituted C_1-C_4 alkylene, $-CH=CH-$, $-C\equiv C-$, substituted or unsubstituted C_3-C_6 cycloalkylene, $-Y^2-L^8-$ or $-L^8-Y^2-L^8-$; Y^1 is $-C(=O)NR^c-$, $-C(=O)-$, $-SO_2NR^c-$, $-C(=O)O-$, $-C(=NR^c)-$, $-C(=N-OR^c)-$, $-C(=NR^c)NR^c-$, or $-C(=N-OR^c)-NR^c-$; each L^8 is independently substituted or unsubstituted C_1-C_4 alkylene or substituted or unsubstituted C_3-C_6 cycloalkylene; Y^2 is $-O-$, $-S-$, $-S(=O)-$, $-SO_2-$, $-NR^c-$, $-C(=O)NR^c-$, $-C(=O)-$, $-NR^cC(=O)-$, $-SO_2NR^c-$, $-NR^cSO_2-$, $-OC(=O)-$, $-C(=O)O-$, $-OC(=O)O-$, $-OC(=O)NR^c-$, $-NR^cC(=O)O-$, or $-NR^cC(=O)NR^c-$; each R^c is independently H or substituted or unsubstituted C_1-C_6 alkyl.


[0043] In some embodiments, R^1 is , and R^2 is $-Z^1-L^4-R^4$.

[0044] In some embodiments, R^1 is $-Z^1-L^4-R^4$, and R^2 is .

[0045] In some embodiments, the compound of Formula (I) has one of the following structures, or a pharmaceutically acceptable salt or solvate thereof:





[0046] In some embodiments, the compound of Formula (I) has the structure of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein:



Formula (II).

[0047] In some embodiments, the compound of Formula (II) has one of the following structures, or a pharmaceutically acceptable salt or solvate thereof:







[0048] In some embodiments,  is a phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl. In some embodiments, ring A is phenyl. In some embodiments, ring A is naphthyl. In some embodiments, ring A is monocyclic heteroaryl. In some embodiments, ring A is bicyclic heteroaryl.

[0049] In some embodiments,  is a monocyclic 5- or 6-membered heteroaryl containing 0-4 N and 0 or 1 O or S atom.

[0050] In some embodiments,  is a monocyclic 5-membered heteroaryl. In some embodiments, ring A is furanyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, or thiadiazolyl. In some embodiments, ring A is furanyl. In some embodiments, ring A is thienyl. In some embodiments, ring A is pyrrolyl. In some embodiments, ring A is oxazolyl. In some embodiments, ring A is imidazolyl. In some embodiments, ring A is triazolyl. In some embodiments, ring A is tetrazolyl. In some embodiments, ring A is isoxazolyl. In some embodiments, ring A is isothiazolyl. In some embodiments, ring A is oxadiazolyl. In some embodiments, ring A is thiadiazolyl.




[0052] In some embodiments,  is a monocyclic 6-membered heteroaryl that is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl. In some embodiments, ring A is pyridinyl. In some embodiments, ring A is pyrimidinyl. In some embodiments, ring A is pyrazinyl. In some embodiments, ring A is pyridazinyl. In some embodiments, ring A is triazinyl.




[0054] In some embodiments,  is a bicyclic heteroaryl containing 0-4 N and 0 or 1 O or S atom.

[0055] In some embodiments,  is a bicyclic heteroaryl that is quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, indolizinyl, azaindolizinyl, indolyl, azaindolyl, indazolyl, azaindazolyl, benzimidazolyl, azabenzimidazolyl, benzotriazolyl, azabenzotriazolyl, benzoxazolyl, azabenzoxazolyl, benzisoxazolyl, azabenzisoxazolyl, benzofuranyl, azabenzofuranyl, benzothienyl, azabenzothienyl, benzothiazolyl, azabenzothiazolyl, or purinyl. In some embodiments, ring A is quinolinyl. In some embodiments, ring A is isoquinolinyl. In some embodiments, ring A is cinnolinyl. In some embodiments, ring A is phthalazinyl. In some embodiments, ring A is quinazolinyl. In some embodiments, ring A is quinoxalinyl. In some embodiments, ring A is naphthyridinyl. In some embodiments, ring A is pteridinyl. In some embodiments, ring A is indolizinyl. In some embodiments, ring A is azaindolizinyl. In some embodiments, ring A is indolyl. In some embodiments, ring A is azaindolyl. In some embodiments, ring A is indazolyl. In some embodiments, ring A is azaindazolyl. In some embodiments, ring A is benzimidazolyl. In some embodiments, ring A is azabenzimidazolyl. In some embodiments, ring A is benzotriazolyl. In some embodiments, ring A is azabenzotriazolyl. In some embodiments, ring A is benzoxazolyl. In some embodiments, ring A is azabenzoxazolyl. In some embodiments, ring A is benzisoxazolyl. In some embodiments, ring A is azabenzisoxazolyl. In some embodiments, ring A is benzofuranyl. In some embodiments, ring A is azabenzofuranyl. In some embodiments, ring A is benzothienyl. In some embodiments, ring A is azabenzothienyl. In some embodiments, ring A is benzothiazolyl. In some embodiments, ring A is azabenzothiazolyl. In some embodiments, ring A is purinyl.





[0057] In some embodiments, the compound of Formula (I) has the structure of Formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein:




Formula (III).

[0058] In some embodiments, the compound of Formula (III) has one of the following structures, or a pharmaceutically acceptable salt or solvate thereof:





[0059] In some embodiments, the compound of Formula (I) has the structure of Formula (IV) or a pharmaceutically acceptable salt or solvate thereof, wherein:



Formula (IV)

wherein,

X^6 is NR^b , N, O, or S; and

X^7 is N or CR^b .

[0060] In some embodiments, X^2 is N; X^3 is CR^9 ; X^4 is CR^{10} ; and X^5 is CR^{11} .

[0061] In some embodiments, X^2 is CR^8 ; X^3 is N; X^4 is CR^{10} ; and X^5 is CR^{11} .

[0062] In some embodiments, X^2 is CR^8 ; X^3 is CR^9 ; X^4 is N; and X^5 is CR^{11} .

[0063] In some embodiments, X^2 is CR^8 ; X^3 is CR^9 ; X^4 is CR^{10} ; and X^5 is N.


[0064] In some embodiments, X^2 is N; X^3 is CR^9 ; X^4 is N; and X^5 is CR^{11} .


[0065] In some embodiments, X^2 is CR^8 ; X^3 is N; X^4 is CR^{10} ; and X^5 is N.

[0066] In some embodiments, X^2 is N; X^3 is CR^9 ; X^4 is CR^{10} ; and X^5 is N.

[0067] In some embodiments, X^2 is CR^8 ; X^3 is N; X^4 is N; and X^5 is CR^{11} .

[0068] In some embodiments, the compound of Formula (IV) has one of the following structures, or a pharmaceutically acceptable salt or solvate thereof:





[0069] In some embodiments, R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are independently selected from H, halogen, -CN, -OH, -OR¹³, substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstituted C₁-C₆fluoroalkyl, and substituted or unsubstituted C₁-C₆heteroalkyl.

[0070] In some embodiments, R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from H, F, Cl, Br, -CN, -OH, -OCH₃, -OCH₂CH₃, -OCF₃, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -CFH₂, -CF₂H, -CF₃, -CH₂OH, -CH₂OCH₃, -CH₂CH₂OH, -CH₂CH₂OCH₃, -CH₂NH₂, -CH₂NHCH₃, and -CH₂N(CH₃)₂. In some embodiments, R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from H, F, Cl, Br, -CN, -OH, -OCH₃, -OCH₂CH₃, -OCF₃, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -CFH₂, -CF₂H, and -CF₃. In some embodiments, R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from H, F, Cl, Br, -CN, -OH, -OCH₃, -OCF₃, -CH₃, -CFH₂, -CF₂H, and -CF₃. In some embodiments, R^7 , R^8 , R^9 , R^{10} , and R^{11} are H.

[0071] In some embodiments, L² is -L⁷-Y¹-, -Y²-L⁸-Y¹-, or -L⁸-Y²-L⁸-Y¹-; L⁷ is absent, substituted or unsubstituted C₁-C₄alkylene, -CH=CH-, -C≡C-, or substituted or unsubstituted C₃-C₆cycloalkylene; Y¹ is -C(=O)NR^c-, -C(=O)-, or -C(=O)O-; each L⁸ is independently substituted or unsubstituted C₁-C₄alkylene or substituted or unsubstituted C₃-C₆cycloalkylene; Y² is -O-, -S-, or -NR^c-; and R³ is H or -L³-R⁵.

[0072] In some embodiments, L^2 is $-L^7-Y^1$. In some embodiments, $-Y^2-L^8-Y^1$ or $-L^8-Y^2-L^8-Y^1$. In some embodiments, $-Y^2-L^8-Y^1$. In some embodiments, $-L^8-Y^2-L^8-Y^1$.

[0073] In some embodiments, L^7 is absent, $-CH_2-$, $-CH_2-CH_2-$, $-CH_2CH_2-$, $-CH=CH-$, $-C\equiv C-$, cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene.

[0074] In some embodiments, Y¹ is -C(=O)NR^c-, -C(=O)-, -SO₂NR^c-, -C(=O)O-, -C(=NR^c)-, -C(=N-OR^c)-, -C(=NR^c)NR^c-, or -C(=N-OR^c)-NR^c-. In some embodiments, Y¹ is -C(=O)NR^c-, -C(=O)-, -C(=O)O-, or -C(=N-OR^c)-NR^c-. In some embodiments, Y¹ is -C(=O)NR^c-. In some embodiments, Y¹ is -C(=O)-. In some embodiments, Y¹ is -C(=O)O-. In some embodiments, Y¹ is -C(=N-OR^c)-NR^c-.

[0075] In some embodiments, -CH₂-, -CH₂-CH₂-, -CH₂CH₂-, cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene.

[0076] In some embodiments, Y² is -O-. In some embodiments, Y² is -S-. In some embodiments, Y² is -NR^c-.

[0077] In some embodiments, R^3 is H. In some embodiments, $R^3-L^3-R^5$.

[0078] In some embodiments, L³ is absent, substituted or unsubstituted C₁-C₆alkylene, or substituted or unsubstituted C₁-C₆heteroalkylene. In some embodiments, L³ is absent. In some embodiments, L³ is

substituted or unsubstituted C₁-C₆alkylene. In some embodiments, L³ is substituted or unsubstituted C₁-C₆heteroalkylene.

[0079] In some embodiments, R⁵ is H, substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, R⁵ is H. In some embodiments, R⁵ is substituted or unsubstituted C₃-C₁₀cycloalkyl. In some embodiments, R⁵ is substituted or unsubstituted C₂-C₁₀heterocycloalkyl. In some embodiments, R⁵ is substituted or unsubstituted aryl. In some embodiments, R⁵ is substituted or unsubstituted heteroaryl.

[0080] In some embodiments, R³ and R^c are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle.

[0081] In some embodiments, R⁵ is a substituted or unsubstituted monocyclic C₂-C₈heterocycloalkyl containing at least 1 N atom in the ring.

[0082] In some embodiments, R⁵ is substituted or unsubstituted aziridinyl, substituted or unsubstituted azetidiny, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted azepanyl. In some embodiments, R⁵ is substituted or unsubstituted aziridinyl. In some embodiments, R⁵ is substituted or unsubstituted azetidiny. In some embodiments, R⁵ is substituted or unsubstituted pyrrolidinyl. In some embodiments, R⁵ is substituted or unsubstituted morpholinyl. In some embodiments, R⁵ is substituted or unsubstituted thiomorpholinyl. In some embodiments, R⁵ is substituted or unsubstituted piperidinyl. In some embodiments, R⁵ is substituted or unsubstituted piperazinyl. In some embodiments, R⁵ is substituted or unsubstituted azepanyl.

[0083] In some embodiments, R⁵ is substituted or unsubstituted monocyclic C₂-C₈heterocycloalkyl containing 1 N atom in the ring that is a β-lactam, γ-lactam, δ-lactam or ε-lactam. In some embodiments, R⁵ is substituted or unsubstituted monocyclic C₂-C₈heterocycloalkyl containing 1 N atom in the ring that is a β-lactam. In some embodiments, R⁵ is substituted or unsubstituted monocyclic C₂-C₈heterocycloalkyl containing 1 N atom in the ring that is a γ-lactam. In some embodiments, R⁵ is substituted or unsubstituted monocyclic C₂-C₈heterocycloalkyl containing 1 N atom in the ring that is a δ-lactam. In some embodiments, R⁵ is substituted or unsubstituted monocyclic C₂-C₈heterocycloalkyl containing 1 N atom in the ring that is a ε-lactam.

[0084] In some embodiments, R⁵ is a substituted or unsubstituted bicyclic C₅-C₁₀heterocycloalkyl.

[0085] In some embodiments, R⁵ is a substituted or unsubstituted bicyclic C₅-C₁₀heterocycloalkyl that is a substituted or unsubstituted fused bicyclic C₅-C₁₀heterocycloalkyl. In some embodiments, R⁵ is a substituted or unsubstituted bicyclic C₅-C₁₀heterocycloalkyl that is substituted or unsubstituted bridged bicyclic C₅-C₁₀heterocycloalkyl. In some embodiments, R⁵ is a substituted or unsubstituted bicyclic C₅-C₁₀heterocycloalkyl that is substituted or unsubstituted spiro bicyclic C₅-C₁₀heterocycloalkyl.

[0086] In some embodiments, Z^1 is $-NR^d$ - or $-O$ -; and L^4 is absent or $-L^5-L^6$ -. In some embodiments, Z^1 is $-NR^d$ -. In some embodiments, Z^1 is $-O$ -. In some embodiments, L^4 is absent. In some embodiments, L^4 is $-L^5-L^6$ -.

[0087] In some embodiments, L^5 is substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, substituted or unsubstituted phenylene or substituted or unsubstituted monocyclic heteroaryl. In some embodiments, L^5 is substituted or unsubstituted C_1 - C_6 alkylene. In some embodiments, L^5 is substituted or unsubstituted C_1 - C_6 heteroalkylene. In some embodiments, L^5 is substituted or unsubstituted phenylene. In some embodiments, L^5 is substituted or unsubstituted monocyclic heteroaryl.

[0088] In some embodiments, L^6 is absent, substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, $-NR^6$ -, $-C(=O)NR^6$ -, $-NR^6C(=O)$ -, or $-NR^6C(=O)NR^6$ -. In some embodiments, L^6 is absent. In some embodiments, L^6 is substituted or unsubstituted C_1 - C_6 alkylene. In some embodiments, L^6 is substituted or unsubstituted C_1 - C_6 heteroalkylene. In some embodiments, L^6 is $-NR^6$ -. In some embodiments, L^6 is $-C(=O)NR^6$ -. In some embodiments, L^6 is $-NR^6C(=O)$ -. In some embodiments, L^6 is $-NR^6C(=O)NR^6$ -.

[0089] In some embodiments, R^4 is H, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted monocyclic heteroaryl. In some embodiments, R^4 is H. In some embodiments, R^4 is substituted or unsubstituted C_3 - C_{10} cycloalkyl. In some embodiments, R^4 is substituted or unsubstituted C_2 - C_{10} heterocycloalkyl. In some embodiments, R^4 is substituted or unsubstituted phenyl. In some embodiments, R^4 is substituted or unsubstituted monocyclic heteroaryl.

[0090] In some embodiments, R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle.

[0091] In some embodiments, L^4 is absent or $-L^5-L^6$ -. In some embodiments, L^4 is absent. In some embodiments, L^4 is $-L^5-L^6$ -. In some embodiments, L^5 is substituted or unsubstituted C_1 - C_6 alkylene. In some embodiments, L^6 is absent or $-NR^6$ -. In some embodiments, L^6 is absent. In some embodiments, L^6 is $-NR^6$ -.

[0092] In some embodiments, R^4 is substituted or unsubstituted monocyclic C_2 - C_6 heterocycloalkyl.

[0093] In some embodiments, R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted monocyclic N-containing C_2 - C_6 heterocycloalkyl.

[0094] In some embodiments, L^5 is $-CH_2CH_2$ -, $-CH_2CH_2CH_2$ -, or $-CH_2CH_2CH_2CH_2$ -. In some embodiments, L^5 is $-CH_2CH_2$ -. In some embodiments, L^5 is $-CH_2CH_2CH_2$ -. In some embodiments, L^5 is $-CH_2CH_2CH_2CH_2$ -.

[0095] In some embodiments, R^4 is substituted or unsubstituted monocyclic C_2 - C_6 heterocycloalkyl that is a substituted or unsubstituted aziridinyl, substituted or unsubstituted azetidiny, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or


substituted or unsubstituted azepanyl. In some embodiments, R⁴ is substituted or unsubstituted aziridinyl. In some embodiments, R⁴ is substituted or unsubstituted azetidiny. In some embodiments, R⁴ is substituted or unsubstituted pyrrolidinyl. In some embodiments, R⁴ is substituted or unsubstituted morpholinyl. In some embodiments, R⁴ is substituted or unsubstituted thiomorpholinyl. In some embodiments, R⁴ is substituted or unsubstituted piperidinyl. In some embodiments, R⁴ is substituted or unsubstituted piperazinyl. In some embodiments, R⁴ is substituted or unsubstituted azepanyl.

[0096] In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form a substituted or unsubstituted monocyclic N-containing C₂-C₆heterocycloalkyl that is a substituted or unsubstituted aziridinyl, substituted or unsubstituted azetidiny, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted azepanyl. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted aziridinyl. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted azetidiny. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted pyrrolidinyl. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted morpholinyl. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted thiomorpholinyl. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted piperidinyl. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted piperazinyl. In some embodiments, R⁴ and R⁶ are taken together with the N atom to which they are attached to form substituted or unsubstituted azepanyl.

[0097] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.


[0098] In some embodiments, compounds of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof, include but are not limited to those found in the following tables.

Table 1.













































Ex.			
38			
























Table 2.
















































Ex	R¹¹			
1	H			






















Ex	R ¹¹			
2	H			
3	H			
4	H			
5	H			
6	H			
7	H			

























Ex	R ¹¹			
8	H			
9	H			
10	H			
11	H			
12	H			
13	H			




























Ex	R ¹¹			
14	H			
15	H			
16	H			
17	H			
18	H			
19	H			
20	H			


































Ex	R ¹¹			
21	H			
22	H			
23	H			
24	H			
25	H			
26	H			
27	H			




























Ex	R ¹¹			
28	H			
29	H			
30	H			
31	H			
32	H			
33	H			
34	H			



















Ex	R ¹¹			
35	H			
36a	H			
36b	H			
37	H			
42	H			
43	H			

























Ex	R ¹¹			
44	H			
45	H			
46	H			
47	H			
48	H			
49	H			
50	H			

























Ex	R ¹¹			
51	H			
52	H			
53	H			
54	H			
55	H			
56	H			
57	H			
58	H			



























Ex	R ¹¹			
59	H			
60	H			
61	H			
62	H			
63	H			
64	H			
65	H			
66	H			
67	H			
68	H			

























Ex	R ¹¹			
69	H			
70	H			
71	H			
72	H			
73	Br			
74	Br			
75	Me			
76	Me			






















Ex	R ¹¹			
77	Me			
78	H			
79	H			
80	H			
81	H			






















Ex	R ¹¹			
82	H			
83	H			
84	H			
85	H			
86	H			
87	H			
88	H			

























Ex	R ¹¹			
89	H			
90	H			
91	H			
92	H			
93	H			
94	H			
95	H			






















Ex	R ¹¹			
96	H			
97	H			
98a	H			
98b	H			
99	H			
100	H			
101	H			
102	H			






















Ex	R ¹¹			
103	H			
104	H			
105	H			
106	H			
107	H			
108	H			
109	H			






















Ex	R ¹¹			
110	H			
111	H			
112	H			
113	H			
114	H			
115	H			






















Ex	R ¹¹			
116	H			
117	H			
118a	H			
118b	H			
119	H			
120	H			

Ex	R ¹¹			
121	H			
122	H			
123	H			
124	H			
125	H			
126	H			
127	H			

Ex	R ¹¹			
128	H			
129	H			
130	H			
131	H			
132	H			
133	H			

Ex	R ¹¹			
134	H			
135	H			
136	H			
137	H			
138	Cl			
139	H			

Ex	R ¹¹			
140	H			
141	H			
142	H			
143	H			
144	H			
145	H			

Ex	R ¹¹			
146	H			
147	H			
148	H			
149	H			
150	H			
151	H			
























Ex	R ¹¹			
152	H			
153	H			
154	H			
155	H			
156	H			
157	H			

Table 3.









Ex.			
39			


Table 4.





Ex.			
41			


Table 5.

			
Ex.			
40			

[0099] In some embodiments, R^{11} , , and $-Z^1-L^4-R^4$ are defined as in Table 1, Table 2, Table 3, Table 4, or Table 5.

[00100] In some embodiments, compounds of Formula (I), or a pharmaceutically acceptable salt, or

solvate thereof, have the structure , wherein R^{11} , , and $-Z^1-L^4-R^4$ are defined as in Table 1, Table 2, Table 3, Table 4, or Table 5. In some embodiments,

R^{11} , , and $-Z^1-L^4-R^4$ are defined as in Table 2.

[00101] In some embodiments, compounds of Formula (I) include, but are not limited to:

N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide;

N-(2-(dimethylamino)ethyl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide;

ethyl 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzamide;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)benzamide;

N-(2-(dimethylamino)ethyl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;

1-methyl-N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-2-carboxamide;

N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-3-(trifluoromethyl)benzamide;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-3-(trifluoromethyl)benzamide;

1-methyl-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-2-carboxamide;

1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

methyl 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate;

5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

3-cyano-N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;

N1,N1-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)isophthalamide;
1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;
3-cyano-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(3-(piperidin-1-yl)propoxy)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;
5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide;
5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide;
5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide;
N-(2-(dimethylamino)ethyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;
N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;
piperazin-1-yl(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone;
N,N-diethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;
(1-ethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)(4-ethylpiperazin-1-yl)methanone;
(4-ethylpiperazin-1-yl)(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone;
N-(3-(piperidin-1-yl)propyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,5-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,7-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(2-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-4-yl)benzamide;
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((3-morpholinopropyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((2-(piperidin-1-yl)ethyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((3-(piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((3-(4-(methylsulfonyl)piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
4-(4-((2-(Dimethylamino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
N,N-diethyl-4-(4-(3-(4-methylpiperazin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide;

N,N-diethyl-4-(4-(2-morpholinoethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(2-(4-methylpiperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(tetrahydro-2H-pyran-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(2-(piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(2-(4-(methylsulfonyl)piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-(4-methoxyphenylamino)-1,6-naphthyridin-2-yl)benzamide;
4-(4-(4-(Dimethylamino)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
4-(4-(4-((Dimethylamino)methyl)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
N,N-Diethyl-4-(4-(4-(2-methoxyethylamino)phenylamino)-1,6-naphthyridin-2-yl)benzamide;
4-(4-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
4-(4-((3-(1,1-Dioxidothiomorpholino)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
N,N-Diethyl-4-(4-(1-methylpyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
4-(4-((1-Methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-((pyridin-4-ylmethyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide;
N,N-Diethyl-4-(8-methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide;
4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide;
N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide;
N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide;
1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide;

1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

(1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone;

1-methyl-N-((1-methylpiperidin-4-yl)methyl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-yl)butan-2-ylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

(1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone;

1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-1H-indole-2-carboxamide;

1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-indole-2-carboxamide;

N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N-(3-(Piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N-(2-(Dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide;

6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide;

(4-Ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)methanone;

N,N-diethyl-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide;

N-(1-methylpiperidin-4-yl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide;

N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide;

3-(4-(4-(ethyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-((1-ethylpiperidin-4-yl)methyl)propanamide;

4-cyano-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide;

(4-ethylpiperazin-1-yl)(5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone;

N-(3-(piperidin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

N-(2-(dimethylamino)ethyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole-2-carboxamide;

N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-3H-imidazo[4,5-b]pyridine-2-carboxamide;

N-(1-methylpiperidin-4-yl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenoxy)acetamide;

N-(3-(piperidin-1-yl)propyl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide;

N,N-diethyl-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide;

N-(1-methylpiperidin-4-yl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide;

N-((1-ethylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

N-((1-methylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

N-(2-(4-methyl-1,4-diazepan-1-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)-N-(piperidin-4-ylmethyl)acetamide;

N-(2-(1-methylpiperidin-4-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)propanamide;

methyl-N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide;

(E)-N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(2-(Dimethylamino)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(3-(Piperidin-1-yl)propyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-((1-Ethylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N,N-Diethyl-3-(4-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

N-(1-Methylpiperidin-4-yl)-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N,N-Diethyl-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

3-(4-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-yl)propanamide;

N-(2-(Diethylamino)-2-oxoethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propenamide;

N-(1-Ethylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-(2-(1-methylpiperidin-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide;

N-((1-methylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide;

N-(2-(1-methylazepan-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide;

(Z)-N'-hydroxy-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzimidamide;

(Z)-4-(8-chloro-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide;

(Z)-N'-methoxy-N-(1-methylpiperidin-4-yl)-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzimidamide;

N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzo[b]thiophene-2-carboxamide;

N,N-diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

N-(1-ethylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

(4-methylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone;

Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone;

(4-ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone;

(E)-N,N-Diethyl-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide;

(E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide;

(E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide;

(E)-3-(5-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylic acid;

(E)-N,N-Diethyl-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide;

(E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide;

Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone;

Morpholino(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone;

N,N-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]oxazole-2-carboxamide;

N,N-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazole-2-carboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

[00102] Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.

Further forms of Compounds

[00103] In one aspect, the compound of Formula (I), (II), (III), or (IV), possesses one or more stereocenters and each stereocenter exists independently in either the R or S configuration. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. The compounds and methods provided herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. In certain embodiments, compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds/salts, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, resolution of enantiomers is carried out using covalent diastereomeric derivatives of the compounds described herein. In another embodiment, diastereomers are separated by separation/resolution techniques based upon differences in solubility. In other embodiments, separation of stereoisomers is performed by chromatography or by the forming diastereomeric salts and separation by recrystallization, or chromatography, or any combination thereof. Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981. In one aspect, stereoisomers are obtained by stereoselective synthesis.

[00104] In some embodiments, compounds described herein are prepared as prodrugs. A "prodrug" refers to an agent that is converted into the parent drug *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. In some embodiments, the design of a prodrug increases the effective water solubility. An example, without limitation, of a prodrug is a compound described herein, which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. In certain embodiments, upon *in vivo* administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the

compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.

[00105] In one aspect, prodrugs are designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacokinetic, pharmacodynamic processes and drug metabolism *in vivo*, once a pharmaceutically active compound is known, the design of prodrugs of the compound is possible. (see, for example, Nogrady (1985) *Medicinal Chemistry A Biochemical Approach*, Oxford University Press, New York, pages 388-392; Silverman (1992), *The Organic Chemistry of Drug Design and Drug Action*, Academic Press, Inc., San Diego, pages 352-401, Rooseboom *et al.*, *Pharmacological Reviews*, 56:53-102, 2004; Aesop Cho, "Recent Advances in Oral Prodrug Discovery", *Annual Reports in Medicinal Chemistry*, Vol. 41, 395-407, 2006; T. Higuchi and V. Stella, *Pro-drugs as Novel Delivery Systems*, Vol. 14 of the A.C.S. Symposium Series).

[00106] In some embodiments, some of the herein-described compounds may be a prodrug for another derivative or active compound.

[00107] In some embodiments, sites on the aromatic ring portion of compounds described herein are susceptible to various metabolic reactions. Therefore incorporation of appropriate substituents on the aromatic ring structures will reduce, minimize or eliminate this metabolic pathway. In specific embodiments, the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a halogen, or an alkyl group.

[00108] In another embodiment, the compounds described herein are labeled isotopically (e.g. with a radioisotope) or by another other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[00109] Compounds described herein include isotopically-labeled compounds, which are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, and iodine such as, for example, ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{35}S , ^{18}F , ^{36}Cl , and ^{125}I . In one aspect, isotopically-labeled compounds described herein, for example those into which radioactive isotopes such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. In one aspect, substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased *in vivo* half-life or reduced dosage requirements.

[00110] In additional or further embodiments, the compounds described herein are metabolized upon administration to an organism in need to produce a metabolite that is then used to produce a desired effect, including a desired therapeutic effect.

[00111] "Pharmaceutically acceptable" as used herein, refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic,

i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[00112] The term “pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, pharmaceutically acceptable salts are obtained by reacting a compound of Formula (I), (II), (III), or (IV) with acids. Pharmaceutically acceptable salts are also obtained by reacting a compound of Formula (I), (II), (III), or (IV) with a base to form a salt.

[00113] Compounds described herein may be formed as, and/or used as, pharmaceutically acceptable salts. The type of pharmaceutical acceptable salts, include, but are not limited to: (1) acid addition salts, formed by reacting the free base form of the compound with a pharmaceutically acceptable: inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, and the like; (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion (e.g. lithium, sodium, potassium), an alkaline earth ion (e.g. magnesium, or calcium), or an aluminum ion. In some cases, compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, compounds described herein may form salts with amino acids such as, but not limited to, arginine, lysine, and the like. Acceptable inorganic bases used to form salts with compounds that include an acidic proton, include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.

[00114] It should be understood that a reference to a pharmaceutically acceptable salt includes the solvent addition forms, particularly solvates. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein can be conveniently prepared or formed during the processes described herein. In addition, the compounds

provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.

Methods of Synthesis

[00115] In some embodiments, the syntheses of compounds described herein are accomplished using means described in the chemical literature, using the methods described herein, or by a combination thereof. In addition, solvents, temperatures and other reaction conditions presented herein may vary.

[00116] In other embodiments, the starting materials and reagents used for the synthesis of the compounds described herein are synthesized or are obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, FisherScientific (Fisher Chemicals), and AcrosOrganics.

[00117] In further embodiments, the compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein as well as those that are recognized in the field, such as described, for example, in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for the preparation of compounds as disclosed herein may be derived from reactions and the reactions may be modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the formulae as provided herein. As a guide the following synthetic methods may be utilized.

[00118] In the reactions described, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, in order to avoid their unwanted participation in reactions. A detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosure).

Definitions

[00119] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise. Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.

[00120] The terms below, as used herein, have the following meanings, unless indicated otherwise:

[00121] “Oxo” refers to the =O substituent.

[00122] “Alkyl” refers to a straight or branched hydrocarbon chain radical, having from one to twenty carbon atoms, and which is attached to the rest of the molecule by a single bond. An alkyl comprising up to 10 carbon atoms is referred to as a C₁-C₁₀ alkyl, likewise, for example, an alkyl comprising up to 6 carbon atoms is a C₁-C₆ alkyl. Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarly. Alkyl groups include, but are not limited to, C₁-C₁₀ alkyl, C₁-C₉ alkyl, C₁-C₈ alkyl, C₁-C₇ alkyl, C₁-C₆ alkyl, C₁-C₅ alkyl, C₁-C₄ alkyl, C₁-C₃ alkyl, C₁-C₂ alkyl, C₂-C₈ alkyl, C₃-C₈ alkyl and C₄-C₈ alkyl. Representative alkyl groups include, but are not limited to, methyl, ethyl, *n*-propyl, 1-methylethyl (*i*-propyl), *n*-butyl, *i*-butyl, *s*-butyl, *n*-pentyl, 1,1-dimethylethyl (*t*-butyl), 3-methylhexyl, 2-methylhexyl, 1-ethyl-propyl, and the like. In some embodiments, the alkyl is methyl or ethyl. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted as described below.

[00123] “Alkylene” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group. In some embodiments, the alkylene is -CH₂-, -CH₂CH₂-, or -CH₂CH₂CH₂-. In some embodiments, the alkylene is -CH₂-. In some embodiments, the alkylene is -CH₂CH₂-. In some embodiments, the alkylene is -CH₂CH₂CH₂-.

[00124] “Alkoxy” refers to a radical of the formula -OR where R is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted as described below. Representative alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy. In some embodiments, the alkoxy is methoxy. In some embodiments, the alkoxy is ethoxy.

[00125] “Heteroalkyl” refers to an alkyl radical as described above where one or more carbon atoms of the alkyl is replaced with a O, N (i.e. NH, -Nalkyl) or S atom. “Heteroalkylene” refers to a straight or branched divalent heteroalkyl chain linking the rest of the molecule to a radical group. Unless stated otherwise specifically in the specification, the heteroalkyl or heteroalkylene group may be optionally substituted as described below. Representative heteroalkyl groups include, but are not limited to -OCH₂OMe, -OCH₂CH₂OMe, or -OCH₂CH₂OCH₂CH₂NH₂. Representative heteroalkylene groups include, but are not limited to -OCH₂CH₂O-, -OCH₂CH₂OCH₂CH₂O-, or -OCH₂CH₂OCH₂CH₂OCH₂CH₂O-.

[00126] “Alkylamino” refers to a radical of the formula -NHR or -NRR where each R is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted as described below.

[00127] The term “aromatic” refers to a planar ring having a delocalized π -electron system containing $4n+2$ π electrons, where n is an integer. Aromatics can be optionally substituted. The term “aromatic” includes both aryl groups (e.g., phenyl, naphthalenyl) and heteroaryl groups (e.g., pyridinyl, quinolinyl).

[00128] “Aryl” refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom. Aryl groups can be optionally substituted. Examples of aryl groups include, but are not limited to phenyl, and naphthyl. In some embodiments, the aryl is phenyl. Depending on the structure, an aryl group can be

[00133] “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, *e.g.*, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.

[00134] “Haloalkoxy” refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above, *e.g.*, trifluoromethoxy, difluoromethoxy, fluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, 1,2-difluoroethoxy, 3-bromo-2-fluoropropoxy, 1,2-dibromoethoxy, and the like. Unless stated otherwise specifically in the specification, a haloalkoxy group may be optionally substituted.


[00135] “Heterocycloalkyl” or “heterocyclyl” or “heterocyclic ring” refers to a stable 3- to 14-membered non-aromatic ring radical comprising 2 to 10 carbon atoms and from one to 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical may be a monocyclic, or bicyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. The nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized. The nitrogen atom may be optionally quaternized. The heterocycloalkyl radical is partially or fully saturated. Examples of such heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl. The term heterocycloalkyl also includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. In some embodiments, heterocycloalkyls have from 2 to 8 carbons in the ring. In some embodiments, heterocycloalkyls have from 2 to 8 carbons in the ring and 1 or 2 N atoms. In some embodiments, heterocycloalkyls have from 2 to 10 carbons, 0-2 N atoms, 0-2 O atoms, and 0-1 S atoms in the ring. In some embodiments, heterocycloalkyls have from 2 to 10 carbons, 1-2 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (*i.e.* skeletal atoms of the heterocycloalkyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl group may be optionally substituted.

[00136] “Heteroaryl” refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. The heteroaryl is monocyclic or bicyclic. Illustrative examples of monocyclic heteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl,

oxadiazolyl, thiadiazolyl, furazanyl, indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. Illustrative examples of monocyclic heteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl. Illustrative examples of bicyclic heteroaryls include indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. In some embodiments, heteroaryl is pyridinyl, pyrazinyl, pyrimidinyl, thiazolyl, thienyl, thiadiazolyl or furyl. In some embodiments, a heteroaryl contains 0-4 N atoms in the ring. In some embodiments, a heteroaryl contains 1-4 N atoms in the ring. In some embodiments, a heteroaryl contains 0-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments, a heteroaryl contains 1-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments, heteroaryl is a C₁-C₉heteroaryl. In some embodiments, monocyclic heteroaryl is a C₁-C₅heteroaryl. In some embodiments, monocyclic heteroaryl is a 5-membered or 6-membered heteroaryl. In some embodiments, a bicyclic heteroaryl is a C₆-C₉heteroaryl.

[00137] The term “optionally substituted” or “substituted” means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, -CN, alkyne, C₁-C₆alkylalkyne, halogen, acyl, acyloxy, -CO₂H, -CO₂alkyl, nitro, and amino, including mono- and di-substituted amino groups (e.g. -NH₂, -NHR, -N(R)₂), and the protected derivatives thereof. In some embodiments, optional substituents are independently selected from alkyl, alkoxy, haloalkyl, cycloalkyl, halogen, -CN, -NH₂, -NH(CH₃), -N(CH₃)₂, -OH, -CO₂H, and -CO₂alkyl. In some embodiments, optional substituents are independently selected from fluoro, chloro, bromo, iodo, -CH₃, -CH₂CH₃, -CF₃, -OCH₃, and -OCF₃. In some embodiments, substituted groups are substituted with one or two of the preceding groups. In some embodiments, an optional substituent on an aliphatic carbon atom (acyclic or cyclic) includes oxo (=O).

[00138] A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The compounds presented herein may exist as tautomers. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Some examples of tautomeric interconversions include:



[00139] The terms “co-administration” or the like, as used herein, are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different time.

[00140] The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of an agent or a compound being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate “effective” amount in any individual case may be determined using techniques, such as a dose escalation study.

[00141] The term “pharmaceutical combination” as used herein, means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term “fixed combination” means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific intervening time limits, wherein such administration provides effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.

[00142] The term “subject” or “patient” encompasses mammals. Examples of mammals include, but are not limited to, humans. In one embodiment, the mammal is a human.

[00143] The terms “treat,” “treating” or “treatment,” as used herein, include alleviating, abating or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.

[00144] An “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (*see, e.g.,* Lieberman, *Pharmaceutical Dosage Forms* (vols. 1-3, 1992); Lloyd, *The Art, Science and Technology of Pharmaceutical Compounding* (1999); Pickar, *Dosage Calculations* (1999); and *Remington: The Science and Practice of Pharmacy*, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

Pharmaceutical compositions

[00145] In one aspect, the compounds described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be found, for example, in *Remington: The Science and Practice of Pharmacy*, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., *Pharmaceutical Dosage Forms*, Marcel Decker, New York, N.Y., 1980; and *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Seventh Ed. (Lippincott Williams & Wilkins 1999), herein incorporated by reference for such disclosure.

[00146] A pharmaceutical composition, as used herein, refers to a mixture of a compound of Formula (I), (II), (III), or (IV) with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents,

solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof. The pharmaceutical composition facilitates administration of the compound to an organism.

[00147] Pharmaceutical formulations described herein are administrable to a subject in a variety of ways by multiple administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular, intramedullary injections, intrathecal, direct intraventricular, intraperitoneal, intralymphatic, intranasal injections), intranasal, buccal, topical or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.

[00148] In some embodiments, the compounds of Formula (I), (II), (III), or (IV) are administered orally.

[00149] In some embodiments, the compounds of Formula (I), (II), (III), or (IV) are administered topically. In such embodiments, the compound of Formula (I), (II), (III), or (IV) is formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, shampoos, scrubs, rubs, smears, medicated sticks, medicated bandages, balms, creams or ointments. In one aspect, the compounds of Formula (I), (II), (III), or (IV) are administered topically to the skin.

[00150] In another aspect, the compounds of Formula (I), (II), (III), or (IV) are administered by inhalation.

[00151] In another aspect, the compounds of Formula (I), (II), (III), or (IV) are formulated for intranasal administration. Such formulations include nasal sprays, nasal mists, and the like.

[00152] In another aspect, the compounds of Formula (I), (II), (III), or (IV) are formulated as eye drops.

[00153] In any of the aforementioned aspects are further embodiments in which the effective amount of the compound of Formula (I), (II), (III), or (IV) is: (a) systemically administered to the mammal; and/or (b) administered orally to the mammal; and/or (c) intravenously administered to the mammal; and/or (d) administered by inhalation to the mammal; and/or (e) administered by nasal administration to the mammal; or and/or (f) administered by injection to the mammal; and/or (g) administered topically to the mammal; and/or (h) administered by ophthalmic administration; and/or (i) administered rectally to the mammal; and/or (j) administered non-systemically or locally to the mammal.

[00154] In any of the aforementioned aspects are further embodiments comprising single administrations of the effective amount of the compound of Formula (I), (II), (III), or (IV), including further embodiments in which (i) the compound is administered once; (ii) the compound is administered to the mammal multiple times over the span of one day; (iii) continually; or (iv) continuously.

[00155] In any of the aforementioned aspects are further embodiments comprising multiple administrations of the effective amount of the compound of Formula (I), (II), (III), or (IV), including further embodiments in which (i) the compound is administered continuously or intermittently: as in a

single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours. In further or alternative embodiments, the method comprises a drug holiday, wherein the administration of the compound of Formula (I), (II), (III), or (IV) is temporarily suspended or the dose of the compound being administered is temporarily reduced; at the end of the drug holiday, dosing of the compound is resumed. In one embodiment, the length of the drug holiday varies from 2 days to 1 year.

[00156] In certain embodiments, the compound of Formula (I), (II), (III), or (IV) is administered in a local rather than systemic manner.

[00157] In some embodiments, the compound of Formula (I), (II), (III), or (IV) is administered topically. In some embodiments, the compound of Formula (I), (II), (III), or (IV) is administered systemically.

[00158] In some embodiments, the pharmaceutical formulation is in the form of a tablet. In other embodiments, pharmaceutical formulations of the compounds of Formula (I), (II), (III), or (IV) are in the form of a capsule.

[00159] In one aspect, liquid formulation dosage forms for oral administration are in the form of aqueous suspensions or solutions selected from the group including, but not limited to, aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups.

[00160] For administration by inhalation, a compound of Formula (I), (II), (III), or (IV) is formulated for use as an aerosol, a mist or a powder.

[00161] For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.

[00162] In some embodiments, compounds of Formula (I), (II), (III), or (IV) are prepared as transdermal dosage forms.

[00163] In one aspect, a compound of Formula (I), (II), (III), or (IV) is formulated into a pharmaceutical composition suitable for intramuscular, subcutaneous, or intravenous injection.

[00164] In some embodiments, the compound of Formula (I), (II), (III), or (IV) is administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams or ointments.

[00165] In some embodiments, the compounds of Formula (I), (II), (III), or (IV) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas.

Methods of Dosing and Treatment Regimens

[00166] In one aspect, the compounds of Formula (I), (II), (III), or (IV) are used in the preparation of medicaments for the treatment of diseases or conditions described herein. In addition, a method for treating any of the diseases or conditions described herein in a subject in need of such treatment, involves administration of pharmaceutical compositions that include at least one compound of Formula (I), (II),

(III), or (IV) or a pharmaceutically acceptable salt, active metabolite, prodrug, or solvate thereof, in therapeutically effective amounts to said subject.

[00167] In certain embodiments, the compositions containing the compound of Formula (I), (II), (III), or (IV) are administered for prophylactic and/or therapeutic treatments. In certain therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest at least one of the symptoms of the disease or condition. Amounts effective for this use depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician. Therapeutically effective amounts are optionally determined by methods including, but not limited to, a dose escalation clinical trial.

[00168] In prophylactic applications, compositions containing the compounds of Formula (I), (II), (III), or (IV) are administered to a patient susceptible to or otherwise at risk of a particular disease, disorder or condition.

[00169] In certain embodiments, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (*i.e.*, a “drug holiday”).

[00170] Doses employed for adult human treatment are typically in the range of 0.01mg-5000 mg per day or from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose is conveniently presented in a single dose or in divided doses.

Combination Treatments

[00171] In certain instances, it is appropriate to administer at least one compound of Formula (I) in combination with another therapeutic agent.

[00172] In one specific embodiment, a compound of Formula (I), (II), (III), or (IV) is co-administered with a second therapeutic agent, wherein the compound of Formula (I), (II), (III), or (IV) and the second therapeutic agent modulate different aspects of the disease, disorder or condition being treated, thereby providing a greater overall benefit than administration of either therapeutic agent alone.

[00173] For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug(s) employed, on the specific drug(s) employed, on the disease or condition being treated and so forth. In additional embodiments, when co-administered with one or more other therapeutic agents, the compound provided herein is administered either simultaneously with the one or more other therapeutic agents, or sequentially.

[00174] If administration is simultaneous, the multiple therapeutic agents are, by way of example only, provided in a single, unified form, or in multiple forms.

[00175] In some embodiments, the one or more agents used in the treatment of a metabolic disorder include, but are not limited to, a statin, an insulin sensitizing drug, (such as sitagliptin, vildagliptin, saxagliptin, linagliptin, anagliptin, teneligliptin, alogliptin, gemigliptin, or dutogliptin), meglitinide, sulfonylurea, peroxisome proliferator-activated receptor (alpha-glucosidase inhibitor, amylin agonist, dipeptidyl-peptidase 4 (DPP-4) inhibitor PPAR)-gamma agonist (e.g., a thiazolidinedione (TZD) [such as

ioglitazone, rosiglitazone, rivoglitazone, or troglitazone], aleglitazar, farglitazar, muraglitazar, or tesaglitazar), a glucagon-like peptide (GLP) agonist, anti-inflammatory agent (e.g., oral corticosteroid), or a combination thereof. In some embodiments, the one or more agents used in the treatment of a metabolic disorder include, but are not limited to, a statin, HMG-CoA reductase inhibitor, fish oil, fibrate, niacin or other treatment for dyslipidemia. In some embodiments retinoic acid is also administered. In one example, nicotinamide ribonucleoside and/or nicotinamide ribonucleoside analogs are also administered.

[00176] In some embodiments, the additional therapeutic agent is a peroxisome proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a glucagon-like peptide-1 (GLP-I) analog, insulin or an insulin analog, an insulin secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a human amylin analog, a biguanide, a glucophage, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, a sulfonylurea, or any combination thereof.

[00177] In some embodiments, the additional therapeutic agent is an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, diuretic, calcium channel blocker, inhibitor of renin-angiotensin system (RAS), blood-thinning medication, a statin, a fibrate, or any combination thereof.

Methods of Inhibition

[00178] In one aspect, described herein is a method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity comprising contacting the low molecular weight protein tyrosine phosphatase (LMPTP) with a compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt or solvate thereof.

[00179] In some embodiments, the mammal has insulin resistance, metabolic syndrome, type 2 diabetes, cardiovascular disease, or combinations thereof. In some embodiments, the mammal has insulin resistance. In some embodiments, the mammal has metabolic syndrome. In some embodiments, the mammal has type 2 diabetes. In some embodiments, the mammal has cardiovascular disease. In some embodiments, the mammal has an impaired glucose tolerance. In some embodiments, the mammal is pre-diabetic. In some embodiments, the mammal is obese. In some embodiments, the mammal has a disease or condition that would benefit from inhibition of LMPTP activity. In some embodiments, the disease or condition is described herein.

Methods of Treatment

[00180] In one aspect, described herein is a method of treating a disease or condition including administering to a subject in need thereof an effective amount of a compound of Formula (I), (II), (III), or (IV).

[00181] In some embodiments, the disease or condition is type II diabetes, heart disease, coronary artery disease, hyperlipidemia, lipodystrophy, insulin resistance, rheumatic disease, atherosclerosis, myocardial infarction, stroke, high blood pressure (hypertension), obesity, elevated fasting plasma glucose, high

serum triglycerides, elevated blood cholesterol, cardiac hypertrophy, heart failure (e.g., hypertrophy-induced heart failure) or metabolic syndrome.


[00182] In an aspect is provided a method of treating a disease associated with low molecular weight protein tyrosine phosphatase (LMPTP) activity including administering to a subject in need thereof an effective amount of a compound described herein. In some embodiments, the disease is associated with aberrant low molecular weight protein tyrosine phosphatase (LMPTP) activity. For example, studies have shown that inhibition of low molecular weight protein tyrosine phosphatase (LMPTP) activity may be a target for cardiac diseases (e.g., heart failure). See, e.g., Wade et al., *J. Pathol.*, 2015, pages 1-13 (DOI: 10.1002/path.4594), which is hereby incorporated by reference in its entirety.

[00183] In some embodiments, the method includes administering a second agent (e.g. therapeutic agent). In some embodiments, the method includes administering a second agent (e.g. therapeutic agent) in a therapeutically effective amount. Examples of a second agent include therapeutic agents known in the art for the treatment of diabetes, heart disease, coronary artery disease, hyperlipidemia, lipodystrophy, insulin resistance, rheumatic disease, atherosclerosis, myocardial infarction, stroke, high blood pressure (hypertension), obesity, elevated fasting plasma glucose, high serum triglycerides, elevated blood cholesterol, cardiac hypertrophy, heart failure (e.g., hypertrophy-induced heart failure) or metabolic syndrome. Thus, in some embodiments, the method includes administering to a subject in need thereof an effective amount of a compound described herein in combination with a second therapeutic agent for the treatment of diabetes, heart disease, coronary artery disease, hyperlipidemia, lipodystrophy, insulin resistance, rheumatic disease, atherosclerosis, myocardial infarction, stroke, high blood pressure (hypertension), obesity, elevated fasting plasma glucose, high serum triglycerides, elevated blood cholesterol, cardiac hypertrophy, heart failure (e.g., hypertrophy-induced heart failure) or metabolic syndrome.

EXAMPLES

[00184] These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein. The starting materials and reagents used for the synthesis of the compounds described herein may be synthesized or can be obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Acros Organics, Fluka, and Fischer Scientific.

Example 1: Synthesis of N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide

**Step 1:**

[00185] To a solution of Na (1.035 g, 45 mmol) in EtOH (30 mL) until the mixture was clear. Then diethyl malonate (5.76 g, 36 mmol), EtOH (10 mL) and methyl 4-aminonicotinate (5 g, 30 mmol) in EtONa (1.5 M, 30 mL). Then the mixture was stirred at 90 °C for overnight. Then the solvent was removed under reduce pressure in vacuum, the mixture was dissolved in 50 mL H₂O and adjusted to pH= 5-6 with 1 M HCl. Extracted with EA (100 mL), filtered and the residue was desired compound which used to next step directly. A white solid (5 g), yield: 65%.

Step 2:

[00186] To a solution of Ethyl 2,4-dihydroxy-1,6-naphthyridine-3-carboxylate (4.7 g, 20 mmol) in 27% HCl (100 mL). Then the mixture was stirred at 90°C for overnight. Then the mixture was adjusted to pH= 5-6 with 30% NaOH under ice-water bath. Filtered and the residue was desired compound which used to next step directly. A white solid (2.5 g), yield: 69.4%. LC-MS (ESI): 163 (M + 1)⁺.

Step 3:

[00187] A mixture of 1,6-naphthyridine-2,4-diol (810 mg, 5 mmol) and in POCl₃ (20 mL) was stirred at 110°C for 5 hrs. Then the solvent was removed under reduce pressure in vacuum, the mixture was dissolved in 100 mL DCM and adjusted to pH= 8-9 with NaHCO₃ saturated aqueous solution. Extracted with DCM (100 mL), washed with brine, dried over Na₂SO₄. Evaporation of the organic phase and the residue was purified by flash column to afford a white solid (700 mg). Yield: 70%; LC-MS (ESI): 198, 200 (M + 1)⁺.

Step 4:


[00188] A mixture of 2,4-dichloro-1,6-naphthyridine (500 mg, 2.52 mmol) and 3-(piperidin-1-yl)propan-1-amine (358 mg, 2.52 mmol) in CH₃CN (30 mL) and was stirred at 70°C for 2hours. Filtered and the mixture was evaporated and the residue was purified by Pre-TLC to afford the desired compound as a white solid (300 mg), yield: 39%; LC-MS (ESI): 305 (M + 1)⁺.

Step 5:

[00189] The mixture of 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine (152 mg, 0.5 mmol), N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (152 mg, 0.5 mmol), Pd(PPh₃)₄ (58 mg, 0.05 mmol) and Na₂CO₃ (106 mg, 1 mmol) in Dioxane/H₂O (3 mL/0.3 mL) was stirred

at for 120 °C 1 hour by MW,. The mixture was diluted with DCM, washed with water (20 mL ×3) and brine (20 mL ×1), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by Prep-TLC to afford N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide (28.5 mg, 40%) as a white solid. HPLC/UV purity = 96%; LC-MS (ESI): 446.2 (M + 1)⁺; ¹H NMR (CD₃OD) δ 9.57 (s, 1H), 8.61 (d, *J* = 6.1 Hz, 1H), 8.15 - 8.24 (m, 2H), 7.81 (d, *J* = 6.1 Hz, 1H), 7.54 - 7.61 (m, 2H), 7.15 (s, 1H), 3.69 (t, *J* = 6.7 Hz, 2H), 3.55 - 3.66 (m, 3H), 3.50 (m, 1H), 3.37 (d, *J* = 6.7 Hz, 2H), 3.26 - 3.32 (m, 2H), 3.15 (m, 1H), 3.05 (m, 1H), 2.23 - 2.36 (m, 2H), 1.90 (m, 6H), 1.31 (t, *J* = 6.9 Hz, 3H), 1.19 (t, *J* = 6.9 Hz, 3H).

Example 2: Synthesis of *N*-(2-(dimethylamino)ethyl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxamide



Step 1:


[00190] The mixture of Ethyl 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxylate (350 mg, 0.74 mmol) and LiOH·H₂O (94 mg, 2.23 mmol) in THF/H₂O (12 mL/3 mL) was stirred at room temperature overnight. The mixture was acidified with HCl solution (2 M) to pH = 2, then concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 444.2 (M + 1)⁺.

Step 2:

[00191] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxylic acid (100 mg, 0.24 mmol), *N,N*-dimethylethane-1,2-diamine (132 mg, 0.36 mmol), HATU (137 mg, 0.36 mmol) and DIPEA (65 mg, 0.48 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried


over Na_2SO_4 , filtered and concentrated. The residue was purified by the Prep-HPLC to afford *N*-(2-(dimethylamino)ethyl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxamide as a white solid (20 mg, 16% yield). LC-MS (ESI): 514.3 ($M + 1$)⁺; ¹H NMR (CD_3OD) δ 9.70 (br, s, 1H), 8.86 (d, $J = 6.0$ Hz, 1H), 8.41 (d, $J = 1.2$ Hz, 1H), 7.90 - 7.96 (m, 2H), 7.79 (d, $J = 9.2$ Hz, 1H), 7.34 (s, 1H), 7.26 (s, 1H), 4.15 (s, 3H), 3.78 - 3.87 (m, 4H), 3.57 (d, $J = 12$ Hz, 3H), 3.42 (t, $J = 11.6$ Hz, 2H), 3.02 (s, 6H), 2.92 - 2.96 (m, 3H), 2.27 - 2.34 (m, 2H), 1.76 - 1.86 (m, 4H), 1.50 - 1.61 (m, 2H).

Example 3: Synthesis of 1-methyl-*N*-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxamide




[00192] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxylic acid (100 mg, 0.24 mmol), 1-methylpiperidin-4-amine (72 mg, 0.5 mmol), HATU (114 mg, 0.30 mmol) and DIPEA (96 mg, 0.75 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the Prep-HPLC to afford 1-methyl-*N*-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxamide as a white solid (30 mg, 12% yield). LC-MS (ESI): 540.3 ($M + 1$)⁺; ¹H NMR (CD_3OD) δ 9.70 (br, s, 1H), 8.87 (d, $J = 5.2$ Hz, 1H), 8.40 (d, $J = 1.6$ Hz, 1H), 7.90 - 7.96 (m, 2H), 7.78 (d, $J = 8.8$ Hz, 1H), 7.26 (d, $J = 11.2$ Hz, 2H), 4.15 - 4.23 (m, 1H), 4.10 (s, 3H), 3.84 (t, $J = 6.8$ Hz, 2H), 3.57 (t, $J = 13.2$ Hz, 4H), 3.18 - 3.25 (m, 3H), 2.91 - 2.99 (m, 3H), 2.27 - 2.33 (m, 4H), 1.94 - 1.97 (m, 5H), 1.76 - 1.83 (m, 4H), 1.50 - 1.60 (m, 2H).

Example 4: Synthesis of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-*N*-(piperidin-4-yl)-1*H*-indole-2-carboxamide



[00193] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (100 mg, 0.24 mmol), *tert*-butyl 4-aminopiperidine-1-carboxylate (100 mg, 0.5 mmol), HATU (114 mg, 0.30 mmol) and DIPEA (96 mg, 0.75 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was added TFA (1 mL) and DCM (10 mL) and stirred at room temperature overnight. The mixture was concentrated and purified by the Prep-HPLC to afford 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-*N*-(piperidin-4-yl)-1H-indole-2-carboxamide as a white solid (30 mg, 24% yield). LC-MS (ESI): 526.3 ($M + 1$)⁺; ¹H NMR (CD₃OD) δ 9.72 (br, s, 1H), 8.84 (d, $J = 6.0$ Hz, 1H), 8.40 (d, $J = 1.6$ Hz, 1H), 7.92 - 7.95 (m, 2H), 7.75 (d, $J = 8.8$ Hz, 1H), 7.25 (d, $J = 15.6$ Hz, 2H), 4.17 - 4.24 (m, 1H), 4.09 (s, 3H), 3.84 (t, $J = 13.6$ Hz, 2H), 3.49 - 3.60 (m, 5H), 3.32 - 3.34 (m, 2H), 3.16 - 3.21 (m, 3H), 2.93 - 2.99 (m, 2H), 2.22 - 2.36 (m, 5H), 1.81 - 1.96 (m, 5H).

Example 5: Synthesis of ethyl 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate



Step 1:

[00194] To the mixture of ethyl 5-bromo-1H-indole-2-carboxylate (8.04 g, 30 mmol) and K_2CO_3 (11.5 g, 90 mmol) in DMF (50 mL) was added MeI (2.43 mL, 39 mmol), then the mixture was heated to 60 °C overnight. After cooling to room temperature, water (500 mL) was added. The mixture was extracted with EA three times. The combined organic layers were washed with water ($\times 3$) and brine ($\times 1$), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 10% EA in PE) to afford ethyl 5-bromo-1-methyl-1H-indole-2-carboxylate as a white solid (7.5 g, 88% yield). LC-MS (ESI): 282.0 ($M + 1$)⁺.


Step 2:

[00195] The mixture of ethyl 5-bromo-1-methyl-1H-indole-2-carboxylate (7.5 g, 26.7 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (7.46 g, 29.4 mmol), $Pd_2(dba)_3$ (0.49 g, 0.53 mmol), PCy_3 (0.60 g, 2.14 mmol) and KOAc (3.92 g, 40 mmol) in dioxane (60 mL) protected under N_2 atmosphere was heated to 110 °C overnight. After cooling to room temperature, the mixture was concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 10% EA in PE) to afford ethyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate as a yellow solid (7.8 g, 89% yield). LC-MS (ESI): 330.2 ($M + 1$)⁺.

Step 3:

[00196] The mixture of 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine (1.5 g, 5 mmol, the mixture of two isomers) and ethyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate (1.8 g, 5.5 mmol), Na_2CO_3 (1.6 g, 15 mmol) and $Pd(PPh_3)_4$ (0.15 g, 0.13 mmol) in dioxane/ H_2O (40 mL/8 mL) protected by N_2 atmosphere was heated to 100 °C overnight. After cooling to room temperature, water (60 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water ($\times 3$) and brine ($\times 1$), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 10% MeOH in DCM) to afford ethyl 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate as a white solid (0.35 g, 30% yield). LC-MS (ESI): 472.3 ($M + 1$)⁺; ^1H NMR (CD_3OD) δ 9.41 (s, 1H), 8.48 (d, $J = 6.0$ Hz, 1H), 8.28 (d, $J = 1.2$ Hz, 1H), 7.97 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.68 (d, $J = 6.0$ Hz, 1H), 7.51 (d, $J = 8.8$ Hz, 1H), 7.29 (s, 1H), 6.97 (s, 1H), 4.31 (q, $J = 7.2$ Hz, 2H), 4.02 (s, 3H), 3.60 - 3.63 (m, 3H), 3.15 - 3.25 (m, 6H), 2.21 - 2.29 (m, 2H), 1.84 - 1.88 (m, 5H), 1.56 (t, $J = 7.0$ Hz, 3H).

Example 6: Synthesis of 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid

**Step 1:**

[00197] To a solution of 4-bromobenzoic acid (2.21 g, 11 mmol) in SOCl_2 and MeOH (50 mL) and was stirred at 80°C for 2 hours. Evaporated the solvent to give desired compound which was used to next step directly. Isolated weight: 2.3 g, yield: 99%, color: white, state: solid.

Step 2:

[00198] The mixture of methyl 4-bromobenzoate (2.15 g, 10 mmol), 4,4,4',4'',5,5,5',5''-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.54 g, 10 mmol), Pd(dppf)Cl_2 (816 mg, 1 mmol) and KOAc (1.96 g, 20 mmol) in Dioxane (150 mL) was stirred at 90°C for 6 hours. The mixture was diluted with DCM (200 mL), washed with water (50 mL $\times$ 3) and brine (30 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The crude product was purified by silica gel column chromatography to afford the desired compound. Isolated weight: 2.01 g, yield: 77 % as a white solid.

Step 3:

[00199] Diethyl malonate (6.3 g, 39.5 mmol) and ethyl 4-aminonicotinate (5 g, 30 mmol) were added to fresh EtONa (1.8 M, 73 mL, 131.6 mmol) solution. Then the mixture was stirred at 90°C for overnight. Then the solvent was removed under reduce pressure in vacuum, the mixture was dissolved in 50 mL H_2O and adjusted to pH= 5-6 with 1 M HCl. Extracted with EA (100 mL), filtered and the residue was used directly in the next step. A white solid (4.2 g), yield: 54.6%, as a white solid.

Step 4:

[00200] To a solution of Ethyl 2,4-dihydroxy-1,6-naphthyridine-3-carboxylate (4.2 g, 17.9 mmol) in 27% HCl (50 mL). Then the mixture was stirred at 90°C for overnight. Then the mixture was adjusted to pH= 5-6 with 30% NaOH under ice-water bath. Filtered and the residue of the desired compound was used to next step directly. A white solid (2.6 g), yield: 89.6%, color: white, state: solid. LC-MS (ESI): 163 (M + 1)⁺.

Step 5:

[00201] A mixture of 1,6-naphthyridine-2,4-diol (3.24 g, 20 mmol) and in POCl₃ (50 mL) was stirred at 110°C for overnight. Then the solvent was removed under reduce pressure in vacuum, the mixture was dissolved in 100 mL DCM and adjusted to pH= 5-6 with NaHCO₃ saturated aqueous solution. Extracted with EA (100 mL), washed with brine, dried over Na₂SO₄. Evaporation of the organic phase provides a yellow solid which was purified by flash column chromatography to afford the desired compound. Isolated weight: 2.8 g; Yield: 70%; Color: white; State: solid. LC-MS (ESI): 198, 200(M + 1)⁺.

Step 6:

[00202] A mixture of 2,4-dichloro-1,6-naphthyridine (1.0 g, 5 mmol), K₂CO₃ (1.38 g, 10 mmol) and 3-(piperidin-1-yl)propan-1-amine (0.71 g, 5 mmol) in CH₃CN (50 mL) and was stirred at 80°C for overnight. 100 mL H₂O was added and extracted with EA (200 mL) washed with brine, dried over Na₂SO₄. Evaporated the solvent and the residue to afford the desired compound which used to next step directly. Isolated weight: 1.22 g, yield: 80%, color: white, state: solid. LC-MS (ESI): 305 (M + 1)⁺.


Step 7:

[00203] The mixture of 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,8-naphthyridin-4-amine (1.52 g, 5 mmol), methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.305 g, 0.5 mmol), Pd(PPh₃)₄ (577 mg, 0.5 mmol) and NaHCO₃ saturated aqueous solution (3 ml) in dioxane (30 mL) was stirred at 100°C for overnight. The mixture was diluted with EA, washed with water (30 mL ×3) and brine (20 mL ×1), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by silica gel column chromatography to afford the desired compound (1.603 g, 80%) as a white solid. LC-MS (ESI): 405 (M + 1)⁺.

Step 8:

[00204] To a solution of methyl 4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzoate (162 mg, 0.4 mmol) and LiOH.H₂O (41 mg, 1 mmol) in CH₃OH/H₂O (30 mL/3 mL). Then the mixture was stirred at 75°C for 2 hours. 1 mL 1M HCl aq. was added and the mixture was adjusted to pH = 5 and the residue was purified by Prep-HPLC to afford the desired compound. Isolated weight: 50 mg; Yield: 32%; Color: white; State: solid. LC-MS (ESI): 391 (M + 1)⁺. ¹H NMR (DMSO-*d*₆) δ 9.96 (br. s., 1H), 9.06 (br. s., 1H), 8.24 - 8.34 (m, 2H), 8.06 - 8.15 (m, 2H), 7.98 (m, 1H), 7.29 (s, 1H), 3.84 (t, J = 6.9 Hz, 2H), 3.58 (d, J = 12.2 Hz, 2H), 3.27 - 3.30 (m, 2H), 2.88 - 2.99 (m, 2H), 2.21 - 2.36 (m, 2H), 1.95 (d, J = 14.6 Hz, 2H), 1.69 - 1.89 (m, 3H), 1.40 - 1.59 (m, 1H).

Example 7: Synthesis of 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzamide




Step 1:

[00205] To a solution of 4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzoic acid (117 mg, 0.3 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (60 mg, 0.3 mmol), HATU (137 mg, 0.36 mmol) and DIPEA (129 mg, 1 mmol) in DMF (5 mL) and was stirred at r.t. for 2 hours. 100 mL H₂O was added and extracted with EA (100 mL) wash with brine, dried over Na₂SO₄. Evaporated the solvent and the residue to give desired compound which was purified by TLC to afford the desired compound. Isolated weight: 123 mg, yield: 71.5%, color: white, state: solid. LC-MS (ESI): 573 (M + 1)⁺.

Step 2:

[00206] To a solution of tert-butyl 4-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamido)piperidine-1-carboxylate (114 mg, 0.2 mmol) in TFA/DCM (1 mL/10 mL) and was stirred at r.t. for 2 hours. Evaporated the solvent and the residue to give desired compound which was purified by prep-HPLC to afford the desired compound. Isolated weight: 48 mg, yield: 50%, color: yellow, state: solid. LC-MS (ESI): 473 (M + 1)⁺. ¹H NMR (CD₃OD) δ 9.83 (br. s., 1H), 8.93 (br. s., 1H), 8.14 (s, 4H), 7.96 (d, *J* = 4.6 Hz, 1H), 7.30 (s, 1H), 4.25 (tt, *J* = 11.0, 4.1 Hz, 1H), 3.86 (t, *J* = 6.9 Hz, 2H), 3.47 - 3.66 (m, 4H), 3.33 - 3.36 (m, 2H), 3.20 (td, *J* = 12.8, 3.0 Hz, 2H), 2.88 - 3.03 (m, 2H), 2.20 - 2.39 (m, 4H), 1.71 - 2.01 (m, 7H), 1.54 (qd, *J* = 12.6, 3.9 Hz, 1H).

Example 8: Synthesis of 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)benzamide




[00207] To a solution of 4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzoic acid (78 mg, 0.2 mmol), 2-(pyridin-4-yl)ethanamine (24.4 mg, 0.2 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5 mL) and was stirred at r.t. for 2 hours. 100 mL H₂O was added and

extracted with EA (100 mL) wash with brine, dried over Na₂SO₄. Evaporated the solvent and the residue to give desired compound which was purified by TLC to afford the desired compound. Isolated weight: 40 mg, yield: 40%, color: yellow, state: solid.


[00208] LC-MS (ESI): 495 (M + 1)⁺. ¹H NMR (CD₃OD) δ 9.48 (s, 1H), 8.53 (d, *J* = 6.1 Hz, 1H), 8.44 (d, *J* = 5.8 Hz, 2H), 8.09 - 8.17 (m, *J* = 8.5 Hz, 2H), 7.87 - 7.94 (m, *J* = 8.2 Hz, 2H), 7.73 (d, *J* = 5.8 Hz, 1H), 7.38 (d, *J* = 6.1 Hz, 2H), 7.05 (s, 1H), 3.69 (t, *J* = 7.2 Hz, 2H), 3.60 (t, *J* = 6.7 Hz, 2H), 3.12 - 3.31 (m, 6H), 3.01 (t, *J* = 7.0 Hz, 2H), 2.18 - 2.30 (m, 2H), 1.79 - 1.92 (m, 4H), 1.66 (m, 2H).

Example 9: Synthesis of N-(2-(dimethylamino)ethyl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide



[00209] To a solution of 4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzoic acid (78 mg, 0.2 mmol), N1,N1-dimethylethane-1,2-diamine (17 mg, 0.2 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5 mL) and was stirred at r.t. for 2 hours. 100 mL H₂O was added and extracted with EA (100 mL) wash with brine, dried over Na₂SO₄. Evaporated the solvent and the residue to give desired compound which was purified by Prep-TLC to afford the desired compound. Isolated weight: 40 mg, yield: 43%, color: white, state: solid. LC-MS (ESI): 461 (M + 1)⁺. ¹H NMR (CD₃OD) δ 9.58 (s, 1H), 8.59 (d, *J* = 6.0 Hz, 1H), 8.22 (d, *J* = 8.8 Hz, 2H), 8.07 (d, *J* = 8.4 Hz, 2H), 7.82 (d, *J* = 6.0 Hz, 1H), 7.15 (s, 1H), 3.74 - 3.66 (m, 4H), 3.20-3.15 (m, 5H), 3.07 - 3.04 (m, 2H), 2.70 (s, 6H), 2.25 - 2.29 (m, 2H), 1.88-1.86 (m, 4H), 1.69 - 1.65 (m, 2H), 1.30 (s, 1H).


Example 10: Synthesis of 1-methyl-N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



[00210] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (88 mg, 0.2 mmol), 3-(4-methylpiperazin-1-yl)propan-1-amine (47 mg, 0.3


mmol), HATU (91 mg, 0.24 mmol) and DIPEA (78 mg, 0.6 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford 1-methyl-*N*-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxamide as a white solid (20 mg, 12% yield). LC-MS (ESI): 538.4 ($M + 1$)⁺; ¹H NMR (CD₃OD) δ 9.83 (br, s, 1H), 8.97 (br, s, 1H), 8.38 (d, J = 1.6 Hz, 1H), 7.91 (dd, J = 8.8, 1.6 Hz, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.24 (d, J = 2.4 Hz, 2H), 4.09 (s, 3H), 3.82 (t, J = 6.8 Hz, 2H), 3.56 (d, J = 12.4 Hz, 2H), 3.46 (t, J = 6.8 Hz, 2H), 3.32 - 3.39 (m, 6H), 2.86 - 3.13 (m, 8H), 2.83 (s, 3H), 2.28 - 2.35 (m, 2H), 1.93 - 2.00 (m, 4H), 1.74 - 1.87 (m, 3H), 1.50 - 1.56 (m, 1H).

Example 11: Synthesis of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-*N*-(2-(pyridin-4-yl)ethyl)-1*H*-indole-2-carboxamide




[00211] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1*H*-indole-2-carboxylic acid (88 mg, 0.2 mmol), 2-(pyridin-4-yl)ethanamine (37 mg, 0.3 mmol), HATU (91 mg, 0.24 mmol) and DIPEA (78 mg, 0.6 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-*N*-(2-(pyridin-4-yl)ethyl)-1*H*-indole-2-carboxamide as a white solid (20 mg, 20% yield). LC-MS (ESI): 548.3 ($M + 1$)⁺; ¹H NMR (CD₃OD) δ 9.79 (br, s, 1H), 8.93 (br, s, 3H), 8.38 (d, J = 1.6 Hz, 1H), 8.08 (br, s, 2H), 7.91 (dd, J = 8.8, 1.6 Hz, 2H), 7.74 (d, J = 8.8 Hz, 1H), 7.24 (s, 1H), 7.19 (s, 1H), 4.05 (s, 3H), 3.79 - 3.87 (m, 4H), 3.56 (d, J = 12 Hz, 2H), 3.24 - 3.27 (m, 4H), 2.92 (t, J = 12.2 Hz, 2H), 2.28 - 2.35 (m, 2H), 1.94 - 1.97 (m, 2H), 1.74 - 1.86 (m, 3H), 1.50 - 1.57 (m, 1H).

Example 12: Synthesis of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-*N*-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indole-2-carboxamide



[00212] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (65 mg, 0.15 mmol), tetrahydro-2H-pyran-4-amine (20 mg, 0.19 mmol), HATU (87 mg, 0.26 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-2-carboxamide as a white solid (15 mg, 19% yield). LC-MS (ESI): 527.3 (M + 1)⁺; ¹H NMR (CD₃OD) δ 9.47 (br, s, 1H), 8.58 (br, s, 1H), 8.34 (s, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.79 (s, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.17 (s, 1H), 7.08 (s, 1H), 4.09 - 4.17 (m, 1H), 4.05 (s, 3H), 4.00 (d, J = 8.8 Hz, 2H), 3.52 - 3.62 (m, 4H), 2.95 - 3.11 (m, 6H), 2.11 - 2.19 (m, 2H), 1.92 - 1.96 (m, 2H), 1.70 - 1.79 (m, 6H), 1.60 (s, 2H).


Example 13: Synthesis of N-(1,1-dioxotetrahydro-2H-thiopyran-4-yl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



[00213] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (65 mg, 0.15 mmol), 4-aminotetrahydro-2H-thiopyran 1,1-dioxide (28 mg, 0.19 mmol), HATU (87 mg, 0.26 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford N-(1,1-dioxotetrahydro-2H-thiopyran-4-yl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide as a white solid (19 mg, 22% yield). LC-MS (ESI): 575.3 (M + 1)⁺; ¹H NMR (CD₃OD) δ 8.89 (br, s, 1H), 8.03 (br, s, 1H), 7.03 - 7.05 (m, 2H), 6.87 (d, J = 8.8 Hz, 1H), 6.36 (d, J = 6.8 Hz, 2H), 3.34 - 3.40 (m, 1H), 3.19 (s, 3H), 2.94 (t, J = 6.8 Hz, 2H), 2.67 (d, J = 12.8 Hz, 2H), 2.46

- 2.49 (m, 4H), 2.23 (d, $J = 11.6$ Hz, 3H), 2.06 (t, $J = 12.8$ Hz, 2H), 1.37 - 1.45 (m, 7H), 1.04 - 1.15 (m, 2H), 0.91 - 0.94 (m, 3H).

Example 14: Synthesis of N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-3-(trifluoromethyl)benzamide



Step 1:

[00214] To a mixture of 4-bromo-3-(trifluoromethyl)benzoic acid (1 g, 3.73mmol) and HATU(1.7 g, 4.47mmol) in DCM (20 mL) was added diethylamine (386 μ l, 3.73mmol) and DIPEA (2 mL, 11.2mmol), then the mixture was stirred at rt overnight. The reaction mixture was poured into water (20 mL), extracted with DCM (10 mL x3), the combined organic layers was washed with water and brine, dried over Na_2SO_4 , the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Combiflash (silica gel, eluting with 20% EA in PE) to afford 4-bromo-N,N-diethyl-3-(trifluoromethyl)benzamide (1.2 g, 99%) as a colorless oil. HPLC/UV purity: 92%; LC-MS (ESI): 324 ($M + 1$)⁺.

Step 2:

[00215] The mixture of 4-bromo-N,N-diethyl-3-(trifluoromethyl)benzamide (1.2 g, 3.7 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)(1.13 g, 4.4 mmol), $\text{Pd}(\text{dppf})\text{Cl}_2$ (302 mg, 0.37mmol) and KOAc (710 mg, 16.2 mmol) in 1,4-Dioxane (20 mL) was heated to 100°C and held for 18hrs under N_2 atmosphere. The reaction mixture was cooled to rt and filtered by a pad of celite, the resulting filtrate was concentrated under the reduced pressure to get the residue which was purified with Combiflash ((silica gel, eluting with 25% EA in PE) to afford N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzamide (1.2 g, 87%) as an oil. HPLC/UV purity: 80%; LC-MS (ESI): 372 ($M + 1$)⁺.

Step 3:


[00216] The mixture of 2,4-dichloro-1,6-naphthyridine (1 g, 5 mmol), 3-(piperidin-1-yl)propan-1-amine (710 mg, 5 mmol) and K_2CO_3 (1.38 g, 10 mmol) in CH_3CN (20 mL) was heated to 80°C until TLC

analysis indicated the total consumption of the starting material. The reaction mixture was filtered and the filtrate was concentrated to get the residue which was purified with Combiflash (silica gel, eluting with 10% methanol in DCM) to afford the mixture of 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine and 4-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-2-amine, the mixture was impossible to separate, so it was used to the next step without further purification.

Step 4:

[00217] A 20-mL microwave vial was charged with 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine (200 mg, 0.655 mmol), N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzamide (365 mg, 0.983 mmol), Pd(PPh₃)₄ (75 mg, 0.0655 mmol) and Na₂CO₃ (138 mg, 1.31 mmol) dissolved 1,4-dioxane (3 mL) and H₂O (0.5 mL). A stir bar is added, the vial is sealed, and the resulting brown solution is heated for 2 h in a Biotage Initiator Eight Microwave Reactor held at a constant temperature of 120°C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The adsorbed material was loaded onto a column and purified using Prep-TLC (silica gel, eluting with 10% methanol in DCM) to afford N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-3-(trifluoromethyl)benzamide (40 mg, 12%) as a yellow solid HPLC/UV purity: 94%; LC-MS (ESI): 514 (M + 1)⁺. ¹H NMR (DMSO-*d*₆) δ 9.55 (s, 1H), 8.62 (d, *J* = 5.8 Hz, 1H), 7.86 (s, 1H), 7.75 - 7.81 (m, 1H), 7.66 - 7.73 (m, 2H), 6.80 (s, 1H), 3.49 - 3.68 (m, 4H), 3.33 (d, *J* = 1.8 Hz, 2H), 3.03 - 3.18 (m, 4H), 2.10 - 2.22 (m, 2H), 1.82 (m, 4H), 1.65 (m, 2H), 1.29 (d, *J* = 5.2 Hz, 5H), 1.11 - 1.22 (m, 3H).

Example 15: Synthesis of 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-3-(trifluoromethyl)benzamide



Step 1:


[00218] A 20-mL microwave vial was charged with 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine (200 mg, 0.655 mmol), tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)benzamido)piperidine-1-carboxylate (488 mg, 0.983 mmol), Pd(PPh₃)₄ (75 mg, 0.0655 mmol) and Na₂CO₃ (138 mg, 1.31 mmol) dissolved 1,4-dioxane (3 mL) and H₂O (0.5 mL). A stir bar is added, the vial is sealed, and the resulting brown solution is heated for 2 h in a Biotage Initiator Eight Microwave Reactor held at a constant temperature of 120 °C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The adsorbed material was loaded onto a column and purified using Prep-TLC (silica gel, eluting with 10% methanol in DCM) to afford N,N-diethyl-4-(4-

((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-3-(trifluoromethyl)benzamide (40 mg, 11%) as a yellow solid HPLC/UV purity: 94%; LC-MS (ESI): 641 (M + 1)⁺.

Step 2:


[00219] To a solution of N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-3-(trifluoromethyl)benzamide (35 mg, 0.057 mmol) in DCM (1 mL) was added TFA (1 mL), then the reaction mixture was stirred at rt for 2hrs. The solvent was removed under the reduced pressure to get the crude product which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm*250 mm, 10 um, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-3-(trifluoromethyl)benzamide (30 mg, 90%) as a TFA salt. HPLC/UV purity: 96%; LC-MS (ESI): 541 (M + 1)⁺; ¹H NMR (CD₃OD) δ 9.80 (s, 1H), 8.89 (d, *J* = 6.1 Hz, 1H), 8.46 (s, 1H), 8.34 (d, *J* = 7.9 Hz, 1H), 7.89 (d, *J* = 7.9 Hz, 1H), 7.77 (d, *J* = 6.1 Hz, 1H), 7.15 (s, 1H), 4.15 - 4.32 (m, 1H), 3.73 (t, *J* = 7.0 Hz, 2H), 3.53 (t, *J* = 14.0 Hz, 4H), 3.12 - 3.27 (m, 4H), 2.93 (t, *J* = 12.4 Hz, 2H), 2.18 - 2.32 (m, 4H), 1.90 - 1.98 (m, 4H), 1.74 - 1.90 (m, 3H), 1.50 (d, *J* = 12.2 Hz, 1H).

Example 16: Synthesis of 1-methyl-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-2-carboxamide



[00220] The mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (35 mg, 0.08mmol), tetrahydro-2H-thiopyran-4-amine (14 mg, 0.12mmol), HATU (36 mg, 0.09 mmol) and DIPEA (31 mg, 0.24mmol) in DMF (1mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford 1-methyl-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-2-carboxamide as a yellow oil (14.7 mg, 35% yield). LC-MS (ESI): 543.2 (M + 1)⁺; ¹H NMR (CD₃OD) δ 9.71 (s, 1H), 8.85 (d, *J* = 5.8 Hz, 1H), 8.39 (d, *J* = 1.6 Hz, 1H), 7.87 - 7.97 (m, 2H), 7.76 (d, *J* = 8.9 Hz, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 4.07 (s, 3H), 3.78 - 3.97 (m, 3H), 3.59 (d, *J* = 12.2 Hz, 2H), 3.32 - 3.36 (m, 2H), 2.96 (t, *J* = 12.5 Hz, 2H), 2.78 - 2.89 (m, 2H), 2.63 - 2.74 (m, 2H), 2.20 - 2.37 (m, 4H), 1.95 (d, *J* = 14.3 Hz, 2H), 1.69 - 1.87 (m, 5H), 1.51 (d, *J* = 12.2 Hz, 1H).

Example 17: Synthesis of 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide

**Step 1:**

[00221] The mixture of 2,4-dichloro-1,6-naphthyridine (1 g, 5.07 mmol), propan-1-amine (299 mg, 5.07 mmol) and K_2CO_3 (1.4 g, 10.14 mmol) in acetonitrile (30 mL) was heated to 90 °C overnight. After cooling to room temperature, water (40 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 1) and brine (15 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to EA) to afford 2-chloro-N-propyl-1,6-naphthyridin-4-amine as a yellow solid (0.33 g, 30% yield). LC-MS (ESI): 222.0 ($M + 1$)⁺.

Step 2:

[00222] The mixture of 2-chloro-N-propyl-1,6-naphthyridin-4-amine (300 mg, 1.35 mmol), and ethyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate (534 mg, 1.62 mmol), Na_2CO_3 (286 mg, 2.7 mmol) and $Pd(PPh_3)_4$ (312 mg, 0.27 mmol) in dioxane/ H_2O (10 mL/2 mL) protected by N_2 atmosphere was heated to 100 °C overnight. After cooling to room temperature, water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (15 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 10% MeOH in DCM) to afford ethyl 1-methyl-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate as a yellow solid (322 mg, 61% yield). LC-MS (ESI): 389.1 ($M + 1$)⁺; ^1H NMR ($DMSO-d_6$) δ 9.60 (s, 1H), 8.51 - 8.62 (m, 2H), 8.28 (dd, $J = 8.9, 1.6$ Hz, 1H), 7.79 (br. s., 1H), 7.73 (d, $J = 8.9$ Hz, 1H), 7.67 (d, $J = 5.6$ Hz, 1H), 7.43 (s, 1H), 7.13 (s, 1H), 4.37 (m, $J = 7.0$ Hz, 2H), 4.01 - 4.13 (m, 3H), 3.39 - 3.50 (m, 2H), 1.70 - 1.85 (m, 2H), 1.37 (t, $J = 7.1$ Hz, 3H), 1.05 (t, $J = 7.4$ Hz, 3H).

Step 3:


[00223] The mixture of Ethyl 1-methyl-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (322 mg, 0.83 mmol) and $LiOH \cdot H_2O$ (348 mg, 8.3 mmol) in MeOH/ H_2O (15 mL/3 mL) was stirred at room temperature overnight. The mixture was acidified with HCl aqueous solution (2 M) to pH

= 2, then concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 361.1 ($M + 1$)⁺.

Step 4:

[00224] The mixture of 1-methyl-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (100 mg, 0.28 mmol), 1-methylpiperidin-4-amine (0.05 ml, 0.41 mmol), HATU (128 mg, 0.34 mmol) and DIPEA (0.15 ml, 0.84 mmol) in DMF (2 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide as a yellow solid (8 mg, 6% yield). LC-MS (ESI): 457.2 ($M + 1$)⁺; ¹H NMR (CD₃OD) δ 9.72 (s, 1H), 8.84 (d, J = 5.8 Hz, 1H), 8.34 - 8.40 (d, J = 1.6 Hz, 1H), 7.87 - 7.95 (m, 2H), 7.76 (d, J = 8.9 Hz, 1H), 7.29 (s, 1H), 7.19 (s, 1H), 4.19 (s, 1H), 4.09 (s, 3H), 3.71 (t, J = 7.3 Hz, 2H), 3.62 (d, J = 12.5 Hz, 2H), 3.11 - 3.26 (m, 2H), 2.91 (s, 3H), 2.28 (d, J = 14.3 Hz, 2H), 1.96 - 2.06 (m, 2H), 1.84 - 1.94 (m, 2H), 1.12 (t, J = 7.5 Hz, 3H).

Example 18: Synthesis of 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide



Step 1:

[00225] The mixture of 2,4-dichloro-1,6-naphthyridine (1 g, 5.0 mmol), methanamine in THF (2.5 ml, 5.0 mmol) and K₂CO₃ (1.38 g, 10.0 mmol) in acetonitrile (30 ml) was heated to 90 °C overnight. After cooling to room temperature, water (40 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 1) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to EA) to afford 2-chloro-N-methyl-1,6-naphthyridin-4-amine as a yellow solid (0.16 g, 17% yield). LC-MS (ESI): 194.0 ($M + 1$)⁺.

Step 2:

[00226] The mixture of 2-chloro-N-methyl-1,6-naphthyridin-4-amine (160 mg, 0.83 mmol, and ethyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate (286 mg, 0.87 mmol), Na₂CO₃ (175 mg, 1.66 mmol) and Pd(PPh₃)₄ (191 mg, 0.16 mmol) in dioxane/H₂O (10 mL/2 mL) protected by N₂ atmosphere was heated to 100 °C overnight. After cooling to room temperature, water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 10% MeOH in DCM) to afford ethyl 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate as a yellow solid (100 mg, 33% yield). LC-MS (ESI): 361.1(M + 1)⁺.


Step 3:

[00227] The mixture of ethyl 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (100 mg, 0.27 mmol) and LiOH·H₂O (116 mg, 2.7 mmol) in MeOH/H₂O (5 mL/1 mL) was stirred at room temperature overnight. The mixture was acidified with HCl solution (2 M) to pH = 2, then concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 333.1 (M + 1)⁺.

Step 4:

[00228] The mixture of 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (92 mg, 0.28 mmol), 1-methylpiperidin-4-amine (0.05 ml, 0.42 mmol), HATU (128 mg, 0.34 mmol) and DIPEA (0.15 ml, 0.87 mmol) in DMF (2 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide as a yellow oil (2.6 mg, 2% yield). LC-MS (ESI): 429.2 (M + 1)⁺; ¹H NMR (CD₃OD) δ 9.44 (s, 1H), 8.63 (d, *J* = 6.1 Hz, 1H), 8.38 (d, *J* = 1.6 Hz, 1H), 7.94 - 8.02 (m, 1H), 7.80 (d, *J* = 5.8 Hz, 1H), 7.66 (d, *J* = 8.9 Hz, 1H), 7.24 (s, 1H), 7.03 (s, 1H), 4.15 (t, *J* = 10.8 Hz, 1H), 4.06 (s, 3H), 3.47 (d, *J* = 12.5 Hz, 2H), 3.19 (s, 3H), 2.98 - 3.13 (m, 2H), 2.81 (s, 3H), 2.22 (d, *J* = 11.3 Hz, 2H), 1.89 - 2.01 (m, 2H).

Example 19: Synthesis of 5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide

**Step 1:**

[00229] The mixture of 2,4-dichloro-1,6-naphthyridine (1 g, 5.0 mmol), ethanamine in THF (2.5 ml, 5.0 mmol) and K_2CO_3 (1.38 g, 10.0 mmol) in acetonitrile (30 ml) was heated to 90 °C overnight. After cooling to room temperature, water (40 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 1) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to EA) to afford 2-chloro-N-ethyl-1,6-naphthyridin-4-amine as a yellow solid (0.24 g, 23% yield). LC-MS (ESI): 208.0 ($M + 1$)⁺.

Step 2:

[00230] The mixture of 2-chloro-N-ethyl-1,6-naphthyridin-4-amine (216 mg, 1.04 mmol), and ethyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate (360 mg, 1.09 mmol), Na_2CO_3 (220 mg, 2.08 mmol) and $Pd(PPh_3)_4$ (240 mg, 0.21 mmol) in dioxane/ H_2O (10 mL/2 mL) protected by N_2 atmosphere was heated to 100 °C overnight. After cooling to room temperature, water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 10% MeOH in DCM) to afford ethyl 5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate as a yellow solid (135 mg, 34% yield). LC-MS (ESI): 375.1 ($M + 1$)⁺.


Step 3:

[00231] The mixture of ethyl 5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate (135 mg, 0.36 mmol) and $LiOH \cdot H_2O$ (151 mg, 3.6 mmol) in MeOH/ H_2O (5 mL/1 mL) was stirred at room temperature overnight. The mixture was acidified with HCl solution (2 M) to pH = 2, then concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 347.1 ($M + 1$)⁺.

Step 4:

[00232] The mixture of 5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylic acid (125 mg, 0.36 mmol), 1-methylpiperidin-4-amine (0.06 ml, 0.54 mmol), HATU (164 mg, 0.43 mmol) and DIPEA (0.19 ml, 1.08 mmol) in DMF (2 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford 5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide as a yellow solid (11.1 mg, 7% yield). LC-MS (ESI): 443.2 (M + 1)⁺; ¹H NMR (DMSO-*d*₆) δ 9.78 (s, 1H), 9.46 (br. s., 1H), 8.84 (d, *J* = 5.8 Hz, 1H), 8.59 (d, *J* = 7.0 Hz, 1H), 8.40 (d, *J* = 1.2 Hz, 1H), 7.98 (d, *J* = 7.5 Hz, 1H), 7.92 (d, *J* = 6.0 Hz, 1H), 7.81 (d, *J* = 9.0 Hz, 1H), 7.31 (s, 1H), 7.18 (s, 1H), 4.06 (s, 5H), 3.74 (dt, *J* = 13.1, 6.9 Hz, 3H), 3.12 (m, 2H), 2.80 (s, 3H), 2.00 - 2.18 (m, 2H), 1.85 (d, *J* = 11.8 Hz, 2H), 1.38 (t, *J* = 7.3 Hz, 3H).

Example 20: Synthesis of 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide

**Step 1:**

[00233] The mixture of 1-(bromomethyl)-4-nitrobenzene (5.0 g, 23.1 mmol) and pyrrolidine (4.1 g, 57.8 mmol) in THF (50 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (50 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. Purified by the flash column chromatography (silica gel, eluting with DCM to 10% MeOH in DCM) to afford 1-(4-nitrobenzyl)pyrrolidine as a yellow oil (4.5 g, 95% yield). LC-MS (ESI): 207 (M + 1)⁺.

Step 2:

[00234] The mixture of 1-(4-nitrobenzyl)pyrrolidine (3.5 g, 17.0 mmol) and Pd/C (350 mg, 10%) in MeOH (50 mL) under H₂ atmosphere was stirred at room temperature overnight. The catalyst was

removed by reduced pressure and the filtration was concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 30% MeOH in DCM) to afford 4-(pyrrolidin-1-ylmethyl)aniline as a yellow oil (1.0 g, 33% yield). LC-MS (ESI): 177 ($M + 1$)⁺.

Step 3:

[00235] The mixture of ethyl 5-(4-chloro-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate (73 mg, 0.20 mmol), and 4-(pyrrolidin-1-ylmethyl)aniline (46 mg, 0.26 mmol), Na₂CO₃ (43 mg, 0.40 mmol), xantphos (34 mg, 0.06 mmol) and Pd₂(dba)₃ (30 mg, 0.03 mmol) in i-PrOH (5 mL) protected by N₂ atmosphere was heated to 110°C under microwave conditions for 1.5 hrs. After cooling to room temperature, water (60 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by Prep-TLC (10% MeOH in DCM) to afford ethyl 1-methyl-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate as a yellow solid (55 mg, 50% yield). LC-MS (ESI): 506 ($M + 1$)⁺.


Step 4:

[00236] The mixture of ethyl 1-methyl-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (60 mg, 0.12 mmol) and LiOH·H₂O (16 mg, 0.36 mmol) in THF/H₂O (6 mL/2 mL) was stirred at room temperature overnight. The mixture was acidified with HCl solution (2 M) to pH = 2, then concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 478 ($M + 1$)⁺.

Step 5:

[00237] The mixture of 1-methyl-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (50 mg, 0.1 mmol), 1-methylpiperidin-4-amine (18 mg, 0.13 mmol), HATU (45 mg, 0.12 mmol) and DIPEA (40 mg, 0.3 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. Purification by Prep-HPLC to afford ethyl 1-methyl-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate as a yellow solid (30 mg, 53% yield). LC-MS (ESI): 574 ($M + 1$)⁺; ¹H NMR (CD₃OD) δ 9.51 (br, s, 1H), 8.41 (d, J = 7.6 Hz, 1H), 8.29 (s, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.88 (br, s, 1H), 7.62 (d, J = 8.8 Hz, 1H), 7.55 (s, 1H), 7.46 (m, 4H), 7.21 (s, 1H), 4.13 (m, 1H), 3.99 (s, 3H), 3.73 (m, 4H), 2.93 (br, s, 2H), 2.60 (s, 3H), 2.31 (m, 4H), 1.82 (m, 2H), 1.76 (m, 4H), 1.67 (m, 2H).

Example 21: Synthesis of N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide

**Step 1:**

[00238] To a solution of 4-bromobenzene-1,2-diamine (4.78 g, 25.5 mmol) in AcOH (50 mL) at 0°C was added 5-bromo-2-(trichloromethyl)-1H-benzodimidazole (5.0 g, 28.3 mmol), then the mixture was stirred at room temperature for 3 hrs. Water was added and the precipitate was collected by filtration. The solid was washed with water, then dried under vacuum to afford the crude product that was used directly in the next step without further purification. LC-MS (ESI): 312 (M + 1)⁺.

Step 2:

[00239] The mixture of 5-bromo-2-(trichloromethyl)-1H-benzodimidazole (1.0 g, 3.18 mmol) and Na₂CO₃ (405 mg, 3.82 mmol) in EtOH (10 mL) was stirred at 75°C overnight. The solvent was concentrated under reduced pressure and residue was poured into water, extracted with EA (50 mL). The organic layer was washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 20% EA in PE) to afford ethyl 5-bromo-1H-benzodimidazole-2-carboxylate as a brown solid (731 mg, 85% yield). LC-MS (ESI): 270 (M + 1)⁺.

Step 3:

[00240] The mixture of ethyl 5-bromo-1H-benzodimidazole-2-carboxylate (5.7 g, 21.1 mmol), SEMCl (5.3 g, 31.6 mmol) and Et₃N (6.4 g, 63.3 mmol) in DCM (40 mL) was stirred at room temperature overnight. The solvent was concentrated under reduced pressure and residue was poured into water, extracted with DCM (50 mL). The organic layer was washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 20% EA in PE) to afford ethyl 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzodimidazole-2-carboxylate as a brown oil (3.25 g, 39%). LC-MS (ESI): 400 (M + 1)⁺.

Step 4:

[00241] To a solution of 3-(piperidin-1-yl)propan-1-amine (1.4 g, 10.0 mmol) in DCM (5 mL) was added $\text{Al}(\text{CH}_3)_3$ (10 mL, 10 mmol) dropwise at 0°C under nitrogen, then the mixture was stirred at rt for 30mins, the reaction mixture was cooled to 0°C again. A solution of ethyl ethyl 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxylate (400 mg, 1.0 mmol) in DCM (5mL) was added dropwise, the resulting reaction mixture was stirred at rt for 18hrs. The reaction mixture was quenched by water(10 mL), then extracted with DCM (10 mL x3), the combined organic layers were washed with water and brine, dried over Na_2SO_4 , the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Combiflash (silica gel, eluting with 30% methanol in DCM) to afford 5-bromo-N-(3-(piperidin-1-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (454 mg, 91%) as a yellow oil. LC-MS (ESI): 495 ($\text{M} + 1$)⁺.

Step 5:

[00242] The mixture of 5-bromo-N-(3-(piperidin-1-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (120 mg, 0.24 mmol), 4,4,4',4',5,5,5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (80 mg, 0.29 mmol), $\text{Pd}_2(\text{dba})_3$ (30 mg, 0.03 mmol), tricyclohexylphosphine (20 mg, 0.07 mmol) and KOAc (36 mg, 0.36 mmol) in 1,4-Dioxane (20 mL) was heated to 100°C and held for 18hrs under N_2 atmosphere. The reaction mixture was cooled to rt and filtered by a pad of celite, the resulting filtrate was concentrated under the reduced pressure to get the residue which was diluted with EA(30 mL), then washed by water and brine, dried over Na_2SO_4 , the drying agent was filtered off and the filtrate was concentrated in vacuo to get a crude boric acid ester which was purified with Combiflash (silica gel, eluting with 10% methanol in DCM) to afford N-(3-(piperidin-1-yl)propyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (100 mg, 77%) as a brown oil. LC-MS (ESI): 543 ($\text{M} + 1$)⁺.

Step 6:


[00243] The mixture of 2,4-dichloro-1,7-naphthyridine (20 mg, 0.10 mmol), N-(3-(piperidin-1-yl)propyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (60 mg, 0.11 mmol), $\text{Pd}(\text{PPh}_3)_4$ (29 mg, 0.025 mmol) and Na_2CO_3 (26 mg, 0.25 mmol) were dissolved in 1,4-dioxane (5 mL) and H_2O (1 mL). The resulting brown suspension was stirred at 110°C overnight. The solvent was concentrated under reduced pressure and residue was poured into water, extracted with EA (50 mL). The organic layer was washed with water (30 mL) and brine (30 mL), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by Prep- TLC (eluting with DCM to 20% MeOH in DCM) to get 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide as a yellow solid (15 mg, 26% yield). LC-MS (ESI): 579 ($\text{M} + 1$)⁺.

Step 7:

[00244] The mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (29 mg, 0.05 mmol), 3-(piperidin-

1-yl)propan-1-amine (13 mg, 0.10 mmol) and K_2CO_3 (13 mg, 0.10 mmol) in DMF (3 mL) was heated to 90°C and held for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue, which was dissolved in TFA (1 mL) and DCM (10 mL), then stirred at rt for 18hrs. The solvent was removed under the reduced pressure to afford the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm*250 mm, 10 μ m, eluting with 40% CH_3CN in 1% TFA in H_2O) to afford N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide. (5 mg, 9% yield) as a TFA salt. LC-MS (ESI): 555 ($M + 1$)⁺. ¹H NMR ($DMSO-d_6$) δ 10.09 (br, s, 1H), 9.92 (s, 1H), 9.71 (br, s, 1H), 9.26 (s, 1H), 8.88 (d, $J = 5.6$ Hz, 1H), 8.40 (s, 1H), 7.98 - 8.03 (m, 2H), 7.86 - 7.89 (m, 1H), 7.30 (s, 1H), 3.82 - 3.84 (m, 2H), 3.42 - 3.48 (m, 6H), 3.23-3.25 (m, 2H), 3.12-3.16 (m, 2H), 2.87-2.92 (m, 4H), 2.15-2.20 (m, 2H), 1.97-2.02 (m, 2H), 1.80-1.83 (m, 4H), 1.63-1.69 (m, 6H), 1.37-1.41 (m, 2H).


Example 22: Synthesis of methyl 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate



[00245] The mixture of methyl 3-carbamoyl-4-(4-chloro-1,6-naphthyridin-2-yl)benzoate (330 mg, 0.96 mmol), 3-(piperidin-1-yl)propan-1-amine (274 mg, 1.93 mmol) and K_2CO_3 (266 mg, 1.93 mmol) in DMF (5 mL) was heated to 80 °C and held for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue which was purified with Combiflash (silica gel, eluting with 10% methanol in DCM) to afford methyl 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (200 mg, 46%) as an orange solid. HPLC/UV purity: 94%; LC-MS (ESI): 448 ($M + 1$)⁺.

[00246] ¹H NMR ($DMSO-d_6$) δ 9.58 (s, 1H), 8.58 (d, $J = 4.6$ Hz, 1H), 8.10 (d, $J = 8.0$ Hz, 1H), 7.97 - 8.06 (m, 3H), 7.87 (d, $J = 8.0$ Hz, 1H), 7.60 (d, $J = 5.7$ Hz, 1H), 7.49 (s, 1H), 6.80 (s, 1H), 3.92 (s, 3H), 3.33 (m, 4H), 2.39 (m, 4H), 1.87 (m, 2H), 1.52 (m, 4H), 1.39 (m, 2H).

Example 23: Synthesis of 5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide

**Step 1:**

[00247] The mixture of 2,4-dichloro-1,6-naphthyridine (1.5 g, 4.93 mmol), ethyl 5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-methyl-1H-indol-2-yl)-1-methyl-1H-indole-2-carboxylate (1.94 g, 5.92 mmol), Pd(PPh₃)₄ (569 mg, 0.493 mmol) and Na₂CO₃ (1.04 g, 9.86 mmol) in 1,4-Dioxane (20 mL) and H₂O (4 mL) was heated to 90°C and held for 18hrs under nitrogen atmosphere. The reaction mixture was filtered by a pad of celite, the filtrate was concentrated to get the residue which was washed by water (30 mL) and EA (30 mL), ethyl 5-(4-chloro-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate (1.7 g, 94%) to afford a yellow solid. HPLC/UV purity: 90%; LC-MS (ESI): 366 (M + 1)⁺. ¹H NMR (DMSO-*d*₆) δ 9.55 (s, 1H), 8.85 (d, *J* = 5.8 Hz, 1H), 8.77 (s, 1H), 8.60 (s, 1H), 8.46 (d, *J* = 8.0 Hz, 1H), 8.01 (d, *J* = 6.1 Hz, 1H), 7.80 (d, *J* = 9.2 Hz, 1H), 7.43 (s, 1H), 4.37 (q, *J* = 7.2 Hz, 2H), 4.10 (s, 3H), 1.37 (t, *J* = 7.0 Hz, 3H).

Step 2:


[00248] To a mixture of ethyl 5-(4-chloro-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate (500 mg, 1.37 mmol) in Methanol (6 mL) was added 1N LiOH aqueous (4.1 mL), then the reaction mixture was heated to 50°C and held for 2hrs. LCMS analysis showed complete consumption of start materials. Methanol was removed under the reduced pressure to get a slurry. Water (5 mL) was added, then pH of the mixture was adjusted to 4 with 1N HCl aqueous. The solvent was removed under the reduced pressure to afford crude 5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylic acid (500 mg, 99%) which was used to the next step without further purification.

Step 3:

[00249] To a mixture of 5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylic acid (495 mg, 1.37 mmol) and HATU (625 mg, 1.64 mmol) in DMF (4 mL) was added 1-methylpiperidin-4-amine (156 mg, 1.37 mmol) and DIPEA (530 mg, 4.11 mmol), then the resulting mixture was stirred at rt for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL x3), the combined organic layers was washed with water and brine, dried over Na₂SO₄, the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Combiflash (silica gel, eluting with 5% methanol in DCM) to afford 5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide (200 mg, 34%) as a solid. HPLC/UV

purity: 94%; LC-MS (ESI): 430 ($M + 1$)⁺ ¹H NMR (DMSO-*d*₆) δ 9.44 (s, 1H), 8.71(d, J = 6.0 Hz, 1H), 8.65 (s, 1H), 8.43 (d, J = 7.6 Hz, 1H), 8.31 (dd, J = 8.9, 1.5 Hz, 1H), 7.85 (d, J = 5.8 Hz, 1H), 7.74(s, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.23 (s, 1H), 4.25 (s, 3H), 4.03 (s, 3H), 3.70 - 3.81 (m, 1H), 2.80 (d, J = 11.6 Hz, 2H), 2.18 (s, 3H), 1.97 (t, J = 11.1 Hz, 2H), 1.80 (d, J = 10.7 Hz, 2H), 1.52 - 1.69 (m, 2H).

Example 24: Synthesis of 3-cyano-N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide



Step 1:

[00250] To a solution of methyl 4-hydroxy-3-iodobenzoate (5 g, 18 mmol) in DMF (6 mL) was added cyanocopper (1.77 g, 19.8 mmol) and cyanosodium (97 mg, 1.98 mmol), the mixture was heated to 105°C for 18hrs. The reaction was cooled to rt and poured into water (50 mL), the gradual formation of a grey-green precipitate was observed, the precipitate was filtered and the filtrate was extracted with EA(50 mL) for three times, and the combined organic layers was washed by water and brine, dried over Na₂SO₄. The drying organic layers were filtered off and washed with additional ethyl acetate (20 mL). The combined filtrate is concentrated in vacuo to afford the crude product methyl 3-cyano-4-hydroxybenzoate (1.77 g, 55%) as a grey solid which was used to the next step without further purification. HPLC/UV purity: 90%; LC-MS (ESI): 178 ($M + 1$)⁺. ¹H NMR (DMSO-*d*₆) δ 12.11 (s, 1H), 8.16 (d, J = 2.1 Hz, 1H), 8.06 (dd, J = 8.7, 2.3 Hz, 1H), 7.12 (d, J = 8.9 Hz, 1H), 3.84(s, 3H).

Step 2:

[00251] To a suspension of methyl 3-cyano-4-hydroxybenzoate (1.77 g, 10 mmol) in DCM (20 mL) was added pyridine (1.17 g, 15 mmol), then the mixture was cooled to 0°C, trifluoromethanesulfonic anhydride (3.38 g, 12 mmol) was dropwise added at 0°C. The mixture was stirred at rt overnight. Another

20 mL of DCM was added, the solution was washed with 1N HCl (15 mL) twice, washed with water and brine, and the organic layers were dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the residue which was purified with Combiflash (silica gel, eluting with 10-20% PE in EA) to afford Methyl 3-cyano-4-(((trifluoromethyl)sulfonyl)oxy)benzoate (2.5 g, 81%) as a colorless oil. HPLC/UV purity: 90%; LC-MS (ESI): 309 (M + 1)⁺.

Step 3:

[00252] The mixture of 3-cyano-4-(((trifluoromethyl)sulfonyl)oxy)benzoate (2.5 g, 8.1 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.45 g, 9.7 mmol), Pd(dppf)Cl₂ (661 mg, 0.81 mmol) and KOAc (1.5 g, 16.2 mmol) in 1,4-Dioxane (20 mL) was heated to 100 °C and held for 18 hrs under N₂ atmosphere. The reaction mixture was cooled to rt and filtered by a pad of celite, the resulting filtrate was concentrated under the reduced pressure to get the residue which was diluted with EA (30 mL), then washed by water and brine, dried over Na₂SO₄, the drying agent was filtered off and the filtrate was concentrated in vacuo to afford a crude boric acid ester which was used to the next step without purification.

Step 4:

[00253] A 20-mL microwave vial was charged with 2,4-dichloro-1,6-naphthyridine (500 mg, 2.5 mmol), methyl 3-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.16 mmol, 3 mmol), Pd(PPh₃)₄ (289 mg, 0.25 mmol) and NaHCO₃ (420 mg, 5 mmol) dissolved in 1,4-dioxane (10 mL) and H₂O (1 mL). A stir bar is added, the vial is sealed, and the resulting brown solution is heated for 1 h in a Biotage Initiator Eight Microwave Reactor held at a constant temperature of 100 °C. The resulting solutions were concentrated by rotary evaporation (55 °C, 20 mmHg). The adsorbed material was loaded onto a column and purified using silica gel chromatography (silica gel, eluting with 2-5% methanol in DCM) to afford methyl 4-(4-chloro-1,6-naphthyridin-2-yl)-3-cyanobenzoate (400 mg, 50%) as a yellow solid HPLC/UV purity: 80%; LC-MS (ESI): 324 (M + 1)⁺ and methyl 3-carbamoyl-4-(4-chloro-1,6-naphthyridin-2-yl)benzoate (330 mg, 38%) as a brown solid. HPLC/UV purity: 95%; LC-MS (ESI): 342 (M + 1)⁺.

Step 5:

[00254] The mixture of methyl 4-(4-chloro-1,6-naphthyridin-2-yl)-3-cyanobenzoate (400 mg, 1.27 mmol), 3-(piperidin-1-yl)propan-1-amine (368 mg, 2.59 mmol) and K₂CO₃ (357 mg, 2.59 mmol) in DMF (3 mL) was heated to 80 °C and held for 18 hrs. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue which was purified with Combiflash (silica gel, eluting with 10% methanol in DCM) to afford methyl 3-cyano-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (250 mg, 45%) as a yellow solid. HPLC/UV purity: 90%; LC-MS (ESI): 430 (M + 1)⁺.


Step 6:

[00255] To a solution of methyl 3-cyano-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (200 mg, 0.465 mmol) in methanol (2 mL) and THF (2 mL) was added 1N LiOH aqueous (1.86 mL, 1.86 mmol), then the reaction mixture was stirred at rt overnight. The solvent was removed and water (5mL) was added, then the pH of the water phase was adjusted with 1N HCl aqueous to 5, then it was cryodesiccated to afford a crude product (250 mg) as a yellow solid.

Step 7:

[00256] To a mixture of 3-cyano-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid (60 mg, 0.144 mmol) and HATU (65 mg, 0.17 mmol) in DMF (2 mL) was added diethylamine (13 mg, 0.17 mmol) and DIPEA (70 mg, 0.342 mmol), then the resulting mixture was stirred at rt for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL x3), the combined organic layers was washed with water and brine, dried over Na₂SO₄, the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Prep-TLC (silica gel, eluting with 10% methanol in DCM) to afford 3-cyano-N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide (15 mg, 22%) as a solid. HPLC/UV purity: 97%; LC-MS (ESI): 471 (M + 1)⁺. ¹H NMR (CDCl₃) δ 9.53 (s, 1H), 8.61 (d, *J* = 6.4 Hz, 1H), 8.02 (d, *J* = 8.0 Hz, 1H), 7.96 (s, 1H), 7.84 (d, *J* = 8.0 Hz, 1H), 7.78 (d, *J* = 6.0 Hz, 1H), 7.06 (s, 1H), 3.52 - 3.65 (m, 4H), 3.34 (d, *J* = 8.2 Hz, 2H), 2.58 - 2.72 (m, 5H), 2.01 - 2.12 (m, 2H), 1.61 - 1.72 (m, 4H), 1.52 (m, 2H), 1.26 - 1.34 (m, 4H), 1.13 - 1.22 (m, 3H).

Example 25: Synthesis of N1,N1-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)isophthalamide

**Step 1:**

[00257] To a solution of methyl 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (200 mg, 0.446 mmol) in methanol (2 mL) and THF (2 mL) was added 1N LiOH aqueous (1.78 mL, 1.78 mmol), then the reaction mixture was stirred at 50°C for 2hrs. The solvent was removed and water (5mL) was added, then the pH of the water phase was adjusted with 1N HCl aqueous to 4, then it was cryodesiccated to afford a crude product (200 mg) as a tan solid.


Step 2:

[00258] To a mixture of 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid (100 mg, 0.23 mmol) and HATU (102 mg, 0.27 mmol) in DMF (2 mL) was added

diethylamine (20 mg, 0.27 mmol) and DIPEA (89 mg, 0.69 mmol), then the resulting mixture was stirred at rt for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mLx3), the combined organic layers was washed with water and brine, dried over Na₂SO₄, the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Prep-TLC (silica gel, eluting with 10% methanol in DCM) to afford 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid (20 mg, 18%) as a solid. HPLC/UV purity: 92%; LC-MS (ESI): 489 (M + 1)⁺.

[00259] ¹H NMR (CD₃OD) δ 9.50 (s, 1H), 8.59 (d, *J* = 5.5 Hz, 1H), 7.83 (d, *J* = 7.6 Hz, 1H), 7.74 (d, *J* = 5.8 Hz, 1H), 7.60 - 7.67 (m, 2H), 6.89 (s, 1H), 3.54 - 3.62 (m, 4H), 3.32 - 3.46 (m, 6H), 3.19 - 3.26 (m, 2H), 2.13 - 2.26 (m, 2H), 1.86 (m, 4H), 1.27 - 1.33 (m, 5H), 1.17 (t, *J* = 6.7 Hz, 3H).

Example 26: Synthesis of 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



Step 1:

[00260] The mixture of 2,4-dichloro-1,6-naphthyridine (1 g, 5.0 mmol), methanamine in THF (2.5 mL, 5.0 mmol) and K₂CO₃ (1.38 g, 10.0 mmol) in acetonitrile (30 mL) was heated to 90 °C overnight. After cooling to room temperature, water (40 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to EA) to afford 2-chloro-N-methyl-1,6-naphthyridin-4-amine as a yellow solid (0.16 g, 17% yield).

Step 2:

[00261] The mixture of 2-chloro-N-methyl-1,6-naphthyridin-4-amine (160 mg, 0.83 mmol), and ethyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-2-carboxylate (286 mg, 0.87 mmol), Na₂CO₃ (175 mg, 1.66 mmol) and Pd(PPh₃)₄ (191 mg, 0.16 mmol) in dioxane/H₂O (10 mL/2 mL) protected by N₂ atmosphere was heated to 100 °C overnight. After cooling to room temperature, water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers

were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 10% MeOH in DCM) to afford ethyl 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate as a yellow solid (100 mg, 33% yield).


Step 3:

[00262] The mixture of ethyl 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (100 mg, 0.27 mmol) and $\text{LiOH}\cdot\text{H}_2\text{O}$ (116 mg, 2.7 mmol) in MeOH/ H_2O (5 mL/1 mL) was stirred at room temperature overnight. The mixture was acidified with HCl solution (2 M) to pH = 2, then concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 333.1 ($\text{M} + 1$)⁺.

Step 4:

[00263] The mixture of 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (50 mg, 0.15 mmol), NH_4Cl (40 mg, 0.75 mmol), HATU (87 mg, 0.23 mmol) and DIPEA (142 mg, 1.10 mmol) in DMF (3 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. Purification by Prep-TLC and HPLC to afford 1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide as a yellow solid (25 mg, 51% yield). LC-MS (ESI): 332 ($\text{M} + 1$)⁺; ^1H NMR (CD_3OD) δ 9.59 (s, 1H), 8.85 (d, J = 5.6 Hz, 1H), 8.39 (s, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 5.6 Hz, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.15 (s, 1H), 4.12 (s, 3H), 3.31 (s, 3H).

Example 27: Synthesis of 3-cyano-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide




[00264] To a mixture of 3-cyano-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid (60 mg, 0.144 mmol) and HATU (65 mg, 0.17 mmol) in DMF (2 mL) was added 1-methylpiperidin-4-amine (19 mg, 0.17 mmol) and DIPEA (70 mg, 0.342 mmol), then the resulting mixture was stirred at rt for 1 hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL $\times$ 3), the combined organic layers was washed with water and brine, dried over Na_2SO_4 , the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Prep-TLC (silica gel, eluting with 10% methanol in DCM) to afford 3-cyano-N-(1-methylpiperidin-4-yl)-

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide (20 mg, 25%) as a solid.

HPLC/UV purity: 97%; LC-MS (ESI): 512 ($M + 1$)⁺. ¹H NMR (CD₃OD) δ 9.54 (s, 1H), 8.63 (d, $J = 5.8$ Hz, 1H), 8.37 (d, $J = 1.5$ Hz, 1H), 8.26 (dd, $J = 8.2, 1.8$ Hz, 1H), 8.04 (d, $J = 8.2$ Hz, 1H), 7.79 (d, $J = 5.8$ Hz, 1H), 7.09 (s, 1H), 3.94 - 4.06 (m, 1H), 3.10 (d, $J = 11.9$ Hz, 2H), 2.84 - 3.02 (m, 5H), 2.40 - 2.55 (m, 5H), 2.13 - 2.23 (m, 2H), 2.07 (d, $J = 11.3$ Hz, 2H), 1.72 - 1.83 (m, 6H), 1.59 (m, 2H), 1.27 - 1.37 (m, 3H).

Example 28: Synthesis of 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(3-(piperidin-1-yl)propoxy)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



Step 1:


[00265] The solution of 5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide (200 mg, 0.466 mmol) in 40% HBr in water was heated to 100°C and held for 3hrs. LCMS analysis showed complete consumption of start material. The water was removed under the reduced pressure to get the residue which was purified with Prep-HPLC (eluting with 30% methanol in water) to obtain 5-(4-hydroxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide (190 mg, 95%) as a solid. HPLC/UV purity: 90%; LC-MS (ESI): 416 ($M + 1$)⁺. ¹H NMR (DMSO-*d*₆) δ 9.11 (s, 1H), 8.37 (d, $J = 7.6$ Hz, 1H), 8.19 - 8.28 (m, 2H), 7.98 (d, $J = 9.2$ Hz, 1H), 7.56 (d, $J = 9.2$ Hz, 1H), 7.35 (d, $J = 6.4$ Hz, 1H), 7.17 (s, 1H), 6.57 (s, 1H), 4.00 (s, 3H), 3.74 (d, $J = 8.2$ Hz, 1H), 2.78 (d, $J = 11.0$ Hz, 2H), 2.17 (s, 3H), 1.92 - 1.99 (m, 2H), 1.78 (d, $J = 10.7$ Hz, 2H), 1.52 - 1.67 (m, 2H).

Step 2:

[00266] The mixture of 5-(4-hydroxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide (140 mg, 0.336 mmol) and Cs₂CO₃ (325 mg, 1 mmol) in DMF (2 mL) was heated to 70°C and held for 2hrs, then the mixture was cooled to 0°C, 1-(3-chloropropyl)piperidine hydrochloride (80 mg, 0.404 mmol) was added in one portion, then the resulting reaction mixture was heated to 70°C and held for 1hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3),


the combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue which was purified with Prep-TLC (silica gel, DCM/Methanol/ $\text{NH}_3 \cdot \text{H}_2\text{O}$ =10/1/0.1) to afford 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(3-(piperidin-1-yl)propoxy)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide (5 mg, 3%), HPLC/UV purity: 95 %; LC-MS (ESI): 541 ($M + 1$)⁺. ¹H NMR (CD_3OD) δ 9.51 (s, 1H), 8.67 (d, J = 6.1 Hz, 1H), 8.53 (s, 1H), 8.20 (d, J = 8.9 Hz, 1H), 7.92 (d, J = 6.1 Hz, 1H), 7.60 - 7.70 (m, 2H), 7.25 (s, 1H), 4.60 (t, J = 5.6 Hz, 2H), 4.16 (m, 1H), 4.07 (s, 3H), 3.36 - 3.56 (m, 6H), 3.12 (d, J = 11.3 Hz, 2H), 2.83 (s, 3H), 2.48 (dd, J = 9.9, 6.0 Hz, 2H), 2.14 - 2.29 (m, 2H), 1.75 - 2.05 (m, 10H).

Example 29: Synthesis of 5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide



[00267] A mixture of tert-butyl 4-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (130 mg, 0.162 mmol) and TFA (2 mL) in DCM (4 mL) was heated to 40°C and held for 2hrs, the solvent was removed under the reduced pressure to get the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm*250 mm, 10 μm , eluting with 20% CH_3CN in 1% TFA in H_2O) to afford 5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide (30 mg, 33%) as a TFA salt. HPLC/UV purity: 93%; LC-MS (ESI): 513 ($M + 1$)⁺. ¹H NMR (CD_3OD) δ 9.75 (s, 1H), 8.90 (d, J = 6.0 Hz, 1H), 8.40 (s, 1H), 7.93 - 8.01 (m, 3H), 7.29 (s, 1H), 4.27 (m, 1H), 3.85-3.89 (t, J = 6.8 Hz, 2H), 3.51 - 3.62 (m, 4H), 3.34 (m, 2H), 3.18-3.25 (t, J = 12.8 Hz, 2H), 2.94-3.00 (m, 2H), 2.26-2.35 (m, 4H), 1.78 - 2.03 (m, 7H), 1.51-1.54 (m, 1H).

Example 30: Synthesis of 5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide



[00268] The mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (120 mg, 0.2 mmol), and methylamine (0.5 mL, 1.0 mmol, 2 M THF solution) in DMA (3 mL) was heated to 100°C and held for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined


organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue, which was dissolved in TFA (1 mL) and DCM (10 mL), then stirred at rt for 18hrs. The solvent was removed under the reduced pressure to get the residue which was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm*250 mm, 10 μm , eluting with 40% CH_3CN in 1% TFA in H_2O) to afford 5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide. (30 mg, 39% yield) as a TFA salt. LC-MS (ESI): 444 ($\text{M} + 1$)⁺. ¹H NMR (CD_3OD) δ 9.64 (s, 1H), 8.88 (d, $J = 6.0$ Hz, 1H), 8.40 (s, 1H), 7.90 - 7.98 (m, 3H), 7.19 (s, 1H), 3.58 - 3.61 (m, 4H), 3.35 (s, 3H), 3.22-3.26 (m, 2H), 2.96-2.99 (m, 2H), 2.11-2.14 (m, 2H), 1.97-2.01 (m, 2H), 1.80-1.85 (m, 3H), 1.50-1.54 (m, 1H).

Example 31: Synthesis of 5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide



[00269] The mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (100 mg, 0.17 mmol), and ethyl amine (0.5 mL, 1.0 mmol, 2 M THF solution) in DMA (3 mL) was heated to 100°C and held for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue, which was dissolved in TFA (1 mL) and DCM (10 mL), then stirred at rt for 18hrs. The solvent was removed under the reduced pressure to get the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm*250 mm, 10 μm , eluting with 40% CH_3CN in 1% TFA in H_2O) to afford 5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide. (25 mg, 32% yield) as a TFA salt. LC-MS (ESI): 458 ($\text{M} + 1$)⁺. ¹H NMR (CD_3OD) δ 9.74 (s, 1H), 8.88 (d, $J = 6.0$ Hz, 1H), 8.38 (s, 1H), 7.89 - 7.99 (m, 3H), 7.23 (s, 1H), 3.80 (q, $J = 7.2$ Hz, 2H), 3.80 (t, $J = 6.8$ Hz, 4H), 3.22-3.26 (m, 2H), 2.95-2.99 (m, 2H), 2.10-2.15 (m, 2H), 1.96-2.01 (m, 2H), 1.78-1.86 (m, 3H), 1.53-1.60 (m, 1H), 1.50 (t, $J = 7.2$ Hz, 3H).

Example 32: Synthesis of N-(2-(dimethylamino)ethyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide

**Step 1:**

[00270] To a solution of N1,N1-dimethylethane-1,2-diamine (880 mg, 10.0 mmol) in DCM (5 mL) was added $\text{Al}(\text{CH}_3)_3$ dropwise at 0°C under nitrogen, then the mixture was stirred at rt for 30mins, the reaction mixture was cooled to 0°C again. A solution of ethyl ethyl 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxylate (800 mg, 2.0 mmol) in DCM (5 mL) was added dropwise, the resulting reaction mixture was stirred at rt for 18hrs. The reaction mixture was quenched by water (10 mL), then extracted with DCM (10mL x3), the combined organic layers was washed with water and brine, dried over Na_2SO_4 , the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Combiflash (silica gel, eluting with 30% methanol in DCM) to afford 5-bromo-N-(2-(dimethylamino)ethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (484 mg, 54%) as a yellow oil. LC-MS (ESI): 441.1 ($\text{M} + 1$)⁺.

Step 2:

[00271] The mixture of 5-bromo-N-(2-(dimethylamino)ethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (484 mg, 1.06mmol), 4,4',4',5,5,5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (323 mg, 1.27 mmol), $\text{Pd}_2(\text{dba})_3$ (97 mg, 0.106mmol), tricyclohexylphosphine (60 mg, 0.21 mmol) and KOAc (311 mg, 3.18 mmol) in 1,4-Dioxane (20 mL) was heated to 100°C and held for 18hrs under N_2 atmosphere. The reaction mixture was cooled to rt and filtered by a pad of celite, the resulting filtrate was concentrated under the reduced pressure to get the residue which was diluted with EA (30 mL), then washed by water and brine, dried over Na_2SO_4 , the drying agent was filtered off and the

filtrate was concentrated in vacuo to get a crude boric acid ester which was purified with Combiflash (silica gel, eluting with 10% methanol in DCM) to afford N-(2-(dimethylamino)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (711 mg, 100%) as a brown oil. LC-MS (ESI): 489.3 (M + 1)⁺.

Step 3:

[00272] A 10-mL microwave vial was charged with 2,4-dichloro-1,6-naphthyridine (100 mg, 0.5 mmol), N-(2-(dimethylamino)ethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (292 mg, 0.6 mmol), Pd(PPh₃)₄ (58 mg, 0.05 mmol) and Na₂CO₃ (106 mg, 1.0 mmol) dissolved 1,4-dioxane (3 mL) and H₂O (0.5 mL). A stir bar is added, the vial is sealed, and the resulting brown solution is heated for 2 h in a Biotage Initiator Eight Microwave Reactor held at a constant temperature of 110°C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The adsorbed material was loaded onto a column and purified using silica gel chromatography (silica gel, eluting with 10% methanol in DCM) to afford 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(2-(dimethylamino)ethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (75 mg, 28%) as a yellow oil LC-MS (ESI): 525.2 (M + 1)⁺.


Step 4:

[00273] The mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(2-(dimethylamino)ethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (75 mg, 0.14 mmol), 3-(piperidin-1-yl)propan-1-amine (40 mg, 0.28 mmol) and K₂CO₃ (38 mg, 0.28 mmol) in DMF (1 mL) was heated to 90°C and held for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to afford the residue which was purified with prep-TLC to afford N-(2-(dimethylamino)ethyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (50 mg, 55%) as a light yellow solid. LC-MS (ESI): 631.3 (M + 1)⁺.

Step 5:


[00274] The mixture of N-(2-(dimethylamino)ethyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (50 mg, 0.08 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at rt for 18hrs, then the solvent was removed under the reduced pressure to get the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm*250 mm, 10 μm, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford N-(2-(dimethylamino)ethyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (21.7 mg, 54%) as a TFA salt. HPLC/UV purity: 97%; LC-MS (ESI): 501.1 (M + 1)⁺. ¹H NMR (DMSO-*d*₆) δ 9.80 (s, 1H), 9.54 (br. s., 2H), 9.30 (br. s., 1H), 8.89 (m, 1H), 8.41 (m, 1H), 8.01 - 7.94 (m, 3H), 7.29 (s, 1H), 3.79 (m, 2H), 3.71 (d, *J* = 6.2 Hz, 2H), 3.46 (d, *J* = 11.8 Hz, 2H), 3.35 (d, *J* = 5.6 Hz, 2H), 3.22 (dd, *J* = 10.3, 5.2 Hz, 2H), 2.89 (d, *J* = 4.6 Hz, 6H), 2.13 (d, *J* = 7.0 Hz, 2H), 1.95 - 2.08 (m, 1H), 1.82 (d, *J* = 15.3 Hz, 2H), 1.51 - 1.74 (m, 4H), 1.38 (d, *J* = 12.1 Hz, 1H).

Example 33: Synthesis of N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide



[00275] A mixture of N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (70 mg, 0.1 mmol) and TFA (1 mL) in DCM (1 mL) was heated to 40°C and held for 2hrs, the solvent was removed under the reduced pressure to afford the residue which was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm*250 mm, 10 um, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (50 mg, 65%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 570 (M + 1)⁺. ¹H NMR (CD₃OD) δ 9.74 (s, 1H), 8.87 (d, *J* = 6.1 Hz, 1H), 8.38 (s, 1H), 7.86 - 8.00 (m, 3H), 7.27 (s, 1H), 3.85 (t, *J* = 6.9 Hz, 2H), 3.52 - 3.64 (m, 9H), 3.47 (m, 3H), 3.32 - 3.35 (m, 2H), 3.14 - 3.23 (m, 2H), 2.92 - 3.00 (m, 5H), 2.25 - 2.37 (m, 2H), 2.03 - 2.14 (m, 2H), 1.95 (d, *J* = 14.3 Hz, 2H), 1.69 - 1.88 (m, 3H), 1.51 (d, *J* = 12.5 Hz, 1H).

Example 34: Synthesis of piperazin-1-yl(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone



[00276] To a solution of tert-butyl piperazine-1-carboxylate (2.09 g, 11.25 mmol) in DCM (10 mL) was added $\text{Al}(\text{CH}_3)_3$ dropwise at 0°C under nitrogen, then the mixture was stirred at rt for 30mins, the reaction mixture was cooled to 0°C again. A solution of ethyl 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxylate (900 mg, 2.25 mmol) in DCM (5mL) was added dropwise, the resulting reaction mixture was stirred at rt for 18hrs. The reaction mixture was quenched by water(10 mL), then extracted with DCM (10mL x3), the combined organic layers was washed with water and brine, dried over Na_2SO_4 , the drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue which was purified with Combiflash (silica gel, eluting with 20% methanol in DCM) to afford tert-butyl 4-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (780 mg, 65%) as a white solid. HPLC/UV purity: 90%; LC-MS (ESI): 539 ($\text{M} + 1$)⁺.

[00277] The mixture of tert-butyl 4-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (850 mg, 1.57mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)(480 g, 1.89 mmol), Pd₂(dba)₃(144 mg, 0.157mmol), tricyclohexylphosphine (90 mg, 0.32 mmol) and KOAc (308 g, 3.14 mmol) in 1,4-Dioxane (20 mL) was heated to 100°C and held for 18hrs under N₂ atmosphere. The reaction mixture was cooled to rt and filtered by a pad of celite, the resulting filtrate was concentrated under the reduced pressure to get the residue which was diluted with EA(30 mL), then washed by water and brine, dried over Na₂SO₄, the drying agent was filtered off and the filtrate was concentrated in vacuo to get a crude boric acid ester

which was purified with Combiflash (silica gel, eluting with 20% methanol in DCM) to afford tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (1.5 g, 100%) as a white solid. HPLC/UV purity: 60%; LC-MS (ESI): 587 (M + 1)⁺.

Step 3

[00278] A 20-mL microwave vial was charged with 2,4-dichloro-1,6-naphthyridine (426 mg, 2.13 mmol), tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (1.5 g, 2.55 mmol), Pd(PPh₃)₄ (246 mg, 0.213 mmol) and Na₂CO₃ (451 mg, 4.26 mmol) dissolved in 1,4-dioxane (10 mL) and H₂O (1 mL). A stir bar is added, the vial is sealed, and the resulting brown solution is heated for 2 h in a Biotage Initiator Eight Microwave Reactor held at a constant temperature of 110°C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The adsorbed material was loaded onto a column and purified using silica gel chromatography (silica gel, eluting with 2-5% methanol in DCM) to afford tert-butyl 4-(5-(4-chloro-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (500 mg, 37%) as a yellow solid. HPLC/UV purity: 80%; LC-MS (ESI): 623 (M + 1)⁺.

Step 4:


[00279] The mixture of tert-butyl 4-(5-(4-chloro-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (500 mg, 0.803 mmol), 3-(piperidin-1-yl)propan-1-amine (171 mg, 1.2 mmol) and K₂CO₃ (221 mg, 1.6 mmol) in DMF (2 mL) was heated to 80°C and held for 18 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue which was purified with Combiflash (silica gel, eluting with 10% methanol and 1% NH₃ in DCM) to afford tert-butyl 4-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (310 mg, 53%) as a yellow solid. HPLC/UV purity: 90%; LC-MS (ESI): 729 (M + 1)⁺.

Step 5:

[00280] The mixture of tert-butyl 4-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (310 mg, 0.429 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at rt for 18 hrs, then the solvent was removed under the reduced pressure to get the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm*250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford piperazin-1-yl(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone (300 mg, 88%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 499 (M + 1)⁺. ¹H NMR (CD₃OD) δ 9.73 (s, 1H), 8.87 (d, J = 6.2 Hz, 1H), 8.40 (d, J = 1.3 Hz, 1H), 7.95 - 8.01 (m, 1H), 7.88 - 7.94 (m, 2H), 7.28 (s, 1H), 4.08 (m, 2H), 3.85 (t, J = 6.9 Hz, 2H), 3.58 (d, J = 12.1 Hz, 2H), 3.42 (m, 4H), 3.31 - 3.35 (m, 4H),


2.95 (t, $J = 12.4$ Hz, 2H), 2.25 - 2.36 (m, 2H), 1.94 (d, $J = 15.0$ Hz, 2H), 1.71 - 1.88 (m, 3H), 1.51 (m, 1H).

Example 35: Synthesis of N,N-diethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide



[00281] A mixture of N,N-diethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (100 mg, 0.162 mmol) and TFA (1 mL) in DCM (1 mL) was heated to 40°C and held for 2hrs, the solvent was removed under the reduced pressure to get the residue which was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm*250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford N,N-diethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (80 mg, 80%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 486 (M + 1)⁺. ¹H NMR (CD₃OD) δ 9.73 (s, 1H), 8.87 (d, $J = 6.1$ Hz, 1H), 8.40 (s, 1H), 7.85 - 8.02 (m, 3H), 7.29 (s, 1H), 4.06 (q, $J = 7.0$ Hz, 2H), 3.85 (t, $J = 6.9$ Hz, 2H), 3.54 - 3.70 (m, 4H), 3.34 (d, $J = 3.4$ Hz, 2H), 2.96 (t, $J = 12.4$ Hz, 2H), 2.23 - 2.37 (m, 2H), 1.95 (d, $J = 14.3$ Hz, 2H), 1.69 - 1.88 (m, 3H), 1.45 - 1.58 (m, 1H), 1.27 - 1.35 (m, 6H).

Example 36: Synthesis of (4-ethylpiperazin-1-yl)(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone and (1-ethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)(4-ethylpiperazin-1-yl)methanone




[00282] The mixture of piperazin-1-yl(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone (100 mg, 0.2 mmol) and K₂CO₃ (82 mg, 0.6 mmol) in DMF (1mL) was stirred at rt for 30 min, then iodoethane (34 mg, 0.22 mmol) was added dropwise, the resulting reaction mixture was stirred at rt for 2 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the

residue which was purified with Prep-TLC (silica gel, DCM/Methanol/ $\text{NH}_3 \cdot \text{H}_2\text{O}$ = 10/1/0.1) to afford two products including (4-ethylpiperazin-1-yl)(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone (10 mg), HPLC/UV purity: 99%; LC-MS (ESI): 527 ($M + 1$)⁺. ¹H NMR (CD_3OD) δ 9.49 (s, 1H), 8.59 (d, $J = 6.2$ Hz, 1H), 8.38 (s, 1H), 8.09 (d, $J = 8.6$ Hz, 1H), 7.82 (d, $J = 6.7$ Hz, 2H), 7.14 (s, 1H), 4.44 (m, 2H), 3.90 (m, 2H), 3.66 (t, $J = 6.7$ Hz, 2H), 3.04 (d, $J = 7.8$ Hz, 6H), 2.67 (t, $J = 4.8$ Hz, 4H), 2.56 (q, $J = 7.2$ Hz, 2H), 2.16 - 2.26 (m, 2H), 1.75 - 1.86 (m, 4H), 1.63 (m, 2H), 1.19 (t, $J = 7.3$ Hz, 3H).

[00283] And (1-ethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)(4-ethylpiperazin-1-yl)methanone (5 mg), HPLC/UV purity: 98%; LC-MS (ESI): 555 ($M + 1$)⁺. ¹H NMR (CD_3OD) δ 9.37 (s, 1H), 8.47 (d, $J = 5.8$ Hz, 1H), 8.31 (s, 1H), 8.07 (d, $J = 8.9$ Hz, 1H), 7.64 - 7.73 (m, 2H), 7.03 (s, 1H), 4.35 (q, $J = 7.1$ Hz, 2H), 3.80 (m, 2H), 3.58 - 3.68 (m, 2H), 3.53 (t, $J = 6.7$ Hz, 2H), 2.87 (d, $J = 7.0$ Hz, 6H), 2.56 (t, $J = 4.6$ Hz, 2H), 2.35 - 2.50 (m, 4H), 2.00 - 2.12 (m, 2H), 1.61 - 1.72 (m, 4H), 1.50 (m, 2H), 1.41 (t, $J = 7.2$ Hz, 3H), 1.05 (t, $J = 7.2$ Hz, 3H).

Example 37: Synthesis of N-(3-(piperidin-1-yl)propyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide



Step 1:

[00284] The mixture of methyl 5-bromobenzo[b]thiophene-2-carboxylate (5 g, 18.4 mmol), 4,4',4'',5,5',5'',4'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (5.6 g, 22.1 mmol), Pd(dppf)Cl₂ (1.3 g, 1.84 mmol), and KOAc (3.6 g, 36.8 mmol) in dioxane (50 mL) protected under N₂ atmosphere was heated to

95°C overnight. After cooling to room temperature, the mixture was concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 10% EA in PE) to afford methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophene-2-carboxylate to afford as a white solid (2.12 g, 36% yield). LC-MS (ESI): 319.1 (M + 1)⁺.

Step 2:

[00285] A 20-mL microwave vial was charged with 2,4-dichloro-1,6-naphthyridine (1.1 g, 5.5 mmol), methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophene-2-carboxylate (2.12 g, 6.6 mmol), Pd(PPh₃)₄ (0.63 g, 0.1 mmol) and Na₂CO₃ (1.1 g, 11 mmol) dissolved 1,4-dioxane (10 mL) and H₂O (2 mL). A stir bar is added, the vial is sealed, and the resulting brown solution is heated for 2 h in a Biotage Initiator Eight Microwave Reactor held at a constant temperature of 110°C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The adsorbed material was loaded onto a column and purified using silica gel chromatography (silica gel, eluting with PE to 50% EA in PE) to afford methyl 5-(4-chloro-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (1.0 g, 52%) as a yellow oil, LC-MS (ESI): 355.0 (M + 1)⁺.

Step 3:

[00286] The mixture of methyl 5-(4-chloro-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (1.0 g, 2.8 mmol), 3-(piperidin-1-yl)propan-1-amine (0.48 g, 3.36 mmol) and K₂CO₃ (0.78 g, 5.6 mmol) in DMF (1 mL) was heated to 90°C and held for 18 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to afford the residue which was purified with prep-TLC to afford methyl 5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (136 mg, 9%) as a yellow solid. LC-MS (ESI): 461.1 (M + 1)⁺.

Step 4:


[00287] The mixture of methyl 5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (136 mg, 0.29 mmol) and LiOH·H₂O (124 mg, 2.95 mmol) in MeOH/H₂O (5 mL/1 mL) was stirred at room temperature overnight. The mixture was acidified with HCl solution (2 M) to pH = 2, then concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 447.1 (M + 1)⁺.

Step 5:

[00288] The mixture of 5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (100 mg, 0.22 mmol), 3-(piperidin-1-yl)propan-1-amine (63 mg, 0.45 mmol), HATU (125 mg, 0.33 mmol) and DIPEA (0.11 mL, 0.66 mmol) in DMF (2 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL x 3) and brine (20 mL x 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford N-(3-(piperidin-1-yl)propyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide

as a yellow oil (2.6 mg, 2% yield). LC-MS (ESI): 571.3 ($M + 1$)⁺; ¹H NMR (CD₃OD) δ 9.66 (s, 1H), 8.79 (d, $J = 5.2$ Hz, 1H), 8.53 (s, 1H), 8.16 (d, $J = 8.5$ Hz, 1H), 8.10 (s, 1H), 7.96 (d, $J = 8.5$ Hz, 1H), 7.83 (d, $J = 5.8$ Hz, 1H), 7.23 (s, 1H), 3.77 (t, $J = 6.7$ Hz, 2H), 3.39 - 3.54 (m, 6H), 3.25 (s, 2H), 3.06 - 3.14 (m, 2H), 2.76 - 2.92 (m, 4H), 2.15 - 2.29 (m, 2H), 1.96 - 2.07 (m, 2H), 1.80 - 1.92 (m, 4H), 1.62 - 1.79 (m, 6H), 1.34 - 1.50 (m, 2H).

Example 38: Synthesis of N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,5-naphthyridin-2-yl)benzamide



Step 1:

[00289] To a solution of methyl 3-aminopicolinate (3.04 g, 20 mmol) and pyridine (4.74 g, 60 mmol) in THF (120 mL). Then ethyl 3-chloro-3-oxopropanoate (4.5 g, 30 mmol) was added dropwise under 65°C. Then the mixture was stirred at 65°C for 2 hours. Then the solvent was removed under reduce and the residue was purified by flash column chromatography to afford desired compound. Isolated weight: 2.6 g, yield: 48.87%, as a yellow oil.

Step 2:

[00290] To a solution of Na (345 mg, 15 mmol) in EtOH (30 mL) until the mixture was clear. Then methyl 3-(3-ethoxy-3-oxopropanamido)picolinate (2.6 g, 9.77 mmol) was added. Then the mixture was stirred at 70°C for 2 hours. Then the solvent was removed under reduce to afford desired crude product which used to next step directly.

Step 3:

[00291] To a solution of Ethyl 2,4-dihydroxy-1,5-naphthyridine-3-carboxylate (2.0 g, 9.75 mmol) in 27% HCl (30 mL). Then the mixture was stirred at 90°C for 3 hours. Filtered and the residue was desired compound which used to next step directly. A white solid (1.2 g), yield: 76%. LC-MS (ESI): 163 ($M + 1$)⁺.

Step 4:

[00292] A mixture of 1,5-naphthyridine-2,4-diol (648 mg, 4 mmol) and in POCl₃ (30 mL) was stirred at 120°C for overnight. Then the solvent was removed under reduce pressure in vacuum, the mixture was dissolved in 100 mL DCM and adjusted to pH = 8-9 with NaHCO₃ saturated aqueous solution. Extracted with DCM (100 mL), washed with brine, dried over Na₂SO₄. Evaporation of the organic phase and the residue was purified by flash column to afford a white solid (600 mg). Yield: 75%; LC-MS (ESI): 198, 200 (M + 1)⁺.


Step 5:

[00293] A mixture of 2,4-dichloro-1,5-naphthyridine (400 mg, 2 mmol) and 3-(piperidin-1-yl)propan-1-amine (284 mg, 2.0 mmol) in CH₃CN (20 mL) and was stirred at 90°C for 3 hours. Filtered and the mixture was evaporated and the residue was purified by Prep-TLC to give desired compound as a white solid (340 mg), yield: 56%. LC-MS (ESI): 305 (M + 1)⁺.

Step 6:

[00294] The mixture of 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,5-naphthyridin-4-amine (60.8 mg, 0.2 mmol), N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (121 mg, 0.4 mmol), Pd(PPh₃)₄ (24 mg, 0.02 mmol) and Na₂CO₃ (85 mg, 0.8 mmol) in Dioxane/H₂O (5 mL/0.5 mL) was stirred at for 120°C 1 hour by MW. The mixture was diluted with DCM, washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by Prep-TLC to afford N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,5-naphthyridin-2-yl)benzamide (15 mg, 16.6%) as an white solid. HPLC/UV purity = 92.5%; LC-MS (ESI): 446.2 (M + 1)⁺; ¹H NMR (CD₃OD) δ 8.76 (dd, *J* = 4.3, 1.1 Hz, 1H), 8.45 (m, 1H), 7.83 - 7.90 (m, 2H), 7.77 - 7.81 (m, 1H), 7.53 - 7.59 (m, 2H), 7.31 - 7.42 (m, 1H), 3.79 (t, *J* = 6.9 Hz, 2H), 3.60 (d, *J* = 7.6 Hz, 4H), 3.39 (d, *J* = 6.4 Hz, 2H), 3.33 (m, 1H), 3.23 - 3.29 (m, 1H), 2.99 (t, *J* = 12.4 Hz, 2H), 2.22 - 2.34 (m, 2H), 1.91 - 2.00 (m, 2H), 1.85 (m, 3H), 1.54 (d, *J* = 12.4 Hz, 1H), 1.29 (t, *J* = 6.5 Hz, 3H), 1.19 (t, *J* = 6.5 Hz, 3H).

Example 39: Synthesis of N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,7-naphthyridin-2-yl)benzamide

**Step 1:**

[00295] To a solution of Na (1.0 g, 45.1 mmol) in EtOH (50 mL) was stirred at rt for 2hrs, A solution of methyl 3-aminoisonicotinate (5.0 g, 30.1 mmol) and diethyl malonate (5.7 g, 36.1mmol) in EtOH (30mL) was added dropwise, the resulting reaction mixture was heated to 90 °C overnight. After cooling to room temperature, the mixture was concentrated. The residue was adjusted to PH= 5-6 with 1N HCl, extracted with EtOAc (30 mL × 3) dried over Na₂SO₄, filtered and concentrated to get crude ethyl 2,4-dihydroxy-1,7-naphthyridine-3-carboxylate (1.09g, 15%yield) which was used to the next step without further purification.LC-MS (ESI): 235.0 (M + 1)⁺.

Step 2:

[00296] The mixture of ethyl 2,4-dihydroxy-1,7-naphthyridine-3-carboxylate (1.09 g, 4.6 mmol) in 27% HCl (20 mL) was stirred at 72°C overnight. After cooling to room temperature, the mixture was filtered to get 1,7-naphthyridine-2,4-diol (0.3 g, 40%yield) which was used to the next step without further purification.LC-MS (ESI): 163.0 (M + 1)⁺.

Step 3:

[00297] A mixture of 1,7-naphthyridine-2,4-diol (250 mg, 1.5mmol) and in POCl₃ (2 mL) was stirred at 120°C overnight. After cooling to room temperature, the mixture was concentrated. The residue was dissolved in 10 mL DCM and adjusted to pH = 8-9 with NaHCO₃ saturated aqueous solution. Extracted with EtOAc (10 mL × 3), washed with brine, dried over Na₂SO₄. Filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 20% EA in PE) to afford 2,4-dichloro-1,7-naphthyridine as a yellow oil (146 mg, 47% yield). LC-MS (ESI): 198.9 (M + 1)⁺.

Step 4:

[00298] The mixture of 2,4-dichloro-1,7-naphthyridine (146 mg, 0.73 mmol), 3-(piperidin-1-yl)propan-1-amine (104 mg, 0.73 mmol) and K₂CO₃ (201 mg, 1.46 mmol) in CH₃CN (5 mL) was heated to 90°C

and held for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL x3), the combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue which was purified Prep-TLC to afford 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,7-naphthyridin-4-amine (76 mg, 34%) as a yellow solid. LC-MS (ESI): 305.1 (M + 1)⁺.

Step 5:

[00299] The mixture of 4-bromobenzoic acid (3 g, 14.9 mmol), diethylamine (4.6 ml, 44.7 mmol), HATU (8.5 g, 22.3 mmol) and DIPEA (6.6 ml, 44.7 mmol) in DCM (30 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 20% EA in PE) to afford 4-bromo-N,N-diethylbenzamide as a brown oil (2.8 g, 73% yield). LC-MS (ESI): 256.9 (M + 1)⁺.


Step 6:

[00300] The mixture of 4-bromo-N,N-diethylbenzamide (2.8 g, 11.2 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (3.4 g, 13.4 mmol), PdCl₂(dppf) (0.8 g, 1.12 mmol), and KOAc (2.2 g, 22.4 mmol) in dioxane (50 mL) protected under N₂ atmosphere was heated to 90°C overnight. After cooling to room temperature, the mixture was concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 3% MeOH in DCM) to afford N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide as a brown solid (2.3 g, 69% yield). LC-MS (ESI): 303.9 (M + 1)⁺.

Step 7:

[00301] A 10-mL microwave vial was charged with 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,7-naphthyridin-4-amine (76 mg, 0.25 mmol), N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (151 mg, 0.5 mmol), Pd(PPh₃)₄ (58 mg, 0.05 mmol) and Na₂CO₃ (53 mg, 0.5 mmol) dissolved 1,4-dioxane (2.5 mL) and H₂O (0.5 mL). A stir bar is added, the vial is sealed, and the resulting brown solution is heated for 1 h in a Biotage Initiator Eight Microwave Reactor held at a constant temperature of 120°C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The mixture was filtered off and the filtrate was concentrated under the reduced pressure to get the residue which was purified with Prep-TLC to afford N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,7-naphthyridin-2-yl)benzamide (32 mg, 28%) as a yellow solid. LC-MS (ESI): 446.2 (M + 1)⁺. ¹H NMR (CD₃OD) δ 8.94 (s, 1H), 8.18 (d, J = 5.5 Hz, 1H), 7.55 - 7.62 (m, 4H), 7.52 (d, J = 5.5 Hz, 1H), 7.00 (s, 1H), 3.66 - 3.71 (m, 2H), 3.52 - 3.63 (m, 2H), 3.39 (d, J = 6.8 Hz, 2H), 3.29 - 3.32 (m, 2H), 3.09 - 3.28 (m, 4H), 2.13 - 2.24 (m, 2H), 1.87 (m, 4H), 1.68 (m, 2H), 1.25 - 1.33 (m, 3H), 1.19 (t, J = 6.4 Hz, 3H).

Example 40: Synthesis of N,N-diethyl-4-(2-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-4-yl)benzamide


**Step 1:**

[00302] A mixture of 2,4-dichloro-1,8-naphthyridine (1.0 g, 5 mmol) and 3-(piperidin-1-yl)propan-1-amine (0.71 g, 5 mmol) in CH₃CN (50 mL) and was stirred at 90 °C for 2 hours. Filtered and the mixture was evaporated and the residue was purified by Prep-TLC to give the desired compound (200 mg). LC-MS (ESI): 305 (M + 1)⁺.

Step 2:

[00303] The mixture of 4-chloro-N-(3-(piperidin-1-yl)propyl)-1,8-naphthyridin-2-amine (61 mg, 0.205 mmol), N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (120 mg, 0.4 mmol), Pd(PPh₃)₄ (23 mg, 0.02 mmol) and Na₂CO₃ (43 mg, 0.4 mmol) in Dioxane/H₂O (2.5 mL/0.5 mL) was stirred at for 120 °C 1 hour under MW,. The mixture was diluted with DCM, washed with water (10 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by the Prep-HPLC to N,N-diethyl-4-(2-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-4-yl)benzamide (43 mg, yield: 48%) as an white solid. HPLC/UV purity = 95%; LC-MS (ESI): 446.2 (M + 1)⁺; ¹H NMR (CD₃OD) δ 8.87 (br. s., 1H), 8.14 (d, *J* = 7.3 Hz, 1H), 7.52 - 7.62 (m, 4H), 7.28 - 7.39 (m, 1H), 6.89 (s, 1H), 3.60 (d, *J* = 6.9 Hz, 3H), 3.33 - 3.52 (m, 5H), 3.18 - 3.27 (m, 2H), 3.04 (m, 1H), 3.00 (m, 1H), 2.07 - 2.20 (m, 2H), 1.87 - 1.96 (m, 4H), 1.80 (m, 1H), 1.59 (m, 1H), 1.29 (t, *J* = 6.6 Hz, 3H), 1.19 (t, *J* = 6.6 Hz, 3H).

Example 41: Synthesis of N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-2-yl)benzamide



Step 1:

[00304] To a solution of Na (1.035 g, 45 mmol) in EtOH (30 mL) until the mixture was clear. Then diethyl malonate (5.76 g, 36 mmol), EtOH (10 mL) and ethyl 2-aminonicotinate (5 g, 30 mmol) in EtONa (1.5 M, 30 mL). Then the mixture was stirred at 90 °C for overnight. Then the solvent was removed under reduce pressure in vacuum, the mixture was dissolved in 50 mL H₂O and adjusted to pH= 5-6 with 1 M HCl. Extracted with EA (100 mL), filtered and the residue was used in next step directly. A white solid (3.5 g), yield: 49.6%.

Step 2:

[00305] To a solution of Ethyl 2,4-dihydroxy-1,8-naphthyridine-3-carboxylate (3.5 g, 14.89 mmol) in 27% HCl (100 mL). Then the mixture was stirred at 90 °C for overnight. Then the mixture was adjusted to pH= 5-6 with 30% NaOH under ice-water bath. Filtered and the residue was used in next step directly. A white solid (2.02 g), yield: 83.7%. LC-MS (ESI): 163 (M + 1)⁺.

Step 3:

[00306] A mixture of 1,8-naphthyridine-2,4-diol (2.02 g, 12.47 mmol) and in POCl₃ (100 mL) was stirred at 90 °C for overnight. Then the solvent was removed under reduce pressure in vacuum, the mixture was dissolved in 100 mL DCM and adjusted to pH= 5-6 with NaHCO₃ saturated aqueous solution. Extracted with DCM (100 mL), washed with brine, dried over Na₂SO₄. Evaporation of the organic phase provides a yellow solid (1.9 g) for use in the next step without further purification. Yield: 76%; LC-MS (ESI): 198, 200 (M + 1)⁺.


Step 4:

[00307] A mixture of 2,4-dichloro-1,8-naphthyridine (1.0 g, 5 mmol) and 3-(piperidin-1-yl)propan-1-amine (0.71 g, 5 mmol) in CH₃CN (50 mL) and was stirred at 90 °C for 2 hours. Filtered and the mixture was evaporated and the residue was purified by-TLC to give desired compound (400 mg). LC-MS (ESI): 305 (M + 1)⁺.

Step 5:

[00308] The mixture of 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,8-naphthyridin-4-amine (63 mg, 0.205 mmol), N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (121 mg, 0.4 mmol), Pd(PPh₃)₄ (23.1 mg, 0.02 mmol) and Na₂CO₃ (42 mg, 0.4 mmol) in Dioxane/H₂O (2 mL/0.2 mL) was stirred at for 120 °C 1 hour by MW. The mixture was diluted with DCM, washed with water (20 mL ×3) and brine (20 mL ×1), dried over Na₂SO₄, filtered and concentrated. The crude product was purified by the Prep-HPLC to N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-2-yl)benzamide (7.5 mg, 8.2%) as an off-white solid. HPLC/UV purity = 95%; LC-MS (ESI): 446 (M + 1)⁺; ¹H NMR (CD₃OD) δ 8.96 (d, J = 3.7 Hz, 1H), 8.69 - 8.76 (m, 1H), 8.17 (d, J = 8.2 Hz, 2H), 7.44 - 7.62 (m, 3H), 7.03 (s, 1H), 3.56 - 3.73 (m, 4H), 3.31 - 3.41 (m, 6H), 3.28 (m, 2H), 2.17 - 2.35 (m, 2H), 1.86 (m, 4H), 1.68 (m, 2H), 1.29 (t, J = 6.9 Hz, 3H), 1.17 (t, J = 6.7 Hz, 3H).

Example 42: Synthesis of N,N-Diethyl-4-(4-((3-morpholinopropyl)amino)-1,6-naphthyridin-2-yl)benzamide

**Step 1:**

[00309] The mixture of 4-bromobenzoic acid (5.0 g, 24.9 mmol), diethylamine (703 mg, 27.4 mmol), HATU (11.4 g, 29.9 mmol) and DIPEA (6.4 g, 49.8 mmol) in DMF (20 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (10 mL), and then extracted with EA (20 mL $\times$ 3). The organic layer was washed with water (20 mL $\times$ 3) and brine (30 mL), dried over Na_2SO_4 , concentrated and purified by flash column chromatography (silica gel, eluting with 5% to 20% EA/PE) to afford 4-Bromo-N,N-diethylbenzamide (6.0 g, 94%) as oil. LC-MS (ESI): 256.9 ($\text{M} + 1$)⁺.

Step 2:

[00310] The mixture of 4-bromo-N,N-diethylbenzamide (6.0 g, 23.4 mmol), bis(pinacolato)diboron (7.1 g, 27.4 mmol), $\text{Pd}(\text{dppf})\text{Cl}_2$ (1.7 g, 2.34 mmol) and KOAc (4.6 g, 46.8 mmol) in 1,4-dioxane (20 mL) was stirred at 90°C under N_2 for 18 hrs. The reaction mixture was diluted with DCM (20 mL), washed with water (20 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by flash column chromatography (silica gel, eluting with 10% to 50% EA/PE) to afford N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1.8 g, 25%) as brown solid. LC-MS (ESI): 303.9 ($\text{M} + 1$)⁺.

Step 3: 4-(4-Chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide.


[00311] The mixture of N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1.8 g, 5.9 mmol), 2,4-dichloro-1,6-naphthyridine (7.1 g, 5.4 mmol), $\text{Pd}(\text{PPh}_3)_4$ (624 mg, 0.54 mmol) and Na_2CO_3 (1.1 g, 10.8 mmol) in 1,4-dioxane/ H_2O (8 mL / 2 mL) was stirred at 100°C under N_2 for 16 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 1% to 3% MeOH/DCM) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (1.8 g, 90%) as yellow solid. LC-MS (ESI): 339.9 ($\text{M} + 1$)⁺.

Step 4:

[00312] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (100 mg, 0.29 mmol) in DMF (5 mL) were added 3-morpholinopropan-1-amine (62 mg, 0.44 mmol) and K_2CO_3 (80 mg, 0.58 mmol). After stirred at 100°C overnight, the reaction mixture was quenched with water (5 mL), and


extracted with DCM (10 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na₂SO₄, concentrated and purified by prep-TLC to afford N,N-diethyl-4-(4-((3-morpholinopropyl)amino)-1,6-naphthyridin-2-yl)benzamide (10 mg, 8%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 448.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.77 (s, 1H), 8.89 (d, J = 6.4 Hz, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 6.4 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.29 (s, 1H), 4.13-4.02 (m, 2H), 3.88 (t, J = 6.8 Hz, 2H), 3.84-3.75 (m, 2H), 3.63 (q, J = 7.2 Hz, 2H), 3.59-3.50 (m, 2H), 3.43-3.34 (m, 4H), 3.26-3.15 (m, 2H), 2.38-2.32 (m, 2H), 1.32 (t, J = 7.2 Hz, 3H), 1.18 (t, J = 7.2 Hz, 3H).

Example 43: Synthesis N,N-Diethyl-4-(4-((2-(piperidin-1-yl)ethyl)amino)-1,6-naphthyridin-2-yl)benzamide



[00313] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (100 mg, 0.29 mmol) in DMF (5 mL) were added 2-(piperidin-1-yl)ethan-1-amine (56 mg, 0.44 mmol) and K₂CO₃ (80 mg, 0.58 mmol). After stirred at 100°C overnight, the reaction mixture was quenched with water (5 mL), and extracted with DCM (10 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na₂SO₄, concentrated and purified by prep-HPLC to afford N,N-diethyl-4-(4-((2-(piperidin-1-yl)ethyl)amino)-1,6-naphthyridin-2-yl)benzamide (30 mg, 24%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 432.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.73 (s, 1H), 8.87 (d, J = 6.0 Hz, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 6.0 Hz, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.36 (s, 1H), 4.21 (t, J = 6.0 Hz, 2H), 3.73 (d, J = 11.2 Hz, 2H), 3.64-3.58 (m, 4H), 3.36-3.30 (m, 2H), 3.05 (t, J = 10.8 Hz, 2H), 1.95-1.84 (m, 5H), 1.55-1.59 (m, 1H), 1.30 (t, J = 7.2 Hz, 3H), 1.18 (t, J = 7.2 Hz, 3H).

Example 44: Synthesis of N,N-Diethyl-4-(4-((3-(piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide




Step 1:

[00314] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (300 mg, 0.88 mmol) in DMF (5 mL) were added tert-butyl 4-(3-aminopropyl)piperazine-1-carboxylate (321 mg, 1.32 mmol) and K_2CO_3 (240 mg, 1.76 mmol). After stirred at 100°C overnight, the reaction mixture was quenched with water (5 mL), and extracted with DCM (10 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-HPLC to afford tert-butyl 4-(3-((2-(4-(diethylcarbamoyl)phenyl)-1,6-naphthyridin-4-yl)amino)propyl)piperazine-1-carboxylate (300 mg, 62%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 547.2 ($M + 1$)⁺.

Step 2:

[00315] To a solution of tert-butyl 4-(3-((2-(4-(diethylcarbamoyl)phenyl)-1,6-naphthyridin-4-yl)amino)propyl)piperazine-1-carboxylate (300 mg, 0.55 mmol) in DCM was added TFA (125 mg, 1.10 mmol). After stirred at room temperature for 2 hrs, the reaction mixture was concentrated and purified by prep-HPLC to afford N,N-diethyl-4-(4-((3-(piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide (200 mg, 82 %) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 447.3 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.74 (s, 1H), 8.87 (d, $J = 6.4$ Hz, 1H), 8.09 (d, $J = 8.4$ Hz, 2H), 7.90 (d, $J = 6.0$ Hz, 1H), 7.68 (d, $J = 8.8$ Hz, 2H), 7.27 (s, 1H), 3.86 (t, $J = 6.8$ Hz, 2H), 3.61 (q, $J = 6.8$ Hz, 2H), 3.46-3.43 (m, 4H), 3.36-3.32 (m, 2H), 3.32-3.30 (m, 4H), 3.16 (t, $J = 7.6$ Hz, 2H), 2.28-2.21 (m, 2H), 1.30 (t, $J = 7.2$ Hz, 3H), 1.17 (t, $J = 7.2$ Hz, 3H).


Example 45: Synthesis of N,N-Diethyl-4-(4-((3-(4-(methylsulfonyl)piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide



[00316] To a solution of N,N-diethyl-4-(4-((3-(piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide (200 mg, 0.45 mmol) in DCM were added MsCl (57 mg, 0.50 mmol) and Et₃N (91 mg, 0.90 mmol). After stirred at room temperature overnight, the reaction mixture was quenched with water (5 mL), and extracted with DCM (10 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-HPLC to afford N,N-diethyl-4-(4-((3-(4-(methylsulfonyl)piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide (25 mg, 11%) as yellow solid. HPLC/UV purity: 99%; LC-MS (ESI): 525.2 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.48 (s, 1H), 8.57 (d, $J = 6.0$ Hz, 1H), 8.13 (d, $J = 7.8$ Hz, 2H), 7.78 (d, $J = 6.0$ Hz, 1H), 7.56 (d, $J = 8.4$ Hz,


2H), 7.08 (s, 1H), 3.60 (t, $J = 6.6$ Hz, 4H), 3.35 (s, 2H), 3.21 (s, 4H), 2.83 (s, 3H), 2.63-2.60 (m, 6H), 2.02 (t, $J = 6.6$ Hz, 2H), 1.29-1.27 (m, 3H), 1.16 (t, $J = 6.6$ Hz, 3H).

Example 46: Synthesis of N,N-Diethyl-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide




[00317] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (100 mg, 0.29 mmol) in DMF (5 mL) were added 1-methylpiperidin-4-amine (50 mg, 0.44 mmol) and K_2CO_3 (80 mg, 0.58 mmol). After stirred at 100°C overnight, the reaction mixture was quenched with water (5 mL), and extracted with DCM (10 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-HPLC to afford N,N-diethyl-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide (15 mg, 12 %) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 418.3 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ 9.84 (s, 1H), 8.87 (d, $J = 6.0$ Hz, 1H), 8.12 (d, $J = 8.0$ Hz, 2H), 7.93 (d, $J = 6.0$ Hz, 1H), 7.68 (d, $J = 8.0$ Hz, 2H), 7.40 (s, 1H), 4.49 (m, 1H), 3.71 (d, $J = 12.4$ Hz, 2H), 3.64-3.59 (m, 2H), 3.34-3.24 (m, 4H), 2.95 (s, 3H), 2.43 (d, $J = 13.2$ Hz, 2H), 2.23-2.14 (m, 2H), 1.30 (t, $J = 7.2$ Hz, 3H), 1.16 (t, $J = 7.2$ Hz, 3H).

Example 47: Synthesis of 4-(4-((2-(Dimethylamino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide



[00318] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (50 mg, 0.15 mmol) in DMF (3 mL) were added N,N-dimethylethane-1,2-diamine (19 mg, 0.22 mmol) and K_2CO_3 (40 mg, 0.29 mmol). The reaction mixture was stirred at 100 °C overnight, then quenched with water (3 mL), and extracted with DCM (10 mL $\times$ 3). The organic mixture was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-HPLC to afford 4-(4-((2-(dimethylamino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (20 mg, 58 %) as yellow oil. HPLC/UV purity: 100%; LC-MS (ESI): 392.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.74 (s, 1H), 8.87 (d, $J = 6.0$ Hz, 1H), 8.15 (d, $J = 7.8$ Hz, 2H), 7.96 (d, $J = 6.0$ Hz, 1H), 7.67 (d, $J = 8.4$ Hz, 2H), 7.39 (s, 1H), 4.20 (t, $J = 6.0$ Hz, 2H), 3.66 - 3.59 (m, 4H), 3.35 - 3.31 (m, 2H), 3.03 (s, 6H), 1.31 (t, $J = 7.2$ Hz, 3H), 1.16 (t, $J = 7.2$ Hz, 3H).

Example 48: Synthesis of N,N-diethyl-4-(4-(3-(4-methylpiperazin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide




Step 1:


[00319] The mixture of 2,4-dichloro-1,6-naphthyridine (345 mg, 1.72 mmol), N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (785 mg, 2.59 mmol), Pd(PPh₃)₄ (198 mg, 0.1 mmol) and Na₂CO₃ (365 mg, 2.0 mmol) in 1,4-dioxane (10 mL) and H₂O (2 mL) under N₂ atmosphere was heated to 100 °C overnight. After cooling to room temperature, the mixture was concentrated by rotary evaporation (55 °C, 20 mmHg). The residue was purified by the flash column chromatography (silica gel, eluting with DCM to 3% MeOH in DCM) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide as a colorless oil (452 mg, 77%). LC-MS (ESI): 340.1 (M + 1)⁺.

Step 2:

[00320] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (100 mg, 0.29 mmol), 3-(4-methylpiperazin-1-yl)propan-1-amine (68 mg, 0.43 mmol) and K₂CO₃ (80 mg, 0.58 mmol) in DMF (1 mL) was heated at 100 °C for 18 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL × 3). The combined organic layers were washed by water (10 mL × 3) and brine (10 mL), dried over Na₂SO₄, filtered and the filtrate was concentrated under the reduced pressure to give the residue which was purified prep-TLC to afford N,N-diethyl-4-(4-(3-(4-methylpiperazin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide (14.8 mg, 10%) as a yellow oil. HPLC/UV purity: 100%; LC-MS (ESI): 461.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.74 (s, 1H), 8.90 (d, J = 6.2 Hz, 1H), 8.04 - 8.16 (d, J = 8.3 Hz, 2H), 7.91 (d, J = 6.2 Hz, 1H), 7.62 - 7.75 (d, J = 8.3 Hz, 2H), 7.28 (s, 1H), 3.86 (t, J = 6.9 Hz, 2H), 3.63 (q, J = 6.8 Hz, 2H), 3.34 - 3.44 (m, 6H), 2.99 - 3.15 (m, 4H), 2.96 (t, J = 7.3 Hz, 2H), 2.91 (s, 3H), 2.10 - 2.24 (m, 2H), 1.32 (t, J = 7.0 Hz, 3H), 1.19 (t, J = 7.0 Hz, 3H).

Example 49: Synthesis of N,N-diethyl-4-(4-(2-morpholinoethylamino)-1,6-naphthyridin-2-yl)benzamide


[00321] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (150 mg, 0.44 mmol), 2-morpholinoethanamine (86 mg, 0.66 mmol) and K_2CO_3 (121 mg, 0.88 mmol) in DMF (1 mL) was heated at 100°C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 and filtered. The filtrate was concentrated under the reduced pressure to get the residue which was purified prep-TLC to afford N,N-diethyl-4-(4-(2-morpholinoethylamino)-1,6-naphthyridin-2-yl)benzamide (28 mg, 15%). HPLC/UV purity: 100%; LC-MS (ESI): 434.3 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.72 (s, 1H), 8.88 (d, $J = 5.9$ Hz, 1H), 8.09 - 8.19 (d, $J = 8.6$ Hz, 2H), 7.95 (d, $J = 6.2$ Hz, 1H), 7.60 - 7.71 (d, $J = 8.3$ Hz, 2H), 7.38 (s, 1H), 4.23 (t, $J = 6.2$ Hz, 2H), 3.91-3.93 (m, 4H), 3.67 (t, $J = 6.2$ Hz, 2H), 3.56 - 3.63 (m, 2H), 3.31 - 3.38 (m, 4H), 1.30 (t, $J = 7.0$ Hz, 3H), 1.16 (t, $J = 7.0$ Hz, 3H).

Example 50: Synthesis of N,N-diethyl-4-(4-(2-(4-methylpiperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide

[00322] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (150 mg, 0.44 mmol), 2-(4-methylpiperazin-1-yl)ethanamine (94 mg, 0.66 mmol) and K_2CO_3 (121 mg, 0.88 mmol) in DMF (1 mL) was heated at 100°C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the residue which was purified prep-TLC to afford N,N-diethyl-4-(4-(2-(4-methylpiperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide. (8 mg, 4%). HPLC/UV purity: 100%; LC-MS (ESI): 447.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.76 (s, 1H), 8.90 (d, $J = 6.2$ Hz,


1H), 8.08 - 8.17 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 6.2 Hz, 1H), 7.64 - 7.74 (d, J = 8.3 Hz, 2H), 7.30 (s, 1H), 3.95 (t, J = 6.2 Hz, 2H), 3.63 (q, J = 6.8 Hz, 2H), 3.32 - 3.47 (m, 10H), 3.06 (t, J = 6.2 Hz, 2H), 2.92 (s, 3H), 1.32 (t, J = 7.0 Hz, 3H), 1.18 (t, J = 7.0 Hz, 3H).

Example 51: Synthesis of N,N-diethyl-4-(4-(tetrahydro-2H-pyran-4-ylamino)-1,6-naphthyridin-2-yl)benzamide



[00323] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (100 mg, 0.29 mmol), tetrahydro-2H-pyran-4-amine (43 mg, 0.43 mmol) and K_2CO_3 (121 mg, 0.88 mmol) in DMF (1 mL) was heated at 100°C for 18 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 . Filtered and the filtrate was concentrated under the reduced pressure to give the residue which was purified by prep-TLC to afford N,N-diethyl-4-(4-(tetrahydro-2H-pyran-4-ylamino)-1,6-naphthyridin-2-yl)benzamide (10 mg, 9%). HPLC/UV purity: 99%; LC-MS (ESI): 405.2 ($M + 1$)⁺. ¹HNMR (METHANOL- d_4) δ : 9.62 (s, 1H), 8.62 (d, J = 5.9 Hz, 1H), 8.13 (d, J = 8.1 Hz, 2H), 7.80 (d, J = 5.9 Hz, 1H), 7.58 (d, J = 8.3 Hz, 2H), 7.19 (s, 1H), 4.00 - 4.22 (m, 4H), 3.55 - 3.72 (m, 4H), 3.34 - 3.36 (m, 1H), 2.11 (d, J = 12.9 Hz, 2H), 1.79-1.89 (m, 2H), 1.32 (t, J = 7.0 Hz, 3H), 1.17 (t, J = 6.7 Hz, 3H).

Example 52: Synthesis of N,N-diethyl-4-(4-(2-(piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide




Step 1:

[00324] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (278 mg, 0.82 mmol), tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate (281 mg, 1.23 mmol) and K_2CO_3 (226 mg, 1.64 mmol) in DMF (1 mL) was heated at 100°C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 . Filtered and the filtrate was concentrated under the reduced pressure to give the residue which was purified prep-TLC to afford tert-butyl 4-(2-(4-(diethylcarbamoyl)phenyl)-1,6-naphthyridin-4-ylamino)ethyl)piperazine-1-carboxylate (90 mg, 20%). LC-MS (ESI): 533.3($M + 1$)⁺.

Step 2:


[00325] The mixture of tert-butyl 4-(2-(2-(4-(diethylcarbamoyl)phenyl)-1,6-naphthyridin-4-ylamino)ethyl)piperazine-1-carboxylate (90 mg, 0.16mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 18hrs. Then the solvent was removed under the reduced pressure to give the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm × 250 mm, 10 um, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford N,N-diethyl-4-(4-(2-(piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide (13 mg, 18%) as a TFA salt. HPLC/UV purity: 99%; LC-MS (ESI): 433.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.90 (d, J = 6.1 Hz, 1H), 8.07 - 8.18 (d, J = 8.2 Hz, 2H), 7.94 (d, J = 5.8 Hz, 1H), 7.65 - 7.74 (d, J = 8.5 Hz, 2H), 7.32 (s, 1H), 4.00 (t, J = 6.1 Hz, 2H), 3.63 (d, J = 7.3 Hz, 2H), 3.34 - 3.40 (m, 6H), 3.01 - 3.18 (m, 6H), 1.32 (t, J = 7.0 Hz, 3H), 1.18 (t, J = 7.0 Hz, 3H).

Example 53: Synthesis of N,N-diethyl-4-(4-(2-(4-(methanesulfonyl)piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide




[00326] The mixture of N,N-diethyl-4-(4-(2-(piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide (50 mg, 0.11 mmol) and Et₃N (0.03 mL, 0.22mmol) in DCM (5 mL) was cooled to 0°C. Then methanesulfonyl chloride (20 mg, 0.17 mmol) added. The mixture was stirred at room temperature for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL × 3). The combined organic layers were washed by water (10 mL) and brine (10 mL), dried over Na₂SO₄. Filtered and the filtrate was concentrated under the reduced pressure to give the crude mixture which was purified by prep-TLC to afford N,N-diethyl-4-(4-(2-(4-(methanesulfonyl)piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide (7 mg, 29%) . HPLC/UV purity: 99%; LC-MS (ESI): 511.2(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.52 (s, 1H), 8.62 (d, J = 5.8 Hz, 1H), 8.10 - 8.20 (d, J = 7.9 Hz, 2H), 7.82 (d, J = 6.1 Hz, 1H), 7.53 - 7.63 (d, J = 7.9 Hz, 2H), 7.16 (s, 1H), 3.72 (t, J = 6.4 Hz, 2H), 3.61 (d, J = 7.0 Hz, 2H), 3.35 - 3.41 (m, 2H), 3.22 - 3.30 (m, 4H), 2.82 - 2.92 (m, 5H), 2.68 - 2.77 (m, 4H), 1.31 (t, J = 6.9 Hz, 3H), 1.19 (t, J = 6.7 Hz, 3H).

Example 54: Synthesis of N,N-Diethyl-4-(4-(4-methoxyphenylamino)-1,6-naphthyridin-2-yl)benzamide




[00327] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (67.6 mg, 0.2 mmol), 4-methoxyaniline (27 mg, 0.22 mmol), $\text{Pd}_2(\text{dba})_3$ (18 mg, 0.02 mmol), Xphos (9.1 mg, 0.02 mmol) and Cs_2CO_3 (183 mg, 0.2 mmol) in 1,4-dioxane (5 mL) was stirred at 120°C overnight. The reaction mixture was filtered, concentrated and purified by silica gel column chromatography to give N,N-diethyl-4-(4-(4-methoxyphenylamino)-1,6-naphthyridin-2-yl)benzamide (36 mg, 42%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 427.3 ($\text{M} + 1$)⁺. ¹H NMR (METHOL- d_4) δ : 9.53 (s, 1H), 8.51 (d, $J = 6.0$ Hz, 1H), 7.85 (d, $J = 8.0$ Hz, 2H), 7.73 (d, $J = 6.0$ Hz, 1H), 7.39 (d, $J = 8.0$ Hz, 2H), 7.28 (d, $J = 8.8$ Hz, 2H), 7.03 (s, 1H), 6.98 (d, $J = 8.8$ Hz, 2H), 3.76 (s, 3H), 3.48 - 3.44 (m, 2H), 3.21 - 3.19 (m, 2H), 1.17 (t, $J = 6.4$ Hz, 3H), 1.03 (t, $J = 6.4$ Hz, 3H).

Example 55: Synthesis of 4-(4-(4-(Dimethylamino)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide




[00328] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (68 mg, 0.2 mmol), N^1, N^1 -dimethylbenzene-1,4-diamine (32 mg, 0.24 mmol), $\text{Pd}_2(\text{dba})_3$ (19 mg, 0.02 mmol), Xphos (10 mg, 0.02 mmol), and Cs_2CO_3 (130 mg, 0.2 mmol) in 1,4-dioxane (5 mL) was stirred at 120°C overnight. The reaction mixture was filtered, concentrated and purified by silica gel column chromatography (DCM/MeOH = 10/ 1) to give 4-(4-(4-(dimethylamino)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (40 mg, 45%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 440.3 ($\text{M} + 1$)⁺. ¹H NMR (METHOL- d_4) δ : 9.65 (s, 1H), 8.62 (d, $J = 6.0$ Hz, 1H), 7.96 (d, $J = 8.4$ Hz, 2H), 7.83 (d, $J = 6.4$ Hz, 1H), 7.51 (d, $J = 8.0$ Hz, 2H), 7.32-7.20 (m, 2H), 7.12 (s, 1H), 6.93 (m, 2H), 3.59 (q, $J = 6.8$ Hz, 2H), 3.33-3.31 (m, 2H), 3.02 (s, 6H), 1.29 (t, $J = 7.2$ Hz, 3H), 1.15 (t, $J = 7.2$ Hz, 3H).

Example 56: Synthesis of 4-(4-(4-((Dimethylamino)methyl)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide




[00329] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (68 mg, 0.2 mmol), 4-((dimethylamino)methyl)iline (33 mg, 0.24 mmol), $\text{Pd}_2(\text{dba})_3$ (18 mg, 0.02 mmol), Xphos (10 mg, 0.02 mmol), and Cs_2CO_3 (130 mg, 0.2 mmol) in 1,4-dioxane (5 mL) was stirred at 120°C overnight. The reaction mixture was filtered, concentrated and purified by silica gel column chromatography to give 4-(4-(4-((dimethylamino)methyl)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (40 mg, 44%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 454.3 ($\text{M} + 1$)⁺. ¹H NMR (METHOL- d_4) δ : 9.68 (s, 1H), 8.67(d, $J = 6.0$ Hz, 1H), 8.05 (d, $J = 8.4$ Hz, 2H), 7.89 (d, $J = 6.0$ Hz, 1H), 7.57 - 7.52 (m, 7H), 3.97 (s, 2H), 3.59 (q, $J = 6.4$ Hz, 2H), 3.34 - 3.33 (m, 2H), 2.63 (s, 6H), 1.29 (t, $J = 6.8$ Hz, 3H), 1.16 (t, $J = 6.8$ Hz, 3H).

Example 57: Synthesis of N,N-Diethyl-4-(4-(4-(2-methoxyethylamino)phenylamino)-1,6-naphthyridin-2-yl)benzamide




[00330] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (102 mg, 0.3 mmol), N^1 -(2-methoxyethyl)benzene-1,4-diamine (60 mg, 0.36 mmol), $\text{Pd}_2(\text{dba})_3$ (19 mg, 0.02 mmol), Xphos (10 mg, 0.02 mmol), and Cs_2CO_3 (130 mg, 0.2 mmol) in 1,4-Dioxane (5 mL) was stirred at 120°C overnight. The reaction mixture was filtered, concentrated and purified by silica gel column chromatography to give N,N-diethyl-4-(4-(4-(2-methoxyethylamino)phenylamino)-1,6-naphthyridin-2-yl)benzamide (70 mg, 50%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 470.3 ($\text{M} + 1$)⁺. ¹H NMR (METHOL- d_4) δ : 9.62 (s, 1H), 8.59 (t, $J = 6.0$ Hz, 1H), 7.93 (d, $J = 7.6$ Hz, 2H), 7.81(d, $J = 6.0$ Hz, 1H), 7.48 (d, $J = 7.6$ Hz, 2H), 7.21(d, $J = 8.0$ Hz, 2H), 7.07 (s, 1H), 6.80 (d, $J = 8.4$ Hz, 2H), 3.62 (t, $J = 5.2$ Hz, 2H), 3.58 - 3.54 (m, 2H), 3.40 (s, 3H), 3.33 - 3.30 (m, 4H), 1.26 (t, $J = 6.8$ Hz, 3H), 1.13 (t, $J = 6.8$ Hz, 3H).

Example 58: Synthesis of 4-(4-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide




[00331] 4-(4-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide was synthesized in a similar fashion as Example 52, Step 1. HPLC/UV purity: 100%; LC-MS (ESI): 482.2 ($M + 1$)⁺. ¹H NMR (METHOL-*d*₄) δ : 9.74 (s, 1H), 8.89 (d, $J = 5.6$ Hz, 1H), 8.12 (d, $J = 7.2$ Hz, 2H), 7.91 (d, $J = 5.6$ Hz, 1H), 7.70 (d, $J = 7.6$ Hz, 2H), 7.32 (s, 1H), 3.93 (t, $J = 5.2$ Hz, 2H), 3.61 - 3.63 (m, 2H), 3.34 - 3.36 (m, 2H), 3.22-3.24 (m, 4H), 3.15 - 3.17 (m, 4H), 3.10 (t, $J = 5.2$ Hz, 2H), 1.31 (t, $J = 6.4$ Hz, 3H), 1.18 (t, $J = 6.4$ Hz, 3H).

Example 59: Synthesis of 4-(4-((3-(1,1-Dioxidothiomorpholino)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide



[00332] 4-(4-((3-(1,1-Dioxidothiomorpholino)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide was synthesized in a similar fashion as Example 52, Step 1. HPLC/UV purity: 100%; LC-MS (ESI): 496.2 ($M + 1$)⁺. ¹H NMR (METHOL-*d*₄) δ : 9.78 (s, 1H), 8.89 (d, $J = 5.6$ Hz, 1H), 8.12 (d, $J = 7.2$ Hz, 2H), 7.93 (d, $J = 5.6$ Hz, 1H), 7.69 (d, $J = 7.6$ Hz, 2H), 7.30 (s, 1H), 3.88 (t, $J = 6.4$ Hz, 2H), 3.68 - 3.72 (m, 4H), 3.61 - 3.63 (m, 2H), 3.48 - 3.52 (m, 4H), 3.32 - 3.37 (m, 4H), 2.31 (t, $J = 7.2$ Hz, 2H), 1.31 (t, $J = 6.4$ Hz, 3H), 1.18 (t, $J = 6.8$ Hz, 3H).


Example 60: Synthesis of N,N-Diethyl-4-(4-(1-methylpyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide



[00333] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (135 mg, 0.4 mmol), 1-methylpyrrolidin-3-amine (60 mg, 0.7 mmol) and K₂CO₃ (138 mg, 1 mmol) in DMF (5 mL) was stirred at 115°C overnight. After adding 200 mL water, the mixture was extracted with EA (100 mL), washed with brine, concentrated and purified by flash column chromatography to give N,N-diethyl-4-(4-(1-

methylpyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide (20 mg, 12.4%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 404.2 ($M + 1$)⁺. ¹H NMR (METHOL-*d*₄) δ : 9.94 (s, 1H), 8.92 (s, 1H), 8.15 (d, $J = 8.4$ Hz, 2H), 7.98 (s, 1H), 7.67 (d, $J = 8.0$ Hz, 2H), 7.32 (s, 1H), 4.37 - 4.35 (m, 1H), 4.05 - 3.91 (m, 2H), 3.62 - 3.58 (m, 2H), 3.35 - 3.30 (m, 4H), 3.06 (s, 3H), 2.96 - 2.80 (m, 1H), 2.51 - 2.46 (m, 1H), 1.29 (t, $J = 6.8$ Hz, 3H), 1.16 (t, $J = 6.8$ Hz, 3H).

Example 61: Synthesis of N,N-Diethyl-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide




Step 1:


[00334] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide (100 mg, 0.29 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (118 mg, 0.59 mmol), and K₂CO₃ (122 mg, 0.88 mmol) in DMF (2 mL) was stirred at 80°C overnight. The reaction mixture was quenched with water (5 mL), extracted with EA (5 mL $\times$ 3), washed with water (10 mL) and brine (20 mL), and dried over Na₂SO₄. After filtration, the filtrate was concentrated and purified by prep-TLC (DCM/MeOH= 10/1) to afford tert-butyl 4-(2-(4-(diethylcarbamoyl)phenyl)-1,6-naphthyridin-4-ylamino)piperidine-1-carboxylate (30 mg, 21.7%) as yellow solid. LC-MS (ESI): 504.6 ($M + 1$)⁺.

Step 2:

[00335] Tert-butyl 4-(2-(4-(diethylcarbamoyl)phenyl)-1,6-naphthyridin-4-ylamino)piperidine-1-carboxylate (30 mg, 0.05 mmol) in DCM was added TFA (0.5mL). After stirred at room temperature for 2 hrs, the reaction mixture was concentrated and purified by prep-TLC to afford N,N-diethyl-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide (1.6mg, 6.6 %) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 404.2 ($M + 1$)⁺. ¹H NMR (DMSO-*d*₆) δ : 9.92 (s, 1H), 8.87 (d, $J = 6.4$ Hz, 1H), 8.80 (d, $J = 9.6$ Hz, 1H), 8.61 (d, $J = 9.6$ Hz, 1H), 8.15 (d, $J = 7.6$ Hz, 2H), 7.94 (d, $J = 6.0$ Hz, 1H), 7.66 (d, $J = 8.4$ Hz, 2H), 7.39 (s, 1H), 4.43 - 4.41 (m, 1H), 3.49 - 3.46 (m, 4H), 3.23 - 3.22 (m, 2H), 3.15 - 3.06 (m, 2H), 2.20 - 2.17 (m, 2H), 1.99 - 1.89 (m, 2H), 1.24 (t, $J = 6.8$ Hz, 3H), 1.10 (t, $J = 6.8$ Hz, 3H).

Example 62: Synthesis of N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzamide



**Step 1:**

[00336] The mixture of methyl 4-(4-chloro-1,6-naphthyridin-2-yl)benzoate (100 mg, 0.33 mmol), 1-methylpyrrolidin-3-amine (60 mg, 0.6 mmol) and K_2CO_3 (138 mg, 1.0 mmol) in DMF (10 mL) was stirred at 75°C overnight. After completion, water (10 mL) was added, and then the mixture was extracted with EA (20 mL) three times. The combined organic layers were washed with water (10 mL) and brine (10 mL), dried over Na_2SO_4 , filtered, concentrated and purified by prep-TLC to give methyl 4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzoate (60 mg, 50%) as brown solid. LC-MS (ESI): 362.1 ($M + 1$)⁺.


Step 2:

[00337] The solution of methyl 4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzoate (110 mg, 0.3 mmol) and $LiOH \cdot H_2O$ (38 mg, 0.9 mmol) in THF/ H_2O (10 mL/3 mL) was stirred at room temperature overnight. The mixture was acidified with 2 N aq. HCl solution to pH=2, then concentrated to give the crude product as white solid that was used directly in the next step without further purification. LC-MS (ESI): 349.1 ($M + 1$)⁺.

Step 3:


[00338] The mixture of 4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzoic acid (72 mg, 0.2 mmol), 1-methylpiperidin-4-amine (35 mg, 0.3 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (52 mg, 0.4 mmol) in DMF (5 mL) was stirred at room temperature overnight. After completion, water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (10 mL) and brine (10 mL), dried over Na_2SO_4 , filtered, concentrated and purified by pre-HPLC to give N-(1-methylpiperidin-4-yl)-4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzamide (10 mg, 11%. HPLC/UV purity: 100%; LC-MS (ESI): 445.1 ($M + 1$)⁺. ¹H NMR (METHOL- d_4) δ : 9.80 (s, 1H), 8.77 (d, $J = 8.4$ Hz, 1H), 8.22 (d, $J = 8.4$ Hz, 2H), 8.09 (d, $J = 8.4$ Hz, 2H), 7.94 (d, $J = 8.4$ Hz, 1H), 7.27 (s, 1H), 4.20 - 4.23 (m, 2H), 3.61 - 3.66 (m, 4H), 3.46 - 3.50 (m, 2H), 3.20 - 3.25 (m, 2H), 3.08 (s, 3H), 2.93 (s, 3H), 2.44 - 2.50 (m, 1H), 2.26 - 2.35 (m, 2H), 1.94 - 2.05 (m, 3H).

Example 63: Synthesis of 4-(4-((1-Methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide



[00339] 4-(4-((1-Methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide was synthesized in a similar fashion as Example 62, Step 3. HPLC/UV purity: 100%; LC-MS (ESI): 473.3 (M + 1)⁺. ¹H NMR (METHOL-d₄) δ : 9.54 (s, 1H), 8.77 (d, *J* = 6.0 Hz, 1H), 8.14 (d, *J* = 8.4 Hz, 2H), 7.98 (d, *J* = 8.4 Hz, 2H), 7.78 (d, *J* = 6.0 Hz, 1H), 7.02 (s, 1H), 4.45 - 4.47 (m, 1H), 3.48 (t, *J* = 8.4 Hz, 2H), 3.00 - 3.05 (m, 1H), 2.89 - 2.95 (m, 1H), 2.82 - 2.86 (m, 1H), 2.68 - 2.74 (m, 5H), 2.61 - 2.65 (m, 1H), 2.52 - 2.57 (m, 1H), 2.46 - 2.52 (m, 3H), 1.92 - 2.03 (m, 4H), 1.70 - 1.74 (m, 4H), 1.55 - 1.57 (m, 2H).

Example 64: Synthesis of N-(3-(Piperidin-1-yl)propyl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide



Step 1:


[00340] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide (150 mg, 0.367 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (147 mg, 0.733 mmol) and K₂CO₃ (152 mg, 1.1 mmol) in DMF (10 mL) was stirred at 100°C overnight. Then 100 mL water was added and the mixture was extracted with EA (100 mLx2), washed with brine, dried over Na₂SO₄, concentrated and purified with silica gel column chromatography to give tert-butyl 4-(2-(4-(3-(piperidin-1-yl)propylcarbamoyl)phenyl)-1,6-naphthyridin-4-ylamino)piperidine-1-carboxylate (100 mg, 46%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 573.3 (M + 1)⁺.

Step 2:

[00341] The solution of tert-butyl 4-(2-(4-(3-(piperidin-1-yl)propylcarbamoyl)phenyl)-1,6-naphthyridin-4-ylamino)piperidine-1-carboxylate (57 mg, 0.1 mmol) in TFA/DCM (1 mL/5 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mmx250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to give N-(3-(piperidin-1-yl)propyl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide (8 mg, 16.8%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 473.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.84 (s, 1H), 8.86 (d, *J* = 6.0 Hz, 1H), 8.17 - 8.11 (m, 4H), 7.93 (d, *J* = 6.0 Hz, 1H), 7.42 (s, 1H), 4.51 - 4.46 (m, 1H), 3.59 - 3.52 (m, 6H), 3.31 - 3.23 (m, 2H), 3.23 - 3.18 (m, 2H), 2.96 (t, *J* = 12.0 Hz,


2H), 2.39 (d, $J = 13.2$ Hz, 2H), 2.14 - 2.04 (m, 4H), 1.98 (d, $J = 14.8$ Hz, 2H), 1.88 - 1.74 (m, 3H), 1.55 - 1.51 (m, 1H).

Example 65: Synthesis of N-(1-Methylpiperidin-4-yl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide




[00342] The solution of tert-butyl 4-(2-(4-(1-methylpiperidin-4-ylcarbamoyl)phenyl)-1,6-naphthyridin-4-ylamino)piperidine-1-carboxylate (16.3 mg, 0.03 mmol) in TFA/DCM (1 mL/5 mL) was stirred at room temperature for 2 hrs. The solution was concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to give N-(1-methylpiperidin-4-yl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide (7 mg, 52.5%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 445.2 (M + 1). ¹H NMR (METHANOL-d₄) δ : 9.58 (s, 1H), 8.58 (d, $J = 6.0$ Hz, 1H), 8.15 (d, $J = 8.4$ Hz, 2H), 8.00 (d, $J = 8.8$ Hz, 2H), 7.80 (d, $J = 6.0$ Hz, 1H), 7.14 (s, 1H), 4.63 - 4.60 (m, 1H), 3.99 - 3.95 (m, 1H), 3.30 - 3.15 (m, 2H), 2.99 - 2.87 (m, 4H), 2.35 (s, 3H), 2.22 (t, $J = 12.4$ Hz, 4H), 2.06 - 1.96 (m, 2H), 1.78 - 1.69 (m, 4H).

Example 66: Synthesis of N,N-diethyl-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide




[00343] N,N-diethyl-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide was synthesized in a similar fashion as Example 64. HPLC/UV purity: 100%; LC-MS (ESI): 390.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.89 (s, 1H), 8.85 (d, $J = 6.0$ Hz, 1H), 8.15 (d, $J = 8.0$ Hz, 2H), 7.97 (d, $J = 6.0$ Hz, 1H), 7.66 (d, $J = 8.0$ Hz, 2H), 7.35 (s, 1H), 3.82-3.87 (m, 1H), 3.50-3.68 (m, 5H), 3.30-3.34 (m, 3H), 2.60-2.66 (m, 1H), 2.41-2.44 (m, 1H), 1.29 (t, $J = 6.4$ Hz, 3H), 1.16 (t, $J = 6.8$ Hz, 3H).

Example 67: Synthesis of N-(3-(Piperidin-1-yl)propyl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide




[00344] N-(3-(Piperidin-1-yl)propyl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide was synthesized in a similar fashion as Examples 62 and 64. HPLC/UV purity: 100%; LC-MS (ESI): 459.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.96 (s, 1H), 8.86 (d, $J = 6.0$ Hz, 1H), 8.22 (d, $J = 8.0$ Hz, 2H), 8.15 (d, $J = 8.0$ Hz, 2H), 8.01 (d, $J = 6.0$ Hz, 1H), 7.39 (s, 1H), 3.81 - 3.86 (m, 1H), 3.68 - 3.71 (m, 2H), 3.56 - 3.61 (m, 6H), 3.22 (d, $J = 6.0$ Hz, 2H), 2.98 (d, $J = 12.4$ Hz, 2H), 2.63 - 2.67 (m, 1H), 2.42 - 2.48 (m, 1H), 2.11 - 2.15 (m, 2H), 1.97 - 2.01 (m, 2H), 1.81 - 1.88 (m, 3H), 1.56 - 1.58 (m, 1H).

Example 68: Synthesis of N-(1-Methylpiperidin-4-yl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide



[00345] N-(1-Methylpiperidin-4-yl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide was synthesized in a similar fashion as Examples 62 and 64. HPLC/UV purity: 100%; LC-MS (ESI): 431.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.90 (s, 1H), 8.84 (d, $J = 6.4$ Hz, 1H), 8.20 (d, $J = 8.4$ Hz, 2H), 8.12 (d, $J = 8.0$ Hz, 2H), 7.99 (d, $J = 6.4$ Hz, 1H), 7.36 (s, 1H), 4.20 - 4.25 (m, 1H), 3.83 - 3.86 (m, 1H), 3.45 - 3.72 (m, 6H), 3.22 (d, $J = 12.4$ Hz, 2H), 2.92 (s, 3H), 2.62 - 2.66 (m, 1H), 2.42 - 2.48 (m, 1H), 2.27 - 2.31 (m, 2H), 1.97 - 2.05 (m, 2H).

Example 69: Synthesis of N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide

**Step 1:**

[00346] The mixture of 4-Bromobenzoic acid (2.0 g, 9.9 mmol), 1-methylpiperidin-4-amine (2.3 g, 19.8 mmol), HATU (5.7 g, 14.9 mmol) and DIPEA (2.6 g, 19.8 mmol) in DMF (30 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (20 mL), extracted with DCM (20 mL $\times$ 3). The combined organic layer was washed with water (20 mL $\times$ 3) and brine (30 mL), dried over Na_2SO_4 , concentrated and purified by flash column chromatography (silica gel, eluting with DCM to 10% MeOH/DCM) to afford 4-bromo-N-(1-methylpiperidin-4-yl)benzamide (2.4 g, 81%) as yellow solid. LC-MS (ESI): 297.1 ($\text{M} + 1$)⁺.

Step 2

[00347] The mixture of 4-bromo-N-(1-methylpiperidin-4-yl)benzamide (500 mg, 1.68 mmol), bis(pinacolato)diboron (1.3 g, 5.04 mmol), Pd(dppf)Cl_2 (123 mg, 0.168 mmol) and KOAc (330 g, 3.36 mmol) in 1,4-dioxane (15 mL) was stirred at 95 °C under N_2 for 8 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with DCM to 10% MeOH/DCM) to afford N-(1-methylpiperidin-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (300 mg, 52%) as brown solid. LC-MS (ESI): 345.1 ($\text{M} + 1$)⁺.


Step 3:

[00348] The mixture of N-(1-methylpiperidin-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (300 mg, 0.87 mmol), 2,4-dichloro-1,6-naphthyridine (143 mg, 0.72 mmol), $\text{Pd(PPh}_3)_4$ (83 mg, 0.072 mmol) and Na_2CO_3 (153 mg, 1.44 mmol) in 1,4-dioxane/ H_2O (12 mL/3 mL) was stirred at 100°C under N_2 for 16 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 1% to 3% MeOH/DCM) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide (30 mg, 9%) as oil. LC-MS (ESI): 381.1 ($\text{M} + 1$)⁺.

Step 4:

[00349] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide (30 mg, 0.08 mmol) in DMF (2 mL) were added 1-methylpiperidin-4-amine (18 mg, 0.16 mmol) and K_2CO_3 (22 mg, 0.16 mmol). The reaction mixture was stirred at 100 °C overnight, then quenched with water (5 mL), and extracted with DCM (5 mL $\times$ 3). The organic layer was washed by water (10 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 , concentrated and purified by prep-TLC to afford N-(1-methylpiperidin-4-yl)-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide (5 mg, 14%) as yellow oil. HPLC/UV purity: 100%; LC-MS (ESI): 459.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.83(s, 1H), 8.86 (d, $J = 6.0$ Hz, 1H), 8.13 (m, 4H), 7.92 (d, $J = 6.0$ Hz, 1H), 7.40 (s, 1H), 4.42 - 4.49 (m, 1H), 4.24 - 4.18 (m, 1H), 3.70 (d, $J = 12.8$ Hz, 2H), 3.62 (d, $J = 12.4$ Hz, 2H), 3.27 - 3.18 (m, 4H), 2.93 (d, $J = 13.6$ Hz, 6H), 2.42 (d, $J = 13.6$ Hz, 2H), 2.29 (d, $J = 13.6$ Hz, 2H), 2.21 - 2.13(m, 2H), 2.04 - 1.92 (m, 2H).

Example 70: Synthesis of N-(3-(Piperidin-1-yl)propyl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide

**Step 1:**


[00350] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)benzoic acid (250 mg, 0.88 mmol), 3-(piperidin-1-yl)propan-1-amine (151 mg, 1.06 mmol), HATU (403 mg, 1.06mmol) and DIPEA (227 g, 1.76 mmol) in DMF (8 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with DCM (10 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 , concentrated and purified by prep-TLC (MeOH/DCM=10/1) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide (300 mg, 83%) as yellow oil. LC-MS (ESI): 409.1 ($M + 1$)⁺.

Step 2:

[00351] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide (100 mg, 0.24 mmol) in DMF (5 mL) were added tetrahydro-2H-pyran-4-amine (36 mg, 0.36 mmol) and K_2CO_3 (66 mg, 0.48 mmol). The reaction mixture was stirred at 100 °C overnight, then quenched with water (5 mL), and extracted with DCM (5 mL $\times$ 3). The organic layer was washed with water(10 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 , concentrated and purified by prep-PLC to afford N-(3-(piperidin-


1-yl)propyl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide (10 mg, 9%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 474.2 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.83 (s, 1H), 8.85 (d, $J = 6.0$ Hz, 1H), 8.13 (s, 4H), 7.90 (d, $J = 6.0$ Hz, 1H), 7.36 (s, 1H), 4.44-4.36 (m, 1H), 4.07 (d, $J = 11.6, 4.0$ Hz, 2H), 3.68-3.53 (m, 6H), 3.20 (t, $J = 7.6$ Hz, 2H), 2.96 (t, $J = 11.6$ Hz, 2H), 2.14-2.09 (m, 4H), 1.99-1.75 (m, 7H), 1.59-1.50 (m, 1H).

Example 71: Synthesis of N-(3-(Piperidin-1-yl)propyl)-4-(4-((pyridin-4-ylmethyl)amino)-1,6-naphthyridin-2-yl)benzamide



[00352] To a solution of 4-(4-chloro-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide (100 mg, 0.24 mmol) in DMF (5 mL) were added pyridin-4-ylmethanamine (52 mg, 0.48 mmol) and K₂CO₃ (66 mg, 0.48 mmol). The reaction mixture was stirred at 80 °C overnight, then quenched with water (5 mL), and extracted with DCM (5 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (20 mL), dried over Na₂SO₄, concentrated and purified by prep-PLC to afford N-(3-(piperidin-1-yl)propyl)-4-(4-((pyridin-4-ylmethyl)amino)-1,6-naphthyridin-2-yl)benzamide (1.6 mg, 1%) as yellow oil. HPLC/UV purity: 100%; LC-MS (ESI): 481.3 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.82 (s, 1H), 8.90 (d, $J = 6.0$ Hz, 1H), 8.72 (s, 2H), 8.08-8.01 (m, 5H), 7.90 (d, $J = 5.6$ Hz, 2H), 7.17 (s, 1H), 5.22 (d, $J = 7.6$ Hz, 2H), 3.58-3.50 (m, 4H), 3.18 (t, $J = 7.6$ Hz, 2H), 2.95 (t, $J = 11.2$ Hz, 2H), 2.12-2.06 (m, 2H), 1.97 (d, $J = 15.2$ Hz, 2H), 1.87-1.73 (m, 3H), 1.60-1.51 (m, 1H).

Example 72: Synthesis of N-(1-Methylpiperidin-4-yl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide



Step 1:

[00353] The mixture of 2,4-dichloro-1,6-naphthyridine (1.0 g, 5.0 mmol), (4-(methoxycarbonyl)phenyl)boronic acid (1.1 g, 6.0 mmol), Pd(PPh₃)₄ (578 mg, 0.5 mmol) and Na₂CO₃ (1.06 g, 10.0 mmol) in 1,4-dioxane/H₂O (20/5 mL) was stirred at 100°C under N₂ for 3 hrs. The reaction mixture was concentrated, diluted with DCM (30 mL), washed with water (10 mL × 3) and brine (20 mL), and dried over Na₂SO₄. After filtration, the filtrate was concentrated and purified by flash column chromatography (silica gel, eluting with 10% to 20% EA/PE) to afford methyl 4-(4-chloro-1,6-naphthyridin-2-yl)benzoate (1.0 g, 67%) as white solid. LC-MS(ESI): 299.0 (M + 1)⁺.

Step 2:

[00354] To a solution of methyl 4-(4-chloro-1,6-naphthyridin-2-yl)benzoate (200 mg, 0.67 mmol) in DMF (5 mL) were added tetrahydro-2H-pyran-4-amine (102 mg, 1.01 mmol) and K₂CO₃ (185 mg, 1.34 mmol). The reaction mixture was stirred at 80 °C overnight, then quenched with water (5 mL), and extracted with DCM (10 mL × 3). The organic layer was washed with water (10 mL × 3) and brine (20 mL), dried over Na₂SO₄, concentrated and purified by flash column chromatography (silica gel, eluting with 10% to 50% EA/PE) to afford methyl 4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzoate (150 mg, 8%) as yellow solid. LC-MS (ESI): 364.1 (M + 1)⁺;


Step 3:

[00355] To a solution of methyl 4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzoate (150 mg, 0.42 mmol) in MeOH (5 mL) was added 1N aq. LiOH solution (1.68 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated, acidified with 1N aq. HCl solution to pH=2, and then lyophilized to afford 4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzoic acid as brown solid. The crude product was used in the next step without further purification. LC-MS (ESI): 350.1 (M + 1)⁺.

Step 4:

[00356] The mixture of 4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzoic acid (50 mg, 0.14 mmol), 1-methylpiperidin-4-amine (19 mg, 0.17 mmol), HATU (65 mg, 0.17 mmol) and DIPEA (36 mg, 0.28 mmol) in DMF (5 mL) was stirred at room temperature for 2 h. The reaction mixture was quenched with water (5 mL), extracted with DCM (10 mL × 3), washed with water (10 mL × 3) and brine (20 mL), dried over Na₂SO₄, concentrated and purified by prep-TLC to afford N-(1-methylpiperidin-4-yl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide as yellow solid (60 mg, 94%). LC-MS (ESI): 446.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.83 (s, 1H), 8.85 (d, J = 6.0 Hz, 1H), 8.18-8.10 (m, 4H), 7.89 (d, J = 6.0 Hz, 1H), 7.36 (s, 1H), 4.43-4.37 (m, 1H), 4.24-4.18 (m, 1H), 4.07 (dd, J = 11.6, 4.0 Hz, 2H), 3.68-3.62 (m, 4H), 3.20 (t, J = 11.6 Hz, 2H), 2.91 (s, 3H), 2.28 (d, J = 12.0 Hz, 2H), 2.09 (d, J = 10.4 Hz, 2H), 2.02-1.87(m, 4H).

Example 73: Synthesis of 4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide

**Step 1:**

[00357] The mixture of methyl 4-(4-chloro-1,6-naphthyridin-2-yl)benzoate (90 mg, 0.30 mmol) and Br₂ (53 mg, 0.33 mmol) in acetic acid (10 mL) was stirred at 70°C overnight. The solvent was removed under reduced pressure and the residue was poured into saturated NaHCO₃ solution (10 mL). The mixture was extracted with EA (20 mL) three times. The combined organic layers were washed with water (10 mL × 3) and brine (10 mL), dried over Na₂SO₄, filtered, concentrated, and purified by prep-TLC to give methyl 4-(8-bromo-4-chloro-1,6-naphthyridin-2-yl)benzoate (80 mg, 72%) as brown solid. LC-MS (ESI): 376.9 (M + 1)⁺.

Step 2

[00358] The mixture of methyl 4-(8-bromo-4-chloro-1,6-naphthyridin-2-yl)benzoate (50 mg, 0.13 mmol), 3-(piperidin-1-yl)propan-1-amine (22 mg, 0.16 mmol) and K₂CO₃ (36 mg, 0.26 mmol) in DMA (2 mL) was stirred at 70°C overnight. Then water (10 mL) was added, and the mixture was extracted with EA (20 mL) three times. The combined organic layers were washed with water (10 mL×3) and brine (10 mL×1), dried over Na₂SO₄, filtered, concentrated and purified by prep-TLC to give methyl 4-(8-bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (48 mg, 77%) as brown oil. LC-MS (ESI): 482.8 (M + 1)⁺.

Step 3:


[00359] The mixture of methyl 4-(8-bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (48 mg, 0.10 mmol) and LiOH·H₂O (12 mg, 0.30 mmol) in THF/H₂O (3 mL/1.5 mL) was stirred at room temperature overnight. The mixture was acidified with 2N aq. HCl solution to pH=4, and then concentrated to give the crude product as brown solid that was used directly in the next step without further purification. LC-MS (ESI): 468.8 (M + 1)⁺.

Step 4:

[00360] Step 4 to synthesize 4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide was completed in a similar fashion as Example 72, Step 4. LC-MS (ESI): 523.8


(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.59 (s, 1H), 8.97 (s, 1H), 8.33 (d, *J* = 8.0 Hz, 2H), 7.61 (d, *J* = 8.0 Hz, 2H), 7.33 (s, 1H), 3.75 (t, *J* = 6.8 Hz, 2H), 3.58-3.64 (m, 4H), 3.33-3.39 (m, 2H), 3.29-3.31 (m, 2H), 2.98 (t, *J* = 12.4 Hz, 2H), 2.25-2.30 (m, 2H), 1.95-1.99 (m, 2H), 1.77-1.84 (m, 3H), 1.51-1.58 (m, 1H), 1.32 (t, *J* = 6.8 Hz, 3H), 1.19 (t, *J* = 6.8 Hz, 3H).

Example 74: Synthesis of 4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide



[00361] 4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide was synthesized in a similar fashion as Example 73. LC-MS (ESI): 565.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.39 (s, 1H), 8.79 (s, 1H), 8.29 (d, *J* = 8.0 Hz, 2H), 7.92 (d, *J* = 8.0 Hz, 2H), 7.22 (s, 1H), 4.08-4.12 (m, 1H), 3.60 (t, *J* = 6.8 Hz, 2H), 3.45-3.52 (m, 4H), 3.15-3.19 (m, 2H), 3.11 (t, *J* = 12.8 Hz, 2H), 2.81-2.89 (m, 5H), 2.13-2.21 (m, 4H), 1.80-1.86 (m, 4H), 1.34-1.75 (m, 3H), 1.40-1.46 (m, 1H).

Example 75: Synthesis of N,N-Diethyl-4-(8-methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide



Step 1:

[00362] The mixture of methyl 4-(8-bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (48 mg, 0.10 mmol), dimethylzinc solution in THF (0.2 mL, 0.20 mmol) and Pd(t-Bu₃P)₂ (10 mg, 0.02 mmol) in dioxane (8 mL) was stirred at 80 °C under N₂ atmosphere for 3 hours. Then water (10 mL) was added, and the mixture was extracted with EA (20 mL). The organic layer was washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄, filtered, concentrated and purified by flash chromatography to give methyl 4-(8-methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (32 mg, 78%) as yellow oil. LC-MS (ESI): 418.8 (M + 1)⁺.

Step 2:


[00363] The mixture of 4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate (140 mg, 0.33 mmol) and LiOH·H₂O (42 mg, 1.0 mmol) in THF/H₂O (10 mL/5 mL) was stirred at room temperature overnight. Then the mixture was acidified with 1N aq. HCl solution to pH =

2, and concentrated to give the crude product as brown solid that was used directly in the next step without further purification. LC-MS (ESI): 404.8 ($M + 1$)⁺.

Step 3:


[00364] Step 3 to synthesize N,N-Diethyl-4-(8-methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide was completed in a similar fashion as Example 72, Step 4. LC-MS (ESI): 459.8($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.49 (s, 1H), 8.46 (s, 1H), 8.24 (d, $J = 8.4$ Hz, 2H), 7.49 (d, $J = 8.4$ Hz, 2H), 7.25 (s, 1H), 3.63 (t, $J = 6.8$ Hz, 2H), 3.46 - 3.51 (m, 4H), 3.21 - 3.26 (m, 2H), 3.18 - 3.23 (m, 2H), 2.86 (t, $J = 12.0$ Hz, 2H), 2.69 (s, 3H), 2.13 - 2.20 (m, 2H), 1.84 - 1.93 (m, 2H), 1.65 - 1.76 (m, 3H), 1.38 - 1.50 (m, 1H), 1.23 (t, $J = 6.8$ Hz, 3H), 1.07 (t, $J = 6.8$ Hz, 3H).

Example 76: Synthesis of 4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide



[00365] 4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide was synthesized in a similar fashion as Example 72, Step 4. LC-MS (ESI): 501.4 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.68 (s, 1H), 8.55 (s, 1H), 8.36 (d, $J = 8.0$ Hz, 2H), 8.01 (d, $J = 8.0$ Hz, 2H), 7.37 (s, 1H), 4.17 - 4.24 (m, 1H), 3.72 (t, $J = 6.0$ Hz, 2H), 3.60 (t, $J = 14.6$ Hz, 4H), 3.30 - 3.34 (m, 2H), 3.20 (t, $J = 12.0$ Hz, 2H), 2.90 - 2.98 (m, 5H), 2.79 (s, 3H), 2.26 - 2.29 (m, 4H), 1.92 - 1.98 (m, 4H), 1.73 - 1.84 (m, 3H), 1.50 - 1.56 (m, 1H).


Example 77: Synthesis of 4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide



[00366] Synthesis of 4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide was synthesized in a similar fashion as Example 72, Step 4. LC-MS (ESI): 529.4 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.58 (s, 1H), 8.44 (s, 1H), 8.29 (d, $J = 8.4$ Hz, 2H), 7.95 (d, $J = 8.4$ Hz, 2H), 7.29 (s, 1H), 3.63 (t, $J = 6.8$ Hz, 2H), 3.42-3.49 (m, 6H), 3.23-3.26 (m, 2H), 3.09

(t, $J = 8.0$ Hz, 2H), 2.85 (t, $J = 8.4$ Hz, 4H), 2.70 (s, 3H), 2.16-2.21 (m, 2H), 1.96-2.01 (m, 2H), 1.83-1.90 (m, 4H), 1.68-1.75 (m, 6H), 1.37-1.45 (m, 2H).

Example 78: Synthesis of N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide




Step 1:

[00367] A 20-mL microwave vial was charged with 2,4-dichloro-1,6-naphthyridine (633 mg, 3.2 mmol), methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate (1 g, 3.8 mmol), Pd(PPh₃)₄ (364 mg, 0.32 mmol), Na₂CO₃ (670 mg, 6.32 mmol), 1,4-dioxane (10 mL) and H₂O (1 mL). The vial is sealed, and the resulting brown solution was heated for 2 hrs in a Biotage Initiator Eight Microwave Reactor at a constant temperature of 110 °C. The resulting solution was concentrated by rotary evaporation (55°C, 20 mmHg). The residue was purified by Prep-TLC (silica gel, eluting with 5% methanol in DCM) to give methyl 5-(4-chloro-1,6-naphthyridin-2-yl)picolinate (900 mg, 95%) as a yellow solid. HPLC/UV purity: 94%; LC-MS (ESI): 300.1 (M + 1)⁺.

Step 2:

[00368] The mixture of methyl 5-(4-chloro-1,6-naphthyridin-2-yl)picolinate (600 mg, 2 mmol), 3-(piperidin-1-yl)propan-1-amine (569 mg, 2.4 mmol) and K₂CO₃ (552 mg, 4 mmol) in DMF (3 mL) was heated at 80 °C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL × 3). The combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the crude product, which was purified by Prep-TLC (silica gel, eluting with 10% methanol and 1% NH₃.H₂O in DCM) to afford N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide (400 mg, 39%) as a yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 516.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.49 (s, 1H), 9.30 (d, $J = 2.1$ Hz, 1H), 8.55 - 8.65 (m, 2H), 8.24 (d, $J = 8.1$ Hz, 1H), 7.80 (d, $J = 6.2$ Hz, 1H), 7.11 (s, 1H), 3.50-3.58 (m, $J = 17.9, 6.8$ Hz, 4H), 2.41 - 2.63 (m, 12H), 1.97 - 2.08 (m, 2H), 1.83 - 1.95 (m, 2H), 1.60 - 1.74 (m, 8H), 1.47 - 1.59 (m, 4H).

Example 79: Synthesis of N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide


**Step 1:**

[00369] To a solution of 1-methylpiperidin-4-amine (301 mg, 2.64 mmol) in DCM (10 mL) was added $\text{Al}(\text{CH}_3)_3$ (2.6 mL, 2.64 mmol) drop wise at 0°C under nitrogen. The mixture was stirred at room temperature for 30mins, and then was cooled to 0°C again. A solution of methyl 5-(4-chloro-1,6-naphthyridin-2-yl)picolinate (158 mg, 0.53 mmol) in DCM (5mL) was added drop wise, and the resulting reaction mixture was stirred at room temperature for 18hrs. The reaction mixture was quenched by water (10 mL), then extracted with DCM (10mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated in vacuo to give the crude mixture, which was purified with Prep-TLC (silica gel, eluting with 10% methanol and 1% $\text{NH}_3\cdot\text{H}_2\text{O}$ in DCM) to afford 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)picolinamide (120 mg, 60%) as a white solid. HPLC/UV purity: 90%; LC-MS (ESI): 382.3 ($\text{M} + 1$)⁺.

Step 2:

[00370] The mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)picolinamide (120 mg, 0.3 mmol), 3-(piperidin-1-yl)propan-1-amine (65 mg, 0.45 mmol) and K_2CO_3 (83 mg, 0.6 mmol) in DMF (2 mL) was heated at 70°C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the crude product, which was purified by Prep-TLC (silica gel, eluting with 10% methanol and 1% $\text{NH}_3\cdot\text{H}_2\text{O}$ in DCM) to afford N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide (20 mg, 14%) as a yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 488.2($\text{M} + 1$)⁺. ^1H NMR (METHANOL- d_4) δ : 9.48 (s, 1H), 9.29 (d, $J = 1.8$ Hz, 1H), 8.53 - 8.64 (m, 2H), 8.22 (d, $J = 8.2$ Hz, 1H), 7.79 (d, $J = 6.1$ Hz, 1H), 7.10 (s, 1H), 3.91 - 3.96 (m, 1H), 3.56 (t, $J = 6.9$ Hz, 2H), 2.95 (d, $J = 11.6$ Hz, 2H), 2.47 - 2.68 (m, 6H), 2.35 (s, 3H), 2.28 (t, $J = 11.4$ Hz, 2H), 1.95 - 2.11 (m, 4H), 1.77 (d, $J = 9.8$ Hz, 2H), 1.64-1.67 (m, 4H), 1.49-1.52 (m, 2H).

Example 80: Synthesis of 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide

**Step 1:**

[00371] The mixture of ethyl 5-(4-chloro-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate (400 mg, 1.09 mmol), (4-(piperidin-1-ylmethyl)phenyl)methanamine (447 mg, 2.19 mmol) and K_2CO_3 (302 mg, 2.19 mmol) in DMF (1 mL) was heated at 90°C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the residue which was purified by silica gel flash column chromatography to afford ethyl 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (163 mg, 28%). LC-MS (ESI): 534.1 ($M + 1$)⁺.

Step 2:

[00372] The mixture of ethyl 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (163 mg, 0.30 mmol) and 1N aq. LiOH solution (1.2 mL, 1.22 mmol) in MeOH (5 mL) was stirred at room temperature overnight. The mixture was acidified with 1N aq. HCl solution (3 mL) to pH=2. The water phase was concentrated to give the crude product which was used directly in the next step without further purification. LC-MS (ESI): 506.3 ($M + 1$)⁺.


Step 3:

[00373] The mixture of 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (40 mg, 0.08 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (32 mg, 0.16 mmol), HATU (45 mg, 0.12 mmol) and DIPEA (30 mg, 0.24 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL $\times$ 3). The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the Prep-TLC to obtain tert-butyl 4-(1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamido)piperidine-1-carboxylate (36 mg, 66%). LC-MS (ESI): 688.4 ($M + 1$)⁺.

Step 4:

[00374] The mixture of tert-butyl 4-(1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamido)piperidine-1-carboxylate (36 mg, 0.05 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 2hrs. The reaction mixture was removed under the reduced pressure to give the residue which was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm × 250 mm, 10 μm, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide (30 mg, 90%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 588.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.74 (s, 1H), 8.88 (d, J = 6.1 Hz, 1H), 8.30 (s, 1H), 7.92 (d, J = 6.1 Hz, 1H), 7.70 - 7.82 (m, 2H), 7.60 - 7.67 (d, J = 7.9 Hz, 2H), 7.50 - 7.58 (d, J = 8.2 Hz, 2H), 7.27 (s, 1H), 7.13 (s, 1H), 5.04 (s, 2H), 4.27 (s, 2H), 4.15 - 4.23 (m, 1H), 4.08 (s, 3H), 3.50 (d, J = 13.4 Hz, 2H), 3.40 (d, J = 12.8 Hz, 2H), 3.11 - 3.23 (m, 2H), 2.92 (t, J = 11.4 Hz, 2H), 2.23 (d, J = 11.6 Hz, 2H), 1.82 - 1.96 (m, 4H), 1.61 - 1.82 (m, 3H), 1.45-1.50 (m, 1H).


Example 81: Synthesis of 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



[00375] The mixture of 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (56 mg, 0.11 mmol), 1-methylpiperidin-4-amine (25 mg, 0.22 mmol), HATU (62 mg, 0.16 mmol) and DIPEA (42 mg 0.33 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL × 3). The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by Prep-HPLC(Welch, XB-C18, 21.2 mm × 250 mm, 10 μm, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide (30 mg, 90%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 602.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.79 (s, 1H), 8.90 (d, J = 4.8 Hz, 1H), 8.31 (s, 1H), 7.96 (d, J = 5.7 Hz, 1H), 7.78 - 7.83 (d, 1H), 7.72 - 7.77 (d, 1H), 7.63 - 7.68 (d, J = 8.0 Hz, 2H), 7.54 - 7.60 (d, J = 7.8 Hz, 2H), 7.28 (s, 1H), 7.15 (s, 1H), 5.06 (s, 2H), 4.29 (s, 2H), 4.20-4.22 (m, 1H), 4.09 (s, 3H), 3.64 (d, J = 12.4 Hz, 2H), 3.42 (d, J = 12.1 Hz,


2H), 3.22 (t, J = 12.5 Hz, 2H), 2.88 - 2.99 (m, 5H), 2.29 (d, J = 13.5 Hz, 2H), 1.93 - 2.03 (m, 2H), 1.81 - 1.89 (m, 2H), 1.81 (d, J = 13.0 Hz, 1H), 1.64 - 1.76 (m, 2H), 1.42 - 1.52 (m, 1H).

Example 82: Synthesis of (1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone




[00376] The mixture of 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (56 mg, 0.11 mmol), 1-methylpiperazine (22 mg, 0.22 mmol), HATU (62 mg, 0.16 mmol) and DIPEA (42 mg, 0.33 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL×3). The combined organic layers were washed with water (20 mL×3) and brine (20 mL×1), dried over Na₂SO₄, filtered and concentrated. The residue was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm × 250 mm, 10 μm, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford (1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone (9 mg, 14%) as a TFA salt. HPLC/UV purity: 98%; LC-MS (ESI): 588.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.78 (s, 1H), 8.90 (d, J = 5.7 Hz, 1H), 8.31 (s, 1H), 7.96 (d, J = 6.0 Hz, 1H), 7.81 (d, J = 8.9 Hz, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.62 - 7.68 (d, J = 7.8 Hz, 2H), 7.53 - 7.60 (d, J = 7.8 Hz, 2H), 7.15 (s, 1H), 7.02 (s, 1H), 5.06 (s, 2H), 4.29 (s, 2H), 3.94 (s, 3H), 3.53-3.71 (m, 2H), 3.35-3.52 (m, 4H), 3.33-3.34 (m, 4H), 3.00 (s, 3H), 2.94 (t, J = 11.7 Hz, 2H), 1.90 (d, J = 14.4 Hz, 2H), 1.81 (d, J = 12.8 Hz, 1H), 1.65 - 1.77 (m, 2H), 1.41 - 1.54 (m, 1H).

Example 83: Synthesis of 1-methyl-N-((1-methylpiperidin-4-yl)methyl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



[00377] The mixture of 1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (30 mg, 0.06mmol), (1-methylpiperidin-4-yl)methanamine (15 mg, 0.12 mmol), HATU (34 mg, 0.09 mmol) and DIPEA (23 mg 0.18 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL×3). The combined organic layers were washed with water (20 mL×3) and brine (20 mL×1), dried over Na₂SO₄, filtered and concentrated. The residue was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm × 250 mm, 10 um, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford 1-methyl-N-((1-methylpiperidin-4-yl)methyl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide (10 mg, 27%) as a yellow oil. HPLC/UV purity: 99%; LC-MS (ESI): 616.2(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.78 (s, 1H), 8.90 (d, J = 5.2 Hz, 1H), 8.32 (s, 1H), 7.95 (d, J = 5.8 Hz, 1H), 7.72 - 7.84 (m, 2H), 7.66 (d, J = 7.9 Hz, 2H), 7.52 - 7.61 (m, 2H), 7.26 (s, 1H), 7.16 (s, 1H), 5.06 (s, 2H), 4.29 (s, 2H), 4.10 (s, 3H), 3.58 (d, J = 11.0 Hz, 2H), 3.36 - 3.46 (m, 4H), 2.88 - 3.08 (m, 7H), 2.10 (d, J = 14.6 Hz, 2H), 1.90 - 1.99 (m, 3H), 1.81 (d, J = 12.5 Hz, 1H), 1.70 (d, J = 12.2 Hz, 2H), 1.42 - 1.65 (m, 3H).

Example 84: Synthesis of 1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide



Step 1:

[00378] The mixture of ethyl 5-(4-chloro-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate (150 mg, 0.41 mmol), N-methyl-3-(piperidin-1-yl)propan-1-amine (128 mg, 0.82 mmol) and K_2CO_3 (113 mg, 0.82 mmol) in DMF (1 mL) was heated at 90°C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the residue which was purified by silica gel flash column chromatography to afford ethyl 1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (102 mg, 51%). LC-MS (ESI): 486.3(M + 1)⁺.


Step 2:

[00379] The mixture of ethyl 1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (102 mg, 0.21 mmol) and 1N aq. LiOH solution (0.84 mL, 0.84 mmol) in MeOH (5 mL) was stirred at room temperature overnight. The mixture was acidified with 1N aq. HCl solution (10 mL) to pH=2. The water phase was concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 458.3 (M + 1)⁺.

Step 3:

[00380] The mixture of 1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (48 mg, 0.11 mmol), (1-methylpiperidin-4-yl)methanamine (24 mg, 0.21 mmol), HATU (60 mg, 0.16 mmol) and DIPEA (40 mg 0.32 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL $\times$ 3). The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm $\times$ 250 mm, 10 μ m, eluting with 40% CH_3CN in 1% TFA in H_2O) to afford 1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide (6 mg, 10%) as a yellow oil. HPLC/UV purity: 100%; LC-MS (ESI): 554.3(M + 1)⁺. ¹H NMR (METHANOL- d_4) δ : 9.63 (s, 1H), 8.83 (d, J = 5.9 Hz, 1H), 8.42 (d, J = 1.6 Hz, 1H), 7.92 - 8.01 (m, 2H), 7.80 (d, J = 8.9 Hz, 1H), 7.39 (s, 1H), 7.30 (s, 1H), 4.16 - 4.27 (m, 1H), 4.09 (s, 3H), 4.05 (t, J = 7.5 Hz, 2H), 3.72 (s, 3H), 3.57 - 3.67 (m, 4H), 3.14 - 3.30 (m, 4H), 2.88 - 3.03 (m, 5H), 2.36 - 2.46 (m, 2H), 2.31 (d, J = 13.2 Hz, 2H), 1.73 - 2.03 (m, 7H), 1.44-1.54 (m, 1H).

Example 85: Synthesis of 1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-yl)butan-2-ylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide

**Step 1:**

[00381] To a solution of 3-aminobutan-1-ol (2g, 22.4mmol) and NaHCO_3 (2.8g 33.3mmol) in THF (30 mL) and H_2O (5 mL) was added benzyl carbonochloridate (4.6g 27.0mmol) at 0°C . After stirred at room temperature overnight, the mixture was extracted with EA(30mL). The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , concentrated and purified by flash chromatography to give crude benzyl 4-hydroxybutan-2-ylcarbamate as yellow oil (3g, 60%) LC-MS (ESI):223.7($\text{M}+1$)⁺.

Step 2:

[00382] To a stirred and cooled (0°C) solution of benzyl 4-hydroxybutan-2-ylcarbamate (3g, 13.5mmol) and Et_3N (2g, 19.8mmol) in dry DCM (20mL) was added the solution of MsCl (1.7g, 14.9mmol) in dry DCM (10mL) within 10min. After addition, the mixture was stirring for 1hr at 0°C and 2hrs at room temperature. The reaction mixture was poured into 1N aq. NaHCO_3 solution (50mL) and extracted with EA (10 mL $\times$ 3). The organic phase layer was separated, washed with brine, dried over Na_2SO_4 , and concentrated to give 3-(benzyloxycarbonylamino)butyl methanesulfonate (4g, crude) as yellow oil. LC-MS (ESI):301.8 ($\text{M}+1$)⁺.

Step 3:

[00383] A solution of 3-(benzyloxycarbonylamino)butyl methanesulfonate (4g, crude), piperidine (1.3g, 15.2mmol) and Et_3N (1.6g, 15.8mmol) in CH_3CN was stirred at 50°C for 3hrs. The solvent was evaporated under reduce pressure. The residue was diluted with EA, washed with water, dried over anhydrous Na_2SO_4 , concentrated and purified by flash column chromatography to give benzyl 4-(piperidin-1-yl)butan-2-ylcarbamate (2.5g, 65%) as yellow solid. LC-MS (ESI):290.7 ($\text{M}+1$)⁺; ^1H NMR (METHANOL- d_4) δ : 10.92 (s, 1H), 7.41 - 7.28 (m, 5H), 5.53 (s, 2H), 5.10-5.12 (m, 3H), 3.80 - 3.65 (m,

1H), 3.56 (t, $J = 12.1$ Hz, 2H), 3.03 (d, $J = 34.4$ Hz, 2H), 2.59 (d, $J = 8.8$ Hz, 2H), 2.05 - 1.79 (m, 7H), 1.39 (d, $J = 12.3$ Hz, 1H), 1.21 (d, $J = 6.6$ Hz, 3H).

Step 4:

[00384] To a solution of benzyl 4-(piperidin-1-yl)butan-2-ylcarbamate (1g, 3.4mmol) in MeOH (20mL) was added Pd/C (0.2g). Then the mixture was stirred at room temperature under H₂ overnight. The reaction mixture was filtered. The pH was adjusted by NaOH solid to pH=13, concentrated and purified by Prep-HPLC to give 4-(piperidin-1-yl)butan-2-amine (410mg, 76.3%) as yellow oil. LC-MS (ESI): 158.2 (M+ 1)⁺.


Step 5 and Step 6:

[00385] Steps 5 and 6 were completed in a similar fashion as Example 84, Steps 1 and 2.

Step 7:

[00386] The mixture of 1-methyl-5-(4-(4-(piperidin-1-yl)butan-2-ylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (30 mg, 0.06 mmol), 1-methylpiperidin-4-amine (26 mg, 0.23mmol), HATU (59mg, 0.15mmol) and DIPEA (40mg, 0.3 mmol) in DMF (2 mL) was stirred at 50°C for 5hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL × 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄, concentrated and purified by Prep-TLC (silica gel, eluting with 10% methanol and 1% NH₃.H₂O in DCM) to afford 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-yl)butan-2-ylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide (4.7 mg, 12.9%) as yellow solid. HPLC/UV purity: 99%; LC-MS (ESI): 554.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.88 (s, 1H), 8.87 (d, $J = 5.8$ Hz, 1H), 8.52 (s, 1H), 8.01 (d, $J = 8.9$, 1.8 Hz, 1H), 7.95 (d, $J = 6.0$ Hz, 1H), 7.80 (d, $J = 8.9$ Hz, 1H), 7.36 (d, $J = 6.6$ Hz, 2H), 4.61-4.52 (m, 1H), 4.24-4.19 (m, 1H), 4.12 (s, 3H), 3.65-3.57 (m, 4H), 3.51-3.45 (m, 2H), 3.23 (t, $J = 12.6$ Hz, 2H), 3.04-2.93 (m, 6H), 2.49-2.39 (m, 1H), 2.32-2.26 (m, 3H), 2.10 - 1.79 (m, 7H), 1.55 (d, $J = 6.4$ Hz, 3H).

Example 86: Synthesis of 1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



Step 1:

[00387] To a solution of ethyl 5-(4-chloro-1,6-naphthyridin-2-yl)-1-methyl-1H-indole-2-carboxylate (500 mg, 1.37 mmol) in DMF (10 mL) were added 1-methylpiperidin-4-amine (313 mg, 2.74 mmol) and K_2CO_3 (379 mg, 2.74 mmol). The reaction mixture was stirred at 120°C overnight, then quenched with water (5 mL), and extracted with DCM (10 mL $\times$ 3). The organic layer was washed with water (20 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 , concentrated and purified by flash column chromatography (silica gel, eluting with DCM to 10% MeOH/DCM) to afford ethyl 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (250 mg, 40%) as yellow solid. HPLC/UV purity: 99%; LC-MS (ESI): 443.9 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.78 (s, 1H), 8.87 (d, $J = 6.0$ Hz, 1H), 8.45 (d, $J = 1.6$ Hz, 1H), 7.99 (d, $J = 8.8, 1.6$ Hz, 1H), 7.92 (d, $J = 6.4$ Hz, 1H), 7.83 (d, $J = 8.8$ Hz, 1H), 7.50 (s, 1H), 7.38 (s, 1H), 4.48-4.40 (m, 3H), 4.18 (s, 3H), 3.72 (d, $J = 12.0$ Hz, 2H), 3.27 (d, $J = 12.0$ Hz, 2H), 2.96 (s, 3H), 2.45 (d, $J = 15.2$ Hz, 2H), 2.18 (d, $J = 14.0$ Hz, 2H), 1.45 (t, $J = 7.2$ Hz, 3H).


Step 2:

[00388] To a solution of 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate (250 mg, 0.56 mmol) in MeOH (5 mL) was added 1N aq. LiOH solution (2.24 mL). The reaction mixture was stirred at room temperature for 8 h. The reaction mixture was concentrated, acidified with 1N aq. HCl solution to pH=4, and lyophilized to afford 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid as brown solid. The crude product was used in the next step without further purification. LC-MS (ESI): 415.8 ($M + 1$)⁺.

Step 3:


[00389] The mixture of 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (20 mg, 0.048 mmol), 1-methylpiperidin-4-amine (11 mg, 0.096 mmol), HATU (27 mg, 0.072 mmol) and DIPEA (13 mg, 0.096 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with DCM (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-PLC to afford 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide as yellow solid (15 mg, 60%). LC-MS (ESI): 512.3 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.79 (s, 1H), 8.87 (d, $J = 6.4$ Hz, 1H), 8.42 (s, 1H), 7.96 (d, $J = 22.0, 9.2$ Hz, 2H), 7.80 (d, $J = 9.2$ Hz, 1H), 7.39 (s, 1H), 7.29 (s, 1H), 4.53-4.47 (m, 1H), 4.22-4.15 (m, 1H), 4.11 (s, 3H), 3.71 (d, $J = 11.6$ Hz, 2H), 3.63 (d, $J = 12.4$ Hz, 2H), 3.26-3.13 (m, 4H), 2.94 (d, $J = 15.6$ Hz, 6H), 2.45 (d, $J = 13.6$ Hz, 2H), 2.30 (d, $J = 13.6$ Hz, 2H), 2.25-2.12 (m, 2H), 2.03-1.90 (m, 2H).

Example 87: Synthesis of (1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone




[00390] The mixture of 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (65 mg, 0.16 mmol), 1-methylpiperazine (32 mg, 0.32 mmol), HATU (93 mg, 0.24 mmol) and DIPEA (42 mg, 0.32 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with DCM (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na₂SO₄, concentrated and purified by prep-TLC to afford (1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone as yellow solid (30 mg, 38%). LC-MS (ESI): 498.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.79 (s, 1H), 8.86 (d, J = 6.0 Hz, 1H), 8.43 (d, J = 1.6 Hz, 1H), 7.98-7.92 (m, 2H), 7.79 (d, J = 8.8 Hz, 1H), 7.40 (s, 1H), 7.03 (s, 1H), 4.51-1.53(m, 1H), 3.95 (s, 3H), 3.71 (d, J = 12.8 Hz, 2H), 3.67-3.27 (m, 10H), 2.99 (s, 3H), 2.95 (s, 3H), 2.44 (d, J = 13.2 Hz, 2H), 2.20 (t, J = 11.2 Hz, 2H).

Example 88: Synthesis of 1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-1H-indole-2-carboxamide




[00391] The mixture of 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (65 mg, 0.16 mmol), (4-methylpiperazin-1-yl)methanamine (41 mg, 0.32 mmol), HATU (91 mg, 0.24 mmol) and DIPEA (42 mg, 0.32 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with DCM (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na₂SO₄, concentrated and purified by prep-TLC to afford 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-1H-indole-2-carboxamide (30 mg, 37%) as yellow solid. LC-MS (ESI): 526.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.79 (s, 1H), 8.87 (d, J = 6.0 Hz, 1H), 8.42 (s, 1H), 7.96 (d, J = 9.0 Hz, 1.8 Hz, 1H), 7.92 (d, J = 6.0 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.39 (s, 1H), 7.27 (s, 1H), 4.49 - 4.52 (m, 1H), 4.10 (s, 3H), 3.71 (d, J = 12.6 Hz, 2H), 3.57 (d, J = 13.2 Hz, 2H), 3.37 (d, J = 6.6 Hz, 2H), 3.33-3.29 (m, 2H), 3.02 (t, J = 12.6 Hz, 2H), 2.95 (s, 3H), 2.88 (s, 3H), 2.44 (d, J = 13.2 Hz, 2H), 2.18 (q, J = 13.2 Hz, 2H), 2.09 (d, J = 14.4 Hz, 2H), 1.99-1.97 (m, 1H), 1.60-1.53 (m, 2H).

Example 89: Synthesis of 1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide (3-(piperidin-1-yl)propyl)-1H-indole-2-carboxamide



[00392] The mixture of 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylic acid (50 mg, 0.12 mmol), 3-(piperidin-1-yl)propan-1-amine (34 mg, 0.24 mmol), HATU (68 mg, 0.18 mmol) and DIPEA (31 mg, 0.24 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with DCM (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-PLC to afford 1-methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-indole-2-carboxamide (20 mg, 31%) as yellow solid. LC-MS (ESI): 540.3 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.77 (s, 1H), 8.86 (d, $J = 6.0$ Hz, 1H), 8.46 (d, $J = 1.6$ Hz, 1H), 7.98-7.86 (m, 2H), 7.78 (d, $J = 8.8$ Hz, 1H), 7.33 (d, $J = 14.8$ Hz, 2H), 4.53-4.47 (m, 1H), 4.11 (s, 3H), 3.70 (d, $J = 13.2$ Hz, 2H), 3.59 (d, $J = 12.4$ Hz, 2H), 3.53 (t, $J = 6.4$ Hz, 2H), 3.38-3.32 (m, 2H), 3.22 (t, $J = 7.6$ Hz, 2H), 3.01-2.95 (m, 5H), 2.45 (d, $J = 14.0$ Hz, 2H), 2.16-2.08 (m, 4H), 1.99 (d, $J = 14.0$ Hz, 2H), 1.88-1.75 (m, 3H), 1.59-1.51 (m, 1H).

Example 90: Synthesis of N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



Step 1:

[00393] NaH (240 mg, 6 mmol) was added to a solution of ethyl 6-bromo-1H-indole-2-carboxylate (1.34 g, 5 mmol) in DMF/THF (20 mL/40 mL). After SEMCl (913 mg, 5.5 mmol) was added drop wise, the mixture was stirred at room temperature overnight. Then the reaction was **quenched by adding water (100 mL)**. The mixture was extracted with EA(20 mL×3), washed with brine, dried over Na₂SO₄, concentrated and purified by silica gel column chromatography to give ethyl 6-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (1.92 g, 96%) as colorless oil. HPLC/UV purity: 90 %; LC-MS (ESI): 400.1 (M + 1)⁺.

Step 2:

[00394] The mixture of ethyl 6-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (199 mg, 0.5 mmol), 4,4,4',4',5,5',5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (152 mg, 0.6 mmol), KOAc (98 mg, 1 mmol) and Pd (dppf)Cl₂ (41 mg, 0.05 mmol) in 1,4-dioxane (20 mL) was stirred at 100°C overnight. The reaction mixture was filtered, concentrated and purified by silica gel column chromatography to give methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (100 mg, 45%) as yellow oil. HPLC/UV purity: 90 %; LC-MS (ESI): 431.9 (M + 1)⁺.

Step 3:

[00395] The solution of methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (431 mg, 1 mmol), 2,4-dichloro-1,6-naphthyridine (198 mg, 1 mmol), Na₂CO₃ (212 mg, 2 mmol) and Pd(PPh₃)₄ (115 mg, 0.1 mmol) in Dioxane/H₂O (10mL/1 mL) was stirred at 100°C in Biotage Initiator Eight Microwave Reactor for 2 hrs. Then the solvent was removed and the residue was purified by silica gel column chromatography to give ethyl 6-(4-chloro-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (220 mg, 45.7%) as white solid. HPLC/UV purity: 90 %; LC-MS (ESI): 481.7 (M + 1)⁺.

Step 4:

[00396] The mixture of ethyl 6-(4-chloro-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (48.1 mg, 0.1 mmol), 3-(piperidin-1-yl)propan-1-amine (28 mg, 0.2 mmol) and K₂CO₃ (27 mg, 0.2 mmol) in DMF (3 mL) was stirred at 70 °C overnight. The reaction mixture was filtered, concentrated and purified by silica gel column chromatography to give Ethyl 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (40 mg, 68%) as white solid. HPLC/UV purity: 90 %; LC-MS (ESI): 587.9 (M + 1)⁺.

Step 5:

[00397] The solution of ethyl 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylate (2.93 g, 5 mmol) and LiOH·H₂O (410 mg, 10 mmol) in CH₃OH/H₂O (100 mL/10 mL) was stirred at room temperature overnight. After adding 1N aq. HCl solution (11 mL), the solvent was removed to give crude 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-

naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylic acid (2.43 g, 87%) as yellow solid. HPLC/UV purity: 90 %; LC-MS (ESI): 559.8 (M + 1)⁺.


Step 6:

[00398] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylic acid (112 mg, 0.2 mmol), 1-methylpiperidin-4-amine (23 mg, 0.2 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5 mL) was stirred at room temperature overnight. After adding 50 mL water, the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (105 mg, 80%), as white solid. HPLC/UV purity: 90 %; LC-MS (ESI): 655.9 (M + 1)⁺.

Step 7:

[00399] The solution of N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (105 mg, 0.16 mmol) in TFA/DCM (5 mL/5 mL) was stirred at room temperature overnight. Then the solvent was removed. The residue was dissolved in NH₃·H₂O (10 mL) and stirred at room temperature overnight. The reaction mixture was concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide (50 mg, 47.6%) as white solid. HPLC/UV purity: 100 %; LC-MS (ESI): 525.8 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.61 (s, 1H), 8.76 (d, *J* = 6.0 Hz, 1H), 8.03 (s, 1H), 7.93 - 7.77 (m, 2H), 7.59 (d, *J* = 8.4 Hz, 1H), 7.15 (d, *J* = 14.4 Hz, 2H), 4.13 - 4.09 (m, 1H), 3.75 (t, *J* = 6.8 Hz, 2H), 3.54 - 3.48 (m, 4H), 3.24 - 3.20 (m, 2H), 3.11 (t, *J* = 12.2 Hz, 2H), 2.89 - 2.85 (m, 2H), 2.75 (s, 3H), 2.25 - 2.14 (m, 4H), 1.98 - 1.69 (m, 4H), 1.69 - 1.32 (m, 3H), 1.43 - 1.39 (m, 1H).

Example 91: Synthesis of N-(3-(Piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide



Step 1:

[00400] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylic acid (112 mg, 0.2 mmol), 3-(piperidin-1-


yl)propan-1-amine (28 mg, 0.2 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5 mL) was stirred at room temperature overnight. After adding 50 mL water, the reaction mixture was extracted with EA (100 mL), washed with brine, dried over Na_2SO_4 , concentrated and purified by flash column chromatography to give N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (120 mg, 87.6%), as white solid. HPLC/UV purity: 90 %; LC-MS (ESI): 683.9 ($M + 1$)⁺.

Step 2:

[00401] The solution of N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (120 mg, 0.175 mmol) in TFA/DCM (1 mL/10 mL) was stirred at room temperature overnight. The solvent was removed. The residue was dissolved in $\text{NH}_3 \cdot \text{H}_2\text{O}$ /DCM/ CH_3OH (1 mL/10 mL/10 mL) and stirred at room temperature overnight. After removing the solvent, the residue was purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm , eluting with 20% CH_3CN in 1% TFA in H_2O) to give N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide (40 mg, 41%) as white solid.

HPLC/UV purity: 100 %; LC-MS (ESI): 553.9 ($M + 1$)⁺. ^1H NMR (METHANOL- d_4) δ : 9.73 (s, 1H), 8.87 (d, $J = 6.0$ Hz, 1H), 8.15 (s, 1H), 7.93 - 7.91 (m, 2H), 7.70 (d, $J = 8.4, 1.6$ Hz, 1H), 7.22 (s, 2H), 3.86 (t, $J = 6.8$ Hz, 2H), 3.72 - 3.50 (m, 6H), 3.29 - 3.16 (m, 2H), 3.02 - 2.90 (m, 4H), 2.34 - 2.22 (m, 2H), 2.22 - 2.04 (m, 2H), 2.01 - 1.95 (m, 4H), 1.87 - 1.84 (m, 6H), 1.57 - 1.30 (m, 2H).

Example 92: Synthesis of N-(2-(Dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide




Step 1:

[00402] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylic acid (112 mg, 0.2 mmol), N^1, N^1 -dimethylethane-1,2-diamine (18 mg, 0.2 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5 mL) was stirred at room temperature overnight. After adding 50 mL water, the reaction mixture was extracted with EA (100 mL), washed with brine, dried over Na_2SO_4 , concentrated and purified by flash column chromatography to give N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (120 mg, 95%) as white solid. HPLC/UV purity: 95 %; LC-MS (ESI): 629.8 ($M + 1$)⁺.

Step 2:

[00403] The solution of N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (113 mg, 0.2 mmol) in TFA/DCM (1 mL/10 mL) was stirred at room temperature overnight. Then the solvent was removed. The residue was dissolved in $\text{NH}_3\cdot\text{H}_2\text{O}$ /DCM/ CH_3OH (1 mL/10 mL/10 mL) and stirred at room temperature overnight. After removing the solvent, the residue was purified by Prep-HPLC (Welch, XB-C18, 21.2 mm $\times$ 250 mm, 10 μm , eluting with 20% CH_3CN in 1% TFA in H_2O) to give N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide (50 mg, 47.6%) as white solid. HPLC/UV purity: 100 %; LC-MS (ESI): 499.8 ($\text{M} + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.60 (s, 1H), 8.75 (d, $J = 6.0$ Hz, 1H), 8.03 (s, 1H), 7.82-7.78 (m, 2H), 7.59 (d, $J = 8.8$ Hz, 1H), 7.10 (d, $J = 8.8$ Hz, 2H), 3.76 - 3.71 (m, 4H), 3.50 (d, $J = 12.0$ Hz, 2H), 3.36 - 3.32 (m, 2H), 3.24 - 3.22 (m, 2H), 2.96 (s, 6H), 2.92 - 2.83 (m, 2H), 2.25 - 2.18 (m, 2H), 1.87 - 1.84 (m, 2H), 1.76 - 1.63 (m, 3H), 1.43 - 1.40 (m, 1H).

Example 93: Synthesis of 6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide

**Step 1:**


[00404] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylic acid (112 mg, 0.2 mmol), 2-(pyridin-4-yl)ethanamine (24 mg, 0.2 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5 mL) was stirred at room temperature overnight. After adding 50 mL water, the reaction mixture was extracted with EA (100 mL), washed with brine, dried over Na_2SO_4 , concentrated and purified by flash column chromatography to give 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (126 mg, 95%) as white solid. HPLC/UV purity: 90 %; LC-MS (ESI): 663.9 ($\text{M} + 1$)⁺.

Step 2:

[00405] The solution of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamide (120 mg, 0.18 mmol) in TFA/DCM (1 mL/10 mL) was stirred at room temperature overnight. Then the solvent was removed. The residue was dissolved in $\text{NH}_3\cdot\text{H}_2\text{O}$ /DCM/ CH_3OH (1 mL/10 mL/10 mL) and stirred at room temperature overnight. After removing the solvent, the residue was purified by Prep-HPLC (Welch, XB-C18, 21.2 mm $\times$ 250 mm, 10 μm , eluting with 20% CH_3CN in 1% TFA in H_2O) to give 6-(4-(3-(piperidin-1-

yl)propylamino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide (60 mg, 62.5%) as white solid. HPLC/UV purity: 90 %; LC-MS (ESI): 533.8 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.61 (s, 1H), 8.76 (d, *J* = 6.0 Hz, 1H), 8.64 (d, *J* = 6.4 Hz, 2H), 8.02 (s, 1H), 7.90 (d, *J* = 6.4 Hz, 2H), 7.80 (d, *J* = 7.2 Hz, 2H), 7.58 (d, *J* = 8.4 Hz, 1H), 7.12 (s, 1H), 7.05 (s, 1H), 3.75-3.72 (m, 4H), 3.51-3.47 (m, 2H), 3.24-3.17 (m, 4H), 2.86 (t, *J* = 12.4 Hz, 2H), 2.25-2.17 (m, 2H), 1.87-1.83 (m, 2H), 1.76-1.64 (m, 3H), 1.47-1.39 (m, 1H).

Example 94: Synthesis of 6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide




Step 1:

[00406] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylic acid (112 mg, 0.2 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (24 mg, 0.2 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5 mL) was stirred at room temperature overnight. After adding 50 mL water, the reaction mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamido)piperidine-1-carboxylate (126 mg, 95%) as white solid. HPLC/UV purity: 90 %; LC-MS (ESI): 741.9 (M + 1)⁺.

Step 2:

[00407] The solution of tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxamido)piperidine-1-carboxylate (130 mg, 0.18 mmol) in TFA/DCM (1 mL/10 mL) was stirred at room temperature overnight. Then the solvent was removed. The residue was dissolved in NH₃/H₂O/DCM/CH₃OH (1 mL/10 mL/10 mL) and stirred at room temperature overnight. After removing the solvent, the residue was purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide (50 mg, 56%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 511.8 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.72 (s, 1H), 8.87 (d, *J* = 6.0 Hz, 1H), 8.14 (s, 1H), 7.97 - 7.87 (m, 2H), 7.70 (d, *J* = 8.4 Hz, 1H), 7.27 (s, 1H), 7.22 (s, 1H), 4.26-4.21 (m, 1H), 3.86 (t, *J* = 6.7 Hz, 2H), 3.63-3.60 (m, 2H), 3.55-3.52 (m, 2H), 3.36-3.33 (m, 2H), 3.23-3.17 (m, 2H), 3.01-2.94 (t, *J* = 12.4 Hz, 2H), 2.37-2.25 (m, 4H), 2.0-1.71 (m, 7H), 1.57-1.49 (m, 1H).

Example 95: Synthesis of (4-Ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)methanone



Step 1:

[00408] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carboxylic acid (279 mg, 0.5 mmol), tert-butyl piperazine-1-carboxylate (93 mg, 0.5 mmol), HATU (380 mg, 1 mmol) and DIPEA (258 mg, 2 mmol) in DMF (10 mL) was stirred at room temperature for 3 hours. After adding 50 mL water, the reaction mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carbonyl)piperazine-1-carboxylate (290 mg, 80%) as white solid. HPLC/UV purity: 90%; LC-MS (ESI): 727.9 (M + 1)⁺.

Step 2:

[00409] The solution of tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-2-carbonyl)piperazine-1-carboxylate (290 mg, 0.4 mmol) in TFA/DCM (1 mL/10 mL) was stirred at room temperature for 2 hrs. Then the solvent was removed. The residue was dissolved in NH₃·H₂O/DCM/CH₃OH (1 mL/10 mL/10 mL) and stirred at room temperature overnight. After removing the solvent, the residue was purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)methanone (120 mg, 61%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 497.9 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.73 (s, 1H), 8.88 (d, J = 6.4 Hz, 1H), 8.16 (s, 1H), 7.94 (m, 2H), 7.72 (d, J = 8.4, 1.6 Hz, 1H), 7.25 (d, J = 10.8 Hz, 1H), 7.07 (s, 1H), 4.17-4.15 (m, 4H), 3.87 (t, J = 6.8 Hz, 2H), 3.61 (d, J = 12.0 Hz, 2H), 3.42-3.40 (m, 4H), 3.36-3.32 (m, 2H), 2.98 (t, J = 12.4 Hz, 2H), 2.37-2.30 (m, 2H), 1.97 (d, J = 15.2 Hz, 2H), 1.88-1.75 (m, 3H), 1.56-1.52 (m, 1H).


Step 3:

[00410] The mixture of piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)methanone (50 mg, 0.1 mmol) and K₂CO₃ in DMF (5 mL) was stirred at room temperature for 3 h. After adding 50 mL water, the reaction mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (4-ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-

yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)methanone (10 mg, 20%) as yellow solid.

HPLC/UV purity: 100%; LC-MS (ESI): 525.9 ($M + 1$)⁺. ¹H NMR (METHANOL-*d*₄) δ : 9.72 (s, 1H), 8.87 (d, $J = 6.0$ Hz, 1H), 8.15 (s, 1H), 7.92 (d, $J = 7.6$ Hz, 2H), 7.71 (d, $J = 8.8$ Hz, 1.6 Hz, 1H), 7.23 (s, 1H), 7.04 (s, 1H), 4.80 (m, 2H), 3.86 (t, $J = 7.2$ Hz, 2H), 3.63-3.60 (m, 6H), 3.37-3.34 (m, 3H), 3.33-3.30 (m, 3H), 2.98 (t, $J = 12.4$ Hz, 2H), 2.38-2.30 (m, 2H), 1.97 (d, $J = 14.8$ Hz, 2H), 1.86-1.76 (m, 3H), 1.56-1.52 (m, 1H), 1.43 (t, $J = 7.6$ Hz, 3H).

Example 96: Synthesis of N,N-diethyl-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide




Step 1:

[00411] The mixture of 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenol (320 mg, 0.88 mmol) in 1N aq. NaOH solution (0.88 mL) was heated to 100 °C, then a solution of 3-bromopropanoic acid (135 mg, 0.88 mmol) in 1N aq. NaOH solution (0.88 mL) was added. The resulting mixture was stirred at 100 °C and held for 2 hrs. The reaction mixture was cooled to room temperature and quenched with water (5 mL), then extracted with EA (10 mL $\times$ 3). The combined organic layer was discarded and pH of the water phase was adjusted with 1N aq. HCl solution to pH=1. The acidified water phase was lyophilized to get a crude product, which was purified with Prep-HPLC (eluting with 20% CH₃CN and 0.1% TFA in H₂O) to afford 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanoic acid as a yellow solid (80 mg, 20%). HPLC/UV purity: 100 %; LC-MS (ESI): 435.3 ($M + 1$)⁺; ¹H NMR (METHANOL-*d*₄) δ : 9.97 - 10.05 (m, 1H), 8.76 (d, $J = 7.1$, 1H), 8.03 - 8.21 (m, 3H), 7.29 (s, 1H), 6.93 - 7.05 (m, 2H), 3.76 (t, $J = 6.9$ Hz, 2H), 3.61 (d, $J = 12.1$ Hz, 2H), 3.33 - 3.38 (m, 4H), 3.22 (t, $J = 6.3$ Hz, 2H), 2.91 - 3.06 (m, 2H), 2.24 - 2.38 (m, 2H), 1.92 - 2.05 (m, 2H), 1.72 - 1.92 (m, 3H), 1.48-1.53 (m, 1H).

Step 2:


[00412] To a mixture of 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanoic acid (20 mg, 0.045 mmol) and HATU (21 mg, 0.055 mmol) in DMF (1 mL) was added diethylamide (4 mg, 0.055 mmol) and DIPEA (11 mg, 0.09 mmol). The resulting mixture was stirred at room temperature for 1 hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL×3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to get the residue, which was purified with Prep-TLC (silica gel, eluting with 15% methanol in DCM) to afford N,N-diethyl-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide (2 mg, 10%) as a solid. HPLC/UV purity: 100%; LC-MS (ESI): 490.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 10.01 (s, 1H), 8.76 (d, J = 7.0 Hz, 1H), 8.04 - 8.23 (m, 3H), 7.29 (s, 1H), 7.00 (d, J = 8.9 Hz, 2H), 3.76 (t, J = 6.7 Hz, 2H), 3.61 (d, J = 13.2 Hz, 2H), 3.34 - 3.44 (m, 8H), 3.28 - 3.32 (m, 2H), 2.91 - 3.06 (m, 2H), 2.25 - 2.41 (m, 2H), 1.99 (d, J = 15.3 Hz, 2H), 1.72 - 1.93 (m, 3H), 1.51-1.54 (m, 1H), 1.21 (t, J = 7.1 Hz, 3H), 1.08 (t, J = 7.1 Hz, 3H).

Example 97: Synthesis of N-(1-methylpiperidin-4-yl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide



[00413] N-(1-methylpiperidin-4-yl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide was synthesized in a similar fashion as Example 96. HPLC/UV purity: 95%; LC-MS (ESI): 531.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.98 (s, 1H), 8.65-8.67 (d, J = 7.3 Hz, 1H), 8.15-8.17 (d, J = 8.9 Hz, 2H), 8.06-8.08 (d, J = 7.1 Hz, 1H), 7.29 (s, 1H), 6.98- 7.01 (d, J=9.2Hz, 2H), 3.88 (br. s., 1H), 3.74 (t, J = 6.7 Hz, 2H), 3.48 - 3.64 (m, 4H), 2.94 - 3.18 (m, 6H), 2.90 (s, 3H), 2.35-2.38 (m, 2H), 1.52- 2.21 (m, 12H).

Example 98: Synthesis of N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide and 3-(4-(4-(ethyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-((1-ethylpiperidin-4-yl)methyl)propanamide

**Step 1:**

[00414] To a mixture of 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanoic acid (100 mg, 0.23 mmol) and HATU (91 mg, 0.24 mmol) in DMF (1 mL) were added tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (51 mg, 0.24 mmol) and DIPEA (60 mg, 0.46 mmol). The resulting mixture was stirred at room temperature for 1 hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL×3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to give the residue, which was purified with Prep-HPLC (eluting with 20% CH₃CN and 0.1% TFA in H₂O) to get tert-butyl 4-((3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamido)methyl)piperidine-1-carboxylate (80 mg, 55%) as a solid. HPLC/UV purity: 100%; LC-MS (ESI): 631.3 (M + 1)⁺.

Step 2:

[00415] To a solution of tert-butyl 4-((3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamido)methyl)piperidine-1-carboxylate (80 mg, 0.126 mmol) in DCM (1 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 2 hrs. The solvent was removed under the reduced pressure to give the crude product, which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-(piperidin-4-ylmethyl)propanamide (65 mg, 98%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 531.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 10.03 (s, 1H), 8.70 (d, J = 7.1 Hz, 1H), 8.02 - 8.18 (m, 3H), 7.27 (s, 1H), 6.98 (d, J = 8.7 Hz, 2H), 3.74 (t, J = 6.6 Hz, 2H), 3.58 (d, J = 12.2 Hz, 2H), 3.31 - 3.33 (m, 2H), 3.04 - 3.14 (m, 4H), 2.82 - 3.03 (m, 4H), 2.23 - 2.37 (m, 2H), 1.95 (d, J = 15.3 Hz, 2H), 1.68 - 1.89 (m, 7H), 1.52 (d, J = 12.2 Hz, 1H), 1.24 - 1.40 (m, 3H).


Step 3: N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide

[00416] The mixture of 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-(piperidin-4-ylmethyl)propanamide (30 mg, 0.056 mmol) and K_2CO_3 (15 mg, 0.067 mmol) in DMF (1 mL) was stirred at room temperature for 30 min, followed by dropwise addition of iodoethane (10 mg, 0.22 mmol). The resulting reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL×3). The combined organic layers were discarded and the water phase was lyophilized to give a crude product which was purified with Prep-HPLC to generate N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide (20 mg, 64%) as a yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 559.1 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 10.02 (s, 1H), 8.69 (d, J = 7.0 Hz, 1H), 8.13 - 8.22 (d, J = 8.9 Hz, 2H), 8.10 (d, J = 7.3 Hz, 1H), 7.30 (s, 1H), 6.94 - 7.10 (d, J = 8.6 Hz, 2H), 3.75 (t, J = 6.7 Hz, 2H), 3.61 (d, J = 12.4 Hz, 2H), 3.53 (d, J = 12.6 Hz, 2H), 3.36 (d, J = 8.6 Hz, 4H), 3.07 - 3.15 (m, 5H), 2.93 - 3.04 (m, 2H), 2.78 - 2.90 (m, 2H), 2.26 - 2.38 (m, 2H), 1.98 (d, J = 15.0 Hz, 2H), 1.70 - 1.94 (m, 6H), 1.55 (d, J = 12.4 Hz, 1H), 1.26 - 1.49 (m, 7H).

Step 4: 3-(4-(4-(ethyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-((1-ethylpiperidin-4-yl)methyl)propanamide

[00417] The mixture of 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-(piperidin-4-ylmethyl)propanamide (30 mg, 0.056 mmol) and K_2CO_3 (15 mg, 0.11 mmol) in DMF (1 mL) was stirred at room temperature for 30 min, followed by the drop wise addition of iodoethane (10 mg, 0.22 mmol). The resulting reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL ×3). The water phase was lyophilized to give a crude product, which was purified with Prep-HPLC to afford N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide (15 mg, 48%) as a yellow solid. purity: 100%; LC-MS (ESI): 587.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 10.04 (s, 1H), 8.66 (dd, J = 7.3, 1.3 Hz, 1H), 8.21 - 8.30 (d, J = 8.9 Hz, 2H), 8.09 (d, J = 7.0 Hz, 1H), 7.32 (s, 1H), 7.04 - 7.19 (d, J = 8.9 Hz, 2H), 4.18 (q, J = 7.0 Hz, 2H), 3.74 (t, J = 6.7 Hz, 2H), 3.61 (d, J = 12.4 Hz, 2H), 3.48 - 3.57 (m, 2H), 3.34 - 3.41 (m, 4H), 3.10-3.12 (m, 5H), 2.99 (t, J=12.4Hz 2H), 2.76-2.90 (m, 2H), 2.25 - 2.37 (m, 2H), 1.96-2.01 (m, 2H), 1.86 (t, J = 13.4 Hz, 6H), 1.49-1.52 (m, 1H), 1.47 (t, J = 7.0 Hz, 3H), 1.37-1.42 (m, 2H), 1.25 - 1.34 (m, 4H).

Example 99: Synthesis of 4-cyano-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide

**Step 1:**

[00418] To a solution of 3-bromo-4-chlorobenzene-1,2-diamine (4 g, 18 mmol) in AcOH (30 mL) was added methyl 2,2,2-trichloroacetimidate (3.5 g, 20 mmol) drop wise at 0 °C. Then the reaction mixture was stirred at room temperature overnight. The mixture was poured into water (200 mL), and precipitate was collected and dried to give 4-bromo-5-chloro-2-(trichloromethyl)-1H-benzo[d]imidazole (5.5 g, 80%) as a white solid. HPLC/UV purity: 95%; LC-MS (ESI): 349.1 (M + 1)⁺.

Step 2:

[00419] To the solution of 4-bromo-5-chloro-2-(trichloromethyl)-1H-benzo[d]imidazole (7.5 g, 21.5 mmol) in EtOH (100 mL) was added Na₂CO₃ (2.74 g, 25.8 mmol). The resulting mixture was heated at 90 °C for 18 hrs. The reaction mixture was cooled to room temperature and the solvent was removed under the reduced pressure to give slurry, which was diluted with water, and extracted with EA (20 mL×3). The combined organic layers were dried over Na₂SO₄, filtered, and the filtrate was concentrated in vacuo to give the residue, which was purified by flash column chromatography (silica gel, eluting with PE to 30% EA/PE) to afford ethyl 4-bromo-5-chloro-1H-benzo[d]imidazole-2-carboxylate (6.5 g, 98%) as a solid. HPLC/UV purity: 90%; LC-MS (ESI): 304.3 (M + 1)⁺.

Step 3:

[00420] To a solution of ethyl 4-bromo-5-chloro-1H-benzo[d]imidazole-2-carboxylate (7 g, 22.8 mmol) in dcm (50 mL) was added triethylamine (6.9 g, 68.4 mmol). Then the mixture was cooled to 0 °C, and 2-(trimethylsilyl)ethoxymethyl chloride (5.7 g, 34.3 mmol) was added drop wise. The resulting mixture was

stirred at room temperature overnight. The solvent was removed, and the resulting crude mixture was diluted by water (30 mL), extracted with ea (20 mL×3). The combined organic layers were dried over Na₂SO₄, filtered, and the filtrate was concentrated in vacuo to give the crude mixture, which was purified by flash column chromatography (silica gel, eluting with pe to 10% EA/PE) to afford ethyl 4-bromo-5-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxylate (4.9 g, 62%) as a solid. HPLC/UV purity: 90%; LC-MS (ESI): 434.1 (M + 1)⁺.

Step 4:

[00421] To a solution of tert-butyl 4-aminopiperidine-1-carboxylate (4.62 g, 23 mmol) in DCM (20 mL) was added Al(CH₃)₃ (1N in toluene, 23 mL, 23 mmol) drop wise at 0°C under nitrogen. The mixture was stirred at room temperature for 30mins, and then the reaction mixture was cooled to 0°C. A solution of ethyl 4-bromo-5-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxylate (2 g, 4.61 mmol) in DCM (5 mL) was added drop wise. The resulting reaction mixture was stirred at room temperature for 18hrs. The reaction mixture was quenched by water (10 mL), extracted with DCM (10mL ×3). The combined organic layers were washed with water and brine, dried over Na₂SO₄, and the drying agent was filtered off. The filtrate was concentrated in vacuo to give the crude mixture, which was purified by flash column chromatography (silica gel, eluting with PE to 30% EA/PE) to afford tert-butyl 4-(4-bromo-5-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (2.5 g, 92%) as a white solid. HPLC/UV purity: 90%; LC-MS (ESI): 589.3 (M + 1)⁺.

Step 5:

[00422] The mixture of tert-butyl 4-(4-bromo-5-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (2.15 g, 3.66 mmol), Zn(CN)₂ (1.28 g, 11 mmol), Pd₂(dba)₃ (335 mg, 0.366 mmol) and dppf (405 mg, 0.732 mmol) in DMA (8 mL) was heated at 130 °C for 18 hrs under N₂ atmosphere . The reaction mixture was concentrated by rotary evaporation (55°C, 20 mmHg). The residue was purified by silica gel chromatography (silica gel, eluting with PE to 30% EtOAc/PE) to give tert-butyl 4-(5-chloro-4-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (1 g, 51%) as a brown solid HPLC/UV purity: 90%; LC-MS (ESI): 535.2 (M + 1)⁺.

Step 6:

[00423] The mixture of tert-butyl 4-(4-cyano-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (400 mg, 0.75 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (286 mg, 1.13 mmol), Pd₂(dba)₃ (68.7 mg, 0.075 mmol), XPhos (72 mg, 0.15 mmol) and NaOAc (123 mg, 1.5 mmol) in 1,4-dioxane (20 mL) was heated at 110 °C for 18 hrs under N₂ atmosphere. The mixture was cooled to room temperature and the solvent was removed under reduced pressure to give the crude mixture, which was purified by flash column chromatography (silica gel, eluting with CH₂Cl₂ to 2% MeOH/CH₂Cl₂) to afford tert-butyl

4-(4-cyano-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (400 mg, 86%) as a brown oil.

Step 7:

[00424] A 20-mL microwave vial was charged with 2,4-dichloro-1,6-naphthyridine (60 mg, 0.93 mmol), tert-butyl 4-(4-cyano-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (280 mg, 0.45 mmol), Pd(PPh₃)₄ (34 mg, 0.03 mmol), NaHCO₃ (50 mg, 0.6 mmol), 1,4-dioxane (4 mL) and H₂O (0.5 mL). The sealed vial with the resulting brown solution was heated for 2 hrs in a Biotage Initiator Eight Microwave Reactor at a constant temperature of 100°C. The resulting solution was concentrated by rotary evaporation (55°C, 20 mmHg). The residue was purified by silica gel chromatography (silica gel, eluting with 2-5% methanol in DCM) to give tert-butyl 4-(5-(4-chloro-1,6-naphthyridin-2-yl)-4-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (90 mg, 45%) as a yellow solid. HPLC/UV purity: 70%; LC-MS (ESI): 662.2 (M + 1)⁺


Step 8:

[00425] The mixture of tert-butyl 4-(5-(4-chloro-1,6-naphthyridin-2-yl)-4-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (90 mg, 0.147 mmol), 3-(piperidin-1-yl)propan-1-amine (42 mg, 0.294 mmol) and K₂CO₃ (40 mg, 0.294 mmol) in DMF (2 mL) was heated at 80°C for 18 hrs. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL × 3). The combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the residue, which was purified with Prep-TLC (silica gel, eluting with 10% methanol and 1% NH₃ in DCM) to afford tert-butyl 4-(4-cyano-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (15 mg, 13%) as a yellow solid. HPLC/UV purity: 90%; LC-MS (ESI): 768.1 (M + 1)⁺.

Step 9:

[00426] The mixture of tert-butyl 4-(4-cyano-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1-carboxylate (15 mg, 0.019 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 18 hrs. The solvent was removed under reduced pressure to give the crude mixture, which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm × 250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford 4-cyano-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide (5 mg, 50%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 538.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.64 (s, 1H), 8.74 (d, J = 6.1 Hz, 1H), 8.52 (s, 1H), 8.36 (d, J = 1.5 Hz, 1H), 7.83 (d, J = 6.1 Hz, 1H), 7.24 (s, 1H), 4.10 - 4.25 (m, 1H), 3.74 (t, J = 6.9 Hz, 2H), 3.36 - 3.55 (m, 4H), 3.24 - 3.28 (m, 2H), 3.10 (t, J = 12.5, 2.7 Hz, 2H), 2.86 (t, J = 12.5 Hz, 2H), 2.10 - 2.28 (m, 4H), 1.81 - 1.95 (m, 4H), 1.62 - 1.80 (m, 3H), 1.42 - 1.50 (m, 1H).

Example 100: Synthesis of (4-ethylpiperazin-1-yl)(5-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone



Step 1:

[00427] To a solution of tert-butyl piperazine-1-carboxylate (2.2 g, 12 mmol) in DCM (10 mL) was added $\text{Al}(\text{CH}_3)_3$ (1N in toluene, 12 mL, 12 mmol) dropwise at 0°C under nitrogen. The mixture was stirred at room temperature for 30mins, and then it was cooled to 0°C again. A solution of ethyl 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxylate (950 mg, 2.31 mmol) in DCM (5mL) was added drop wise. The resulting reaction mixture was stirred at room temperature for 18hrs. The reaction mixture was quenched by water (10 mL), extracted with DCM (10mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na_2SO_4 , filtered. The filtrate was concentrated in vacuo to give the residue which was purified by flash column chromatography (silica gel, eluting with PE to 30% EA/PE) to afford tert-butyl 4-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (1.2 g, 95%) as a white solid. HPLC/UV purity: 90%; LC-MS (ESI): 539.3 ($\text{M} + 1$)⁺.

Step 2:

[00428] The mixture of tert-butyl 4-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (1.5 g, 2.64 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (804 mg, 3.17 mmol), $\text{Pd}_2(\text{dba})_3$ (241 mg, 0.264 mmol), tricyclohexylphosphine (147 mg, 0.53 mmol) and KOAc (517 mg, 5.28 mmol) in 1,4-Dioxane (20 mL) was heated at 100°C for 18hrs under N_2 atmosphere. The reaction mixture was cooled to room temperature and filtered by a pad of celite. The resulting filtrate was concentrated under reduced pressure to give the crude mixture, which was diluted with EA (30 mL), washed by water and brine, dried over Na_2SO_4 , and filtered. The filtrate was concentrated in vacuo to give a crude boric acid ester, which was purified by flash column chromatography (silica gel, eluting with 30% EA in PE) to afford tert-butyl 4-(5-

(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (1.3 g, 83%) as a oil . HPLC/UV purity: 60%; LC-MS (ESI): 587.2 (M + 1)⁺.

Step 3:

[00429] The mixture of 2,4-dichloro-1,6-naphthyridine (340 mg, 1.7 mmol), tert-butyl 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (1.3 mg, 2.21 mmol), Pd(PPh₃)₄(196 mg, 0.17 mmol), and Na₂CO₃(360 mg, 3.4 mmol) in 1,4-Dioxane (10 mL) and H₂O (2 mL) was heated at 100°C for 18hrs under N₂ atmosphere. The reaction mixture was cooled to room temperature and filtered by a pad of celite. The resulting filtrate was concentrated under reduced pressure to give the residue, which was diluted with EA (30 mL), then washed by water and brine, dried over Na₂SO₄, filtered. The filtrate was concentrated in vacuo to give a crude boric acid ester, which was purified with Combiflash (silica gel, eluting with 5% MeOH in DCM) to afford tert-butyl 4-(5-(4-chloro-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (500 mg, 50%) as a oil . HPLC/UV purity: 60%; LC-MS (ESI): 623.1 (M + 1)⁺.

Step 4:

[00430] A 20-mL microwave vial was charged with tert-butyl 4-(5-(4-chloro-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (170 mg, 0.273 mmol), 4-(pyrrolidin-1-ylmethyl)aniline (53 mg, 0.3 mmol), Pd₂(dba)₃ (25 mg, 0.027 mmol) , Xphos (31 mg, 0.054 mmol), Cs₂CO₃ (138 mg, 1.31 mmol) and 1,4-dioxane (10 mL) . The sealed vial with the resulting brown solution was heated for 1 hr in a Biotage Initiator Eight Microwave Reactor at a constant temperature of 120 °C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The crude mixture was purified by Prep-TLC (silica gel, eluting with 10% methanol in DCM) to give tert-butyl 4-(5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (90 mg, 43%) as a oil. HPLC/UV purity: 90%; LC-MS (ESI): 763.2(M + 1)⁺.


Step 5:

[00431] The mixture of tert-butyl 4-(5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carbonyl)piperazine-1-carboxylate (15 mg, 0.019mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 18hrs. The solvent was removed under reduced pressure to give the crude mixture, which was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm×250 mm, 10 um, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford piperazin-1-yl(5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone (5 mg, 50%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 538.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.91 (s, 1H), 8.94 (d, J = 5.5 Hz, 1H), 8.30 (s, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.87 (s, 2H), 7.71 - 7.84 (m, 4H), 7.37 (s, 1H), 4.50 (s, 2H), 4.06-4.09 (m, 2H), 3.55-3.60 (m, 2H), 3.36-3.43 (m, 4H), 3.263.29 (m, 4H), 2.19-2.23 (m, 2H), 2.05-2.06 (m, 2H).

Step 6:

[00432] The mixture of piperazin-1-yl(5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone (30 mg, 0.059 mmol) and K_2CO_3 (33 mg, 0.24 mmol) in DMF (1 mL) was stirred at room temperature for 30 min, and then iodoethane (10 mg, 0.064 mmol) was added drop wise. The resulting reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under reduced pressure to give the crude mixture, which was purified with Prep-HPLC to give (4-ethylpiperazin-1-yl)(5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone (5 mg, 15%), HPLC/UV purity: 100%; LC-MS (ESI): 561.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.80 (s, 1H), 8.83 (d, $J = 6.1$ Hz, 1H), 8.18 (s, 1H), 7.91 (d, $J = 6.1$ Hz, 1H), 7.70 - 7.80 (m, 2H), 7.58 - 7.70 (m, 4H), 7.25 (s, 1H), 4.38 (s, 2H), 3.59-3.62 (m, 2H), 3.36 - 3.58 (m, 4H), 3.10 - 3.20 (m, 8H), 2.06 - 2.16 (m, 2H), 1.92-1.95 (m, 2H), 1.31 (t, $J = 7.3$ Hz, 3H).

Example 101: Synthesis of N-(3-(piperidin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide

**Steps 1-4:**


[00433] Steps 1-4 were completed in a similar fashion as Example 100, Steps 1-4.

Step 5:

[00434] The mixture of N-(3-(piperidin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (100 mg, 0.139 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at rt for 2 hrs. The solvent was removed under reduced pressure to give the crude mixture, which was purified with Prep-HPLC (Welch, XB-C18,

21.2 mm×250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford N-(3-(piperidin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (75 mg, 92%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 589.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.92 (s, 1H), 8.95 (d, J = 6.1 Hz, 1H), 8.30 (s, 1H), 8.03 (d, J = 6.1 Hz, 1H), 7.70 - 7.92 (m, 6H), 7.35 (s, 1H), 4.50 (s, 2H), 3.53 - 3.67 (m, 6H), 3.18 - 3.30 (m, 4H), 2.90 - 3.05 (m, 2H), 2.14-2.24 (m, 2H), 2.04-1.99 (m, 6H), 1.73 - 1.92 (m, 3H), 1.50-1.54 (m, 1H).

Example 102: Synthesis of N-(2-(dimethylamino)ethyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide




Step 1:

[00435] Step 1 was completed in a similar fashion as Example 100, Step 4.

Step 2:

[00436] The mixture of N-(2-(dimethylamino)ethyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (15 mg, 0.022 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 2 hrs. The solvent was removed under reduced pressure to give the crude mixture, which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford N-(2-(dimethylamino)ethyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (6 mg, 54%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 535.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.76 (s, 1H), 8.80 (d, J = 6.1 Hz, 1H), 8.20 (s, 1H), 7.90 (d, J = 6.1 Hz, 1H), 7.71 - 7.78 (m, 2H), 7.58 - 7.69 (m, 4H), 7.28 (s, 1H), 4.38 (s, 2H), 3.75 (t, J = 5.8 Hz, 2H), 3.48 (br. s., 2H), 3.34 (t, J = 6.0 Hz, 2H), 3.16-3.20 (m, 2H), 2.90 (s, 6H), 2.05-2.12 (m, 2H), 1.95-1.95 (m, 2H).

Example 103: Synthesis of N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide


**Steps 1-4:**

[00437] Steps 1-4 were completed in a similar fashion as Example 100, Steps 1-4.

Step 5:

[00438] The mixture of N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole-2-carboxamide (90 mg, 0.12 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 2 hrs. The solvent was removed under reduced pressure to give the crude mixture, which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide (70 mg, 97%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 604.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.92 (s, 1H), 8.95 (d, J = 6.1 Hz, 1H), 8.29 (s, 1H), 8.03 (d, J = 6.1 Hz, 1H), 7.70 - 7.91 (m, 6H), 7.35 (s, 1H), 4.50 (s, 2H), 3.58 (t, J = 6.7 Hz, 4H), 3.46-3.49 (m, 4H), 3.16 - 3.32 (m, 6H), 3.01 (t, J = 7.3 Hz, 2H), 2.93 (s, 3H), 2.05- 2.24 (m, 2H), 2.03-2.16 (m, 4H).

Example 104: Synthesis of 5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole-2-carboxamide

**Steps 1-3:**

[00439] Steps 1-3 were completed in a similar fashion as Example 100, Steps 1-3.


Step 4:

[00440] Step 4 was completed in a similar fashion as Example 99, Step 8.

Step 5:

[00441] The mixture of 5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole-2-carboxamide (50 mg, 0.075 mmol) and TFA (1 mL) in DCM (1 mL) was heated at 40°C for 2hrs., The solvent was removed under reduced pressure to give the crude product, which was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm×250 mm, 10 um, eluting with 20% CH₃CN in 1% TFA in H₂O) to afford 5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole-2-carboxamide (40 mg, 95%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 535.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.89 (d, J = 5.8 Hz, 1H), 8.77 (d, J = 6.1 Hz, 2H), 8.38 (s, 1H), 8.06 (d, J = 6.1 Hz, 2H), 7.96 - 8.02 (m, 1H), 7.89 - 7.96 (m, 2H), 7.29 (s, 1H), 3.83 - 3.95 (m, 4H), 3.61 (d, J = 12.5 Hz, 2H), 2.97 (t, J = 11.9 Hz, 2H), 2.26 - 2.40 (m, 2H), 1.97 (d, J = 14.3 Hz, 2H), 1.71 - 1.90 (m, 3H), 1.48-1.53 (m, 1H).

Example 105: Synthesis of N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-3H-imidazo[4,5-b]pyridine-2-carboxamide

**Step 1:**

[00442] The solution of 5-bromopyridine-2,3-diamine (5.64 g, 30 mmol) in AcOH (30 mL) was cooled to 0°C. Then methyl 2,2,2-trichloroacetate (6.336g, 36 mmol) was added drop wise. The reaction mixture was stirred at room temperature overnight. After adding water (1000 mL), the mixture was filtered to give 6-bromo-2-(trichloromethyl)-3H-imidazo[4,5-b]pyridine (4.52 g, 85.9%) as white solid. HPLC/UV purity: 95%; LCMS (ESI): 315.8 (M + 1)⁺.

Step 2:

[00443] The mixture of 6-bromo-2-(trichloromethyl)-3H-imidazo[4,5-b]pyridine (4.53 g, 14.38 mmol) and Na₂CO₃ (2.28 g, 21.5 mmol) in EtOH (100 mL) was stirred at 70 °C for 3 hours. Then the mixture was diluted with water (200 mL), extracted with EA (100 mL×2). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The crude product was purified by silica gel column chromatography to give ethyl-6-bromo-3H-imidazo[4,5-b]pyridine-2-carboxylate (2.83 g, 73.5%) as white solid. HPLC/UV purity: 90%; LCMS (ESI): 269.8 (M + 1)⁺.

Step 3:

[00444] To the solution of ethyl-6-bromo-3H-imidazo[4,5-b]pyridine-2-carboxylate (2.7 g, 10 mmol) in DCM (50 mL) was added Al(CH₃)₃ (50 mL, 1M) drop wise at 0°C. The mixture was warmed to room temperature and stirred 30 min. Then 1-methylpiperidin-4-amine (5.7 g, 50 mmol) was added at 0°C and the mixture was stirred at room temperature overnight. The mixture was diluted with DCM, washed with water 200 mL, dried over Na₂SO₄, filtered and concentrated. The crude product was purified by silica gel column chromatography to give 6-bromo-N-(1-methylpiperidin-4-yl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (2.06 g, 61%) as white solid. HPLC/UV purity: 95%; LCMS (ESI): 340.8 (M + 1)⁺.

Step 4:

[00445] The solution of 6-bromo-N-(1-methylpiperidin-4-yl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (1.011 g, 3 mmol) and Et₃N (606 mg, 6 mmol) in DCM (120 mL) was added SEMCl (664 mg, 4 mmol) drop wise. Then the mixture was stirred at room temperature overnight. The solvent was removed and the crude product was purified by silica gel column chromatography to give 6-bromo-N-(1-

methylpiperidin-4-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (960 mg, 68%) as dark solid. HPLC/UV purity: 95%; LCMS (ESI): 469.9 (M + 1)⁺.

Step 5:

[00446] The mixture of 6-bromo-N-(1-methylpiperidin-4-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (910 mg, 1.94 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (741 mg, 2.91 mmol), KOAc (490 mg, 5 mmol), PCy₃ (112 mg, 0.4 mmol) and Pd₂(dba)₃ (183 mg, 0.2 mmol) in 1,4-dioxane (20 mL) was stirred at 110°C overnight. The reaction mixture was filtered, concentrated and purified by silica gel column chromatography to give N-(1-methylpiperidin-4-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (800 mg, 80%) as white solid. HPLC/UV purity: 90%; LCMS (ESI): 515.8 (M + 1)⁺.

Step 6:

[00447] The mixture of N-(1-methylpiperidin-4-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (515 mg, 1 mmol), 2,4-dichloro-1,6-naphthyridine (198 mg, 1 mmol), Na₂CO₃ (212 mg, 2 mmol), Pd(PPh₃)₄ (115 mg, 0.1 mmol) in 1,4-Dioxane (12mL) and H₂O (2 mL) was stirred in a Biotage Initiator Eight Microwave Reactor at 100°C for 2 hrs. Then the mixture was extracted with EA (100 mL×2), washed with H₂O (100 mL) and brine, dried over Na₂SO₄, concentrated and purified by silica gel chromatography to give 6-(4-chloro-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (300 mg, 54.3%) as white solid. HPLC/UV purity: 90%; LCMS (ESI): 551.7 (M + 1)⁺.

Step 7:


[00448] The mixture of 6-(4-chloro-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (300 mg, 0.54 mmol), 3-(piperidin-1-yl)propan-1-amine (142 mg, 1.0 mmol) and K₂CO₃ (138 mg, 1 mmol) in DMF (10 mL) was stirred at 70°C overnight. The mixture was filtered, concentrated and purified by silica gel chromatography to give N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (135 mg, 38%) as white solid. HPLC/UV purity: 90%; LCMS (ESI): 657.9 (M + 1)⁺.

Step 8:

[00449] The solution of N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine-2-carboxamide (132 mg, 0.2 mmol) in TFA/DCM (1 mL/10 mL) was stirred at room temperature overnight. Then the solvent was removed. The residue was dissolved in DCM/CH₃OH/NH₃.H₂O (10 mL/1 mL/1 mL) and stirred at room temperature overnight. The reaction mixture was concentrated and purified by Prep-HPLC(Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-3H-imidazo[4,5-

b]pyridine-2-carboxamide(50 mg, 47.6%) as TFA solid. HPLC/UV purity: 100%; LCMS (ESI): 527.8 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.79 (s, 1H), 9.15 (s, 1H), 8.87 (d, *J* = 6.0 Hz, 1H), 8.80 (s, 1H), 7.95 (d, *J* = 5.4 Hz, 1H), 7.37 (s, 1H), 4.28-4.24 (m, 1H), 3.87 (t, *J* = 6.0 Hz, 2H), 3.67-3.60 (m, 4H), 3.35-3.33 (m, 2H), 3.24 (t, *J* = 12.0 Hz, 2H), 2.99-2.97 (m, 2H), 2.94 (s, 3H), 2.36-2.31 (m, 4H), 2.08-2.0 (m, 2H), 1.98-1.96 (m, 2H), 1.87-1.82 (m, 3H), 1.6-1.51 (m, 1H).

Example 106: Synthesis of N-(1-methylpiperidin-4-yl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenoxy)acetamide



Step 1:

[00450] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)phenol (1 g, 3.89 mmol), methyl 2-bromoacetate (591 mg, 3.89 mmol) and K₂CO₃ (1.07 g, 7.78 mmol) in DMF (1 mL) was stirred at room temperature for 30min. The reaction mixture was poured into water (20 mL), extracted with EA (20 mL×3). The combined organic layers were washed by water (10 mL×3) and brine (10 mL), dried over Na₂SO₄. Filtered and the filtrate was concentrated under the reduced pressure to give the residue which was purified by silica gel flash column chromatography to afford methyl 2-(4-(4-chloro-1,6-naphthyridin-2-yl)phenoxy)acetate (500 mg, 38%) . LC-MS (ESI): 329.3(M + 1)⁺.

Step 2:

[00451] The mixture of methyl 2-(4-(4-chloro-1,6-naphthyridin-2-yl)phenoxy)acetate (500 mg, 1.51 mmol) and 1N aq. LiOH solution (6 mL, 6.07 mmol) in MeOH (5 mL) was stirred at room temperature overnight. The mixture was acidified with 1N aq. HCl solution to pH = 2, then concentrated to give the crude product which was used directly in the next step without further purification. LC-MS (ESI): 315.2 (M + 1)⁺.

Step 3:


[00452] The mixture of 2-(4-(4-chloro-1,6-naphthyridin-2-yl)phenoxy)acetic acid (100 mg, 0.32mmol), 1-methylpiperidin-4-amine (72 mg, 0.63 mmol), HATU (145 mg, 0.38 mmol) and DIPEA (82 mg 0.64 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL × 3). The combined organic layers were washed with water (20 mL × 3) and brine (20 mL × 1), dried over Na₂SO₄, filtered and concentrated. The residue was

purified by Prep-TLC to obtain 2-(4-(4-chloro-1, 6-naphthyridin-2-yl)phenoxy)-N-(1-methylpiperidin-4-yl)acetamide (46 mg, 37%). LC-MS (ESI): 411.3 (M + 1)⁺.

Step 4:

[00453] The mixture of 2-(4-(4-chloro-1,6-naphthyridin-2-yl)phenoxy)-N-(1-methylpiperidin-4-yl)acetamide (46 mg, 0.11 mmol), 3-(piperidin-1-yl)propan-1-amine (23 mg, 0.16 mmol) and K₂CO₃ (30 mg, 0.22 mmol) in DMF (1 mL) was heated at 70 °C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL × 3). The combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the residue which was purified with prep-TLC to afford N-(1-methylpiperidin-4-yl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenoxy)acetamide (10 mg, 17%) as a yellow oil. HPLC/UV purity: 99%; LC-MS (ESI): 517.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.46 (s, 1H), 8.55 (d, J = 6.1 Hz, 1H), 7.93 - 8.04 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 5.8 Hz, 1H), 7.07 - 7.16 (d, J = 8.9 Hz, 2H), 7.01 (s, 1H), 4.56 (s, 2H), 3.96-4.01 (m, 1H), 3.62 (t, J = 6.9 Hz, 2H), 3.36-3.45 (m, 2H), 3.15 - 3.20 (m, 4H), 3.04 (d, J = 7.9 Hz, 4H), 2.76 (s, 3H), 2.13 - 2.25 (m, 2H), 2.00 - 2.07 (m, 2H), 1.84-1.97 (m, 2H), 1.56-1.83 (m, 6H). 4H), 1.96 - 1.85(m, 2H).

Example 107: Synthesis of N-(3-(piperidin-1-yl)propyl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide



Step 1:

[00454] The mixture of 2,4-dichloro-1,6-naphthyridine (1.89 g, 9.44 mmol), 4-(hydroxymethyl)phenylboronic acid (1.58 g, 10.4 mmol), Pd(PPh₃)₄ (545 mg, 0.47 mmol) and Na₂CO₃ (2 g, 18.9 mmol) in 1,4-dioxane (40 mL) and H₂O (8 mL) was heated at 100°C for 18hrs under N₂ atmosphere. The mixture was cooled to room temperature, and then was concentrated under reduced pressure to give the crude mixture, which was purified by flash column chromatography (silica gel, eluting with CH₂Cl₂ to 10% Methanol/CH₂Cl₂) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)phenylmethanol as a white solid (1.9 g, 76%). HPLC/UV purity: 95%; LC-MS (ESI): 271.4 (M + 1)⁺.

Step 2:

[00455] To a mixture of (4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)methanol (500 mg, 1.85 mmol) and 2-bromoacetic acid (283 mg, 2.03 mmol) in DMF (5 mL) was added NaH (148 mg, 3.7 mmol) at 0°C under N₂ atmosphere in one portion. The resulting mixture was stirred at room temperature for 24 hrs. The mixture was quenched by water (10 mL). The pH of the resulting mixture was adjusted with 1N aq. HCl solution (30 mL) to pH 1. The resulting precipitate was filtered off and the filtrate was extracted with EA (10 mL × 3). The combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the EA phase was used to the next step without further purification.


Step 3:

[00456] To a solution of 2-((4-(4-chloro-1,6-naphthyridin-2-yl)benzyl)oxy)acetic acid (400 mg, 1.21 mmol) in EA (10 mL) and Methanol (4 mL) was added (Trimethylsilyl)diazomethane (2 N in THF, 1.42 mL, 2.42 mmol) drop wise at 0°C. The reaction mixture was stirred at room temperature for 2hrs, and then was quenched by water (10 mL). The organic layer was separated from the aqueous phase, and concentrated to give a crude product, which was purified by flash column chromatography (silica gel, eluting with Methanol/CH₂Cl₂=1/30) to afford methyl 2-((4-(4-chloro-1,6-naphthyridin-2-yl)benzyl)oxy)acetate (90 mg, 22%). HPLC/UV purity: 95%; LC-MS (ESI): 343.4 (M + 1)⁺. ¹H NMR (DMSO-d₆) δ: 9.59 (s, 1H), 8.88 (d, J = 5.9 Hz, 1H), 8.58 (s, 1H), 8.34 - 8.42 (d, J = 8.3 Hz, 2H), 8.03 (d, J = 5.9 Hz, 1H), 7.54 - 7.61 (d, J = 8.1 Hz, 2H), 4.68 (s, 2H), 4.27 (s, 2H), 3.70 (s, 3H).

Step 4:

[00457] The mixture of methyl 2-((4-(4-chloro-1,6-naphthyridin-2-yl)benzyl)oxy)acetate (90 mg, 0.26 mmol), 3-(piperidin-1-yl)propan-1-amine (74 mg, 0.52 mmol) and K₂CO₃ (72 mg, 0.52 mmol) in DMF (2 mL) was heated at 70 °C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL×3). The combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under reduced pressure to give the crude product, which was purified with Prep-TLC (silica gel, DCM/Methanol/NH₃.H₂O=10/1/0.1) to afford N-(3-(piperidin-1-yl)propyl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide (40 mg, 27%) as a yellow solid. HPLC/UV purity: %; LC-MS (ESI): 559.1 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.89 (d, J = 5.9 Hz, 1H), 8.01 - 8.11 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 5.9 Hz, 1H), 7.69 - 7.77 (d, J = 8.3 Hz, 2H), 7.25 (s, 1H), 4.80 (s, 2H), 4.09 (s, 2H), 3.86 (t, J = 6.9 Hz, 2H), 3.50 - 3.66 (m, 4H), 3.40 (t, J = 6.7 Hz, 2H), 3.30 - 3.32 (m, 2H), 3.10 - 3.19 (m, 2H), 2.89 - 3.02 (m, 4H), 2.28 - 2.39 (m, 2H), 1.92 - 2.07 (m, 6H), 1.73 - 1.91 (m, 6H), 1.48-1.54 (m, 2H).

Example 108: Synthesis of N,N-diethyl-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide


**Step 1:**

[00458] To a solution of methyl 2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetate (90 mg, 0.2 mmol) in methanol (4 mL) was added 1N aq. LiOH solution (0.6 mL, 0.6 mmol). The reaction mixture was stirred at 50°C for 2hrs. The solvent was removed and water (5 mL) was added. The pH of the water phase was adjusted with 1N aq. HCl solution to pH 4. It was lyophilized to give crude product (90 mg) as a white solid.

Step 2:


[00459] To a mixture of 2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetic acid (45 mg, 0.1 mmol) and HATU (47 mg, 0.12 mmol) in DMF (1 mL) was added diethylamine (15 mg, 0.2 mmol) and DIPEA (27 mg, 0.2 mmol). The resulting mixture was stirred at room temperature for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to generate the crude product, which was purified with Prep-TLC (silica gel, DCM/Methanol=10/1,uv) to give N,N-diethyl-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide (10 mg, 20%) as a solid. HPLC/UV purity: 100%; LC-MS (ESI): 490.1 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.57 (s, 1H), 8.68 (d, J = 5.8 Hz, 1H), 8.00 - 8.10 (d, J = 7.8 Hz, 2H), 7.83 (d, J = 6.0 Hz, 1H), 7.58 - 7.68 (d, J = 7.9 Hz, 2H), 7.14 (s, 1H), 4.71 (s, 2H), 4.31 (s, 2H), 3.73 (t, J = 6.8 Hz, 2H), 3.55 - 3.57 (m, 2H), 3.33 - 3.45 (m, 6H), 2.93 - 2.98 (m, 2H), 2.20 - 2.34 (m, 2H), 1.68-1.85 (m, 6H), 1.09 - 1.23 (m, 6H)

Example 109: Synthesis of N-(1-methylpiperidin-4-yl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide




[00460] To a mixture of 2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetic acid (45 mg, 0.1 mmol) and HATU (47 mg, 0.12 mmol) in DMF (1 mL) was added 1-methylpiperidin-4-amine (17 mg, 0.2 mmol) and DIPEA (27 mg, 0.2 mmol). The resulting mixture was stirred at room temperature for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to generate the crude product, which was purified with Prep-HPLC to give N-(1-methylpiperidin-4-yl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide (15 mg, 28%) as a solid. HPLC/UV purity: 100%; LC-MS (ESI): 531.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.74 (s, 1H), 8.89 (d, J = 5.9 Hz, 1H), 8.01 - 8.09 (d, J = 8.1 Hz, 2H), 7.92 (d, J = 5.9 Hz, 1H), 7.68 - 7.77 (d, J = 8.1 Hz, 2H), 7.24 (s, 1H), 4.79 (s, 2H), 4.04-4.07 (m, 3H), 3.86 (t, J = 7.0 Hz, 2H), 3.53 - 3.69 (m, 4H), 3.27 - 3.30 (m, 2H), 3.10 - 3.21 (m, 2H), 2.96 (d, J = 13.7 Hz, 2H), 2.90 (s, 3H), 2.26 - 2.40 (m, 2H), 2.17 (d, J = 14.0 Hz, 2H), 1.97 (d, J = 15.6 Hz, 2H), 1.71 - 1.93 (m, 5H), 1.48 - 1.53 (m, 1H).

Example 110: Synthesis of N-((1-ethylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide




[00461] The mixture of 2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)-N-(piperidin-4-ylmethyl)acetamide (28 mg, 0.05 mmol), iodoethane (8 mg, 0.05 mmol) and K₂CO₃ (14 mg, 0.1 mmol) in DMF (1 mL) was stirred at room temperature for 2hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3), the combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the crude product which was purified prep-TLC to afford N-((1-ethylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide (4 mg, 14%). HPLC/UV purity: 96%; LC-MS (ESI): 559.4 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.74 (s, 1H), 8.89 (d, J = 5.9 Hz, 1H), 8.01 - 8.09 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 5.9 Hz, 1H), 7.69 - 7.77 (m, J = 8.3 Hz, 2H), 7.25 (s, 1H), 4.80 (s, 2H), 4.03 - 4.10 (m, 2H), 3.86 (t, J = 6.9 Hz, 2H), 3.54 - 3.67 (m, 4H), 3.34-3.37 (m, 2H), 3.25 (d, J = 6.7 Hz, 2H), 3.18 (q, J = 7.3 Hz, 2H), 2.88 - 3.02 (m, 4H), 2.26 - 2.38 (m, 2H), 1.77 - 2.07 (m, 8H), 1.44 - 1.59 (m, 3H), 1.27 - 1.35 (m, 3H).

Example 111: Synthesis of N-((1-methylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide



[00462] The mixture of 2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetic acid (45 mg, 0.10 mmol), (1-methylpiperidin-4-yl)methanamine (14 mg, 0.11 mmol), HATU (45 mg, 0.12 mmol) and DIPEA (25 mg, 0.20 mmol) in DMF (1 mL) was stirred at room temperature for 2 hrs. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL $\times$ 3). The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-TLC to obtain N-((1-methylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide as a yellow oil (17 mg, 30%). HPLC/UV purity: 100%; LC-MS (ESI): 545.3 (M + 1)⁺; ¹H NMR (METHANOL-d₄) δ : 9.53 (s, 1H), 8.59 (d, J = 6.0 Hz, 1H), 8.07 - 8.14 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 6.0 Hz, 1H), 7.56 - 7.64 (d, J = 8.2 Hz, 2H), 7.11 (s, 1H), 4.74 (s, 2H), 4.05 (s, 2H), 3.68 (t, J = 6.8 Hz, 2H), 3.47 (d, J = 12.6 Hz, 2H), 3.33 - 3.34 (m, 2H), 3.16 - 3.29 (m, 7H), 2.90 - 3.02 (m, 2H), 2.82 (s, 3H), 2.20 - 2.34 (m, 2H), 1.92-2.01 (m, 2H), 1.85-1.90 (m, 4H), 1.63-1.75 (m, 2H), 1.50-1.53 (m, 2H).


Example 112: Synthesis of N-(2-(4-methyl-1,4-diazepan-1-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide



[00463] The mixture of 2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetic acid (31 mg, 0.07 mmol), 2-(4-methyl-1,4-diazepan-1-yl)ethanamine (11 mg, 0.07 mmol), HATU (32 mg, 0.08 mmol) and DIPEA (18 mg, 0.14 mmol) in DMF (1 mL) was stirred at room temperature for 2 hrs. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL $\times$ 3). The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-TLC to obtain N-(2-(4-methyl-1,4-diazepan-1-

yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide as a yellow oil (12 mg, 30%). HPLC/UV purity: 100%; LC-MS (ESI): 574.3 ($M + 1$)⁺; ¹H NMR (METHANOL-d₄) δ : 9.81 (s, 1H), 8.84 (d, $J = 6.1$ Hz, 1H), 8.08 - 8.14 (d, $J = 8.5$ Hz, 2H), 7.95 (d, $J = 6.1$ Hz, 1H), 7.68 - 7.76 (d, $J = 8.2$ Hz, 2H), 7.27 (s, 1H), 4.78 (s, 2H), 4.06 - 4.13 (m, 2H), 3.88 (t, $J = 6.9$ Hz, 2H), 3.59 (d, $J = 11.3$ Hz, 2H), 3.39 - 3.52 (m, 6H), 3.32 - 3.36 (m, 2H), 3.26 (d, $J = 16.2$ Hz, 2H), 2.96 - 3.13 (m, 4H), 2.91-2.96 (m, 2H), 2.89 (s, 3H), 2.35 (q, $J = 7.6$ Hz, 2H), 2.09 - 2.21 (m, 2H), 1.82 - 1.96 (m, 5H), 1.51-1.54 (m, 1H).

Example 113: Synthesis of 2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)-N-(piperidin-4-ylmethyl)acetamide




Step 1:

[00464] The mixture of 2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetic acid (31 mg, 0.07 mmol), tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (15 mg, 0.07 mmol), HATU (32 mg, 0.08 mmol) and DIPEA (18 mg 0.14 mmol) in DMF (1 mL) was stirred at room temperature for 2hrs. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL $\times$ 3). The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-TLC to obtain tert-butyl 4-((2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamido)methyl)piperidine-1-carboxylate as a yellow oil (40 mg, 90%). LC-MS (ESI): 631 ($M + 1$)⁺.

Step 2:


[00465] The mixture of tert-butyl 4-((2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamido)methyl)piperidine-1-carboxylate (40 mg, 0.06 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 18hrs, then the solvent was removed under the reduced pressure to get the residue which was purified with Prep-HPLC(Welch, XB-C18, 21.2 mm $\times$ 250 mm, 10 μ m, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford 2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)-N-(piperidin-4-ylmethyl)acetamide (30 mg, 90%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 531.3($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.76 (s, 1H), 8.88 (d, $J = 6.2$ Hz, 1H), 8.02 - 8.09 (d, $J = 8.3$ Hz, 2H), 7.94 (d, $J = 5.9$ Hz, 1H), 7.68 - 7.78 (d, $J = 8.3$ Hz, 2H), 7.25 (s, 1H), 4.80 (s, 2H), 4.07 (s, 2H), 3.86 (t, $J = 6.9$ Hz, 2H), 3.60 (d, $J = 11.8$ Hz, 2H), 3.43 (d, $J = 12.6$ Hz, 2H), 3.33 - 3.35 (m, 2H), 3.25 (d, $J = 6.4$ Hz, 2H), 2.97-3.02 (m, 4H), 2.26 - 2.39 (m, 2H), 1.75 - 2.00 (m, 8H), 1.41 - 1.59 (m, 3H).

Example 114: Synthesis of N-(2-(1-methylpiperidin-4-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide



[00466] The mixture of 2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetic acid (31 mg, 0.07 mmol), 2-(1-methylpiperidin-4-yl)ethanamine (10 mg, 0.07 mmol), HATU (32 mg, 0.08 mmol) and DIPEA (18 mg 0.14 mmol) in DMF (1 mL) was stirred at room temperature for 2 hrs. Water (30 mL) was added, and then the mixture was extracted with EA (20 mL $\times$ 3). The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the Prep-TLC to obtain N-(2-(1-methylpiperidin-4-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide as a yellow oil (14 mg, 35%). HPLC/UV purity: 100%; LC-MS (ESI): 559 ($M + 1$)⁺; ^1H NMR (METHANOL- d_4) δ : 9.75 (s, 1H), 8.89 (d, $J = 5.9$ Hz, 1H), 8.05 (d, $J = 8.3$ Hz, 2H), 7.93 (d, $J = 5.9$ Hz, 1H), 7.72 - 7.74 (d, $J = 8.3$ Hz, 2H), 7.25 (s, 1H), 4.79 (s, 2H), 4.04 (s, 2H), 3.86 (t, $J = 6.9$ Hz, 2H), 3.47 - 3.65 (m, 4H), 3.34 - 3.41 (m, 4H), 2.92 - 3.05 (m, 4H), 2.87 (s, 3H), 2.26 - 2.39 (m, 2H), 2.07 (d, $J = 14.2$ Hz, 2H), 1.97 (d, $J = 14.5$ Hz, 2H), 1.74 - 1.90 (m, 3H), 1.41 - 1.61 (m, 4H).

Example 115: Synthesis of N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)propanamide



Step 1:

[00467] The mixture of 4-(hydroxymethyl)phenylboronic acid (3.8 g, 25 mmol), 2,4-dichloro-1,6-naphthyridine (5 g, 25 mmol), Na₂CO₃ (5.3 g, 50 mmol) and Pd(PPh₃)₄ (1.155 g, 1 mmol) in 1,4-Dioxane (50 mL) and H₂O (5 mL) was stirred at 95°C for 4 hrs. The mixture was filtered, concentrated and purified by silica gel column chromatography to give (4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)methanol (4.9 g, 72%) as white solid. HPLC/UV purity: 95%; LC-MS (ESI): 271.2 (M + 1)⁺.

Step 2:

[00468] The mixture of (4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)methanol (1.355 g, 5 mmol) and 3-(piperidin-1-yl)propan-1-amine (710 mg, 5 mmol) and K₂CO₃ (1.38 g, 10 mmol) in DMF (10 mL) was stirred at 90°C overnight. Then water (50 mL) was added and the mixture was extracted with EA (30 mL×3). The combined organic layer was washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give (4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)methanol (1.138 g, 82%) as white solid. HPLC/UV purity: 95%; LC-MS (ESI): 377.2 (M + 1)⁺.


Step 3:

[00469] The solution of (4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)methanol (752 mg, 2 mmol) in THF (40 mL) was cooled to 0°C, and NaH (120 mg, 60%, 3.0 mmol) was added. After stirred at 0°C for 30 min, ethyl acrylate (200 mg, 2 mmol) was added and the resulting mixture was stirred at room temperature for another 3 hrs. Then water (50 mL) was added and the mixture was extracted with EA (30 mL × 3), washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)propanoic acid (200 mg, 22%) as white solid. HPLC/UV purity: 95%; LC-MS (ESI): 449.3 (M + 1)⁺.

Step 4:

[00470] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)propanoic acid (45 mg, 0.1 mmol), 1-methylpiperidin-4-amine (23 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (40 mg, 0.3 mmol) in DMF (2.0 mL) was stirred at room temperature overnight. Then water (50 mL) was added and the mixture was extracted with EA (30 mL×3), washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give N-(1-methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)propanamide (10 mg, 18.2%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 545.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.72 (s, 1H), 8.88 (d, *J* = 6.0 Hz, 1H), 8.02 (d, *J* = 8.4 Hz, 2H), 7.92 (d, *J* = 5.6 Hz, 1H), 7.65 (d, *J* = 8.0 Hz, 2H), 7.22 (s, 1H), 4.69 (s, 2H), 4.00 - 3.94 (m, 1H), 3.87 - 3.82 (m, 4H), 3.61 - 3.55 (m, 4H), 3.32 - 3.31 (m, 1H), 3.14 (t, *J* = 12.8 Hz, 2H), 2.98 (t, *J* = 13.2 Hz, 2H), 2.88 (s, 3H), 2.55 (t, *J* = 5.6 Hz, 2H), 2.33 - 2.29 (m, 2H), 2.19 (d, *J* = 14.8 Hz, 2H), 2.06 - 1.96 (m, 3H), 1.84 - 1.75 (m, 5H), 1.61 - 1.50 (m, 1H).

Example 116: Synthesis of methyl-N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide



Step 1:

[00471] To a mixture of 6-chloropyridin-3-amine (5 g, 38.9 mmol) and NaOAc (6.37 g, 77.8 mmol) in AcOH (30 mL) was added a solution of bromine (6.8 g, 42.8 mmol) in AcOH (5 mL). The resulting reaction mixture was stirred at room temperature for 18 hrs. Acetic acid was removed under reduced pressure to give the residue, which was dissolved into EA (50 mL), washed by NaHCO₃ aqueous (20 mL × 5), water and brine. The organic layers were dried over Na₂SO₄, and the drying agent was filtered off. The filtrate was concentrated in vacuo to give the crude product, which was purified by silica gel chromatography (silica gel, eluting with 5% methanol in DCM) to give 2-bromo-6-chloropyridin-3-amine (5 g, 62%) as an orange solid. HPLC/UV purity: 90%; LC-MS (ESI): 207.3 (M + 1)⁺.

Step 2:

[00472] To the mixture of 2-bromo-6-chloropyridin-3-amine (5 g, 24.4 mmol), Pd(OAc)₂ (1.09 g, 4.88 mmol), PPh₃ (1.91 g, 7.32 mmol) and triethylamine (10.8 g, 107.3 mmol) in DMF (30 mL) in N₂ atmosphere, was added 2-oxopropanoic acid (5.69 g, 64.6 mmol) by a syringe. The resulting mixture was heated at 115°C for 18 hrs under N₂. The reaction mixture was cooled to room temperature and poured into water (200 mL). The resulting precipitate was filtered and the filtrate was washed with EA (30 mL × 3). The pH of aqueous phase was adjusted with 1N aq. HCl solution to pH 4, and the resulting precipitate was collected by filtration and dried by reduced pressure to give 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (2.44 g, 51%) as a solid. HPLC/UV purity: 90%; LC-MS (ESI): 197.1 (M + 1)⁺.

Step 3:

[00473] To a mixture of 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (2.44 g, 12.44 mmol) and Cs_2CO_3 (8 g, 24.9 mmol) in DMF (10 mL) was added CH_3I (3.85 g, 27.3 mmol) at room temperature. The mixture was heated at 70°C for 18hrs. The reaction mixture was cooled to room temperature and quenched by water (50 mL), extracted with EA (20 mL $\times$ 3). The combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the crude product, which was purified by silica gel chromatography (silica gel, eluting with 20% EA in PE) to give methyl 5-chloro-1-methyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (1.8 g, 64%) as a yellow solid. HPLC/UV purity: 90%; LC-MS (ESI): 225 ($M + 1$)⁺.

Step 4:

[00474] To the mixture of methyl 5-chloro-1-methyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (1.6 g, 7.14 mmol), $\text{Pd}(\text{OAc})_2$ (160 mg, 0.714 mmol) and 1,4-bis(diphenylphosphino)butane (608 mg, 1.43 mmol) in 1,4-dioxane (20 mL) in N_2 atmosphere, was added a solution of 1,1,1,2,2,2-hexamethyldistannane (2.8 g, 8.57 mmol) in 1,4-dioxane (2 mL) by a syringe. The resulting mixture was heated at 100°C for 18hrs under N_2 . The reaction mixture was concentrated to give the residue, which was diluted with EA (50 mL), extracted with EA (20 mL $\times$ 3). The combined organic layers were washed by water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under reduced pressure to give methyl 1-methyl-5-(trimethylstannyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (1.5 g, 59%) as a crude product which was used to the next step without further purification.

Step 5:

[00475] A 20-mL microwave vial was charged with 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine (235 mg, 0.78 mmol), methyl 1-methyl-5-(trimethylstannyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (330 mg, 0.93 mmol), $\text{Pd}_2(\text{dba})_3$ (71 mg, 0.078 mmol), Xphos (90 mg, 0.156 mmol) and 1,4-Dioxane (10 mL). The sealed vial with the resulting brown solution was heated for 2 hrs in a Biotage Initiator Eight Microwave Reactor at a constant temperature of 120°C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The resulting crude mixture was purified using Prep-TLC (silica gel, eluting with 10% methanol in DCM) to give methyl 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (40 mg, 22%) as a white solid. HPLC/UV purity: 95%; LC-MS (ESI): 459.4 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.37 (s, 1H), 8.48 (d, $J = 5.8$ Hz, 1H), 8.41 (d, $J = 8.9$ Hz, 1H), 8.07 (d, $J = 8.8$ Hz, 1H), 7.73 (d, $J = 5.8$ Hz, 1H), 7.59 (s, 1H), 7.36 (s, 1H), 4.07 (s, 3H), 3.88 (s, 3H), 3.52 - 3.60 (m, 2H), 2.83 - 2.99 (m, 6H), 2.05 - 2.15 (m, 2H), 1.61 - 1.78 (m, 4H), 1.48-1.51 (m, 2H).

Step 6:


[00476] To a solution of methyl 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (30 mg, 0.065 mmol) in methanol (1 mL) was added 1N aq. LiOH solution (0.26 mL, 0.26 mmol). The reaction mixture was stirred at 40°C for 2hrs. The solvent was removed and water (5 mL) was added. The pH of the water phase was adjusted with 1N aq. HCl solution

to pH 4. Then it was lyophilized to give a crude product (40 mg) as a white solid. The crude product was used to the next step without purification.

Step 7:


[00477] To a mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (30 mg, 0.065 mmol) and HATU (38 mg, 0.101 mmol) in DMF (2 mL) was added 1-methylpiperidin-4-amine (11 mg, 0.101 mmol) and DIPEA (26 mg, 0.203 mmol). Then the resulting mixture was stirred at rt for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to give the crude product, which was purified with Prep-TLC (silica gel, DCM/Methanol/NH₃.H₂O=10/1/0.1) to give 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide (15 mg, 43%) as a solid. HPLC/UV purity: 100%; LC-MS (ESI): 541 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.36 (s, 1H), 8.46 (d, J = 6.1 Hz, 1H), 8.30 (d, J = 8.8 Hz, 1H), 7.99 (d, J = 8.9 Hz, 1H), 7.71 (d, J = 5.8 Hz, 1H), 7.52 (s, 1H), 7.14 (s, 1H), 3.97 (s, 3H), 3.85-3.92 (m, 1H), 3.50 (t, J = 6.7 Hz, 2H), 2.85 - 2.96 (m, 2H), 2.49 - 2.66 (m, 6H), 2.26 (s, 3H), 2.17 (t, J = 11.6 Hz, 2H), 1.88 - 2.05 (m, 4H), 1.54 - 1.72 (m, 6H), 1.41-1.43 (m, 2H).

Example 117: Synthesis of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide



[00478] To a mixture of 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (10 mg, 0.023 mmol) and HATU (10 mg, 0.027 mmol) in DMF (1 mL) was added ammonium chloride (2.4 mg, 0.045 mmol) and DIPEA (8.7mg, 0.067 mmol). Then the resulting mixture was stirred at rt for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to give the residue, which was purified with Prep-TLC (silica gel, DCM/Methanol/NH₃.H₂O=10/1/0.1) to give 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide (6 mg, 60%) as a solid. HPLC/UV purity: 100%; LC-MS (ESI): 444.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.50 (s, 1H), 8.61 (d, J = 5.9 Hz, 1H), 8.47 (d, J = 8.9 Hz, 1H), 8.16 (d, J = 8.9 Hz, 1H), 7.86 (d, J = 5.9 Hz, 1H), 7.70 (s, 1H), 7.33 (s, 1H), 4.14 (s, 3H), 3.69 (t, J = 6.7 Hz, 2H), 3.01 - 3.27 (m, 6H), 2.17 - 2.32 (m, 2H), 1.71 - 1.92 (m, 4H), 1.64-1.69 (m, 2H).

Example 118: Synthesis of (E)-N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide & (Z)-N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide



Step 1:

[00479] The mixture of methyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylate (198 mg, 1 mmol), 2,4-dichloro-1,6-naphthyridine (206 mg, 1 mmol), Pd(PPh₃)₄ (115 mg, 0.1 mmol) and Na₂CO₃ (212 mg, 2 mmol) in Dioxane/H₂O (20 mL/2 mL) was stirred at 100°C overnight. The mixture was diluted with EA, washed with water (100 mL×3) and brine (100 mL×1), dried over Na₂SO₄, filtered, concentrated to give crude methyl 3-(4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)acrylate (230 mg, 71%) as white solid which was used directly in the next step. HPLC/UV purity: 95%; LC-MS (ESI): 324.8 (M + 1)⁺.

Step 2:

[00480] The mixture of methyl 3-(4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)acrylate (230 mg, 0.7 mmol), K₂CO₃ (290 mg, 2.1 mmol) and 3-(piperidin-1-yl)propan-1-amine (149 mg, 1.05 mmol) in DMF (10 mL) was stirred at 70°C overnight. The mixture was filtered, concentrated and purified by silica gel chromatography to give methyl 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylate (240 mg, 80%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 430.8 (M + 1)⁺.

Step 3:

[00481] The solution of methyl 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylate (129 mg, 0.3 mmol) and LiOH.H₂O (25 mg, 0.6 mmol) in CH₃OH/H₂O (10 mL/1 mL) was stirred at 65 °C for 3 hours. Then the mixture was cooled to room temperature and 0.7 mL 1N aq. HCl solution was added. The solvent was removed to give crude 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid which was used in next step directly. HPLC/UV purity: 95%; LC-MS (ESI): 416.7 (M + 1)⁺.


Step 4:

[00482] The solution of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (42mg, 0.1 mmol), 1-methylpiperidin-4-amine (23 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (39 mg, 0.3 mmol) in DMF (3 mL) was stirred at room temperature overnight. Then 50 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give the desired products.

[00483] (E)-N-(1-methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (6mg, 10.5%). HPLC/UV purity: 100%; LC-MS (ESI): 512.9 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.63 (s, 1H), 8.77 (d, *J* = 6.4 Hz, 1H), 7.95 (d, *J* = 8.4 Hz, 2H), 7.81 (d, *J* = 6.0 Hz, 1H), 7.76 (d, *J* = 8.4 Hz, 2H), 7.57 (d, *J* = 15.6 Hz, 1H), 7.15 (s, 1H), 6.69 (d, *J* = 15.6 Hz, 1H), 4.00 - 3.95 (m, 1H), 3.74 (t, *J* = 6.8 Hz, 2H), 3.53 - 3.47 (m, 4H), 3.23 - 3.18 (m, 2H), 3.22 - 3.10 (m, 2H), 2.88 - 2.77 (m, 5H), 2.21 - 2.12 (m, 4H), 1.76-1.86 (m, 2H), 1.73 - 1.67 (m, 5H), 1.43 - 1.40 (m, 1H).

[00484] (Z)-N-(1-methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (18mg, 31.5%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 512.9 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.63 (s, 1H), 8.77 (d, *J* = 5.6 Hz, 1H), 7.90 (d, *J* = 8.8 Hz, 2H), 7.81 (d, *J* = 5.6 Hz, 1H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.13 (s, 1H), 6.82 (d, *J* = 12.4 Hz, 1H), 6.10 (d, *J* = 12.4 Hz, 1H), 3.95-3.88 (m, 1H), 3.74 (t, *J* = 7.2 Hz, 2H), 3.50 - 3.43 (m, 4H), 3.23 - 3.18 (m, 2H), 3.19 - 3.16 (m, 2H), 2.88 (t, *J* = 12 Hz, 2H), 2.76 (s, 3H), 2.21 - 2.10 (m, 2H), 2.10 - 2.06 (m, 2H), 1.97 - 1.86 (m, 2H), 1.75 - 1.55 (m, 5H), 1.49 - 1.37 (m, 1H).


Example 119: Synthesis of (E)-N-(2-(Dimethylamino)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide



[00485] The solution of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (62 mg, 0.1 mmol), N¹,N¹-dimethylethane-1,2-diamine (18 mg, 0.3 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (3 mL) was stirred at room temperature overnight. Then 100 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (E)-N-(2-(dimethylamino)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (40 mg, 41.9%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 486.8 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.74 (s, 1H), 8.89-8.89 (m,


1H), 8.10 (d, $J = 8.4$ Hz, 2H), 7.93 - 7.85 (m, 3H), 7.70 (d, $J = 15.6$ Hz, 1H), 7.27(s, 1H), 6.84(d, $J = 16$ Hz, 1H), 3.86 (t, $J = 6.8$ Hz, 2H), 3.74 (t, $J = 6.8$ Hz, 2H), 3.62 - 3.58(m, 2H), 3.40 - 3.36 (m, 2H), 3.36 - 3.30 (m, 2H), 3.00 (s, 6H), 2.97 - 2.94 (m, 2H), 2.34 - 2.30 (m, 2H), 1.99 - 1.95 (m, 2H), 1.87 - 1.78 (m, 3H), 1.59 - 1.49 (m, 1H).

Example 120: Synthesis of (E)-N-(3-(Piperidin-1-yl)propyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide



[00486] The mixture of (E)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (84mg, 0.2 mmol), (1-methylpiperidin-4-yl)methanamine (28 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (52 mg, 0.4 mmol) in DMF (4.0 mL) was stirred at room temperature overnight. Then 100 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na_2SO_4 , concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm $\times$ 250 mm, 10 μm , eluting with 20% CH_3CN in 1% TFA in H_2O) to give (E)-N-(3-(piperidin-1-yl)propyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (60 mg, 55%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 540.9 ($\text{M} + 1$) $^+$. ^1H NMR (METHANOL- d_4) δ : 9.84 (s, 1H), 8.95 (s, 1H), 8.09 (d, $J = 8.4$ Hz, 2H), 7.95 (d, $J = 4.0$ Hz, 1H), 7.89 (d, $J = 8.0$ Hz, 2H), 7.69 (d, $J = 15.2$ Hz, 1H), 7.28 (s, 1H), 6.85 (d, $J = 15.6$ Hz, 1H), 3.86 (t, $J = 6.8$ Hz, 2H), 3.62 - 3.59 (m, 4H), 3.46 (t, $J = 6.4$ Hz, 2H), 3.35 - 3.31 (m, 2H), 3.20 - 3.15 (m, 2H), 3.01 - 2.90 (m, 4H), 2.34 - 2.30 (m, 2H), 2.07 - 1.95 (m, 6H), 1.87 - 1.77 (m, 6H), 1.57 - 1.54 (m, 2H).


Example 121: Synthesis of (E)-N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide



[00487] The mixture of (E)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (84mg, 0.2 mmol), (1-methylpiperidin-4-yl)methanamine (26 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (52 mg, 0.4 mmol) in DMF (5.0 mL) was stirred at room


temperature overnight. Then 100 mL water was added and the mixture was extracted with EA (100 mLx2), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (E)-N-((1-methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (60 mg, 57%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 526.9 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.88 (d, *J* = 6.0 Hz, 1H), 8.08 (d, *J* = 8.4 Hz, 2H), 7.93 (d, *J* = 5.6 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 2H), 7.67 (d, *J* = 16.0 Hz, 1H), 7.27 (s, 1H), 6.85 (d, *J* = 15.6 Hz, 1H), 3.86 (t, *J* = 6.4 Hz, 2H), 3.62 - 3.55 (m, 4H), 3.55 - 3.31 (m, 4H), 3.04 - 2.94 (m, 2H), 2.93 - 3.00 (m, 4H), 2.88 (s, 3H), 2.34 - 2.30 (m, 2H), 2.08 - 1.79 (m, 7H), 1.58 - 1.52 (m, 2H).

Example 122: Synthesis of (E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide



[00488] The mixture of (E)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (84mg, 0.2 mmol), 2-(1-methylpiperidin-4-yl)ethanamine (29 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (52 mg, 0.4 mmol) in DMF (10.0 mL) was stirred at room temperature for 3 hours. Then 100 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (E)-N-(2-(1-methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (60 mg, 55%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 540.9 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.88 (d, *J* = 6.0 Hz, 1H), 8.08 (d, *J* = 8.4 Hz, 2H), 7.93 (d, *J* = 6.0 Hz, 1H), 7.88 (d, *J* = 8.8, 2H), 7.65 (d, *J* = 15.6 Hz, 1H), 7.26 (d, *J* = 7.6 Hz, 1H), 6.82 (d, *J* = 15.6 Hz, 1H), 3.86 (t, *J* = 6.8 Hz, 2H), 3.63 - 3.50 (m, 4H), 3.43 (t, *J* = 6.8 Hz, 2H), 3.35 - 3.31 (m, 2H), 3.03 - 2.92 (m, 4H), 2.87 (s, 3H), 2.36 - 2.28 (m, 2H), 2.09 (d, *J* = 14.0 Hz, 2H), 1.97 (d, *J* = 15.6 Hz, 2H), 1.88 - 1.76 (m, 3H), 1.70 - 1.66 (m, 1H), 1.64 - 1.40 (m, 5H).

Example 123: Synthesis of (E)-N-((1-Ethylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide

**Step 1:**

[00489] The mixture of (E)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (83 mg, 0.2 mmol), tert-butyl 4-(aminomethyl)piperidine-1-carboxylate (43 mg, 0.3 mmol), HATU (115 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5.0 mL) was stirred at room temperature overnight. Then 100 mL water was added and the mixture was extracted with EA (50 mLx2), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (E)-tert-butyl 4-((3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamido)methyl)piperidine-1-carboxylate (80 mg, 65.6%) as yellow solid. HPLC/UV purity: 90%; LC-MS (ESI): 612.9 (M + 1)⁺.

Step 2:


[00490] The solution of (E)-tert-butyl 4-((3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamido)methyl)piperidine-1-carboxylate (80 mg, 0.13 mmol) in TFA/DCM (1 mL/5 mL) was stirred at room temperature for 1 hour. The mixture was concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (E)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-ylmethyl)acrylamide (40 mg, 60%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 513.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.63 (s, 1H), 8.76 (d, *J* = 6.0 Hz, 1H), 8.01 - 7.95 (m, 2H), 7.81 - 7.75 (m, 3H), 7.55 (d, *J* = 16.0 Hz, 1H), 7.15 (s, 1H), 6.73 (d, *J* = 16.0 Hz, 1H), 3.78 - 3.72 (m, 2H), 3.49 (d, *J* = 11.2 Hz, 2H), 3.33 (d, *J* = 12.8 Hz, 2H), 3.23 - 3.20 (m, 4H), 2.98 - 2.79 (m, 4H), 2.22 - 2.18 (m, 2H), 2.01 - 1.80 (m, 5H), 1.76 - 1.67 (m, 3H), 1.42 - 1.36 (m, 3H).

Step 3:

[00491] The mixture of (E)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-ylmethyl)acrylamide (31 mg, 0.06 mmol), EtI (15.6 mg, 0.1 mmol) and K₂CO₃ (28 mg, 0.2 mmol) in DMF (5 mL) was stirred at room temperature for 2 hours. Then 100 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and


purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (E)-N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (5 mg, 17%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 541.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.45 (s, 1H), 8.50 (d, *J* = 5.6 Hz, 1H), 8.04 (d, *J* = 8.4 Hz, 2H), 7.71-7.66 (m, 3H), 7.53 (d, *J* = 16.0 Hz, 1H), 7.04 (s, 1H), 6.68 (d, *J* = 15.6 Hz, 1H), 3.61-3.57 (m, 2H), 3.53-3.47 (m, 2H), 3.21-3.17 (m, 2H), 3.10-3.07 (m, 2H), 2.86-2.82 (m, 2H), 2.20-2.16 (m, 2H), 1.99-1.92 (m, 2H), 1.90-1.70 (m, 6H), 1.52-1.40 (m, 4H), 1.26 (t, *J* = 7.6 Hz, 3H), 1.23-1.18 (m, 5H).

Example 124: Synthesis of (E)-N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide



[00492] The mixture of (E)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (205 mg, 0.5 mmol), 2-(4-methyl-1,4-diazepan-1-yl)ethanamine (78 mg, 0.5 mmol), HATU (380 mg, 1 mmol) and DIPEA (129 mg, 1 mmol) in DMF (5.0 mL) was stirred at room temperature overnight. Then 50 mL water was added and the mixture was extracted with EA (200 mL), washed with water (100 mL × 2) and brine (100 mL × 1), dried over Na₂SO₄, filtered, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give (E)-N-(2-(4-methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (100 mg, 36%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 556.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.89 (d, *J* = 6.0 Hz, 1H), 8.09 (d, *J* = 8.4 Hz, 2H), 7.93 (d, *J* = 6.0 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 2H), 7.70 (d, *J* = 16.0 Hz, 1H), 7.28 (s, 1H), 6.84 (d, *J* = 16.0 Hz, 1H), 3.88-3.74 (m, 6H), 3.76 (t, *J* = 5.6 Hz, 2H), 3.66-3.59 (m, 6H), 3.44 (t, *J* = 5.6 Hz, 2H), 3.32-3.30 (m, 2H), 3.01-2.94 (m, 5H), 2.37-2.30 (m, 4H), 1.99-1.95 (m, 2H), 1.88-1.79 (m, 3H), 1.59-1.50 (m, 1H).

Example 125: Synthesis of (E)-N,N-Diethyl-3-(4-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylamide

**Step 1:**

[00493] The mixture of 2,4-dichloro-1,6-naphthyridine (2 g, 10 mmol), (E)-4-(3-methoxy-3-oxoprop-1-en-1-yl)phenylboronic acid (2.47 g, 12 mmol), Pd(PPh₃)₄ (575 mg, 0.5 mmol) and Na₂CO₃ (2.12 g, 20 mmol) in 1,4-dioxane (40 mL) and H₂O (5 mL) was heated at 100 °C for 18 hrs under N₂ atmosphere. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The crude mixture was purified by silica gel chromatography (silica gel, eluting with 10% methanol in DCM) to give (E)-methyl 3-(4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)acrylate (2.87 g, 88%) as a yellow solid HPLC/UV purity: 90%; LC-MS (ESI): 325.3 (M + 1)⁺.


Step 2:

[00494] To a 20-mL microwave vial was charged with (E)-methyl 3-(4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)acrylate (500 mg, 1.54 mmol), 4-(pyrrolidin-1-ylmethyl)aniline (298 mg, 1.69 mmol), Pd₂(dba)₃ (141 mg, 0.154 mmol), Xphos (177 mg, 0.308 mmol), Cs₂CO₃ (1 g, 3.08 mmol) and, 1,4-dioxane (10 mL). The sealed vial with the resulting mixture was heated for 1 hrs in a Biotage Initiator Eight Microwave Reactor at a constant temperature of 120 °C. The resulting solutions were concentrated by rotary evaporation (55°C, 20 mmHg). The crude mixture was purified using silica gel chromatography (silica gel, eluting with 10% methanol in DCM) to give (E)-methyl 3-(4-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylate (380 mg, 53%) as a yellow solid. HPLC/UV purity: 95%; LC-MS (ESI): 465.3 (M + 1)⁺

Step 3:

[00495] To a solution of (E)-methyl 3-(4-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylate (380 mg, 0.818 mmol) in methanol (2 mL) and THF (2 mL) was added


1N aqueous LiOH solution (3.27 mL, 3.27 mmol). The reaction mixture was stirred at room temperature overnight. The solvent was removed and water (5 mL) was added. The pH of the water phase was adjusted with 1N aq. HCl solution to pH 4. It was lyophilized to give crude product (500 mg) as a yellow solid.



Step 4:

[00496] The mixture of (E)-3-(4-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylic acid (100 mg, 0.22 mmol), diethylamine (32 mg, 0.44 mmol), HATU (380.23 g, 0.33 mmol) and DIPEA (57 mg, 0.44 mmol) in DMF (3 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (3 mL), extracted with EtOAc (5 mL x 3), washed with water (5 mL x 3) and brine (10mL), dried over Na₂SO₄, concentrated and purified by prep-PLC to afford (E)-N,N-diethyl-3-(4-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylamide (40 mg, 36%) as yellow solid. LC-MS (ESI): 506.3 (M + 1)⁺. ¹H NMR (400 MHz, CD₃OD) δ 9.89 (s, 1H), 8.92 (d, *J* = 6.0 Hz, 1H), 8.01 (d, *J* = 6.0 Hz, 1H), 7.94 - 7.86 (m, 4H), 7.78 - 7.71 (m, 4H), 7.64 (d, *J* = 15.6 Hz, 1H), 7.30 (s, 1H), 7.22 (d, *J* = 15.6 Hz, 1H), 4.48 (s, 2H), 3.64 - 3.58 (m, 4H), 3.52 (q, *J* = 15.6 Hz, 2H), 3.31-3.26 (m, 2H), 2.14 (d, *J* = 67.2 Hz, 4H), 1.28 (t, *J* = 7.2 Hz, 3H), 1.20 (t, *J* = 7.2 Hz, 3H).

Example 126: Synthesis of N-(1-Methylpiperidin-4-yl)-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide



Step 1

[00497] The mixture of 4-(3-methoxy-3-oxoprop-1-enyl)phenylboronic acid (412 mg, 2 mmol), 2,4-dichloro-1,6-naphthyridine (400mg, 2 mmol), Na₂CO₃ (424 mg, 4 mmol) and Pd(PPh₃)₄ (230 mg, 0.2 mmol) in 1,4-dioxane/H₂O (50 mL/5 mL) was stirred at 100°C overnight. The mixture was diluted with EA, washed with water (100 mL×3) and brine (100 mL×1), dried over Na₂SO₄, filtered, concentrated and purified by silica gel column chromatography to give methyl 3-(4-(4-chloro-1,6-naphthyridin-2-

yl)phenyl)acrylate (420 mg, 65%) as white solid which was used in next step directly. HPLC/UV purity: 100%; LC-MS (ESI): 325.2 (M + 1)⁺.

Step 2:

[00498] The mixture of (E)-methyl 3-(4-(4-chloro-1,6-naphthyridin-2-yl)phenyl)acrylate (324 mg, 1 mmol), 1-methylpiperidin-4-amine (230 mg, 2.0 mmol) and K₂CO₃ (280 mg, 2 mmol) in DMF (20 mL) was stirred at 100°C for 2 hrs. Then 100 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by silica gel column chromatography to give (E)-methyl 3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)acrylate (200 mg, 50%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 403.2 (M + 1)⁺.

Step 3:

[00499] The mixture of (E)-methyl 3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)acrylate (200 mg, 0.5 mmol), Pd/C (10%, 30 mg) in MeOH (40 mL) was stirred under H₂ atmosphere at room temperature overnight. The mixture was filtered and concentrated to give crude methyl 3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanoate (200 mg, 99%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 405.2 (M + 1)⁺.


Step 4:

[00500] The solution of methyl 3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanoate (200 mg, 0.5 mmol) and LiOH·H₂O (41 mg, 1 mmol) in MeOH (10 mL) and H₂O (1 mL) was stirred at 80°C for 6 hrs. Then the mixture was cooled to room temperature and 1.1 mL 1N aq. HCl solution was added. The solvent was removed to give crude 3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid which was used in next step directly. HPLC/UV purity: 100%; LC-MS (ESI): 391.2 (M + 1)⁺.

Step 5:


[00501] The mixture of 3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (78 mg, 0.2 mmol), 1-methylpiperidin-4-amine (34 mg, 0.3 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5.0 mL) was stirred at room temperature for 2 hours. Then 100 mL water was added and the mixture was extracted with EA (100 mLx2), washed with brine, dried over Na₂SO₄, concentrated and purified by silica gel column chromatography to give N-(1-methylpiperidin-4-yl)-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide (5 mg, 5.2%) as white solid. HPLC/UV purity: 90%; LC-MS (ESI): 487.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.80 (s, 1H), 8.86 (d, J = 6.0 Hz, 1H), 7.97 (d, J = 8.0 Hz, 2H), 7.90 (d, J = 6.0 Hz, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.32 (s, 1H), 4.50-4.43 (m, 1H), 3.97-3.85 (m, 1H), 3.70 (d, J = 12.8 Hz, 2H), 3.53 (d, J = 11.6 Hz, 2H), 3.30-3.20 (m, 2H), 3.13-3.04 (m, 4H), 2.94 (s, 3H), 2.85 (s, 3H), 2.57 (t, J = 8.0 Hz, 2H), 2.41 (d, J = 14.0 Hz, 2H), 2.18-2.00 (m, 4H), 1.83-1.62 (m, 2H).

Example 127: Synthesis of N,N-Diethyl-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide



[00502] The solution of 3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (78 mg, 0.2 mmol), diethylamine (22 mg, 0.3 mmol), HATU (114 mg, 0.3 mmol) and DIPEA (65 mg, 0.3 mmol) in DMF (5.0 mL) was stirred at room temperature for 3 hours. Then 100 mL water was added and the mixture was extracted with EA (100 mL x2), washed with brine, dried over Na_2SO_4 , concentrated and purified by silica gel column chromatography to give N,N-diethyl-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide (30 mg, 33%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 446.3 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.82 (s, 1H), 8.89 (d, $J = 6.0$ Hz, 1H), 7.98 (d, $J = 8.0$ Hz, 2H), 7.93 (d, $J = 6.0$ Hz, 1H), 7.60 (d, $J = 8.0$ Hz, 2H), 7.34 (s, 1H), 4.50-4.45 (m, 1H), 3.72 (d, $J = 12.8$ Hz, 2H), 3.42-3.32 (m, 4H), 3.30-3.26 (m, 2H), 3.13 (t, $J = 7.2$ Hz, 2H), 2.97 (s, 3H), 2.79 (t, $J = 7.2$ Hz, 2H), 2.44 (d, $J = 14.4$ Hz, 2H), 2.25-2.15 (m, 2H), 1.19-1.11 (m, 6H).

Example 128: Synthesis of N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide



Step 1:

[00503] The mixture of (E)-methyl 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylate (430 mg, 1 mmol) and Pd/C (80 mg) in MeOH (50 mL) was stirred at 35°C for 3 hours under H_2 balloon protection. The mixture was filtered, concentrated to give crude methyl 3-(4-(4-(3-

(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoate (430 mg, 99%) as yellow solid which was used in next step directly. HPLC/UV purity: 95%; LC-MS (ESI): 432.8 ($M + 1$)⁺.


Step 2:

[00504] The solution of methyl 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoate (430 mg, 0.99 mmol) and LiOH.H₂O (82 mg, 2 mmol) in MeOH/H₂O (20 mL/2 mL) was stirred at 65 °C for 3 hours. Then the mixture was cooled to room temperature and 2.3 mL 1N aq. HCl solution was added. The solvent was removed to give crude 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (400 mg, 95%) as white solid which was used in next step directly. HPLC/UV purity: 90%; LC-MS (ESI): 418.8 ($M + 1$)⁺.

Step 3:

[00505] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (84 mg, 0.2 mmol), (1-methylpiperidin-4-yl)methanamine (26 mg, 0.2 mmol), HATU (76 mg, 0.2 mmol) and DIPEA (52 mg, 0.4 mmol) in DMF (3.0 mL) was stirred at room temperature overnight. Then 50 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give N-((1-methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide (53 mg, 50%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 528.8 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) : 9.73 (s, 1H), 8.88 (d, J = 6.4 Hz, 1H), 7.97 (d, J = 8.4, 2H), 7.92 (d, J = 5.6 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.21 (s, 1H), 3.85 (t, J = 6.4 Hz, 2H), 3.60 (d, J = 12.4 Hz, 2H), 3.53 (d, J = 12.4 Hz, 2H), 3.32-3.29 (m, 2H), 3.14 (d, J = 6.8 Hz, 2H), 3.12 - 3.07 (m, 2H), 3.0 - 2.90 (m, 4H), 2.86 (s, 3H), 2.62 (t, J = 8.4 Hz, 2H), 2.33 - 2.29 (m, 2H), 2.01 - 1.92 (m, 4H), 1.85 - 1.79 (m, 4H), 1.47 - 1.40 (m, 3H).


Example 129: Synthesis of N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide



[00506] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (125 mg, 0.3 mmol), 2-(1-methylpiperidin-4-yl)ethanamine (43 mg, 0.3 mmol), HATU (190 mg, 0.5 mmol) and DIPEA (129 mg, 1 mmol) in DMF (5.0 mL) was stirred at room temperature overnight. Then 50 mL water was added and the mixture was extracted with EA (50 mL×2), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μm, eluting with 20% CH₃CN in 1% TFA in H₂O) to give N-(2-(1-methylpiperidin-4-

yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide (81 mg, 50%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 542.9 ($M + 1$)⁺. ¹H NMR (METHANOL-*d*₄) δ : 9.74 (s, 1H), 8.88 (d, $J = 6.0$ Hz, 1H), 7.97 (d, $J = 8.4$ Hz, 2H), 7.93 (d, $J = 6.0$ Hz, 1H), 7.57 (d, $J = 8.4$ Hz, 2H), 7.22 (s, 1H), 3.85 (t, $J = 6.8$ Hz, 2H), 3.61 (d, $J = 12.4$ Hz, 2H), 3.52 (d, $J = 12.8$ Hz, 2H), 3.34-3.30 (m, 2H), 3.25 (t, $J = 7.2$ Hz, 2H), 3.08 (t, $J = 7.2$ Hz, 2H), 3.01-2.90 (m, 4H), 2.86 (s, 3H), 2.59 (t, $J = 7.2$ Hz, 2H), 2.34-2.29 (m, 2H), 2.06-1.95 (m, 4H), 1.88-1.39 (m, 9H).

Example 130: Synthesis of 3-(4-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-yl)propanamide




Step 1:

[00507] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (125 mg, 0.3 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (60 mg, 0.3 mmol), HATU (190 mg, 0.5 mmol) and DIPEA (129 mg, 1 mmol) in DMF (10.0 mL) was stirred at room temperature overnight. Then 100 mL water was added and the mixture was extracted with EA (50 mL $\times$ 2), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm $\times$ 250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to give tert-butyl 4-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)piperidine-1-carboxylate (100 mg, 55%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 601.3 ($M + 1$)⁺.

Step 2:

[00508] The solution of tert-butyl 4-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)piperidine-1-carboxylate (100 mg, 0.136 mmol) in TFA/DCM (1 mL/5 mL) was stirred at room temperature for 2 hour. Then the solution was concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm $\times$ 250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to give 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-yl)propanamide (40 mg, 47.9%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 502.3 ($M + 1$)⁺. ¹H NMR (METHANOL-*d*₄) δ : 9.73 (s, 1H), 8.88 (d, $J = 6.4$ Hz, 1H), 7.97 (d, $J = 8.0$ Hz, 2H), 7.92 (d, $J = 6.4$ Hz, 1H), 7.60 (d, $J = 8.0$ Hz, 2H), 7.22 (s, 1H), 4.64 (d, $J = 13.6$ Hz, 1H), 4.12 (d, $J = 13.6$ Hz, 1H), 3.85 (t, $J = 7.2$ Hz, 2H), 3.60 (d, $J = 12.0$ Hz, 2H), 3.39 - 3.34 (m, 1H), 3.32 - 3.30 (m, 2H), 3.22 - 3.18 (m, 1H), 3.10 - 3.07 (m, 2H), 2.99 - 2.92 (m, 2H), 2.88 - 2.83 (m, 2H), 2.78-2.70 (m, 1H), 2.33 - 2.29 (m, 2H), 2.12 - 2.01 (m, 2H), 2.01 - 1.95 (m, 2H), 1.85 - 1.75 (m, 3H), 1.58 - 1.45 (m, 3H).

Example 131: Synthesis of N-(2-(Diethylamino)-2-oxoethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propenamide



Step 1:

[00509] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (410 mg, 0.98 mmol), methyl 2-aminoacetate.HCl (250 mg, 2 mmol), HATU (380 mg, 1 mmol) and DIPEA (516 mg, 4 mmol) in DMF (5.0 mL) was stirred at room temperature for 3 hours. Then 100 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give Methyl 2-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)acetate (320 mg, 67%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 490.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.45 (s, 1H), 8.57-8.55 (m, 1H), 7.98 (d, *J* = 8.0 Hz, 2H), 7.78 (d, *J* = 6.0 Hz, 1H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.01 (s, 1H), 3.95 (s, 2H), 3.74 (s, 3H), 3.57 (t, *J* = 6.8 Hz, 2H), 3.05 (t, *J* = 8.0 Hz, 2H), 2.73 - 2.62 (m, 8H), 2.10 - 2.06 (m, 2H), 1.74 - 1.68 (m, 4H), 1.58 - 1.55 (m, 2H).

Step 2:


[00510] The solution of methyl 2-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)acetate (98 mg, 0.2mmol) and LiOH.H₂O (20 mg, 0.5 mmol) in MeOH/H₂O (10 mL/1 mL) was stirred at 65°C for 2 hrs. Then the mixture was cooled to room temperature and 0.7 mL 1N aq. HCl solution was added. The solvent was removed to give 2-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)acetic acid (410 mg, 98%) as white solid which was used to in next step directly. HPLC/UV purity: 100%; LC-MS (ESI): 476.3 (M + 1)⁺.

Step 3:

[00511] The mixture of 2-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)acetic acid (90 mg, 0.189 mmol), diethylamine (22 mg, 0.3 mmol), HATU (114

mg, 0.3 mmol) and DIPEA (77 mg, 4 mmol) in DMF (5.0 mL) was stirred at room temperature for 3 hours. Then 50 mL water was added and the mixture was extracted with DCM/MeOH (100 mL/10 mL), dried over Na₂SO₄, concentrated and purified by flash column chromatography to give N-(2-(diethylamino)-2-oxoethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide (320 mg, 67%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 531.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.72 (s, 1H), 8.71 (d, *J* = 6.0 Hz, 1H), 8.03 (d, *J* = 8.4 Hz, 2H), 7.87 (d, *J* = 6.0 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 2H), 7.17 (s, 1H), 4.07 (s, 2H), 3.79 (t, *J* = 6.8 Hz, 2H), 3.77 - 3.50 (m, 2H), 3.43 - 3.37 (m, 2H), 3.09 (t, *J* = 7.6 Hz, 2H), 2.99 - 2.95 (m, 4H), 2.70 - 2.67 (m, 2H), 2.36 - 2.34 (m, 2H), 1.95 - 1.90 (m, 4H), 1.88 - 1.50 (m, 2H), 1.25 - 1.20 (m, 5H), 1.14 (t, *J* = 7.2 Hz, 3H).

Example 132: Synthesis of N-(1-Ethylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide



Step 1:

[00512] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (400 mg, 0.956 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (200 mg, 1 mmol), HATU (380 mg, 1 mmol) and DIPEA (258 mg, 2 mmol) in DMF (15.0 mL) was stirred at room temperature for 3 hours. Then 200 mL water was added and the mixture was extracted with EA (200 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by flash column chromatography to give tert-butyl 4-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)piperidine-1-carboxylate (500 mg, 83.3%) as white solid. HPLC/UV purity: 90%; LC-MS (ESI): 601.3 (M + 1)⁺.

Step 2:


[00513] The solution of tert-butyl 4-(3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamido)piperidine-1-carboxylate (480 mg, 0.8 mmol) in TFA/DCM (1 mL/5 mL) was stirred at room temperature for 2 hours. Then the solution was concentrated and purified by silica gel column chromatography to give 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-yl)propanamide (390 mg, 98%) as white solid which was used in next step directly. HPLC/UV purity: 95%; LC-MS (ESI): 501.3 (M + 1)⁺.

Step 3:

[00514] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-yl)propanamide (100 mg, 0.2 mmol), EtI (31 mg, 0.2 mmol) and K₂CO₃ (69 mg, 0.5 mmol) in DMF (5 mL) was stirred at room temperature overnight. The mixture was filtered, concentrated and


purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) and TLC to give N-(1-ethylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide (60 mg, 57%) as white solid. HPLC/UV purity: 100%; LC-MS (ESI): 530.4 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.76 (s, 1H), 8.78 (d, J = 5.6 Hz, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.93 (d, J = 6.0 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.23 (s, 1H), 4.68 (d, J = 14.0 Hz, 1H), 4.12 (d, J = 12.8 Hz, 1H), 3.84 (t, J = 6.8 Hz, 2H), 3.65-3.58 (m, 2H), 3.39-3.35 (m, 2H), 3.15-3.07 (m, 6H), 2.89-2.84 (m, 2H), 2.73-2.68 (m, 1H), 2.37-2.33 (m, 2H), 2.16-2.14 (m, 2H), 2.01-1.85 (m, 6H), 1.52-1.48 (m, 4H), 1.36-1.31 (m, 3H).

Example 133: Synthesis of N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide



[00515] The mixture of 3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanoic acid (104 mg, 0.25 mmol), 2-(4-methyl-1,4-diazepan-1-yl)ethanamine (40 mg, 0.25 mmol), HATU (190 mg, 0.5 mmol) and DIPEA (65 mg, 0.5 mmol) in DMF (5.0 mL) was stirred at room temperature for 3 hours. Then 50 mL water was added and the mixture was extracted with EA (100 mL), washed with brine, dried over Na₂SO₄, concentrated and purified by Prep-HPLC (Welch, XB-C18, 21.2 mm×250 mm, 10 μ m, eluting with 20% CH₃CN in 1% TFA in H₂O) to give N-(2-(4-methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide (40 mg, 28.7%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 558.4 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.81 (s, 1H), 8.82 (d, J = 6.0 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 6.0 Hz, 1H), 7.58 (d, J = 8.4 Hz, 2H), 7.24 (s, 1H), 3.87 (t, J = 6.8 Hz, 2H), 3.63 - 3.58 (m, 2H), 3.42 - 3.35 (m, 6H), 3.11 - 3.05 (m, 6H), 2.95 - 2.88 (m, 6H), 2.76 - 2.73 (m, 2H), 2.67 (t, J = 7.2 Hz, 2H), 2.39 - 2.33 (m, 2H), 2.11 - 2.05 (m, 2H), 1.98 - 1.80 (m, 5H), 1.62 - 1.50 (m, 2H).

Example 134: Synthesis of N-(2-(1-methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propiolamide

**Step 1:**

[00516] The mixture of 2,4-dichloro-1,6-naphthyridine (1 g, 5.0 mmol), (4-hydroxyphenyl)boronic acid (1.1 g, 5.25 mmol), Pd(PPh₃)₄ (577 mg, 0.5 mmol) and Na₂CO₃ (1.06 g, 10 mmol) in 1,4-dioxane (20 mL) and H₂O (4 mL) was heated at 100°C for 18hrs under N₂ atmosphere. The mixture was cooled to room temperature, and then the mixture was concentrated under reduced pressure to give the crude mixture, which was purified by flash column chromatography (silica gel, eluting with CH₂Cl₂ to 10% Methanol/CH₂Cl₂) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)phenol as a yellow solid (680 mg, 53%). HPLC/UV purity: 85%; LC-MS (ESI): 257.1 (M + 1)⁺.

Step 2:

[00517] To a mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)phenol (680 mg, 2.66 mmol) and pyridine (311 mg, 3.99 mmol) in DCM (30 mL) was added trifluoromethanesulfonic anhydride (898 mg, 3.18 mmol) drop wise at 0°C, and then the reaction mixture was stirred at room temperature for 1hr. DCM was removed under reduced pressure to give the slurry, which was dissolved into EA (30 mL), washed by water and brine. The organic layers was dried over Na₂SO₄, filtered and the filtrate was concentrated to give the crude product, which was purified by flash column chromatography (silica gel, eluting with PE to 30% EA/PE) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)phenyl trifluoromethanesulfonate (266 mg, 26%) as a white solid. HPLC/UV purity: 90%; LC-MS (ESI): 389.2 (M + 1)⁺.

Step 3:

[00518] The mixture of 4-(4-chloro-1,6-naphthyridin-2-yl)phenyl trifluoromethanesulfonate (180 mg, 0.66 mmol), 3-(piperidin-1-yl)propan-1-amine (113 mg, 0.79 mmol) and K₂CO₃ (182 mg, 1.32 mmol) in CH₃CN (10 mL) was heated at 100°C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL × 3). The combined organic layers were washed by water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to give the crude product, which was purified by flash column chromatography (silica gel, eluting with 10%

methanol in DCM) to afford 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl trifluoromethanesulfonate (170 mg, 52%) as a yellow solid. HPLC/UV purity: 90%; LC-MS (ESI): 495.3 (M + 1)⁺.


Step 4:

[00519] A 10-mL sealed tube, charged with 4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl trifluoromethanesulfonate (170 mg, 0.34 mmol), propiolic acid (48 mg, 0.69 mmol), Pd(PPh₃)₄ (39 mg, 0.03 mmol), DBU (104 mg, 0.69 mmol) and DMSO (2 mL). The mixture was heated at 35°C for 18 hrs. The resulting solution was poured into sat. NaHCO₃ aqueous (20 mL), then washed with EA (10 mL × 3). The pH of the water phase was adjusted to pH 1 with 1N aq. HCl solution. The acidified water phase was lyophilized to give a solid. The solid was dissolved into DCM/Methanol=5/1 (30 mL), then filtered by a pad of celite and the filtrate was concentrated to give the crude acid (300 mg). The crude acid was used to the next step without further purification.

Step 5:


[00520] To a mixture of 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolic acid (40 mg, 0.1 mmol) and HATU (45 mg, 0.12 mmol) in DMF (2 mL) were added 2-(1-methylpiperidin-4-yl)ethanamine (17 mg, 0.17 mmol) and DIPEA (38 mg, 0.3 mmol). The resulting mixture was stirred at rt for 1 hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL × 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to give the crude product, which was purified by Prep-TLC (silica gel, eluting with 10% methanol and 1% NH₃·H₂O in DCM) to afford N-(2-(1-methylpiperidin-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide (5 mg, 10%) as a yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 540.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.49 (s, 1H), 8.58 (d, J = 6.1 Hz, 1H), 8.05 (d, J = 8.5 Hz, 2H), 7.63 - 7.80 (m, 3H), 7.08 (s, 1H), 3.60 - 3.70 (m, 2H), 3.42-3.51 (m, 4H), 2.89-2.95 (m, 4H), 2.76 (s, 3H), 2.13 - 2.24 (m, 2H), 2.08 (d, J = 14.5, 6.6 Hz, 1H), 1.73 - 2.04 (m, 10H), 1.44 - 1.54 (m, 4H), 1.31 - 1.44 (m, 2H).

Example 135: Synthesis of N-((1-methylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide




[00521] To a mixture of 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propionic acid (40 mg, 0.1 mmol) and HATU (45 mg, 0.12 mmol) in DMF (2 mL) were added (1-methylpiperidin-4-yl)methanamine (15 mg, 0.17 mmol) and DIPEA (38 mg, 0.3 mmol). The resulting mixture was stirred at room temperature for 1 hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated in vacuo to give the crude product, which was purified by Prep-TLC (silica gel, eluting with 10% methanol and 1% $\text{NH}_3 \cdot \text{H}_2\text{O}$ in DCM) to afford N-((1-methylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide (5 mg, 10%) as a yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 525.3 ($\text{M} + 1$)⁺. ^1H NMR (METHANOL- d_4) δ : 9.38 (s, 1H), 8.47 (d, $J = 6.1$ Hz, 1H), 8.03 (d, $J = 8.2$ Hz, 2H), 7.61 - 7.73 (m, 3H), 6.98 (s, 1H), 3.49 (t, $J = 6.9$ Hz, 2H), 3.05 - 3.16 (m, 4H), 2.71-2.81 (m, 4H), 2.46 (s, 3H), 2.41-2.45 (m, 2H), 1.97 - 2.05 (m, 2H), 2.01-2.03 (m, 1H), 1.80 (d, $J = 15.6$ Hz, 2H), 1.56 - 1.70 (m, 5H), 1.45-1.50 (m, 3H), 1.32 (t, $J = 12.2$ Hz, 2H).

Example 136: Synthesis of N-(2-(1-methylazepan-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide



[00522] To a mixture of 3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propionic acid (80 mg, 0.19 mmol) and HATU (87 mg, 0.23 mmol) in DMF (2 mL) were added 2-(1-methylazepan-4-yl)ethanamine (36 mg, 0.17 mmol) and DIPEA (74 mg, 0.58 mmol). The resulting mixture was stirred at rt for 1hr. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to give the crude product, which was purified by Prep-HPLC to afford N-(2-(1-methylazepan-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propionamide (5 mg, 5%) as a yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 553.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.75 (s, 1H), 8.88 (d, J = 6.1 Hz, 1H), 8.11 (d, J = 8.5 Hz, 2H), 7.82 - 7.97 (m, 3H), 7.28 (s, 1H), 3.85 (t, J = 6.9 Hz, 2H), 3.57 - 3.68 (m, 6H), 3.52-3.55 (m, 4H), 3.29 - 3.32 (m, 4H), 3.17 (t, J = 6.0 Hz, 2H), 2.92 - 3.03 (m, 5H), 2.19 - 2.36 (m, 4H), 1.97 (d, J = 14.3 Hz, 2H), 1.73 - 1.91 (m, 3H), 1.53-1.56 (m, 1H).

Example 137: Synthesis of (Z)-N'-hydroxy-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzimidamide



Step 1:

[00523] The mixture of 2,4-dichloro-1,6-naphthyridine (2 g, 10 mmol), (4-formylphenyl)boronic acid (1.65 g, 11 mmol), Pd(PPh₃)₄ (577 mg, 0.5mmol) and Na₂CO₃ (2.12 g, 20mmol) in 1,4-dioxane (40 mL) and H₂O (8 mL) was heated at 90°C for 2hrs under N₂ atmosphere. The mixture was cooled to room temperature, and was concentrated under reduced pressure to give the crude product, which was purified by flash column chromatography (silica gel, eluting with 5% methanol/DCM) to afford 4-(4-chloro-1,6-naphthyridin-2-yl)benzaldehyde (2 g, 74%) as a white solid. HPLC/UV purity: 90%; LC-MS (ESI): 269.3 (M + 1)⁺.

Step 2:

[00524] To a suspension of 4-(4-chloro-1,6-naphthyridin-2-yl)benzaldehyde (2 g, 7.43 mmol) in methanol (40 mL) were added NaOAc (1.03 g, 12.6 mmol) and hydroxylamine hydrochloride (545 mg, 7.8 mmol). The resulting mixture was stirred at room temperature for 1hrs, and then the solvent was removed under the reduced pressure to give a slurry, to which water (20 mL) was added, followed by the addition of 10% aq. K₂CO₃ solution until pH=10. The resulting precipitate was collected and dried to give

(E)-4-(4-chloroquinolin-2-yl)benzaldehyde oxime (2.1 g, 100%) as a white solid. HPLC/UV purity: 95%; LC-MS (ESI): 284.3(M + 1)⁺.

Step 3:

[00525] To a mixture of (E)-4-(4-chloroquinolin-2-yl)benzaldehyde oxime (2.3 g, 8.12 mmol) in DMF (15 mL) was added NCS (1.62 g, 12.2 mmol) portion wise at 0°C. The resulting reaction mixture was stirred at room temperature overnight. The mixture was quenched by water (30 mL). The resulting precipitate was collected to give the crude product, a 1:1 mixture of (Z)-4-(4-chloro-1,6-naphthyridin-2-yl)-N-hydroxybenzimidoyl chloride and (Z)-4-(4,8-dichloro-1,6-naphthyridin-2-yl)-N-hydroxybenzimidoyl chloride, which was used to the next step without purification


Step 4:

[00526] To a mixture of (Z)-4-(4-chloro-1,6-naphthyridin-2-yl)-N-hydroxybenzimidoyl chloride (1.7 g, 4.8 mmol) in DMF (6 mL) were added 1-methylpiperidin-4-amine (820 mg, 7.2 mmol) and Et₃N (1.33 mL, 9.6 mmol) and the reaction mixture was stirred at room temperature for 1 hrs. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL × 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to give the crude product, which was purified by flash column chromatography (silica gel, eluting with 10% Methanol/DCM) to afford a mixture of (Z)-4-(4-chloro-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide and (Z)-4-(4,8-dichloro-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide (500 mg, 26%) as a white solid. HPLC/UV purity: 48%; LC-MS (ESI): 396.3(M + 1)⁺.

Step 5:


[00527] To a mixture of (Z)-4-(4-chloro-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide (55 mg, 0.14 mmol) and 3-(piperidin-1-yl)propan-1-amine (39 mg, 0.28 mmol) in n-BuOH (1 mL) was added DIPEA (36 mg, 0.28 mmol). The reaction vessel was sealed, and the reaction mixture was heated at 120°C for 4 hrs. The reaction mixture was poured into water (10 mL), extracted with EA (10 mL × 3). The combined organic layers were washed with water and brine, dried over Na₂SO₄. The drying agent was filtered off and the filtrate was concentrated in vacuo to give the crude mixture, which was purified by Prep-TLC (silica gel, eluting with 10% methanol and 1% NH₃.H₂O in DCM) to afford (Z)-N'-hydroxy-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzimidamide (5 mg, 13%) as a yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 502.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.86 (d, J = 6.2 Hz, 1H), 8.22 (d, J = 8.1 Hz, 2H), 7.96 (d, J = 6.2 Hz, 1H), 7.86 (d, J = 8.3 Hz, 2H), 7.32 (s, 1H), 3.84 (t, J = 6.9 Hz, 2H), 3.48 - 3.68 (m, 5H), 3.32-3.35 (m, 2H), 2.97 (t, J = 12.5 Hz, 4H), 2.82 (s, 3H), 2.27 - 2.39 (m, 2H), 2.18 (d, J = 12.6 Hz, 2H), 1.93 - 2.09 (m, 4H), 1.74 - 1.91 (m, 3H), 1.50-1.53 (m, 1H).

Example 138: Synthesis of (Z)-4-(8-chloro-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide



[00528] (Z)-4-(8-chloro-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide was synthesized in a similar fashion as Example 137. HPLC/UV purity: 100%; LC-MS (ESI): 536.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: ¹H NMR (METHANOL-d₄) δ: 9.48 (s, 1H), 8.74 (s, 1H), 8.54 (d, J = 8.3 Hz, 2H), 7.82 (d, J = 8.3 Hz, 2H), 7.31 (s, 1H), 3.68 (t, J = 6.7 Hz, 3H), 3.45 - 3.62 (m, 4H), 3.30-3.33 (m, 2H), 2.87 - 3.04 (m, 4H), 2.78 (s, 3H), 2.02 - 2.32 (m, 6H), 1.93 (d, J = 14.5 Hz, 2H), 1.67 - 1.88 (m, 3H), 1.44 - 1.57 (m, 1H).

Example 139: Synthesis of (Z)-N'-methoxy-N-(1-methylpiperidin-4-yl)-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzimidamide



Step 1:

[00529] The mixture of 4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzoic acid (300 mg, 0.77mmol), O-methylhydroxylamine (361 mg, 7.7 mmol), HATU (351 mg, 0.92 mmol) and DIPEA (165 mg, 1.54mmol) in DMF (2 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with EtOAc (5 mL × 3), washed with water (10 mL × 3) and brine (20 mL), dried over Na₂SO₄, concentrated and purified by prep-TLC (DCM :MeOH= 10:1) to afford N-methoxy-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide (140 mg, 43.3%) as yellow solid. LC-MS (ESI): 420.2 (M + 1)⁺.


Step 2:

[00530] A solution of N-methoxy-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide (142 mg, 0.338 mmol) in POCl_3 (5mL) was stirred at 100°C for 5h. The reaction was cooled to room temperature. Then the mixture was washed with 30mL saturated NaHCO_3 solution, extracted with DCM (20 mL $\times$ 3 times), dried over Na_2SO_4 , concentrated and purified by flash column chromatography to give (Z)-N-methoxy-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzimidoyl chloride (39mg, 26.3%) as yellow solid. LC-MS (ESI): 439.6 ($M + 1$)⁺.

Step 3:

[00531] A solution of (Z)-N-methoxy-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzimidoyl chloride (39 mg, 0.089 mmol), 1-methylpiperidin-4-amine (31 mg, 0.27 mmol) and pyridine (0.3 mL) in DMF (2 mL) was stirred at 80°C overnight. The reaction was cooled to room temperature, quenched with water (10 mL), and extracted with DCM (10mL $\times$ 3). The organic phase was concentrated and purified by Prep-HPLC to give (Z)-N'-methoxy-N-(1-methylpiperidin-4-yl)-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzimidamide (21.5mg, 46.8%) as white solid. LC-MS (ESI): 516.7 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ 9.64 (s, 1H), 8.69 (d, $J = 5.8$ Hz, 1H), 8.21 (d, $J = 8.4$ Hz, 2H), 7.86 (d, $J = 6.0$ Hz, 1H), 7.73 (d, $J = 8.3$ Hz, 2H), 7.22 (s, 1H), 3.88 (s, 3H), 3.76 (t, $J = 6.8$ Hz, 2H), 3.69 - 3.58 (m, 1H), 3.54 - 3.36 (m, 4H), 3.36 - 3.32 (m, 2H), 3.05 - 2.91 (m, 4H), 2.82 (s, 3H), 2.38 - 2.27 (m, 2H), 2.12 - 2.05 (m, 2H), 1.97 - 1.85 (m, 7H), 1.62 - 1.58 (m, 1H).

Example 140: Synthesis of N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide

**Step 1:**

[00532] The mixture of methyl 6-bromobenzo[b]thiophene-2-carboxylate (5 g, 18.4 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (5.6 g, 22.1 mmol), $\text{PdCl}_2(\text{dppf})$ (1.3 g, 1.84 mmol), and KOAc (3.6 g, 36.8 mmol) in 1,4-dioxane (50 mL) under N_2 atmosphere was heated at 95°C overnight. After cooling to room temperature, the mixture was concentrated. The residue was purified by the flash column chromatography (silica gel, eluting with PE to 10% EA in PE) to methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophene-2-carboxylate as a white solid (3.36 g, 57%). LC-MS (ESI): 319.3 ($\text{M} + 1$)⁺.

Step 2:

[00533] A 20-mL microwave vial was charged with 2,4-dichloro-1,6-naphthyridine (500 mg, 2.5 mmol), methyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophene-2-carboxylate (834 mg, 2.62 mmol), $\text{Pd}(\text{PPh}_3)_4$ (288 mg, 0.25 mmol), Na_2CO_3 (530 mg, 5 mmol), 1,4-dioxane (10 mL) and H_2O (2 mL). The sealed vial with the resulting brown solution is heated for 2 hrs in a Biotage Initiator Eight Microwave Reactor at a constant temperature of 110°C . The resulting solutions were concentrated by rotary evaporation (55°C , 20 mmHg). The adsorbed material was purified by silica gel chromatography (silica gel, eluting with PE to 50% EA in PE) to give methyl 6-(4-chloro-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (705 mg, 80%) as a yellow oil. LC-MS (ESI): 355.0 ($\text{M} + 1$)⁺.

Step 3:

[00534] The mixture of methyl 6-(4-chloro-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (505 mg, 1.43 mmol), 3-(piperidin-1-yl)propan-1-amine (406 mg, 2.86 mmol) and K_2CO_3 (395 mg, 2.86 mmol) in DMF (1 mL) was heated at 80 °C for 18hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL×3). The combined organic layers were washed by water and brine, dried over Na_2SO_4 . Filtered and the filtrate was concentrated under the reduced pressure to give the residue which was purified by prep-TLC to afford methyl 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (310 mg, 47%) as a white solid. LC-MS (ESI): 461.3 ($M + 1$)⁺.


Step 4:

[00535] The mixture of methyl 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylate (310 mg, 0.67 mmol) and LiOH (282 mg, 6.7mmol) in MeOH (5 mL) and H_2O (1 mL) was stirred at room temperature overnight. The mixture was acidified with 1N aq. HCl solution to pH = 2. The mixture was concentrated to give the crude product that was used directly in the next step without further purification. LC-MS (ESI): 447.3 ($M + 1$)⁺.

Step 5:


[00536] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (70 mg, 0.15 mmol), 3-(piperidin-1-yl)propan-1-amine (44 mg, 0.31 mmol), HATU (87 mg, 0.23 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL×3) and brine (20 mL×1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the Prep-HPLC to obtain N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide (6.5 mg, 7%). HPLC/UV purity: 100%; LC-MS (ESI): 571.3 ($M + 1$)⁺; ^1H NMR (METHANOL- d_4) δ : 9.71 (s, 1H), 8.78 (d, J = 5.8 Hz, 1H), 8.72 (s, 1H), 8.06 - 8.16 (m, 3H), 7.89 (d, J = 6.1 Hz, 1H), 7.28 (s, 1H), 3.83 (t, J = 7.0 Hz, 2H), 3.48 - 3.68 (m, 6H), 3.17 - 3.29 (m, 4H), 2.91 - 3.05 (m, 4H), 2.29 - 2.40 (m, 2H), 2.08 - 2.21 (m, 2H), 1.90 - 2.00 (m, 4H), 1.78 - 1.90 (m, 6H), 1.46 - 1.64 (m, 2H).

Example 141: Synthesis of N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide



[00537] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (70 mg, 0.15 mmol), N,N-dimethylethane-1,2-diamine (27 mg, 0.31 mmol), HATU (87 mg, 0.23 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the Prep-HPLC to obtain N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide (4.7 mg, 6%). HPLC/UV purity: 100%; LC-MS (ESI): 517.2 ($M + 1$)⁺; ¹H NMR (METHANOL- d_4) δ : 9.64 (s, 1H), 8.78 (d, $J = 5.8$ Hz, 1H), 8.58 (s, 1H), 8.10 (d, $J = 8.2$ Hz, 1H), 8.02 (s, 1H), 7.91 - 7.97 (m, 1H), 7.82 (d, $J = 6.1$ Hz, 1H), 7.23 (s, 1H), 3.69 - 3.80 (m, 4H), 3.49 (d, $J = 12.5$ Hz, 2H), 3.34 (t, $J = 5.8$ Hz, 2H), 2.75 - 2.98 (m, 10H), 2.14 - 2.25 (m, 2H), 1.85 (d, $J = 14.0$ Hz, 2H), 1.59 - 1.80 (m, 3H), 1.41-1.48 (m, 1H).


Example 142: Synthesis of N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide



[00538] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (70 mg, 0.15 mmol), 1-methylpiperidin-4-amine (38 mg, 0.31 mmol), HATU (87 mg,

0.23 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL×3) and brine (20 mL×1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to obtain N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide (10 mg, 8%). HPLC/UV purity: 100%; LC-MS (ESI): 542.3 (M + 1)⁺; ¹H NMR (METHANOL-d₄) δ: 9.37 (s, 1H), 8.54 (s, 1H), 8.47 (d, J = 6.1 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.90 - 7.99 (m, 2H), 7.70 (d, J = 5.8 Hz, 1H), 7.06 (s, 1H), 3.84 - 4.00 (m, 1H), 3.55 (t, J = 6.7 Hz, 2H), 3.11 (d, J = 11.9 Hz, 2H), 2.93 - 3.03 (m, 4H), 2.83 - 2.93 (m, 2H), 2.42 - 2.58 (m, 5H), 2.05 - 2.17 (m, 2H), 2.00 (d, J = 11.9 Hz, 2H), 1.64 - 1.81 (m, 6H), 1.41-1.60 (m, 2H).

Example 143: Synthesis of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzo[b]thiophene-2-carboxamide



Step 1:


[00539] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (70 mg, 0.15 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (62 mg, 0.31 mmol), HATU (87 mg, 0.23 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL×3) and brine (20 mL×1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-TLC to afford tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamido)piperidine-1-carboxylate (90 mg, 95%). LC-MS (ESI): 629.3 (M + 1)⁺.

Step 2:

[00540] The mixture of tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamido)piperidine-1-carboxylate (90 mg, 0.14 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 18 hrs. Then the solvent was removed under the reduced pressure to give the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm × 250 mm, 10 μm, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzo[b]thiophene-2-carboxamide (15 mg, 20%) as a TFA salt. HPLC/UV purity: 100%; LC-MS (ESI): 529.3 (M + 1)⁺; ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.88 (d, J = 5.7 Hz, 1H), 8.60 - 8.69 (m, 1H), 8.10 - 8.18 (m, 1H), 8.06 - 8.10 (m, 1H), 8.03 (d, J = 7.8 Hz,


1H), 7.94 (d, J = 6.0 Hz, 1H), 7.20 - 7.34 (m, 1H), 4.16 - 4.27 (m, 1H), 3.88 (t, J = 6.6 Hz, 2H), 3.63 (d, J = 11.7 Hz, 2H), 3.54 (d, J = 12.8 Hz, 2H), 3.34 - 3.42 (m, 2H), 3.16 - 3.25 (m, 2H), 2.99 (t, J = 12.2 Hz, 2H), 2.32 - 2.41 (m, 2H), 2.27 (d, J = 11.9 Hz, 2H), 1.91 - 2.02 (m, 4H), 1.76 - 1.90 (m, 3H), 1.41-1.45 (m, 1H).

Example 144: Synthesis of N,N-diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide




[00541] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (70 mg, 0.15 mmol), diethylamine (23 mg, 0.31 mmol), HATU (87 mg, 0.23 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-HPLC to afford N,N-diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide (6.8 mg, 8%). HPLC/UV purity: 100%; LC-MS (ESI): 502.3 (M + 1)⁺; ¹H NMR (METHANOL-d₄) δ : 9.76 (s, 1H), 8.89 (t, J = 5.4 Hz, 1H), 8.68 (d, J = 5.0 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.05 (t, J = 8.4 Hz, 1H), 7.96 (d, J = 6.0 Hz, 1H), 7.67-7.81 (m, 1H), 7.33 (d, J = 9.8 Hz, 1H), 3.89 (t, J = 6.8 Hz, 2H), 3.54 - 3.70 (m, 6H), 3.36 (d, J = 7.6 Hz, 2H), 2.99 (t, J = 12.2 Hz, 2H), 2.25-2.45 (m, 2H), 1.98 (d, J = 14.9 Hz, 2H), 1.72 - 1.91 (m, 3H), 1.54 (d, J = 12.6 Hz, 1H), 1.24-1.40 (m, 6H).

Example 145: Synthesis of N-(1-ethylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide



[00542] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzo[b]thiophene-2-carboxamide (156 mg, 0.19 mmol), iodoethane (29 mg, 0.19 mmol) and K_2CO_3 (79 mg, 0.57 mmol) in DMF (1 mL) was stirred at room temperature for 2hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to obtain the residue which was purified by prep-TLC to afford N-(1-ethylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide (14 mg, 13%). HPLC/UV purity: 100%; LC-MS (ESI): 557.3 ($M + 1$)⁺; ^1H NMR (METHANOL- d_4) δ : 9.40 (s, 1H), 8.53 (s, 1H), 8.46 (d, $J = 5.7$ Hz, 1H), 8.04 (d, $J = 8.2$ Hz, 1H), 7.99 (s, 1H), 7.92 (d, $J = 8.0$ Hz, 1H), 7.67 (d, $J = 5.7$ Hz, 1H), 6.99 - 7.08 (d, 1H), 4.07 (t, $J = 10.8$ Hz, 1H), 3.56 (t, $J = 6.6$ Hz, 2H), 3.48 (d, $J = 11.7$ Hz, 2H), 3.09 - 3.20 (m, 4H), 3.05 (q, $J = 6.9$ Hz, 3H), 2.91-2.99 (m, 2H), 2.10 - 2.21 (m, 4H), 1.87 - 1.99 (m, 2H), 1.71-1.80 (m, 4H), 1.46-1.63 (m, 2H), 1.26 (t, $J = 7.3$ Hz, 3H).


Example 146: Synthesis of (4-methylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone



[00543] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (70 mg, 0.15 mmol), 1-methylpiperazine (31 mg, 0.31 mmol), HATU (87 mg, 0.23 mmol) and DIPEA (58 mg, 0.45 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL $\times$ 3) and brine (20 mL $\times$ 1), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by the Prep-HPLC to afford (4-methylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone.

(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone (12.8 mg, 16%). HPLC/UV purity: 94% ; LC-MS (ESI): 529.2 ($M + 1$)⁺; ¹H NMR (METHANOL-*d*₄) δ : 9.30 (s, 1H), 8.47 (s, 1H), 8.42 (d, *J* = 6.1 Hz, 1H), 7.98 (d, *J* = 8.5 Hz, 1H), 7.88 (d, *J* = 8.5 Hz, 1H), 7.65 (d, *J* = 5.8 Hz, 1H), 7.58 (s, 1H), 6.94 (s, 1H), 3.67 - 3.78 (m, 4H), 3.41 (t, *J* = 6.9 Hz, 2H), 3.16 - 3.24 (m, 2H), 2.49 - 2.59 (m, 4H), 2.39 - 2.46 (m, 4H), 2.25 (s, 3H), 1.87 - 1.98 (m, 2H), 1.50 - 1.62 (m, 4H), 1.35-1.48 (m, 2H).

Example 147: Synthesis of Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone



Step 1:


[00544] The mixture of 6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxylic acid (117 mg, 0.26 mmol), tert-butyl piperazine-1-carboxylate (96 mg, 0.52 mmol), HATU (148 mg, 0.39 mmol) and DIPEA (100 mg, 0.78 mmol) in DMF (1 mL) was stirred at room temperature overnight. Water (30 mL) was added, and then the mixture was extracted with EA three times. The combined organic layers were washed with water (20 mL×3) and brine (20 mL×1), dried over Na₂SO₄, filtered and concentrated. The residue was purified by the Prep-TLC to afford tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carbonyl)piperazine-1-carboxylate (42 mg, 26%). LC-MS (ESI): 615.3 ($M + 1$)⁺;

Step 2:

[00545] The mixture of tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carbonyl)piperazine-1-carboxylate (42 mg, 0.06 mmol) and TFA (1 mL) in DCM (1 mL) was stirred at room temperature for 18hrs. Then the solvent was removed under the reduced pressure to give the residue which was purified with Prep-HPLC (Welch, XB-C18, 21.2 mm ×250 mm, 10 μ m, eluting with 40% CH₃CN in 1% TFA in H₂O) to afford piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone (35 mg, 100%) as a TFA salt. HPLC/UV purity: 99%; LC-MS (ESI): 515.3 ($M + 1$)⁺; ¹H NMR (METHANOL-*d*₄) δ : 9.75 (s, 1H), 8.88 (d, *J* = 6.1 Hz, 1H), 8.70 (s, 1H), 8.20 (d, *J* = 8.5 Hz, 1H), 8.07 (d, *J* = 8.4, 1H), 7.95 (d, *J* = 6.1 Hz, 1H), 7.87 (s, 1H), 7.34 (s, 1H), 4.06 - 4.13 (m, 4H), 3.88 (t, *J* = 6.7 Hz, 2H), 3.61 (d, *J* = 11.9 Hz, 2H), 3.39 -


3.43 (m, 4H), 3.29 - 3.31 (m, 2H), 2.98 (t, J = 12.4 Hz, 2H), 2.27 - 2.41 (m, 2H), 1.97 (d, J = 15.0 Hz, 2H), 1.74 - 1.89 (m, 3H), 1.48-1.54 (m, 1H).

Example 148: Synthesis of (4-ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone



[00546] The mixture of piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone (20 mg, 0.02 mmol), iodoethane (4 mg, 0.02 mmol) and K_2CO_3 (8 mg, 0.06 mmol) in DMF (1 mL) was stirred at room temperature for 2hrs. The reaction mixture was poured into water (20 mL), extracted with EA (10 mL $\times$ 3). The combined organic layers were washed by water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 . The drying agent was filtered off and the filtrate was concentrated under the reduced pressure to get the residue which was purified prep-TLC to afford (4-ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone (5.3 mg, 49%). HPLC/UV purity: 94%; LC-MS (ESI): 543.2 ($M + 1$)⁺; ^1H NMR (METHANOL- d_4) δ : 9.66 (s, 1H), 8.79 (s, 1H), 8.61 (d, J=4.0 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.94 - 8.01 (d, 1H), 7.84 (d, J = 5.8 Hz, 1H), 7.80 (s, 1H), 7.25 (s, 1H), 3.77 (t, J = 6.9 Hz, 2H), 3.48 - 3.60 (m, 6H), 3.22 - 3.29 (m, 4H), 2.96 - 3.20 (m, 4H), 2.86 (t, J = 11.3 Hz, 2H), 2.16 - 2.29 (m, 2H), 1.85 (d, J = 14.6 Hz, 2H), 1.70 (d, J = 15.3 Hz, 3H), 1.42 (d, J = 12.2 Hz, 1H), 1.30 (t, J = 7.3 Hz, 3H).

Example 149: Synthesis of (E)-N,N-Diethyl-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide

**Step 1:**

[00547] The mixture of (5-formylfuran-2-yl)boronic acid (1.0 g, 7.15 mmol), 2,4-dichloro-1,6-naphthyridine (1.2 g, 5.96 mmol), $\text{Pd}(\text{PPh}_3)_4$ (689 mg, 0.596 mmol) and Na_2CO_3 (1.26 g, 11.92 mmol) in 1,4-dioxane/ H_2O (20 mL/5 mL) was stirred at 100 °C under N_2 for 8 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 9% to 33% EA/PE) to afford 5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-carbaldehyde (900 mg, 69%) as yellow solid. LC-MS (ESI): 259.1 ($\text{M} + 1$)⁺.

Step 2:

[00548] Malonic acid (258 mg, 2.48 mmol) was added to the mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-carbaldehyde (400 mg, 1.55 mmol), piperidine (0.04 mL) and pyridine (3 mL). After heated at 80 °C for 1 h and at 100 °C for 4.5 h, the reaction mixture was diluted with EtOAc (10 mL $\times$ 3) and washed with water (10 mL $\times$ 3). The water layer was acidified to pH=2 with 2N aq. HCl solution and extracted with EA (10 mL $\times$ 3). The organic layer was dried over Na_2SO_4 and concentrated to afford crude (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)acrylic acid (90 mg, 19%) as brown solid. LC-MS (ESI): 301.0 ($\text{M} + 1$)⁺.


Step 3:

[00549] The mixture of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)acrylic acid (90 mg, 0.30 mmol), diethylamine (44 mg, 0.60 mmol), HATU (171 mg, 0.45 mmol) and DIPEA (78 mg, 0.60 mmol) in DMF (3 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with EA (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (20 mL), and dried over Na_2SO_4 , concentrated and purified by prep-TLC (EA/PE=1/1) to afford (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)-N,N-diethylacrylamide (20 mg, 19%) as yellow solid. LC-MS (ESI): 356.1 ($\text{M} + 1$)⁺.

Step 4:

[00550] To a solution of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)-N,N-diethylacrylamide (20 mg, 0.056 mmol) in DMF (2 mL) were added 3-(piperidin-1-yl)propan-1-amine (12 mg, 0.084 mmol) and K_2CO_3 (15 mg, 0.11 mmol). The reaction mixture was stirred at 70°C overnight. The reaction mixture was quenched with water (2 mL), and extracted with DCM (5 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-HPLC to afford (E)-N,N-diethyl-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide (5 mg, 19%) as yellow oil. HPLC/UV purity: 100%; LC-MS (ESI): 462.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ : 9.66 (s, 1H), 8.81 (d, $J = 6.0$ Hz, 1H), 7.93 (d, $J = 6.4$, 1H), 7.87 (d, $J = 3.6$ Hz, 1H), 7.53 (d, $J = 15.2$ Hz, 1H), 7.35 (d, $J = 12.8$ Hz, 2H), 7.16 (d, $J = 4.0$ Hz, 1H), 3.82 (t, $J = 6.8$ Hz, 2H), 3.68-3.51 (m, 6H), 2.96 (t, $J = 12.8$ Hz, 2H), 2.32-2.28 (m, 2H), 1.96 (d, $J = 14.8$ Hz, 2H), 1.87-1.77 (m, 3H), 1.56-1.50 (m, 1H), 1.31 (t, $J = 6.8$ Hz, 5H), 1.21 (t, $J = 7.2$ Hz, 3H).

Example 150: Synthesis of (E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide

**Step 1:**


[00551] The mixture of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)acrylic acid (60 mg, 0.20 mmol), 2-(1-methylpiperidin-4-yl)ethan-1-amine (57 mg, 0.40 mmol), HATU (114 mg, 0.30 mmol) and DIPEA (52 mg, 0.40 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with DCM (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 , concentrated and purified by prep-TLC (DCM/MeOH = 10/1) to afford (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)-N-(2-(1-methylpiperidin-4-yl)ethyl)acrylamide (20 mg, 24%) as oil. LC-MS (ESI): 425.1 ($M + 1$)⁺.

Step 2:

[00552] To a solution of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)-N-(2-(1-methylpiperidin-4-yl)ethyl)acrylamide (20 mg, 0.047 mmol) in DMF (3 mL) were added 3-(piperidin-1-yl)propan-1-amine (10 mg, 0.071 mmol) and K_2CO_3 (13 mg, 0.094 mmol). The reaction mixture was stirred at 70°C

overnight, then quenched with water (3 mL). The mixture was extracted with DCM (5 mL $\times$ 3). The organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na₂SO₄, concentrated and purified by prep-HPLC to afford (E)-N-(2-(1-methylpiperidin-4-yl)ethyl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide (8 mg, 32%) as yellow solid. LC-MS (ESI): 531.3 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ : 9.67 (s, 1H), 8.79 (d, J = 6.0 Hz, 1H), 7.96 (d, J = 6.0 Hz, 1H), 7.84 (d, J = 3.6 Hz, 1H), 7.45 (d, J = 15.6 Hz, 1H), 7.31 (s, 1H), 7.06 (d, J = 3.6 Hz, 1H), 6.89 (d, J = 15.6 Hz, 1H), 3.82 (t, J = 6.8 Hz, 2H), 3.59 (d, J = 11.6 Hz, 2H), 3.55 (d, J = 12.4 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 3.01 - 2.93 (m, 4H), 2.85 (s, 3H), 2.33 - 2.27 (m, 2H), 2.06 (d, J = 14.0 Hz, 2H), 1.95 (d, J = 13.6 Hz, 2H), 1.82 - 1.62 (m, 6H), 1.57 (q, J = 6.8 Hz, 2H), 1.53 - 1.41 (m, 3H), 1.31 (d, J = 17.2 Hz, 1H).

Example 151: Synthesis of (E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide



Step 1:


[00553] Malonic acid (302 mg, 2.90 mmol) was added to the mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-carbaldehyde (500 mg, 1.93 mmol), 3-(piperidin-1-yl)propan-1-amine (0.05 mL) and pyridine (5 mL). The mixture was heated at 80°C for 1hr and then at 100°C overnight. The solvent was removed and acidified to pH=2 with 2N aq. HCl solution. Then the mixture was concentrated and purified by prep-TLC to afford (E)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylic acid (35 mg, 4%) as brown solid. LC-MS (ESI): 407.0 (M + 1)⁺.

Step 2:

[00554] The mixture of (E)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylic acid (25 mg, 0.06 mmol), 1-methylpiperidin-4-amine (10 mg, 0.09 mmol), HATU (34 mg, 0.09 mmol) and DIPEA (16 mg, 0.12 mmol) in DMF (2 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (2 mL), extracted with DCM (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (20 mL), dried over Na₂SO₄, concentrated and purified by prep-TLC to afford (E)-

N-(1-methylpiperidin-4-yl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide (5 mg, 16%) as yellow oil. LC-MS (ESI): 503.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.66 (s, 1H), 8.79 (d, *J* = 6.0 Hz, 1H), 7.95 (d, *J* = 6.0 Hz, 1H), 7.82 (d, *J* = 3.6 Hz, 1H), 7.48 (d, *J* = 16.0 Hz, 1H), 7.31 (s, 1H), 7.09 (d, *J* = 4.0 Hz, 1H), 6.86 (d, *J* = 15.6 Hz, 1H), 4.14 - 4.04 (m, 1H), 3.81 (t, *J* = 6.8 Hz, 2H), 3.59 (d, *J* = 12.4 Hz, 2H), 3.48 - 3.31 (m, 4H), 3.17 (t, *J* = 11.2 Hz, 2H), 2.96 (t, *J* = 11.2 Hz, 2H), 2.90 (s, 3H), 2.32 - 1.53 (m, 12H).

Example 152: Synthesis of (E)-3-(5-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylic acid




Step 1:

[00555] The mixture of 5-formylthiophen-2-ylboronic acid (1.0 g, 6.41 mmol), 2,4-dichloro-1,6-naphthyridine (1.15 g, 5.78 mmol), Pd(PPh₃)₄ (689 mg, 0.596 mmol) and Na₂CO₃ (1.26 g, 11.92 mmol) in 1,4-dioxane (20 mL) and H₂O (5 mL) was stirred at 100°C under N₂ for 8 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 9% to 33% EA/PE) to afford 5-(4-chloro-1,6-naphthyridin-2-yl)thiophene-2-carbaldehyde (900 mg, 51%) as yellow solid. LC-MS (ESI): 275.3 (M + 1)⁺.

Step 2:

[00556] Malonic acid (425 mg, 4.08 mmol) was added to the mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)thiophene-2-carbaldehyde (560 mg, 2.04 mmol), 3-(piperidin-1-yl)propan-1-amine (0.05 mL) and pyridine (5 mL). The mixture was heated at 80°C for 1 hr and then at 120°C overnight. The mixture was concentrated and acidified with 1N aq. HCl solution to pH=2. Then the solvent was removed and the residue was purified by prep-PLC to afford (E)-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylic acid (12 mg, 1.4%) as yellow solid. LC-MS (ESI): 423.1 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.36 (s, 1H), 8.51 (d, *J* = 6.0 Hz, 1H), 7.79 (d, *J* = 3.9 Hz, 1H), 7.71 (d, *J* = 6.0 Hz, 1H), 7.46 (d, *J* = 15.6 Hz, 1H), 7.20 (d, *J* = 3.9 Hz, 1H), 7.04 (s, 1H), 6.34 (d, *J* = 15.7 Hz, 1H), 3.61 (t, *J* = 6.8 Hz, 2H), 3.15 - 3.09 (m, 6H), 2.26 - 2.20 (m, 2H), 1.89 - 1.81 (m, 4H), 1.65-1.68 (m, 2H).

Example 153: Synthesis of (E)-N,N-Diethyl-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide



Step 1:

[00557] The mixture of 5-formylthiophen-2-ylboronic acid (2.0 g, 12.8 mmol), 2,4-dichloro-1,6-naphthyridine (2.4 g, 12.06 mmol), $\text{Pd}(\text{PPh}_3)_4$ (1.5 g, 1.28 mmol) and Na_2CO_3 (2.8 g, 26.4 mmol) in 1,4-dioxane (20 mL) and H_2O (5 mL) was stirred at 90°C under N_2 for 3 hrs. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, eluting with 9% to 33% EA/PE) to afford 5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-carbaldehyde (1.26 mg, 36%) as yellow solid. LC-MS (ESI): 275.1 ($\text{M} + 1$)⁺.

Step 2:

[00558] Malonic acid (227 mg, 2.18 mmol) was added to the mixture of 5-(4-chloro-1,6-naphthyridin-2-yl)thiophene-2-carbaldehyde (500 mg, 1.83 mmol), piperidine (1 drop) and pyridine (5 mL). After stirred at 100°C overnight, the mixture was diluted with EA (10 mL) and washed with water (10 mL $\times$ 3). The water layer was acidified to pH=2 with 1N aq. HCl solution, extracted with EA (10 mL $\times$ 3), dried over Na_2SO_4 , and concentrated to afford (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)furan-2-yl)acrylic acid (470 mg, 81.5%) as brown solid. LC-MS(ESI): 317.3 ($\text{M} + 1$)⁺.

Step 3:


[00559] The mixture of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylic acid (100 mg, 0.31 mmol), diethylamine (100 mg, 1.36 mmol), HATU (145 mg, 0.38 mmol) and DIPEA (82 mg, 0.63 mmol) in DMF (2 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with EtOAc (5 mL $\times$ 3). The combined organic layer was washed with water (10 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 , concentrated and purified by prep-TLC to afford (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)thiophen-2-yl)-N,N-diethylacrylamide (110 mg, 93.6%) as yellow solid. LC-MS (ESI): 372.5 ($\text{M} + 1$)⁺. ^1H NMR (DMSO- d_6) δ 9.52 (s, 1H), 8.83 (d, $J = 5.9$ Hz, 1H), 8.59 (s, 1H), 8.23 (d, $J = 4.0$ Hz, 1H), 7.92 - 7.86 (m, 1H), 7.68 (d, $J = 15.1$ Hz, 1H), 7.61 (d, $J = 4.0$ Hz, 1H),

7.01 (d, $J = 15.1$ Hz, 1H), 3.59 - 3.49 (m, 2H), 3.41 - 3.36 (m, 2H), 1.18 (t, $J = 7.0$ Hz, 3H), 1.08 (t, $J = 7.0$ Hz, 3H).

Step 4:

[00560] To a solution of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)thiophen-2-yl)-N,N-diethylacrylamide (110 mg, 0.29 mmol) in DMF (2 mL) were added 3-(piperidin-1-yl)propan-1-amine (55 mg, 0.38 mmol) and K_2CO_3 (82 mg, 0.59 mmol). After stirred at 70°C overnight, the reaction mixture was quenched with water (2 mL), extracted with DCM (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (10 mL), dried over Na_2SO_4 , concentrated and purified by prep-PLC to afford (E)-N,N-diethyl-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide (54 mg, 38.2%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 478.2 ($M + 1$)⁺. ¹H NMR (METHANOL- d_4) δ 9.38 (s, 1H), 8.52 (d, $J = 6.0$ Hz, 1H), 7.87 (d, $J = 3.9$ Hz, 1H), 7.75 (d, $J = 15.1$ Hz, 1H), 7.71 (d, $J = 6.0$ Hz, 1H), 7.42 (d, $J = 3.9$ Hz, 1H), 7.06 (s, 1H), 6.93 (d, $J = 15.1$ Hz, 1H), 3.60 (q, $J = 7.1$ Hz, 2H), 3.55 - 3.49 (m, 4H), 2.58 - 2.51 (m, 6H), 2.09 - 1.96 (m, 2H), 1.74 - 1.62 (m, 4H), 1.48 - 1.53 (m, 2H), 1.32 (t, $J = 7.1$ Hz, 3H), 1.22 (t, $J = 7.1$ Hz, 3H).

Example 154: Synthesis of (E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide



Step 1:

[00561] The mixture of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylic acid (100 mg, 0.31 mmol), 1-methylpiperidin-4-amine (72 mg, 0.63 mmol), HATU (145 mg, 0.38 mmol) and DIPEA (82 mg, 0.63 mmol) in DMF (2 mL) was stirred at room temperature overnight. The reaction mixture was quenched with water (5 mL), extracted with EA (5 mL $\times$ 3), washed with water (10 mL $\times$ 3) and brine (20 mL), dried over Na_2SO_4 , concentrated and purified by prep-TLC to afford (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)thiophen-2-yl)-N-(1-methylpiperidin-4-yl)acrylamide (103 mg, 78.9%) as yellow solid. LC-MS (ESI): 414.8 ($M + 1$)⁺.


Step 2:

[00562] To a solution of (E)-3-(5-(4-chloro-1,6-naphthyridin-2-yl)thiophen-2-yl)-N-(1-methylpiperidin-4-yl)acrylamide (103 mg, 0.25 mmol) in DMF (2 mL) were added 3-(piperidin-1-yl)propan-1-amine (46 mg, 0.32 mmol) and K_2CO_3 (69 mg, 0.5 mmol). After stirred at 70°C overnight, the reaction mixture was quenched with water (2 mL), extracted with DCM (5 mL $\times$ 3). The combined organic layer was washed with water (10 mL $\times$ 3) and brine (10 mL), and dried over Na_2SO_4 . After filtration, the filtrate was concentrated and purified by prep-TLC to afford (E)-N-(1-methylpiperidin-4-yl)-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide as yellow solid.

yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide (12 mg, 9.3%) as yellow solid.

HPLC/UV purity: 100%; LC-MS (ESI): 519.2 ($M + 1$)⁺. ¹H NMR (METHANOL-d₄) δ : 9.35 (s, 1H), 8.51 (d, $J = 6.0$ Hz, 1H), 7.82 (d, $J = 3.9$ Hz, 1H), 7.72 - 7.62 (m, 2H), 7.34 (d, $J = 3.9$ Hz, 1H), 7.01 (s, 1H), 6.52 (d, $J = 15.5$ Hz, 1H), 3.87 - 3.75 (m, 1H), 3.50 (t, $J = 6.8$ Hz, 2H), 2.90 (d, $J = 12.0$ Hz, 2H), 2.56 - 2.45 (m, 6H), 2.32 (s, 3H), 2.20 (t, $J = 10.8$ Hz, 2H), 2.10 - 1.95 (m, 4H), 1.72 - 1.58 (m, 7H), 1.58 - 1.47 (m, 3H).

Example 155: Synthesis of Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone



Steps 1 and 2:

[00563] NaHMDS (4.9 mL, 2M) was added to a solution of 6-bromo-2-chlorobenzo[d]thiazole (1 g, 4.0 mmol) and tert-butyl 4-(cyanomethyl)piperazine-1-carboxylate (1g, 4.4mmol) in dry THF (20 mL) under Ar atmosphere at 0°C. The mixture was stirred overnight at room temperature. Then NiO₂·H₂O (1.77 g, 16.1 mmol) was added and the resulting mixture was stirred for another 10 hrs at room temperature. Solid was filtered off and washed with MeOH. The combined solution was concentrated and purified by silica gel chromatography (silica gel, eluting with 10% EA in PE) to afford tert-butyl 4-(6-bromobenzo[d]thiazole-2-carbonyl)piperazine-1-carboxylate (0.6g, 58.8%) as white solid. LC-MS (ESI):426.5 ($M + 1$)⁺.

Steps 3 and 4:


[00564] The mixture of tert-butyl 4-(6-bromobenzo[d]thiazole-2-carbonyl)piperazine-1-carboxylate (300mg, 0.7mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (232mg, 0.91mmol), Pd(dppf)Cl₂ (51 mg, 0.07 mmol) and KOAc (207mg, 2.1mmol) in 1,4-dioxane (5 mL) was heated to

100°C and held for 18hrs under N₂ atmosphere. The mixture was cooled to room temperature, and then 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine (100mg, 0.32mmol), Pd(PPh₃)₄ (285 mg, 0.25 mmol) and Na₂CO₃ (105 mg, 0.99 mmol) in 1,4-dioxane (5mL) and H₂O (1mL) was added. The resulting mixture was heated to 110°C and held for 18hrs under N₂ atmosphere. The mixture was concentrated under reduced pressure and the residue was purified by flash column chromatography (silica gel, eluting with CH₂Cl₂ to 10% Methanol/CH₂Cl₂) to afford tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazole-2-carbonyl)piperazine-1-carboxylate (30 mg, 6.9%). LC-MS (ESI): 616.7(M + 1)⁺.

Step 5:

[00565] To a solution of tert-butyl 4-(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazole-2-carbonyl)piperazine-1-carboxylate (30 mg, 0.05 mmol) in DCM was added TFA (0.5mL). After stirred at room temperature for 2 h, the reaction mixture was concentrated and purified by prep-TLC to afford piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone (14 mg, 56%) as yellow solid. HPLC/UV purity: 98%; LC-MS (ESI): 516.2 (M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.75 (s, 1H), 8.87 (d, *J* = 5.2 Hz, 2H), 8.39 (d, *J* = 8.7 Hz, 1H), 8.26 (d, *J* = 8.7, 1.7 Hz, 1H), 7.94 (d, *J* = 6.0 Hz, 1H), 7.36 (s, 1H), 3.86 (t, *J* = 6.9 Hz, 2H), 3.61 (d, *J* = 11.8 Hz, 2H), 3.50 - 3.43 (m, 4H), 3.40 - 3.34 (m, 6H), 2.98 (t, *J* = 11.7 Hz, 2H), 2.40 - 2.25 (m, 2H), 1.98 - 1.95 (m, 2H), 1.85 - 1.77 (m, 3H), 1.59-1.52 (m, 1H).

Example 156: Synthesis of Morpholino(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone




[00566] Morpholino(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)methanone was synthesized in a similar fashion as Example 155, Steps 1-3.

[00567] A 10-mL microwave vial was charged with morpholino(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)methanone (147mg, 0.39 mmol), 2-chloro-N-(3-(piperidin-1-yl)propyl)-1,6-naphthyridin-4-amine (100 mg, 0.33 mmol), Pd(PPh₃)₄ (189mg, 0.16 mmol), Na₂CO₃ (69 mg, 0.65 mmol), 1,4-dioxane (5mL) and H₂O (1 mL). The brown solution was heated in a Biotage Initiator Eight Microwave Reactor at 110°C for 1 h. The reaction mixture was concentrated and purified by silica gel chromatography (silica gel, eluting with 10% methanol in DCM) to give morpholino(6-(4-(3-

(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone as white solid (11.6 mg, 5.7%). HPLC/UV purity: 96%; LC-MS (ESI): 517.2(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ 9.36 (s, 1H), 8.66 (s, 1H), 8.47 (s, 1H), 8.19 (d, *J* = 7.8 Hz, 1H), 8.10 (d, *J* = 6.6 Hz, 1H), 7.69 (s, 1H), 7.04 (s, 1H), 4.30 - 4.37 (m, 2H), 3.73 - 3.79 (m, 6H), 3.52 - 3.56 (m, 2H), 2.92 - 2.95 (m, 6H), 2.05 - 2.09 (m, 2H), 1.68 - 1.70 (m, 4H), 1.48 - 1.52 (m, 2H).

Example 157: Synthesis of N,N-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]oxazole-2-carboxamide



Step 1:

[00568] 2-Amino-5-bromophenol (2.00 g, 10.6 mmol) and potassium o-ethyldithiocarbonate (4.26 g, 26.6 mmol) were mixed in a 25 mL microwave vial with 12 mL of PEG400. The reaction mixture was stirred at 165 °C for 20 minutes in a Biotage Initiator Eight Microwave Reactor. The reaction mixture was diluted with water (500 mL), acidified to pH = 3~4 with CH₃COOH. The precipitate was filtered and air-dried to give crude 6-Bromobenzo[d]oxazole-2-thiol (2.3 g) as powder, which can be used in the next step without further purification.

Step 2:

[00569] SOCl₂ (5.6 mL) and DMF (2.8 mL) were added to a stirred solution of 6-bromobenzo[d]oxazole-2-thiol (2.30 g, 10 mmol) in DCM (30 mL) at 0 °C. The reaction mixture was stirred till the solution was clear. Then the reaction mixture was stirred at room temperature overnight. After completion of the reaction, the mixture was poured into cold water (56 mL), neutralized with Na₂CO₃ (solid) carefully over 10 minutes and extracted with DCM. The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated. The crude product was purified by silica gel chromatography (silica gel, eluting with PE) to afford 6-bromo-2-chlorobenzo[d]oxazole (1.46 g, 62.9%) as white solid. LC-MS (ESI): 232.0 (M + 1)⁺.

Step 3:

[00570] NaHMDS (6 mL, 12 mmol) was added to a solution of 6-bromo-2-chlorobenzo[d]oxazole (1.16 g, 4.99 mmol) and 2-(diethylamino)acetonitrile (0.84 mL, 6.49 mmol) in dry THF (50 mL) under Ar atmosphere at 0 °C. The mixture was warmed to room temperature and stirred overnight. Then NiO₂·H₂O (2.2 g, 20 mmol) was added and the resulting mixture was stirred for another 10 hrs at room temperature. Insoluble solid was filtered off and washed with MeOH. The filtrate was concentrated and purified by silica gel chromatography (silica gel, eluting with 10% EA in PE) to afford 6-bromo-*N,N*-diethylbenzo[d]oxazole-2-carboxamide (0.57 g, 38.5%) as white solid. LC-MS (ESI): 297.0 (M + 1)⁺.

Step 4:

[00571] The mixture of 6-bromo-*N,N*-diethylbenzo[d]oxazole-2-carboxamide (0.63 g, 2.11 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (3.2 g, 12.66 mmol), Pd(dppf)Cl₂ (0.17 g, 0.211 mmol), KOAc (0.41 g, 4.22 mmol) and 1,4-dioxane (20 mL) was stirred at 75°C under Ar for 3 hrs. The mixture was cooled to room temperature and filtered. The organic phase was concentrated and purified by silica gel chromatography (silica gel, eluting with 10% EA in PE) to afford *N,N*-diethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole-2-carboxamide (0.63 g, 86.3%) as white solid. LC-MS (ESI): 345.2 (M + 1)⁺.


Step 5:

[00572] A 10-mL microwave vial was charged with *N,N*-diethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole-2-carboxamide (100mg, 0.29 mmol), 2,4-dichloro-1,6-naphthyridine (52 mg, 0.26 mmol), Pd(PPh₃)₄ (168mg, 0.15 mmol), Na₂CO₃ (62 mg, 0.58 mmol), 1,4-dioxane (5 mL) and H₂O (1 mL). The brown solution was heated in a Biotage Initiator Eight Microwave Reactor at 110°C for 1 h. The reaction mixture was concentrated and purified by silica gel chromatography (silica gel, eluting with 10% methanol in DCM) to give 6-(4-chloro-1,6-naphthyridin-2-yl)-*N,N*-diethylbenzo[d]oxazole-2-carboxamide as white solid (90 mg, 81.4%). HPLC/UV purity: 96%; LC-MS (ESI): 382.1(M + 1)⁺.

Step 6:

[00573] The mixture of 6-(4-chloro-1,6-naphthyridin-2-yl)-*N,N*-diethylbenzo[d]oxazole-2-carboxamide (90 mg, 0.24 mmol), 3-(piperidin-1-yl)propan-1-amine (45 mg, 0.32 mmol), and K₂CO₃ (72mg, 0.52mmol) in DMF (2 mL) was stirred at 70°C for 8 hrs. The reaction mixture was filtered, concentrated and purified by TLC to give *N,N*-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]oxazole-2-carboxamide (10.2 mg, 8.86%) as white solid. HPLC/UV purity: 98%; LC-MS (ESI): 486.8(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.78 (s, 1H), 8.89 (d, *J* = 6.0 Hz, 1H), 8.49 (s, 1H), 8.14 (s, 2H), 7.96 (d, *J* = 6.0 Hz, 1H), 7.35 (s, 1H), 3.99 - 3.82(m, 4H), 3.70 - 3.64 (m, 2H), 3.61 (d, *J* = 12.7 Hz, 3H), 2.98 (t, *J* = 12.3 Hz, 2H), 2.40 - 2.26 (m, 2H), 1.99 - 1.95 (m, 2H), 1.92 - 1.72 (m, 4H), 1.60 - 1.49 (m, 1H), 1.40 (t, *J* = 7.0 Hz, 3H), 1.33 (t, *J* = 7.1 Hz, 3H).

Example 158: Synthesis of *N,N*-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazole-2-carboxamide

**Step 1:**

[00574] NaHMDS (2.9 mL, 5.8 mmol) was added to a solution of 6-bromo-2-chlorobenzo[d]thiazole (0.60 g, 2.41 mmol) and 2-(diethylamino)acetonitrile (0.41 mL, 3.14 mmol) in dry THF (40 mL) under Ar atmosphere at 0°C. The mixture was warmed to room temperature and stirred overnight. Then NiO₂·H₂O (1.06 g, 9.7 mmol) was added and the resulting mixture was stirred for another 10 h. Insoluble solid was filtered off and the filtrate was concentrated. The residue was purified by silica gel chromatography (silica gel, eluting with 10% EA in PE) to afford 6-bromo-*N,N*-diethylbenzo[d]thiazole-2-carboxamide (0.46 g, 60.5%) as white solid. LC-MS (ESI): 313.0 (M + 1)⁺.

Step 2:

[00575] The mixture of 6-bromo-*N,N*-diethylbenzo[d]thiazole-2-carboxamide (0.26 g, 0.84 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.28 g, 5.04 mmol), Pd(dppf)Cl₂ (69 mg, 0.08 mmol), KOAc (0.16 g, 1.68 mmol) and 1,4-dioxane (10 mL) was stirred at 75°C under Ar₂ for 3 hrs. The mixture was cooled to room temperature and filtered. The organic phase was concentrated and purified by silica gel chromatography (silica gel, eluting with 10% EA in PE) to afford *N,N*-diethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole-2-carboxamide (0.42 g, 28.6%) as white solid. LC-MS (ESI): 361.2 (M + 1)⁺.

Step 3:

[00576] A 20-mL microwave vial was charged with *N,N*-diethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole-2-carboxamide (213.4 mg, 0.59 mmol), 2,4-dichloro-1,6-naphthyridine (94.3 mg, 0.47 mmol), Pd(PPh₃)₄ (274 mg, 0.24 mmol), Na₂CO₃ (100 mg, 0.95 mmol), 1,4-dioxane (10 mL) and H₂O (2 mL). The resulting brown solution is stirred at 110°C for 2 hrs in a Biotage Initiator Eight Microwave Reactor. The resulting solutions were concentrated and purified via silica gel chromatography (silica gel, eluting with 10% methanol in DCM) to give 6-(4-chloro-1,6-

naphthyridin-2-yl)-N,N-diethylbenzo[d]thiazole-2-carboxamide(50mg, 26.7%) as yellow solid. LC-MS (ESI): 397.3(M + 1)⁺.

Step 4:

[00577] To a solution of 6-(4-chloro-1,6-naphthyridin-2-yl)-N,N-diethylbenzo[d]thiazole-2-carboxamide (308.8 mg, 0.778 mmol) in DMF (5 mL) were added 3-(piperidin-1-yl)propan-1-amine (0.247 mL, 1.556 mmol) and K₂CO₃ (430.1 mg, 3.11 mmol). After stirred at 100°C overnight, the reaction mixture was quenched with water (2 mL), extracted with DCM (5 mL × 3). The combined organic layers was washed with water (10 mL × 3) and brine (10 mL), and dried over Na₂SO₄. After filtration, the filtrate was concentrated and purified by prep-TLC to afford N,N-diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazole-2-carboxamide (92.2 mg, 23.5%) as yellow solid. HPLC/UV purity: 100%; LC-MS (ESI): 503.3(M + 1)⁺. ¹H NMR (METHANOL-d₄) δ: 9.77 (s, 1H), 8.90 (d, *J* = 6.0 Hz, 1H), 8.82 (s, 1H), 8.38 (d, *J* = 8.5, 5.7 Hz, 1H), 8.21 (d, *J* = 8.6, 1.8 Hz, 1H), 7.95 (d, *J* = 6.0 Hz, 1H), 7.36 (s, 1H), 4.22 - 4.04 (m, 2H), 3.88 (t, *J* = 6.9 Hz, 2H), 3.65 (dt, *J* = 21.6, 10.6 Hz, 4H), 3.36 - 3.34 (m, 2H), 2.97 (dd, *J* = 25.5, 13.1 Hz, 2H), 2.42 - 2.25 (m, 2H), 1.97 (d, *J* = 15.2 Hz, 2H), 1.82 (dt, *J* = 26.7, 13.2 Hz, 3H), 1.59-1.50 (m, 1H), 1.41 (t, *J* = 6.9 Hz, 3H), 1.33 (t, *J* = 7.1 Hz, 3H).

PHARMACEUTICAL COMPOSITIONS**Example A-1: Parenteral Pharmaceutical Composition**

[00578] To prepare a parenteral pharmaceutical composition suitable for administration by injection (subcutaneous, intravenous), 1-1000 mg of a water-soluble salt of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, is dissolved in sterile water and then mixed with 10 mL of 0.9% sterile saline. A suitable buffer is optionally added as well as optional acid or base to adjust the pH. The mixture is incorporated into a dosage unit form suitable for administration by injection

Example A-2: Oral Solution

[00579] To prepare a pharmaceutical composition for oral delivery, a sufficient amount of a compound described herein, or a pharmaceutically acceptable salt thereof, is added to water (with optional solubilizer(s), optional buffer(s) and taste masking excipients) to provide a 20 mg/mL solution.

Example A-3: Oral Tablet

[00580] A tablet is prepared by mixing 20-50% by weight of a compound described herein, or a pharmaceutically acceptable salt thereof, 20-50% by weight of microcrystalline cellulose, 1-10% by weight of low-substituted hydroxypropyl cellulose, and 1-10% by weight of magnesium stearate or other appropriate excipients. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 100 -500 mg.

Example A-4: Oral Capsule

[00581] To prepare a pharmaceutical composition for oral delivery, 1-1000 mg of a compound described herein, or a pharmaceutically acceptable salt thereof, is mixed with starch or other suitable

powder blend. The mixture is incorporated into an oral dosage unit such as a hard gelatin capsule, which is suitable for oral administration.

[00582] In another embodiment, 1-1000 mg of a compound described herein, or a pharmaceutically acceptable salt thereof, is placed into Size 4 capsule, or size 1 capsule (hypromellose or hard gelatin) and the capsule is closed.

Example A-5: Topical Gel Composition

[00583] To prepare a pharmaceutical topical gel composition, a compound described herein, or a pharmaceutically acceptable salt thereof, is mixed with hydroxypropyl cellulose, propylene glycol, isopropyl myristate and purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topical administration.

BIOLOGY EXAMPLES

Example B-1: Enzyme assay of inhibition of LMPTP-A

[00584] Phosphatase assays were performed in buffer containing 50 mM Bis-Tris, pH 6.0, 1 mM DTT and 0.01% Triton X-100 at 37°C. For assays conducted with 3-O-methylfluorescein phosphate (OMFP) as substrate, fluorescence was monitored continuously at $\lambda_{\text{ex}}=485$ and $\lambda_{\text{em}}=525$ nm. For assays conducted with para-nitrophenylphosphate (pNPP) as substrate, the reaction was stopped by addition of 2X reaction volume of 1 M NaOH, and absorbance was measured at 405 nm. IC₅₀ values of compounds of Formula (I), (II), (III), or (IV) were determined from plots of inhibitor concentration versus percentage of enzyme activity. For inhibitor selectivity assays, each PTP was incubated with either 0.4 mM OMFP or 5 mM pNPP in the presence of 40 μ M compound or DMSO. Equal units of enzyme activity, comparable to the activity of 10 nM human LMPTP-A, were used. For the inhibitor reversibility assay, 50 nM human LMPTP-A was pre-incubated with 10 μ M of compound of Formula (I), (II), (III), or (IV) or DMSO for 5 min. The enzyme was diluted 100X in phosphatase assay buffer containing 0.4 mM OMFP and fluorescence was measured at the indicated time points.

[00585] Representative data for exemplary compounds disclosed herein is presented in Table 6.

Table 6.

Name	IC ₅₀
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide	A
N-(2-(dimethylamino)ethyl)-1-methyl-5-(4-(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
1-methyl-5-(4-(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide	A
ethyl 1-methyl-5-(4-(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate	A
4-(4-(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid	A
4-(4-(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzamide	A

Name	IC ₅₀
4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)benzamide	A
N-(2-(dimethylamino)ethyl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide	A
1-methyl-N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide	A
1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-2-carboxamide	A
N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-3-(trifluoromethyl)benzamide	A
4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-3-(trifluoromethyl)benzamide	B
1-methyl-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-2-carboxamide	A
1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide	B
5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide	A
1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide	A
methyl 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate	B
5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide	C
3-cyano-N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N1,N1-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)isophthalamide	B
1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	B
3-cyano-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide	B
1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(3-(piperidin-1-yl)propoxy)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	B
5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide	A
5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide	B
5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide	B
N-(2-(dimethylamino)ethyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide	A
N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide	A

Name	IC ₅₀
piperazin-1-yl(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone	A
N,N-diethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide	B
(1-ethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)(4-ethylpiperazin-1-yl)methanone	A
(4-ethylpiperazin-1-yl)(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone	A
N-(3-(piperidin-1-yl)propyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide	B
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,5-naphthyridin-2-yl)benzamide	C
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,7-naphthyridin-2-yl)benzamide	C
N,N-diethyl-4-(2-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-4-yl)benzamide	C
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-2-yl)benzamide	C
N,N-Diethyl-4-(4-((3-morpholinopropyl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-Diethyl-4-(4-((2-(piperidin-1-yl)ethyl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-Diethyl-4-(4-((3-(piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-Diethyl-4-(4-((3-(4-(methylsulfonyl)piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-Diethyl-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide	B
4-(4-((2-(Dimethylamino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide	B
N,N-diethyl-4-(4-(3-(4-methylpiperazin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-diethyl-4-(4-(2-morpholinoethylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-diethyl-4-(4-(2-(4-methylpiperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-diethyl-4-(4-(tetrahydro-2H-pyran-4-ylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-diethyl-4-(4-(2-(piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-diethyl-4-(4-(2-(4-(methylsulfonyl)piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-Diethyl-4-(4-(4-methoxyphenylamino)-1,6-naphthyridin-2-yl)benzamide	B
4-(4-(4-(Dimethylamino)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide	B
4-(4-(4-((Dimethylamino)methyl)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide	B
N,N-Diethyl-4-(4-(4-(2-methoxyethylamino)phenylamino)-1,6-naphthyridin-2-yl)benzamide	B
4-(4-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide	B
4-(4-((3-(1,1-Dioxidothiomorpholino)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide	B
N,N-Diethyl-4-(4-(1-methylpyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-Diethyl-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide	B
N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzamide	B
4-(4-((1-Methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide	B
N-(3-(Piperidin-1-yl)propyl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide	B

Name	IC ₅₀
N-(1-Methylpiperidin-4-yl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide	B
N,N-diethyl-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide	B
N-(3-(Piperidin-1-yl)propyl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide	B
N-(1-Methylpiperidin-4-yl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide	B
N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N-(3-(Piperidin-1-yl)propyl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N-(3-(Piperidin-1-yl)propyl)-4-(4-((pyridin-4-ylmethyl)amino)-1,6-naphthyridin-2-yl)benzamide	B
N-(1-Methylpiperidin-4-yl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide	A
4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide	C
4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide	C
N,N-Diethyl-4-(8-methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide	C
4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide	C
4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide	C
N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide	C
N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide	B
1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide	A
1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
(1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone	A
1-methyl-N-((1-methylpiperidin-4-yl)methyl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide	B
1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-yl)butan-2-ylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	B
1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	A
(1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone	A
1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-1H-indole-2-carboxamide	A

Name	IC ₅₀
1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-indole-2-carboxamide	B
N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	B
N-(3-(Piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	B
N-(2-(Dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide	B
6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide	A
6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide	B
(4-Ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)methanone	A
N,N-diethyl-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide	C
N-(1-methylpiperidin-4-yl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide	C
N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide	C
3-(4-(4-(ethyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-((1-ethylpiperidin-4-yl)methyl)propanamide	C
4-cyano-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide	B
(4-ethylpiperazin-1-yl)(5-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone	C
N-(3-(piperidin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide	A
N-(2-(dimethylamino)ethyl)-5-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide	A
N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide	C
5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole-2-carboxamide	A
N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-3H-imidazo[4,5-b]pyridine-2-carboxamide	A
N-(1-methylpiperidin-4-yl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenoxy)acetamide	C
N-(3-(piperidin-1-yl)propyl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide	B
N,N-diethyl-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide	B
N-(1-methylpiperidin-4-yl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide	A
N-((1-ethylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide	B
N-((1-methylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide	A
N-(2-(4-methyl-1,4-diazepan-1-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide	A
2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)-N-(piperidin-4-yl)methyl)acetamide	A

Name	IC ₅₀
N-(2-(1-methylpiperidin-4-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide	A
N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)propanamide	A
methyl-N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide	B
1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide	B
(E)-N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	A
(E)-N-(2-(Dimethylamino)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	A
(E)-N-(3-(Piperidin-1-yl)propyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	A
(E)-N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	A
(E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	A
(E)-N-((1-Ethylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	B
(E)-N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	A
(E)-N,N-Diethyl-3-(4-(4-((4-(pyrrolidin-1-yl)methyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylamide	B
N-(1-Methylpiperidin-4-yl)-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide	A
N,N-Diethyl-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide	A
N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide	A
N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide	A
3-(4-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-yl)propanamide	A
N-(2-(Diethylamino)-2-oxoethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propenamide	A
N-(1-Ethylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide	A
N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide	A
N-(2-(1-methylpiperidin-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide	B
N-((1-methylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide	B
N-(2-(1-methylazepan-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide	B
(Z)-N'-hydroxy-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzimidamide	B
(Z)-4-(8-chloro-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide	C
(Z)-N'-methoxy-N-(1-methylpiperidin-4-yl)-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzimidamide	A

Name	IC ₅₀
N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide	A
N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide	B
N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide	A
6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzo[b]thiophene-2-carboxamide	A
N,N-diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide	A
N-(1-ethylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide	A
(4-methylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone	A
Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone	A
(4-ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone	B
(E)-N,N-Diethyl-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide	B
(E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide	B
(E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide	C
(E)-3-(5-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylic acid	B
(E)-N,N-Diethyl-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide	C
(E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide	B
Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone	B
Morpholino(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone	B
N,N-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]oxazole-2-carboxamide	B
N,N-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazole-2-carboxamide	B


A: IC₅₀ is ≤1 μM; B: IC₅₀ > 1 μM and <20 μM; and C: IC₅₀ ≥ 20 μM.

[00586] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

CLAIMS


WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt, or solvate thereof:



Formula (I)

wherein,



is an aryl or a heteroaryl;

each R^a is independently H, halogen, $-\text{CN}$, $-\text{OH}$, $-\text{OR}^{13}$, $-\text{SR}^{13}$, $-\text{S}(=\text{O})\text{R}^{13}$, $-\text{S}(=\text{O})_2\text{R}^{13}$, $-\text{N}(\text{R}^{12})\text{S}(=\text{O})_2\text{R}^{13}$, $-\text{S}(=\text{O})_2\text{NR}^{12}\text{R}^{13}$, $-\text{C}(=\text{O})\text{R}^{13}$, $-\text{OC}(=\text{O})\text{R}^{13}$, $-\text{CO}_2\text{R}^{12}$, $-\text{OCO}_2\text{R}^{13}$, $-\text{NR}^{12}\text{R}^{12}$, $-\text{NR}^{12}\text{R}^{13}$, $-\text{C}(=\text{O})\text{NR}^{12}\text{R}^{12}$, $-\text{C}(=\text{O})\text{NR}^{12}\text{R}^{13}$, $-\text{OC}(=\text{O})\text{NR}^{12}\text{R}^{12}$, $-\text{OC}(=\text{O})\text{NR}^{12}\text{R}^{13}$, $-\text{NR}^{12}\text{C}(=\text{O})\text{NR}^{12}\text{R}^{12}$, $-\text{NR}^{12}\text{C}(=\text{O})\text{NR}^{12}\text{R}^{13}$, $-\text{NR}^{12}\text{C}(=\text{O})\text{R}^{13}$, $-\text{NR}^{12}\text{C}(=\text{O})\text{OR}^{13}$, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 fluoroalkyl, or substituted or unsubstituted C_1 - C_6 heteroalkyl;

each R^b is independently H, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 fluoroalkyl, or substituted or unsubstituted C_1 - C_6 heteroalkyl;

m is 0, 1, or 2; n is 0, 1, or 2;

L^2 is $-\text{L}^7-\text{Y}^1$;

L^7 is absent, substituted or unsubstituted C_1 - C_4 alkylene, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, substituted or unsubstituted C_3 - C_6 cycloalkylene, $-\text{Y}^2-\text{L}^8$ -, or $-\text{L}^8-\text{Y}^2-\text{L}^8$;

Y^1 is $-\text{C}(=\text{O})\text{NR}^c$ -, $-\text{C}(=\text{O})$ -, $-\text{SO}_2\text{NR}^c$ -, $-\text{C}(=\text{O})\text{O}$ -, $-\text{C}(=\text{NR}^c)$ -, $-\text{C}(=\text{N}-\text{OR}^c)$ -, $-\text{C}(=\text{NR}^c)\text{NR}^c$ -, or $-\text{C}(=\text{N}-\text{OR}^c)-\text{NR}^c$;

each L^8 is independently substituted or unsubstituted C_1 - C_4 alkylene or substituted or unsubstituted C_3 - C_6 cycloalkylene;

Y^2 is $-\text{O}$ -, $-\text{S}$ -, $-\text{S}(=\text{O})$ -, $-\text{SO}_2$ -, $-\text{NR}^c$ -, $-\text{C}(=\text{O})\text{NR}^c$ -, $-\text{C}(=\text{O})$ -, $-\text{NR}^c\text{C}(=\text{O})$ -, $-\text{SO}_2\text{NR}^c$ -, $-\text{NR}^c\text{SO}_2$ -, $-\text{OC}(=\text{O})$ -, $-\text{C}(=\text{O})\text{O}$ -, $-\text{OC}(=\text{O})\text{O}$ -, $-\text{OC}(=\text{O})\text{NR}^c$ -, $-\text{NR}^c\text{C}(=\text{O})\text{O}$ -, or $-\text{NR}^c\text{C}(=\text{O})\text{NR}^c$;

each R^c is independently H or substituted or unsubstituted C_1 - C_6 alkyl;

R^3 is H or $-\text{L}^3-\text{R}^5$;

L^3 is absent, substituted or unsubstituted C_1 - C_6 alkylene, or substituted or unsubstituted C_1 - C_6 heteroalkylene;

R^5 is H, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

or R^3 and R^c are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;

Z^1 is $-NR^d$ -, $-O$ -, $-S$ -, $-SO_2$ -, $-SO_2NR^d$ -, $-C(=O)NR^d$ -, $-NR^dC(=O)$ -, $-OC(=O)$ -, $-C(=O)O$ -, $-OC(=O)O$ -, $-C(=O)$ -, $-OC(=O)NR^d$ -, $-NR^dC(=O)O$ -, or $-NR^dC(=O)NR^d$ -,
each R^d is independently H or substituted or unsubstituted C_1 - C_6 alkyl;

L^4 is absent or $-L^5-L^6$;

L^5 is substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene;

L^6 is absent, substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, $-NR^6$ -, $-C(=O)NR^6$ -, $-NR^6C(=O)$ -, or $-NR^6C(=O)NR^6$;

R^4 is H, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

or R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle;

X^1 is CR^7 or N;

X^2 is N or CR^8 ;

X^3 is N or CR^9 ;

X^4 is N or CR^{10} ;

X^5 is N or CR^{11} ;

where at least one of X^2 , X^3 , X^4 , and X^5 is N;


R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from H, halogen, $-CN$, $-OH$, $-OR^{13}$, $-SR^{13}$, $-S(=O)R^{13}$, $-S(=O)_2R^{13}$, $-N(R^{12})S(=O)_2R^{13}$, $-S(=O)_2NR^{12}R^{13}$, $-S(=O)_2NR^{12}R^{13}$, $-C(=O)R^{13}$, $-OC(=O)R^{13}$, $-CO_2R^{12}$, $-OCO_2R^{13}$, $-NR^{12}R^{12}$, $-NR^{12}R^{13}$, $-C(=O)NR^{12}R^{12}$, $-C(=O)NR^{12}R^{13}$, $-OC(=O)NR^{12}R^{12}$, $-OC(=O)NR^{12}R^{13}$, $-NR^{12}C(=O)NR^{12}R^{12}$, $-NR^{12}C(=O)NR^{12}R^{13}$, $-NR^{12}C(=O)R^{13}$, $-NR^{12}C(=O)OR^{13}$, substituted or unsubstituted C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 fluoroalkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, a substituted or unsubstituted C_3 - C_6 cycloalkyl, a substituted or unsubstituted C_2 - C_6 heterocycloalkyl, a substituted or unsubstituted aryl, and a substituted or unsubstituted heteroaryl;

each R^{12} is independently selected from the group consisting of H, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, and C_1 - C_6 heteroalkyl;


each R^{13} is independently selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, C_1 - C_6 heteroalkyl, a substituted or unsubstituted C_3 - C_6 cycloalkyl, a substituted or unsubstituted

C₂-C₆heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted -C₁-C₄alkylene-C₃-C₁₀cycloalkyl, a substituted or unsubstituted -C₁-C₄alkylene-C₂-C₁₀heterocycloalkyl, a substituted or unsubstituted -C₁-C₄alkylene-aryl, and a substituted or unsubstituted -C₁-C₄alkylene-heteroaryl;
or when R¹² and R¹³ are attached to the same N atom then R¹² and R¹³ are taken together with the N atom to which they are attached to form a substituted or unsubstituted C₂-C₁₀heterocycle.


2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein:



3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein:




4. The compound of claim 1, wherein the compound of Formula (I) has the structure of Formula (II), or a pharmaceutically acceptable salt or solvate thereof:




Formula (II).


5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:



6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:



7. The compound of claim 6, wherein the compound of Formula (I) has the structure of Formula (III), or a pharmaceutically acceptable salt or solvate thereof:



Formula (III).

8. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:




is a monocyclic 5- or 6-membered heteroaryl containing 0-4 N and 0 or 1 O or S atom.


9. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:



is a monocyclic 5-membered heteroaryl that is furanyl, thienyl, pyrrolyl, oxazolyl, imidazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, or thiadiazolyl.

10. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:






11. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:



is a monocyclic 6-membered heteroaryl that is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl.

12. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:



13. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:




is a bicyclic heteroaryl containing 0-4 N and 0 or 1 O or S atom.

14. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:


(A)

is a bicyclic heteroaryl that is quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, indoliziny, azaindoliziny, indolyl, azaindolyl, indazolyl, azaindazolyl, benzimidazolyl, azabenzimidazolyl, benzotriazolyl, azabenzotriazolyl, benzoxazolyl, azabenzoxazolyl, benzisoxazolyl, azabenzisoxazolyl, benzofuranyl, azabenzofuranyl, benzothienyl, azabenzothienyl, benzothiazolyl, azabenzothiazolyl, or purinyl.

15. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:



16. The compound of claim 13, wherein the compound of Formula (I) has the structure of Formula (IV), or a pharmaceutically acceptable salt or solvate thereof:



Formula (IV)

wherein,

- X^6 is NR^b , N, O, or S; and
 X^7 is N or CR^b .
17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is N;
 X^3 is CR^9 ;
 X^4 is CR^{10} ; and
 X^5 is CR^{11} .
18. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is CR^8 ;
 X^3 is N;
 X^4 is CR^{10} ; and
 X^5 is CR^{11} .
19. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is CR^8 ;
 X^3 is CR^9 ;
 X^4 is N; and
 X^5 is CR^{11} .
20. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is CR^8 ;
 X^3 is CR^9 ;
 X^4 is CR^{10} ; and
 X^5 is N.
21. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is N;
 X^3 is CR^9 ;
 X^4 is N; and
 X^5 is CR^{11} .
22. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is CR^8 ;
 X^3 is N;
 X^4 is CR^{10} ; and

- X^5 is N.
23. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is N;
 X^3 is CR^9 ;
 X^4 is CR^{10} ; and
 X^5 is N.
24. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 X^2 is CR^8 ;
 X^3 is N;
 X^4 is N; and
 X^5 is CR^{11} .
25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^7 , R^8 , R^9 , R^{10} , and R^{11} are independently selected from H, halogen, -CN, -OH, -OR¹³, substituted or unsubstituted C₁-C₆alkyl, substituted or unsubstituted C₁-C₆fluoroalkyl, and substituted or unsubstituted C₁-C₆heteroalkyl.
26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 L^2 is $-L^7-Y^1-$;
 L^7 is absent, substituted or unsubstituted C₁-C₄alkylene, -CH=CH-, -C≡C-, or substituted or unsubstituted C₃-C₆cycloalkylene, -Y²-L⁸-, or -L⁸-Y²-L⁸-;
 Y^1 is -C(=O)NR^c-, -C(=O)-, or -C(=O)O-;
each L⁸ is independently substituted or unsubstituted C₁-C₄alkylene or substituted or unsubstituted C₃-C₆cycloalkylene;
 Y^2 is -O-, -S-, or -NR^c-;
 R^3 is H or $-L^3-R^5$;
 L^3 is absent, substituted or unsubstituted C₁-C₆alkylene, or substituted or unsubstituted C₁-C₆heteroalkylene;
 R^5 is H, substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or R^3 and R^c are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle.
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, wherein:

- R^5 is H, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, or substituted or unsubstituted heteroaryl.
28. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^5 is H.
29. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^5 is a substituted or unsubstituted monocyclic C_2 - C_8 heterocycloalkyl containing at least 1 N atom in the ring.
30. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^5 is a substituted or unsubstituted monocyclic C_2 - C_8 heterocycloalkyl containing at least 1 N atom in the ring that is a substituted or unsubstituted aziridinyl, substituted or unsubstituted azetidiny, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted azepanyl.
31. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^5 is a substituted or unsubstituted monocyclic C_2 - C_8 heterocycloalkyl containing 1 N atom in the ring that is a β -lactam, γ -lactam, δ -lactam or ϵ -lactam.
32. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^5 is a substituted or unsubstituted bicyclic C_5 - C_{10} heterocycloalkyl.
33. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^5 is a substituted or unsubstituted bicyclic C_5 - C_{10} heterocycloalkyl that is a substituted or unsubstituted fused bicyclic C_5 - C_{10} heterocycloalkyl, substituted or unsubstituted bridged bicyclic C_5 - C_{10} heterocycloalkyl, or substituted or unsubstituted spiro bicyclic C_5 - C_{10} heterocycloalkyl.
34. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 Z^1 is $-NR^d$ - or $-O$ -;
 L^4 is absent or $-L^5-L^6$ -;
 L^5 is substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, substituted or unsubstituted phenylene or substituted or unsubstituted monocyclic heteroarylene;

- L^6 is absent, substituted or unsubstituted C_1 - C_6 alkylene, substituted or unsubstituted C_1 - C_6 heteroalkylene, $-NR^6$ -, $-C(=O)NR^6$ -, $-NR^6C(=O)-$, or $-NR^6C(=O)NR^6$;
- R^4 is H, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted monocyclic heteroaryl;
- or R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted N-containing heterocycle.
35. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt or solvate thereof, wherein:
- L^4 is absent or $-L^5-L^6$;
- L^5 is substituted or unsubstituted C_1 - C_6 alkylene;
- L^6 is absent or $-NR^6$;
- R^4 is substituted or unsubstituted monocyclic C_2 - C_6 heterocycloalkyl;
- or R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted monocyclic N-containing C_2 - C_6 heterocycloalkyl.
36. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt or solvate thereof, wherein:
- L^5 is $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, or $-CH_2CH_2CH_2CH_2-$.
37. The compound of any one of claims 1-33, or a pharmaceutically acceptable salt or solvate thereof, wherein:
- R^4 is substituted or unsubstituted monocyclic C_2 - C_6 heterocycloalkyl that is a substituted or unsubstituted aziridinyl, substituted or unsubstituted azetidiny, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted azepanyl;
- or R^4 and R^6 are taken together with the N atom to which they are attached to form a substituted or unsubstituted monocyclic N-containing C_2 - C_6 heterocycloalkyl that is a substituted or unsubstituted aziridinyl, substituted or unsubstituted azetidiny, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted piperazinyl, or substituted or unsubstituted azepanyl.
38. The compound of claim 1, wherein the compound is:
- N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide;
- N-(2-(dimethylamino)ethyl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;
- 1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide;

ethyl 1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxylate;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoic acid;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzamide;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)benzamide;

N-(2-(dimethylamino)ethyl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;

1-methyl-N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-2-carboxamide;

N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-3-(trifluoromethyl)benzamide;

4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-3-(trifluoromethyl)benzamide;

1-methyl-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(tetrahydro-2H-thiopyran-4-yl)-1H-indole-2-carboxamide;

1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

methyl 3-carbamoyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzoate;

5-(4-methoxy-1,6-naphthyridin-2-yl)-1-methyl-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

3-cyano-N,N-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N1,N1-diethyl-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)isophthalamide;
1-methyl-5-(4-(methylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;
3-cyano-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(3-(piperidin-1-yl)propoxy)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;
5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide;
5-(4-(methylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide;
5-(4-(ethylamino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-benzo[d]imidazole-2-carboxamide;
N-(2-(dimethylamino)ethyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;
N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;
piperazin-1-yl(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone;
N,N-diethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;
(1-ethyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)(4-ethylpiperazin-1-yl)methanone;
(4-ethylpiperazin-1-yl)(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone;
N-(3-(piperidin-1-yl)propyl)-5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,5-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,7-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(2-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-4-yl)benzamide;
N,N-diethyl-4-(4-(3-(piperidin-1-yl)propylamino)-1,8-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((3-morpholinopropyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((2-(piperidin-1-yl)ethyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((3-(piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((3-(4-(methylsulfonyl)piperazin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;

4-(4-((2-(Dimethylamino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
N,N-diethyl-4-(4-(3-(4-methylpiperazin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(2-morpholinoethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(2-(4-methylpiperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(tetrahydro-2H-pyran-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(2-(piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(2-(4-(methylsulfonyl)piperazin-1-yl)ethylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-(4-methoxyphenylamino)-1,6-naphthyridin-2-yl)benzamide;
4-(4-(4-(Dimethylamino)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
4-(4-(4-((Dimethylamino)methyl)phenylamino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
N,N-Diethyl-4-(4-(4-(2-methoxyethylamino)phenylamino)-1,6-naphthyridin-2-yl)benzamide;
4-(4-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
4-(4-((3-(1,1-Dioxidothiomorpholino)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
N,N-Diethyl-4-(4-(1-methylpyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-Diethyl-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
4-(4-((1-Methylpyrrolidin-3-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-(piperidin-4-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N,N-diethyl-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-(pyrrolidin-3-ylamino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
N-(3-(Piperidin-1-yl)propyl)-4-(4-((pyridin-4-ylmethyl)amino)-1,6-naphthyridin-2-yl)benzamide;
N-(1-Methylpiperidin-4-yl)-4-(4-((tetrahydro-2H-pyran-4-yl)amino)-1,6-naphthyridin-2-yl)benzamide;
4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N,N-diethylbenzamide;
4-(8-Bromo-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide;
N,N-Diethyl-4-(8-methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzamide;

4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)benzamide;

4-(8-Methyl-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)benzamide;

N-(3-(piperidin-1-yl)propyl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide;

N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)picolinamide;

1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide;

1-methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

(1-methyl-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone;

1-methyl-N-((1-methylpiperidin-4-yl)methyl)-5-(4-(4-(piperidin-1-ylmethyl)benzylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-methyl-5-(4-(methyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(1-methylpiperidin-4-yl)-1H-indole-2-carboxamide;

1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-(4-(piperidin-1-yl)butan-2-ylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

1-Methyl-N-(1-methylpiperidin-4-yl)-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

(1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone;

1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-1H-indole-2-carboxamide;

1-Methyl-5-(4-((1-methylpiperidin-4-yl)amino)-1,6-naphthyridin-2-yl)-N-(3-(piperidin-1-yl)propyl)-1H-indole-2-carboxamide;

N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N-(3-(Piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

N-(2-(Dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indole-2-carboxamide;

6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-indole-2-carboxamide;

6-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-indole-2-carboxamide;

(4-Ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-1H-indol-2-yl)methanone;

N,N-diethyl-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide;

N-(1-methylpiperidin-4-yl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide;

N-((1-ethylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)propanamide;

3-(4-(4-(ethyl(3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenoxy)-N-((1-ethylpiperidin-4-yl)methyl)propanamide;

4-cyano-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)-1H-benzo[d]imidazole-2-carboxamide;

(4-ethylpiperazin-1-yl)(5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazol-2-yl)methanone;

N-(3-(piperidin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

N-(2-(dimethylamino)ethyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

N-(3-(4-methylpiperazin-1-yl)propyl)-5-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)-1H-benzo[d]imidazole-2-carboxamide;

5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N-(2-(pyridin-4-yl)ethyl)-1H-benzo[d]imidazole-2-carboxamide;

N-(1-Methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-3H-imidazo[4,5-b]pyridine-2-carboxamide;

N-(1-methylpiperidin-4-yl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenoxy)acetamide;

N-(3-(piperidin-1-yl)propyl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide;

N,N-diethyl-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide;

N-(1-methylpiperidin-4-yl)-2-((4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzyl)oxy)acetamide;

N-((1-ethylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

N-((1-methylpiperidin-4-yl)methyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

N-(2-(4-methyl-1,4-diazepan-1-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)-N-(piperidin-4-ylmethyl)acetamide;

N-(2-(1-methylpiperidin-4-yl)ethyl)-2-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)acetamide;

N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzyloxy)propanamide;

methyl-N-(1-methylpiperidin-4-yl)-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide;

1-methyl-5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine-2-carboxamide;

(E)-N-(1-Methylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(2-(Dimethylamino)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(3-(Piperidin-1-yl)propyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-((1-Ethylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

(E)-N,N-Diethyl-3-(4-(4-((4-(pyrrolidin-1-ylmethyl)phenyl)amino)-1,6-naphthyridin-2-yl)phenyl)acrylamide;

N-(1-Methylpiperidin-4-yl)-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N,N-Diethyl-3-(4-(4-(1-methylpiperidin-4-ylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-((1-Methylpiperidin-4-yl)methyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

3-(4-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)-N-(piperidin-4-yl)propanamide;

N-(2-(Diethylamino)-2-oxoethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-(1-Ethylpiperidin-4-yl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-(2-(4-Methyl-1,4-diazepan-1-yl)ethyl)-3-(4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)phenyl)propanamide;

N-(2-(1-methylpiperidin-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide;

N-((1-methylpiperidin-4-yl)methyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide;

N-(2-(1-methylazepan-4-yl)ethyl)-3-(4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)phenyl)propiolamide;

(Z)-N'-hydroxy-N-(1-methylpiperidin-4-yl)-4-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)benzimidamide;

(Z)-4-(8-chloro-4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)-N'-hydroxy-N-(1-methylpiperidin-4-yl)benzimidamide;

(Z)-N'-methoxy-N-(1-methylpiperidin-4-yl)-4-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzimidamide;

N-(3-(piperidin-1-yl)propyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

N-(2-(dimethylamino)ethyl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

N-(1-methylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)-N-(piperidin-4-yl)benzo[b]thiophene-2-carboxamide;

N,N-diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

N-(1-ethylpiperidin-4-yl)-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophene-2-carboxamide;

(4-methylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone;

Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone;

(4-ethylpiperazin-1-yl)(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[b]thiophen-2-yl)methanone;

(E)-N,N-Diethyl-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide;

(E)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide;

(E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-((3-(piperidin-1-yl)propyl)amino)-1,6-naphthyridin-2-yl)furan-2-yl)acrylamide;

(E)-3-(5-(4-(3-(Piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylic acid;

(E)-N,N-Diethyl-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide;

(E)-N-(1-Methylpiperidin-4-yl)-3-(5-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)thiophen-2-yl)acrylamide;

Piperazin-1-yl(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone;

Morpholino(6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazol-2-yl)methanone;

N,N-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]oxazole-2-carboxamide;

N,N-Diethyl-6-(4-(3-(piperidin-1-yl)propylamino)-1,6-naphthyridin-2-yl)benzo[d]thiazole-2-carboxamide;

or a pharmaceutically acceptable salt or solvate thereof.

39. A pharmaceutical composition comprising a compound of any one of claims 1-38, or a pharmaceutically acceptable salt, or solvate thereof, and at least one pharmaceutically acceptable excipient.
40. The pharmaceutical composition of claim 39, wherein the pharmaceutical composition is formulated for administration to a mammal by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, dermal administration, or ophthalmic administration.
41. The pharmaceutical composition of claim 39, wherein the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.
42. A method of inhibiting low molecular weight protein tyrosine phosphatase (LMPTP) activity in a mammal comprising administering to the mammal a compound of any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof.
43. The method of claim 42, wherein the mammal has insulin resistance, metabolic syndrome, type 2 diabetes, cardiovascular disease, or combinations thereof.

44. The method of claim 42, wherein the mammal has an impaired glucose tolerance.
45. The method of claim 42, wherein the mammal is pre-diabetic.
46. The method of any one of claims 42-45, wherein the mammal is obese.
47. A method of treating insulin resistance, metabolic syndrome, type 2 diabetes or a combination thereof in a mammal comprising administering to the mammal a compound of any one of claims 1-38, or a pharmaceutically acceptable salt or solvate thereof.
48. The method of claim 47, wherein the mammal has abdominal obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, low high-density cholesterol levels (HDL), or combinations thereof.
49. The method of claim 47, wherein the mammal has an impaired glucose tolerance.
50. The method of claim 47, wherein the mammal is obese.
51. The method of claim 47, wherein the compound modulates glucose and lipid metabolism.
52. The method of any one of claims 42-51, further comprising administering an additional therapeutic agent to the mammal.
53. The method of claim 52, wherein the additional therapeutic agent is a peroxisome proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a dipeptidyl peptidase (IV) inhibitor, a glucagon-like peptide-1 (GLP-I) analog, insulin or an insulin analog, an insulin secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a human amylin analog, a biguanide, a glucophage, an alpha-glucosidase inhibitor, a meglitinide, a thiazolidinedione, a sulfonylurea, or any combination thereof.
54. The method of claim 52, wherein the additional therapeutic agent is an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, diuretic, calcium channel blocker, inhibitor of renin-angiotensin system (RAS), blood-thinning medication, a statin, a fibrate, or any combination thereof.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2018/029749**A. CLASSIFICATION OF SUBJECT MATTER****C07D 471/04(2006.01)i, A61K 31/4375(2006.01)i, A61K 31/404(2006.01)i, A61P 3/00(2006.01)i, A61P 3/04(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 471/04; C07D 215/02; A61K 31/517; A61K 31/4745; A61K 31/4706; C07D 239/91; A61K 31/4375; A61K 31/404; A61P 3/00; A61P 3/04

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal), STN(Registry, Caplus) & keywords: low molecular weight protein tyrosine phosphatase, LMPTP, obesity, metabolic syndrome

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STANFORD, S. M. et al., "Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase", Nature chemical biology, 2017, Vol. 13, No. 6 pages 624-632 (27 March 2017) See abstract; Figure 2	1-16,38
X	SAEED, M. S. et al., "Synthesis of benzo-fused six-membered aromatic heterocycles", Pelagia Research Library, Der Chemica Sinica, 2011, Vol. 2, No. 1, pages 66-69 See page 66, last paragraph; page 68, Reaction scheme.	1,2,4-7
X	WO 2005-056552 A1 (VERTEX PHARMACEUTICALS INCORPORATED) 23 June 2005 See claims 1-23; paragraphs [045], [074].	1-16,38
X	WO 2016-061280 A1 (LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY) 21 April 2016 See abstract; claims 1-25; paragraphs [0332]-[0424].	1-16,38
A	WO 2014-048532 A1 (MERCK PATENT GMBH) 03 April 2014 See the whole document.	1-16,38



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 August 2018 (13.08.2018)

Date of mailing of the international search report

14 August 2018 (14.08.2018)

Name and mailing address of the ISA/KR

International Application Division

Korean Intellectual Property Office

189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea




Facsimile No. +82-42-481-8578

Authorized officer

KAM, Yoo Lim

Telephone No. +82-42-481-3516



INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US2018/029749**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 42-54
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 42-54 pertain to methods for treatment of the human body by surgery or therapy and thus relate to a subject matter which this International Searching Authority is not required to search under PCT Article 17(2)(a)(i) and Rule 39.1(iv).
2. ☒ Claims Nos.: 40, 41, 43-45, 48-51, 53 and 54
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 40, 41, 43-45, 48-51, 53 and 54 are unclear because they refer to multiple dependent claims which do not comply with PCT Rule 6.4(a).
3. ☒ Claims Nos.: 17-37, 39, 42, 46, 47 and 52
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2018/029749

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005-056552 A1	23/06/2005	AU 2004-297241 A1	23/06/2005
		CA 2548009 A1	23/06/2005
		CN 1914204 A	14/02/2007
		EP 1709045 A1	11/10/2006
		IL 176215 A	05/10/2006
		JP 2007-513955 A	31/05/2007
		KR 10-2006-0123452 A	01/12/2006
		MX PA06006532 A	23/08/2006
		NO 20063132 A	11/09/2006
		RU 2006124559 A	20/01/2008
		US 2005-0171141 A1	04/08/2005
		US 2009-0042928 A1	12/02/2009
		US 7446112 B2	04/11/2008
		ZA 200604721 A	26/03/2008
WO 2016-061280 A1	21/04/2016	CA 2964113 A1	21/04/2016
		CN 107427506 A	01/12/2017
		EP 3206689 A1	23/08/2017
		EP 3206689 A4	09/05/2018
		JP 2017-536346 A	07/12/2017
		US 2017-0247340 A1	31/08/2017
WO 2014-048532 A1	03/04/2014	AR 092670 A1	29/04/2015
		AU 2013-324681 A1	07/05/2015
		AU 2013-324681 B2	10/08/2017
		BR 112015006524 A2	04/07/2017
		CA 2886000 A1	03/04/2014
		CN 104662006 A	27/05/2015
		CN 104662006 B	24/10/2017
		EP 2900643 A1	05/08/2015
		EP 2900643 B1	27/09/2017
		ES 2654464 T3	13/02/2018
		HK 1210777 A1	06/05/2016
		IL 237840 A	31/05/2015
		JP 2015-535831 A	17/12/2015
		JP 6276769 B2	07/02/2018
		KR 10-2015-0063474 A	09/06/2015
		MX 2015003570 A	22/06/2015
		RU 2015115576 A	20/11/2016
		RU 2650107 C2	09/04/2018
		SG 11201502120 A	29/04/2015
		US 2015-0239850 A1	27/08/2015
		US 9388142 B2	12/07/2016
		ZA 201502838 B	29/11/2017